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 Abstract 
The focus of the novel research reported in this thesis is the synthesis of glycolipids 
for anti-microbial studies and to act as iNKT cell stimulatory ligands. Simple 
glycolipids, L-aspartic acid based glycolipids, glycoglycerolipids and L-serine based 
glycolipids were explored. 
Simple galactosyl glycolipids containing O- and N-glycosidic linkages and L-aspartic 
acid based glycolipids were constructed as in Chapter 2 with a view to test their 
anti-microbial properties against cystic fibrosis pathogens (Burkholderia cepacia 
complex). Preliminary testing of these glycolipids revealed promising anti-microbial 
activities. Glycolipids were also tested for their organogelator properties, whereby 
two of the compounds exhibited supramolecular assembly to form gels.  
Gl-X is a naturally occurring glycolipid found in the cell walls of certain 
Mycobacteriaceae species and has been reported to be involved in important 
biochemical processes. Intramolecular aglycon delivery, an elegant synthetic 
strategy for the construction of difficult 1,2-cis glycosidic linkages, was used in the 
formation of a Gl-X analogue described in Chapter 3.  
A series of L-serine based analogues of KRN7000, a potent iNKT cell ligand, were 
investigated in Chapter 4 to probe their potential application as 
immunomodulators. Focus was applied to the synthesis of a suitable building block 
which could provide access to a range of different analogues, possessing α- and β-
glycosidic linkages. A short chain α-analogue of KRN7000 was successfully 
synthesised. A benzyl ether protected analogue of KRN7000, containing a 1,4-
disubstituted 1,23-triazole moiety was also synthesised by a copper catalysed azide 
alkyne cycloaddition.  
Preliminary investigations into a new class of rigid macrocyclic L-serinyl analogues 
of KRN7000 was explored in Chapter 5 using a copper catalysed azide alkyne 
cycloaddition as the key synthetic step. The synthesis of a monomeric macrocycle 
and a dimeric macrocycle was explored, both compounds protected as benzyl 
ethers to ultimately function as a new class of rigid iNKT cell stimulatory ligands. 
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1.1. Glycolipids in nature: structure, occurrence and functions 
Glycolipids contain one or more saccharide units bound to a hydrophobic lipid chain 
by a glycosidic bond. These hydrophobic chains can be attached either directly to 
the saccharide or via a linker. As a result of the amphiphilic nature of glycolipids, 
they commonly act as recognition molecules for both hydrophilic and lipophilic 
molecules within the biological system. In the context of medicine, this dual nature 
is often exploited, as is the case in the biological system. As a result the synthesis of 
glycolipids is also of great interests, both to chemists and biochemists alike. 
Found in bacteria, plants and animals, glycolipids play key roles in pathogenesis of 
bacteria,[1] photosynthesis,[2] cellular recognition[3] and immunogenic processes to 
name but a few.[4] Their structures are varied and the carbohydrate component 
ranges from simple monosaccharides to complex oligosaccharides. Glycolipids 
found in bacteria and plants consist of simple alkyl glycolipids, glycoglycerolipids, 
lipopolysaccharides, resin glycolipids and glycosphingolipids. Glycolipids found in 
animals include glycosphingolipids and gangliosides. Figure 1.1 illustrates the 
principal structures of glycolipids commonly found in Nature. Some examples of 
these glycolipids and their biological functions are highlighted in Table 1.1. 
1.1.1. Alkyl glycolipids 
An abundance of simple alkyl glycolipids, comprising of fatty alcohols linked to a 
carbohydrate moiety by a glycosidic linkage, have been found in Nature, from 
animals, plants and microorganisms.[5] One such example is the heterocyst 
glycolipid (Entry 1 in Table 1.1), who’s structure consists of a glucose residue bound 
to a long chain diol through a glycosidic linkage. This glycolipid was isolated from 
the cyanobacterium Anabaena CCY9922 and was found to protect it against oxygen 
intake by creating a hydrophobic barrier.[6] Sophorolipids and rhamnolipids 
(described in Chapter 2) are also nice examples of alkyl glycolipids and they display 
interesting properties such as surfactant and anti-microbial properties.[5, 7] 
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Figure 1.1 Principal structures of glycolipids found in bacteria, plants and animals. 
 
1.1.2. Resin glycolipids 
Resin glycolipids are glycolipids of plant origin, which are mainly isolated from 
Convolvulaceae (Morning Glory family) and Scrophulariaceae plants. Most resin 
glycolipids have macrocyclic structures in the form of a lactone, thus serve as 
interesting targets for total synthesis.[8] Tricolorin A (Entry 2 in Table 1.1), a 
member of the resin glycoside family was first isolated in 1993 by Pereda-Miranda 
from the plant Ipomoea tricolor Cav.,[9] a plant traditionally employed in Mexican 
horticulture as a weed controller. Tricolorin A was found to be the active ingredient 
in the inhibition of weed growth.[9] The macrocycle was also found to have cytotoxic 
activity against human breast cancer cells.[9] Other examples of resin glycolipids 
with biological relevance include woodrosin I, tricolorin G and calonyctin A.[10] 
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Table 1.1 Examples of glycolipids found in nature and their biological function. 
 
1.1.3. Glycoglycerolipids 
Glycoglycerolipids are lipids derived from a glycerol, in which one of the hydroxyl 
groups of the glycerol has been functionalised with a mono- or oligosaccharide. 
They are the most abundant class of glycolipids found in plants and bacteria. 
Monogalactosyldiacylglycerol, a member of the glycoglycerolipids is  the most 
abundant glycolipid found in Nature.[11] Gl-X (Entry 3 in Table 1.1) is a 
glycoglycerolipid found in the bacterial cell walls of C. glutamicum and is involved in 
Entry
Classification 
(Occurrence in Nature)
Example Biological Function Ref
1
Alkyl glycolipid 
(Bacteria, Plants)
cyanobacterial cell wall 
protection against O2 uptake
[6]
2
Resin glycolipids 
(Plants)
phytogrowth inhibitor [9]
3
Glycoglycerolipids 
(Bacteria, Plants)
involved in Gl-LM 
biosynthesis in C. 
glutamicum
[12]
4
Glycoshingolipids 
(Bacteria, Plants, 
Animals)
to maintain the water 
permeability barrier for skin
[18]
5
Gangliosides 
(Vertebrates)
involved in neuronal cell 
death
[22]
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Gl-LM biosynthesis; it is implicated in the pathogenicity of the bacteria (discussed in 
Chapter 3, Section 3.5).[12] Not only are glycoglycerolipids involved in important 
cellular functions such as structural support and membrane anchors, they have 
been shown to exhibit anti-tumour[13] and autoimmune properties.[14] 
Glycophospholipids are glycolipids that contain phosphate groups and a sugar 
moiety, but the majority of this class of compounds also contain a glycerol 
backbone and can be classified as glycoglycerolipids. This group of compounds are 
mainly found in the Corynebacterineae family, which includes M. tuberculosis, one 
of the most serious infectious diseases in the world. 
1.1.4. Lipopolysaccharides 
Lipopolysaccharides (LPS) are complex macromolecules found in Gram-negative 
bacteria that typically consist of a hydrophobic domain known as lipid A (endotoxin) 
linked to inner core oligosaccharides. These, in turn, are linked to outer core 
oligosaccharides which are bound to a distal polysaccharide as shown in Figure 
1.2.[15] They play key roles in the pathogenicity of Gram-negative infection and 
septic shock, and are also implicated in immunomodulation.[16] 
OHO
O
NH
O
P
O
O
OH
R
O
HO
O
HO
R
OOO
O
NH
R
O
O
O
O
R
OHO
P
O
O
R
R
O
O
R = C11H23
Lipid A
Inner
Core
Outer
Core
O-specific
side chain
Polysaccharide
Lipopolysaccharides  
Figure 1.2 Principal structural regions of LPS glycolipids. The structure of Lipid A is given for 
an Escherichia coli strain F515.[17]  
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1.1.5. Glycosphingolipids 
Glycosphingolipids refer to lipids derived from a ceramide, in which the head group 
is either a mono- or oligosaccharide. Glucosylceramide (Entry 4 in Table 1.1) is an 
important glycosphingolipid that has been found in numerous animal tissues, such 
as in spleen and central nervous system as well as in individual cells such as 
erythrocytes.[18] Glucosylceramide has also been found to be a major component of 
skin lipids, and it is believed to maintain a water permeability barrier for the skin.[19] 
Furthermore glucosylceramidesare also of importance in the biosynthesis of 
lactosyl ceramides and gangliosides.[20] Another important glycosphingolipid  
termed α-GalCer (its synthetic analogue is known as KRN7000), was isolated from a 
marine sponge, Agelas Mauritanus.[21] α-GalCer  was found to be the first highly 
toxic iNKT cell stimulatory ligand (discussed in Chapter 4, Section 4.1.2) and has 
shown several promising therapeutic applications.[22] 
1.1.6. Gangliosides 
Gangliosides are oligoglycosylceramides derived from lactosylceramide which 
contain sialic acid residues and are only found in vertebrates. In the naming of 
gangliosides, the Svennerholm designation is most frequently employed. For 
example, in the case of GM3 (Entry 5 in Table 1.1) the G refers to ganglioside, the M 
refers to monosialo- and the 3 refers to the number of neutral sugar chains in the 
ganglioside. Structural functions of gangliosides are varied and include roles in cell 
proliferation, differentiation, development, regeneration and death.[17]  
1.2. Synthetic glycolipids and therapeutic applications 
Huge interest lies in the synthesis of glycolipids sharing the principal structures of 
natural glycolipids for therapeutic applications.[23] Some examples of synthetic 
glycolipids reported in the literature and their biological applications are 
highlighted in Table 1.2.  
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Table 1.2. Examples of synthetic glycolipids and their therapeutic applications. 
 
1.2.1. Alkyl glycolipids 
Despite their biological potential, relatively few studies have been carried out 
relating to the therapeutic applications of synthetic alkyl O-glycolipids. Nonetheless, 
synthetic alkyl glycolipids have been reported possessing anti-tumour[24] and anti-
microbial[25] properties (discussed in detail in Chapter 2). They also have potential 
uses in autoimmune diseases.[26] For example, in vivo studies on mice  were 
performed using the maltose tetrapalmitate glycolipid 1.1 (Entry 1 in Table 1.2) and 
this compound exhibited strong immunogenic properties against cancer cell 
lines.[24b] There is plenty of scope for further study of this simple class of glycolipids. 
 
Entry
Classification (Principal 
Structure)
Example Biological Application Ref
1 anti-tumour properties [24b]
2 anti-tumour properties [27]
3
stimulated a novel subtype of 
NKT cell in a CD1d dependent 
manner
[14]
4 i NKT cell stimulatory ligand [30]
O
HOO
HO
OHO
HO
O
O
14
O
O
14O
O
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O
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O
O
O
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OO
OH
OHO
Ph
O
O
O
1.2
O
R = H or saccharide/s or alkyl chains
R', R'' = alkyl chains
O R''
HN R'
O
OH
Glycosphingolipids
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1.2.2. Macrocyclic glycolipids 
Relatively few studies have been conducted on synthetic macrocyclic glycolipids 
owning to the structural complexities of the compounds, with the syntheses of 
resin glycolipids and their analogues taking up the majority of the scientific interest 
to date (discussed in detail in Chapter 5).[8, 10, 27] The synthesis and biological 
evaluation was carried out on the Ipomoeassin family (Ipomooeassin A-F) by 
Nagano and co-workers, including a non-natural Ipomoeassin analogue 1.2 (Entry 2 
in Table 1.2).[27] This group reported anti-tumour properties against mice cell lines 
for the Ipomoeassin analogue, however weaker cytotoxities were reported 
compared to the parent compound Ipomoeassin F. 
1.2.3. Glycoglycerolipids 
Scientific interest in the synthesis of glycoglycerolipids mainly concern 
phospholipids containing a glycerol backbone. Particular interest is held in the 
synthesis of glycoglycerolipids PIMs, LM and LAM and related glycolipids, which are 
found in the bacterial cell walls of M. tuberculosis (discussed in detail in Chapter 
3).[28] Related to these types of compounds are glucuronic based glycoglycerolipids 
which were also found in species of the Corynebacterinaea family.[12] The synthesis 
of a glucuronic glycoglycerolipid Gl-A 1.3 was executed by Uldrich et al. (Entry 3 in 
Table 1.2).[14]  This compound was found to stimulate a novel subtype of NKT cell, 
thus implicating the glycolipid as a therapeutic agent for cancer treatment. 
Synthetic glycoglycerolipids have also been used as tools in unravelling biological 
processes. For example, synthetic glycoglycerolipids were used in binding studies to 
eukaryotic cells, which provided strong evidence that glycoglycerolipids found in A. 
laidlawii participate in bacterial binding to eukaryotic cells.[29]   
1.2.4. Glycosphingolipids 
Perhaps the most interesting class of synthetic glycolipids found in the literature 
relates to the glycosphingolipids, with the emergence of a synthetic 
glycosphingolipid known as KRN7000 displaying a range of therapeutic applications, 
from anti-viral to autoimmune properties (discussed in Chapter 4).[22] Numerous 
synthetic analogues of this glycosphingolipid have been prepared and one such 
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glycolipid 1.4 is highlighted (Entry 4 in Table 1.2). Kinjo and colleagues synthesised  
a carboxylic glycosphingolipid amongst a range of other glycolipids and observed 
that the compound displayed improved iNKT cell stimulatory properties compared 
to the parent compound.[30]  
1.3. Research aims 
Glycolipids play an important role in a variety of different biological processes, as 
outlined above. The study of glycolipids has aided in the understanding of how 
natural glycolipids interact biologically, and has also carved the path for numerous 
applications of glycolipids as biomedical and medicinal agents.[23] As carbohydrate 
chemists, we are interested in the synthesis of a range of structurally diverse 
glycolipids with a view to assess their bioactivities, as anti-microbial agents or as 
iNKT cell stimulatory ligands.  
In particular, we were interested in the synthesis of glycolipid mimetics 
incorporating amino acids (aspartic acid and serine) as linker moieties (Chapters 2 
and 4). The role of the amino acid allows the introduction of two alkyl chains, for 
increased hydrophobic character. The aspartic acid glycolipids (Chapter 2) were 
designed to perform anti-microbial studies, along with a range of simple glycolipids. 
These anti-microbial studies will be performed in the laboratory of Dr. Siobhan 
McClean (Institute of Technology Tallaght) using the anti-adhesion methodology 
(described in Sectiom 2.2). The serine glycolipids were designed to act as iNKT cell 
stimulatory ligands (described in Section 4.1.2). The biological evaluation will be 
performed by Dr. Derek Doherty (St. James Hospital, Dublin) on human iNKT cells.  
Appropriate functionalization of the serine glycolipid mimetics allowed us to 
explore the synthesis of highly constrained macrocyclic derivatives (Chapter 5). We 
were interested to see whether the strained molecules would alter biological 
binding in the context of iNKT cells (Section 4.1.2). We were also interested in 
synthesising a glycoglycerolipid, a Gl-X analogue (Section 3.5) for biochemical 
studies (Chapter 3). These biochemical studies may ultimately aid in the 
understanding of the role of Gl-X and related glycolipids in bacterial cell walls. 
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Inherently to their amphiphilic nature, glycolipids can also exhibit interesting 
physiochemical properties, prompting them to act as surfactants and 
organogelators.[5, 7, 31] By serendipity, we noted aspartic acid derivatives displayed 
organogelator properties. We completed preliminary investigations on the 
properties of some synthetic glycolipids as a result (Chapter 2).
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2.1. Alkyl O-glycolipids and biological importance 
Owing to their amphiphilic nature, glycolipids are surfactants. Surfactants are 
chemical compounds that display surface activity properties. They are adsorbed 
between different phases (e.g. air-liquid or liquid-liquid) and lower the interfacial 
tension between these phases, i.e. they can facilitate the formation of emulsions. 
Surfactants are thus largely utilised as detergents,  wetting agents, emulsifiers, 
solubilisers, dispersing agents and foaming agents.[7a] Biosurfactants are surfactants 
produced by microorganisms. These compounds offer several advantages over 
other surfactants commonly in use today which include high purity, 
biodegradability and the fact that they are obtained from renewable sources. This 
greater environmental compatibility, amongst other factors, leads to a significant 
commercial interest.[32] Examples of biosurfactants include glycolipids, lipopeptides, 
phospholipids and fatty acids. Of special interest to the biomedical industry are the 
glycolipid biosurfactants, which include sophorolipids and rhamnolipids (Figure 
2.1).[5, 7] 
 
Figure 2.1 Examples of lactonic and acidic sophorolipids and mono- and di-rhamnolipids 
extracted from microorganisms.[7a] 
Sophorolipids are lipids obtained from the yeast Candida species, which were 
originally extracted from C. bomicola.[33] They contain a sophorose disaccharide 
moiety (β-D-Glcpi-(1→2)-D-Glcp)  linked via an α-glycosidic linkage to a fatty acid or 
a lactone ring to the C-4 position of the β-D-Glcp moiety. Rhamnolipids are lipids 
                                                            
i
D-Glcp refers to D-glucopyranose. 
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obtained from the Gram-negative Pseudomonas family which contain rhamnose 
units (a 6-deoxy sugar) linked to fatty acids, originally produced from the cultivation 
of P. aeruginosa.[34] Not only do their surfactant properties lend to their use in 
cosmetics, but they also exhibit anti-microbial and anti-fungal activities. [7a, 35] 
Examples of anti-microbial studies carried out on synthetic alkyl O-glycolipids are 
limited. Matsumura and colleagues reported a range of simple alkyl glycolipids 
(Figure 2.2) that exhibited anti-microbial activity against Gram-positive bacterial 
strains (Staphylococcus aureus and Bacillus subtilis, Sarcinalutea), Gram-negative 
bacterial strains (Pseudomonas aeruginosa) and fungal strains (Saccharomyces 
cerevisiae, Trichophytoninter digitale).[25] A summary of their findings appear in 
Table 2.1,  where anti-microbial activities are represented in terms of minimum 
inhibitory concentrations (MICs). It was generally recognised that glycolipids 2.1-2.7 
showed a broad spectrum of anti-microbial activity. In the glycolipids tested, 
dodecyl-α-D-mannopyransoide 2.3 was found to be the most effective anti-
microbial candidate, with an MIC value of 5 µg/ mL for S. lutea (shown in red). 
Generally, it was observed that anti-microbial properties were influenced by the 
glycopyranosyl residue, the length of the lipid chain and the stereochemistry of the 
anomeric substituent. No glycolipids with longer alkyl substituents than C12 were 
tested in the current study. 
 
 
Figure 2.2 Structures of alkyl glycolipids used in anti-microbial evaluation. 
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Table 2.1 Anti-microbial activity of alkyl glycolipids 2.1-2.7.* 
* Control always produced growth of the microorganism. 
2.2. Anti-adhesion approach for anti-microbial studies 
Anti-adhesion therapies are a novel approach in the treatment of bacterial 
infections. They represent a suitable alternative to the use of traditional antibiotics, 
as bacterial antibiotic resistance is becoming a major problem.[36] This approach 
mimics nature. For example, human breast milk contains many oligosaccharides 
acting as anti-adhesives which protect infants against infection.[37] A schematic 
representation of the anti-adhesion approach is illustrated in Scheme 2.1.[38] The 
bacteria preferentially adhere to free carbohydrates, instead of adhering to the 
carbohydrate epitopes present at the cell surface (the lung epithelial cell, in this 
case). This renders the bacteria effectively unable to infect the cell, and is 
eventually excreted/secreted from the body. 
C12αGlc 
2.1
C12βGlc 
2.2
C12αMan 
2.3
C12βGal 
2.4
C10βGlc  
2.5
C10αMan 
2.6
C10βGal 
2.7
1 S. aureus 10 25 25 200 100 50 100
2 B. subtilis 25 50 25 200 100 50 100
3 S. lutea 10 50 5 200 50 25 50
4 P. aeruginosa 200 >400 >400 >400 200 200 400
5 S. cerevisiae 400 25 10 200 100 50 100
6 T. interdigitale 200 25 10 200 200 50 100
Entry Bacteria/Fungi
MIC (µg/mL)
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Scheme 2.1 Bacterial adhesion to cells can result in infection (left). Free carbohydrates 
binding to the pathogen (right) prevent bacterial adhesion to cells and, as a  result, 
prevents infection.[38]ii 
 
Cystic fibrosis (CF) is a genetically inherited disease caused by mutations in the 
cystic fibrosis transmembrane regulator (CFTR), which affects the transport of ions 
through the chloride channel. The main cause of death in people suffering with CF 
is chronic respiratory infections which result in lung damage and weakening of the 
lung function. Burkholderia cepacia complex (Bcc) is a group of opportunistic CF 
pathogens that invade lung epithelial cells.[39] Studies from several countries 
indicate that two species of Bcc, Burkholderia cenocepacia and Burkholderia 
multivorans, account for most Bcc infection in CF patients.[40] The mechanisms by 
which Bcc strains invade lung epithelial cells are not well understood. Krivan, and 
subsequently Sylvestor, found Bcc isolates bound to galactose containing glycolipid 
receptors on the surface of lung epithelia.[41] Developing their predecessors 
findings, McClean and co-workers provided the first evidence that galactose based 
glycolipids were involved in the invasion of Bcc isolates into lung epithelial cells.[39a] 
                                                          
ii Illustration from Pieter and co-workers was edited. 
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The same research team reported that glycoconjugates containing terminal 
galactose moieties showed promising preliminary results in the inhibition of 
attachment of B. multivorans to human lung cells.[42] The design of galactose 
containing glycolipids which can reduce bacterial adhesion to the lung epithelial 
cells of CF patients, and thus prevent infection, is therefore an attractive potential 
treatment.  
2.3. N-glycosides and biological importance 
N-glycosides contain an N-linked glycosidic bond, and are an important class of 
compounds because they are naturally present in many glycoproteins, 
proteoglycans, peptidoglycans and, to a lesser degree, glycolipids.[43] As a result, 
numerous studies have been dedicated to analyse the biological effects of naturally 
occurring N-glycosides, their analogues and related compounds.[43-44] N-linked 
glycolipids can be included in a special class of compounds, termed glycomimetics. 
Glycomimetics are small organic molecules designed to mimic the function of a 
naturally occurring carbohydrate, with improved pharmacological properties. 
Strong interest lies in the rational design of glycomimetic drugs as alternatives to 
complex and naturally occurring oligosaccharides.[45] Glycomimetic drugs currently 
approved on the market are used for the treatment of diabetes (Voglibose)iii,[46] 
anti-viral agents (Zanamivir)[47] and anticoagulants (Fondaparinux).[48] The 
structures of these compounds are shown in Figure 2.3. Voglibose serves as an 
example of an N-glycoside glycomimetic drug. 
                                                            
iii Brackets contain trade names of currently approved glycomimetic drugs. 
Chapter 2: Alkyl Glycolipids as Anti-Microbial Agents and Organogelators 
17 
 
 
Figure 2.3 Glycomimetic drugs currently on the market:  Voglibose, Zanamivir, 
Fondaparinux, all acting as enzyme inhibitors.[46-48] 
 
Recent progress regarding the use of N-linked glycosides and other glycomimietics 
in microbial anti-adhesion have been reviewed by Imberty and co-workers, and 
many of the processes discussed involve glycoconjugate-lectin interactions.[49] 
Marotte and colleagues described the synthesis of a ligand for PA-IIL, a calcium-
dependent lectin from P. aeruginosa. This bacteria is also an opportunistic 
pathogen which causes respiratory-track infections and may cause death in CF 
patients.[50] As in the case for Bcc isolates described earlier, this lectin displays 
specificity for both D-galactose and L-fucose containing compounds.[51]It was later 
found that this lectin also showed a high affinity for Lewis a (Figure 2.4), with a high 
Kd value of 210 nM.
[52] Marotte and co-workers synthesised the structurally simpler 
glycomimetics 2.8 and 2.9 (Figure 2.4), with an aim to obtain higher affinities than 
that observed for the trisaccharide Lewis a. However, they obtained lower binding 
to the lectin compared to Lewis a (Kd of 310 and 290 Nm, respectively). Undeterred, 
Marotte and colleagues developed a second generation glycomimetic 2.10 (Figure 
2.4), and successfully observed a higher affinity compared to Lewis a (Kd of 90 
nM).[53] To the best of our knowledge, no N-linked glycolipids have been studied for 
their anti-microbial properties with Bcc isolates. 
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Figure 2.4 Structure of ligands for PA-IIL: structure of the natural epitope Lewis a, and 
structures of first generation glycomimetics 2.8 and 2.9 and second generation 
glycomimetic 2.10.[52-53] 
 
2.4. Organogelators 
A gel may be defined as a semi-solid formulation having an external solvent phase, 
which can be organic (in organogels) or aqueous (in hydrogel), and is immobilized 
within the available spaces of a three-dimensional network structure.[54] This 
network is generated by a gelator species. Gels can be classified into two types: 
polymer gels (in which the gelator network is linked by covalent bonds) or 
supramolecular gels (in which the gelator network is held together by non-covalent 
interactions).[55] The polymer gel network is completely covalent in nature, and as a 
direct result the formation of such gels is an irreversible process. Examples of 
polymer gels include silica and cross-linked polymers. Supramolecular gels display 
characteristic reversible transformations from the gel phase to the solution phase 
(generally denoted as gel→sol transitions) at mild temperatures, as a consequence 
of the weaker nature of these non-covalent interaction. Proteins, peptides and 
saccharides can act as gelators in certain solvents to generate supramolecular 
gels.[54] 
 
Low molecular weight organogelators (LMWGs) are low molecular weight 
compounds that can immobilise organic solvents through the formation of 
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supramolecular networks (Figure 2.5).[56] Interactions such as hydrogen-bonding,[57] 
electrostatic interactions,[58] π-π stacking[58] and London dispersion forces[59] play 
fundamental roles in the self-assembly of LMWGs.  
 
Figure 2.5 Schematic representation of LMWG formation by supramolecular networks.[60] 
 
To date, only a limited number of LMWGs have been documented in the literature, 
and most have been found by serendipity rather than by design. Anthracene 
derivatives 2.11 and 2.13,[61] fatty acids such as 2.12,[62] amino acids including 
2.14,[63] the glycolipid 2.15,[31] triazole containing peptidomimetic 2.16[64] and L-
aspartic acid based derivative 2.17[65] are  some representative examples of LMWGs 
(Figure 2.6). 
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Figure 2.6 Chemical structures of some LMWGs.[31, 61-65] 
 
Intense interest lies in the development of LMWGs due to their potential 
applications as organic soft materials. One exciting area involves their use as 
templates for the preparation of nanosized structures.[66] The process involves i) 
formation of the organogel in a polymerisable solvent; ii) polymerisation of the 
matrix; iii) solvent extraction of organic gelling agent. This is termed the “gel-
template leaching process” and allows the formation of porous membranes with 
channels of micrometer and sometimes nanometer dimensions.  Another 
application of LMWGs is in the development of new drug-delivery systems, by 
taking advantage of the thermoreversibility of this class of materials.[67] One such 
example reported the use of L-alanine based organogels encapsulating a bioactive 
agent (leuprolidine) in a solvent mixture of safflower oil and N-methyl pyrrolidone, 
and this formulation was injected subcutaneously into rats. A slow release period of 
14-25 days was observed for the system, with biodegradation of the L-alanine 
based gelling agent, indicating its biocompatability.[68] 
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2.5. Research objective  
This chapter describes the synthesis of the simple O-glycolipids 2.18 and 2.19, a 
simple N-linked glycolipid 2.20 and L-aspartic acid based N-linked glycolipids 2.21- 
2.23 (Figure 2.7). These glycoconjugates were intended for evaluation of their anti-
microbial activities. Importantly, all of the designed glycolipids contain a terminal 
galactose head group. As discussed earlier in section 2.2, McClean et al. reported 
that galactose based glycolipids on lung epithelial cells from CF patients mediated 
bacterial adhesion of Bcc isolates.[39a] With a view to explore their potential usage in 
biomedical applications, we investigated the possibility that synthetic galactosyl 
glycolipids may preferentially bind to Bcc instead of the galactosides on the surface 
of the ephithelial lung cells and therefore, prevent infection by an anti-adhesion 
approach. 
We aimed to synthesise galactose based O-glycolipids 2.18 and 2.19 using Koenig-
Knorr methodologies to compare the different alkyl length on the anti-microbial 
results. As discussed earlier, promising anti-microbial results were reported by 
Marotte et al. of a triazole containing glycolipid 2.10 carried out on the bacterium 
P. aeruginosa.[53] We aimed to synthesise the novel 1,4-disubstituted-1,2,3- triazole 
containing N-glycolipid 2.20 using a CuAAC reaction. Ultimately we aimed to probe 
the effect that the introduction of aromaticity in the glycolipid structure would have 
on their anti-microbial activity. 
We were also interested in the synthesis of a range of novel L-aspartic acid based N-
glycolipid mimetics 2.21-2.23. The presence of the L-aspartic acid linker would 
provide a suitable scaffold for introducing functionalities into the molecule as 
necessary, whereby two different alkyl chains could be introducted to the 
glycolipids. Various different length chains could also be investigated and the anti-
microbial studies performed to invigate the effect of the hydrophobic chains. 
Preliminary anti-microbial studies were carried out on compounds 2.19 and 2.22, as 
representative examples of these synthetic O- and N-glycolipid mimetics, for their 
potential application in an anti-adhesion approach for Bcc infection. By chance, we 
observed organogelator properties for one aspartic acid derivative. Therefore we 
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investigated the ability of some of these amphiphilic glycolipids to act as LMWGs in 
a range of organic solvents of different polarities, in order to explore the potential 
biomedical applications of this type of glycoconjugates. 
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Figure 2.7 Structure of simple O-glycolipids 2.18, 2.19, N-glycolipid 2.20 and L-aspartic acid 
based N-glycolipids 2.21-2.23. 
2.6. Synthesis of simple O-linked glycolipids 2.18 and 2.19 
In carbohydrate chemistry, one of the main challenges is to control the 
stereochemical outcome of the nucleophilic substitution at the anomeric centre 
during the formation of an O-glycosidic bond.[69] Both SN1 and SN2 type reactions 
can occur at the anomeric centre. SN1 reactions give a mixture of anomers as shown 
in Scheme 2.2. The configuration of the product at the anomeric carbon depends on 
which face the nucleophilic attack to the oxycarbenium ion 2.25 takes place, 
allowing the possible formation of both products 2.26 and 2.27. The occurrence of 
an SN1 reaction can depend on various parameters, including solvent choice, 
reaction time and the type of protecting groups used. SN2 reactions result in an 
inversion of stereochemistry at the anomeric position with respect to the 
configuration of the leaving group. An example of an SN2 reaction is shown in 
Scheme 2.2.  
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Scheme 2.2 SN1mechanism allows the formation of 1,2-trans product 2.26 or 1,2-cis 
product 2.27  while  SN2 mechanism involves an inversion of the configuration of the 
anomeric carbon with respect to that of the leaving group, to form the 1,2-trans product 
2.26. R groups refer to any protecting groups; L refers to leaving group. 
 
One strategy for controlling the stereochemical outcome of the glycosylation 
reaction makes use of a phenomenon called neighbouring group participation. An 
ester protecting group, such as an acetyl protecting group at the C-2 position, 
facilitates neighbouring group participation to give the 1,2-trans product 2.31, as 
shown in Scheme 2.3. The leaving group (L) is displaced at the anomeric centre of 
glycosyl donor 2.28 to form the oxycarbenium ion 2.29. Participation by the 
carbonyl oxygen stabilises the oxycarbenium ion 2.29 to form the corresponding 
cyclic oxonium ion 2.30. SN2 type attack of a nucleophile occurs with an inversion of 
configuration to give a 1,2-trans product. For example, a β-galactoside 2.31 was 
selectively formed in Scheme 2.3. If an ester is not present at the C-2 position of the 
sugar, neighbouring group participation cannot occur and the reaction can proceed 
via either an SN1 or SN2 mechanism which can result in a mixture of anomers 
(Scheme 2.2). Thus, in the majority of cases, the synthesis of 1,2-trans glycosides 
(by using of an ester protecting group at the C-2 position) involves simpler 
purification and a more efficient procedure than those used for the corresponding 
1,2-cis glycosides. 
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Scheme 2.3 Formation of a 1,2-trans product  2.31 resulting from neighbouring group 
participation of the C-2 protecting group. 
 
The synthesis of the short chain glycolipid 2.18 was first explored using the classic 
Koenigs Knorr methodology as shown in Scheme 2.4. A Koenings Knorr 
glycosylation involves the reaction of a glycosyl halide, as a glycosyl donor, with a 
variety of glycosyl acceptors, using halophilic activators (such as AgCO3 or AgOTf) to 
activate the anomeric halide leaving group. Many successful glycosylations have 
been reported in the literature using this methodology, due to the straightforward 
synthesis of the glycosyl donors and to the high yields of the glycosylation 
reactions.[70] The synthesis of the galactosyl halide 2.33 was performed following a 
literature procedure, where per-acetylated galactose 2.32 was treated with 33% 
HBr/AcOH to give the desired galactosyl bromide 2.33 in a 96% yield (Scheme 
2.4).[71] The reaction of the galactosyl bromide 2.33 with octanol in the presence of 
Ag2CO3 and I2 for 22 h yielded the acetyl protected β-glycolipid 2.34 in a 17% yield. 
Global deacetylation of the protected glycolipid 2.34 was performed using Zemplén 
conditions (NaOMe in MeOH) to yield the desired glycolipid 2.18 in a 90% yield. The 
spectroscopic data of glycolipid 2.18 was in agreement with the literature.[72] 
 
Scheme 2.4 Reagents and conditions. a) 33% HBr/ AcOH, CH2Cl2, rt, N2, 2 h, 96%; b) Ag2CO3, 
I2, octanol, 4Å MS, N2, 22 h, 17%; c) NaOMe, MeOH, 0 °C, 2 h, 90%. 
 
We envisaged the synthesis of the C22 alkyl chain glycolipid 2.19 (Scheme 2.5) to be 
more difficult than that of the C8 alkyl chain glycolipid 2.18 because of the increased 
length of the hydrocarbon chain, as it is documented that the lipid chain length is 
known to affect glycolipid and fatty alcohol solubility.[73] Initial investigations led us 
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to react the galactosyl halide 2.33 with docosonol under the same reaction 
conditions described earlier using Ag2CO3, I2, and docosonol in CH2Cl2. However, 
none of the desired glycolipid 2.35 was detected by TLC or 1H NMR analysis after 22 
h of reaction time.  
 
Scheme 2.5 Reagents and conditions. a) Ag2CO3, I2, docosonol,CH2Cl2,  4Å MS, N2, 22 h, 
11%; b) NEt3, THF/MeOH/H2O, rt, 48 h, 50%. 
 
Optimisation of the reaction involved grinding of the docosonol with a mortar and 
pestle to increase the surface area of the fatty alcohol particles and improve its 
solubility. A reverse addition approach was used for the glycosylation reaction, 
whereby the glycosyl bromide 2.33 was added to a suspension of ground docosonol 
containing Ag2CO3 and I2 in CH2Cl2 to afford the desired glycolipid 2.35 in an 11% 
yield (Scheme 2.5). Global deprotection of the acetyl protecting groups on 
glycolipid 2.35 involved the use of mild basic hydrolysis using catalytic NEt3 in a 
tricomponent solvent system of THF/H2O/MeOH. The deprotected glycolipid 2.19 
was precipitated in 50% yield after 48 h of reaction time, with the filtrate consisting 
of unreacted starting material 2.35. Attempts to hydrolyse the filtrate using the 
same conditions over a longer period of time (96 h) resulted in degradation of the 
precursor glycolipid 2.35. 
2.7. Synthesis of 1,4-disubstituted 1,2,3-triazole containing β-N-glycolipid 2.20 
As part of our continuing studies on a chemical approach to carbohydrate-based 
antibacterial agents, we were interested in synthesising the 1,4-disubstituted 1,2,3-
triazole containing β-N-glycolipid 2.20. We intended to compare its ability to inhibit 
bacterial adhesion to that of the simple O-glycolipids 2.18 and 2.19 (described in 
Section 2.6). The synthesis of the N-glycolipid 2.20 began with the reaction of the 
per-acetylated galactosyl donor 2.32 with TMSN3, promoted by the Lewis acid SnCl4 
at rt to yield 80% of the β-galactosylazide 2.36 (Scheme 2.6).[74] A subsequent 
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CuAAC reaction (discussed in detail in Chapter 5) with pentadecyne using a 
promoter system of CuSO4.5H2O and sodium ascorbate afforded the novel 1,4-
disubstituted 1,2,3-triazole N-glycolipid 2.37 in a regiospecific manner and in a yield 
of 89%. Global deacetylation was achieved using Zemplén conditions (NaOMe, 
MeOH) at a low temperature to afford the N-glycolipid 2.20 in an 88% yield. 
Structural characterisation was carried out using specific optical rotations and 1H 
NMR, 13C NMR, IR and HR-mass spectrometry on the novel N-glycolipid 2.20. 
 
Scheme 2.6 Reagents and conditions. a) SnCl4, TMSN3, CH2Cl2, N2, 18 h, 80%; b) 
pentadecyne, CuSO4.5H2O, Na ascorbate, THF/MeOH/H2O, 48 h, 89%; c) NaOMe, MeOH, 0 
°C, 1 h,  88%. 
2.8. Synthesis of L-aspartic acid based β-N-glycolipids 2.21-2.23 
The structure of the L-aspartic acid based N-glycolipids 2.21-2.23 were designed to 
introduce a spacer group that would allow the functionalization of the glycolipids 
with two hydrocarbon chains. The naturally occurring amino acid L-aspartic acid 
features an acid group on its side chain, which would allow for the connection with 
the galactosyl moiety through the formation of an amide bond. The carboxylic acid 
and amino groups at the α-carbon of the L-aspartic acid would also allow for the 
introduction of hydrocarbon chains through the formation of amide bonds. We 
were interested in incorporating alkyl chains of different lengths (C10, C16 and C24) 
onto the L-aspartic acid derivatives to compare their effect on the anti-microbial 
properties of each of the N-glycolipids 2.21-2.23 respectively.  
The retrosynthetic approach for the synthesis of the N-glycolipids is shown in 
Scheme 2.7, whereby the easily accessible β-galactosyl azide 2.36 and the 
commercially available protected L-aspartic acid derivative 2.41 serve as suitable 
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building blocks. The glycosyl azide 2.36 serves as a precursor to a glycosyl amine. 
The glycosyl amine can be reacted with aspartic acid derivatives 2.38-2.40 using a 
peptide coupling reaction, followed by global deprotection to yield the N-glycolipids 
2.21-2.23. The aspartic acid derivatives 2.38-2.40 can be obtained by reaction of 
aspartic acid derivative 2.41 with tetradecylamine, followed by N-Boc deprotection 
and a subsequent peptide coupling reaction with fatty acids of various different 
lengths.  
 
Scheme 2.7 Retrosynthesis of L-aspartic acid glycolipids 2.21, 2.22 and 2.23 from the 
building blocks galactosyl azide 2.36 and L-aspartic acid derivative 2.41. 
 
2.8.1. Initial attempts to synthesise the β-N-glycolipid 2.23 
A plethora of methods for the formation of the amide bonds have been reported in 
the literature, with the different types of coupling reagents and conditions evolving 
every day.[75] Various different coupling reagents have been developed, such as 
azides, active esters, acyl halides, anhydrides, carbodiimides, pyrocarbonates, 
isoxazolium, phosphonium and phosphonic salts, immonium salts and aminium 
salts to name but a few.[75] In the realm of this work, only the use of aminium salts 
will be described.  TBTU and HBTU are two popular aminium coupling reagents. 
TBTU (O-benzotriazol-1-yl)-1,13,3-tetramethyluronium tetrafluoroborate), as the 
name suggests was first  believed to have a uronium structure, but crystal and 
solution studies revealed that it has an aminium structure.[76] When used in 
conjunction with HOBt, minimal racemisation occurs during amide bond formation, 
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as HOBt acts as a racemisation suppressant. [77] HOBt was first introduced in 1970 
by Konig and Geiger [78] with carbodiimide coupling reagents, and has been used as 
an additive with various different methodologies ever since. However, present day 
use of HOBt has diminished due to the explosive nature of the anhydrous form 
which has hindered transport due to safety concerns. Oxyma 
(ethyl(hydroxyimino)cyanoacetate),[79] or COMO (1-cyano-2-ethoxy-2-
oxoethylidenaminooxy)-dimethylamino-morpholino-carbenium 
hexafluorophosphate) serve as safer alternatives.[80] A reaction mechanism for the 
coupling of a carboxylic acid and an amine with TBTU and HOBt is proposed in 
Scheme 2.8. The mechanism proceeds with attack of the carboxylate anion 
(generated under basic conditions) to the TBTU aminium carbocation to form an 
active ester species 2.42. Subsequent attack of HOBt to the electrophilic carbon of 
the active ester 2.42 in basic conditions yields a second active ester intermediate 
2.43, which is then attacked by the amine to lead to the formation of a new amide 
bond. 
 
Scheme 2.8 Reaction mechanism of TBTU and HOBt coupling reagents to form a new amide 
bond. 
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First, the synthesis of the β-galactosyl amine 2.44 was performed by reduction of 
the galactosylazide 2.36 (described in Scheme 2.6) by hydrogenolysis to yield 96% 
of the β-galactosyl amine 2.44 (Scheme 2.9).[74]  
 
Scheme 2.9 Reagents and conditions. a) H2, Pd (C), EtOAc, 1 atm, rt, 18 h, 96%. 
The synthesis of the L-aspartic acid derivative 2.48 (Scheme 2.10) commenced with 
the coupling of the commercially available N-Boc-L-aspartic acid-4-benzyl ester 2.41 
with tetradecylamine using TBTU/ HOBt with NEt3 to yield 87% of the building block 
2.45 (L/D). N-Boc deprotection of the amino derivative 2.45(L/D) using TFA in CH2Cl2 
afforded 77% of the desired free amine 2.46(L/D). This material was subsequently 
coupled to tetracosanoic acid using TBTU/HOBt coupling conditions with NEt3 to 
yield 89% of the benzyl ester building block 2.47(L/D). Deprotection of the benzyl 
ester of L-aspartic acid derivative 2.47(L/D) to yield the free carboxylic acid 
2.40(L/D), suitable for coupling to the galactosyl amine 2.44, proved to be a difficult 
task. Attempts at deprotection of the benzyl ester using Lewis acid catalysed 
deprotection (SnCl4 in CH2Cl2);
[81] basic hydrolysis (2 N NaOH solution in CH2Cl2) or 
harshly acidic conditions (10 equivalents of BF3.OEt2 in CH2Cl2) failed. Reduction of 
the benzyl ester could only be achieved by bubbling of the H2 gas (instead of a 
balloon as previously attempted) at 50 °C in EtOAc at 1 atm, to yield the carboxylic 
acid aspartic acid derivative 2.40(L/D) in a 72% yield.  
 
 
Scheme 2.10 Reagents and conditions. a) TBTU, HOBt, NEt3, tetradecylamine, DMF, 4Å MS, 
rt, 3 h, 87%; b)TFA, CH2Cl2, 0 °C, 3 h, 77%; c) tetracosanoic acid , TBTU, HOBt, NEt3, DMF, 4Å 
MS, rt, 18 h, 89%; d) H2, Pd (C), EtOAc, 50 °C, 2 h, 72%. 
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Structural elucidation was carried out on the building block 2.45(L/D) using 1H NMR 
and HR-MS spectrometry, and the 1H NMR values seemed to correlate to the values 
described in the literature for the desired product 2.45(L).[82] However, we 
observed a specific optical rotation value of 0 for the tetradecylamine aspartic acid 
derivative 2.45(L/D), which indicated that racemisation had occurred during the 
reaction. Although the combination of TBTU and HOBt in peptide coupling reactions 
is common place,[75] the activation of the α-carboxylic acid in the building block 2.41 
under these conditions is likely to increase the acidity of the α-proton, and it may 
be abstracted in the presence of a base such as NEt3. To the best of our knowledge, 
the racemisation of this common building block for peptide synthesis under the  
reaction conditions described above had not been explicitly described in the 
literature prior to our report.[83] In order to confirm that racemisation had occurred 
in this step using 1H NMR evidence, the benzyl ester in the racemised aspartic acid 
derivative 2.45(L/D) was deprotected with H2, Pd (C) in EtOAc to yield 97% of the 
carboxylic acid 2.48(L/D). This was then coupled with the galactosylamine 2.44 
using TBTU and HOBt to yield 59% of the N-Boc protected N-glycolipid 2.49(L/D) as 
a racemic mixture (Scheme 2.11).  
 
Scheme 2.11 Reagents and conditions. a) H2, Pd (C), EtOAc, rt, 18 h, 97%, b) TBTU, HOBt, 
DMF, 4Å MS, rt, 18 h, 59%. 
 
The racemisation now only became evident by 1H NMR spectrometry with the 
introduction of the chiral sugar moiety. The 1H NMR spectrum in Figure 2.8 shows 
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N-glycolipid 2.49(L/D) as a mixture of diastereoisomers, which confirms that 
racemisation has occurred. Duplication of the amide protons of the NHBoc 
protecting groups (5.7 and 6.2 ppm) was the clearest indication of this. Also, the 
signals corresponding to the β-protons (2.5 and 2.8 ppm) looked more complicated 
than expected for a single diastereoisomer of compound 2.49(L/D). A  mixture of 
diasteroisomers was much more clearly observed during the synthesis of a more 
flexible aspartic acid derivative 2.51(L/D) (Scheme 2.12), which was being 
undertaken in the Velasco-Torrijos laboratory,[83]  which was obtained from the 
racemised 2.41(L/D), thereby supporting the findings reported herein.  
Figure 2.8 
1H NMR spectrum of racemised N-glycolipid 2.49(L/D) showing duplication of 
certain signals. 
 
Chapter 2: Alkyl Glycolipids as Anti-Microbial Agents and Organogelators 
32 
 
 
Scheme 2.12 Reagents and conditions. a) TBTU, HOBt, NEt3, DMF, 4Å MS, N2, rt, 18 h.
[83]  
 
Song and colleagues recently found that an anomeric mixture of a series of O-
galactolipid derivatives were revealed to be more toxic against several cancer cell 
lines than their  single component with the pure α- or β-configuration.[84] Therefore, 
despite the problematic racemisation, the synthesis of the aspartic acid building 
block 2.23(L/D) (Scheme 2.13) was still desirable to compare the anti-microbial 
properties of the resulting mixture of diastereoisomers 2.23(L/D) to a single L-
diastereoisomer 2.23. The coupling of this derivative 2.40(L/D) with the galactosyl 
amine 2.44 using the TBTU/HOBt methodology using NEt3 in DMF was next 
performed (Scheme 2.13). However, none of the desired product 2.23(L/D) was 
formed, possibly due to the presence of the two long hydrocarbon chains in 
2.40(L/D). The 1H NMR spectrum showed a complicated and unidentifiable mixture 
of products. This approach was abandoned for this reason. 
 
 
Scheme 2.13 Reagents and conditionsa) TBTU, HOBt, NEt3, DMF, 4Å MS, N2, 18 h. 
 
2.8.2. Alternative method to form β-N-glycolipid 2.21- 2.23 
With these observations in mind, we carefully constructed an alternative synthetic 
approach in the quest to synthesise the various L-aspartic acid derivatives 2.21-
2.23. A retrosynthetic pathway was proposed as in Scheme 2.14. We chose to 
introduce the galactosyl moiety early on in the methodology to ensure a means of 
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observation (by NMR spectroscopy) whether racemisation had occurred. We also 
chose to perform the activation of the C-α in the absence of base to maintain the L-
configuration at the α-position of the L-aspartic acid derivatives 2.21-2.23. 
 
Scheme 2.14 Alternative retrosynthesis of β-N-glycolipid 2.21, 2.22 and 2.23 using 
galactosylamine 2.44 and L-aspartic acid derivative 2.52. 
 
The synthesis of the building block 2.53 described previously by Harrison and 
colleagues, was performed by reaction of the galactosyl amine 2.44 and the 
commercially available N-Boc-L-aspartic acid-1-benzyl ester 2.52 using TBTU/HOBT 
coupling conditions with DIPEA in DMF to yield 71% of the β-N-glycoside 2.53 
(Scheme 2.15).[85] Deprotection of the benzyl ester was performed by reaction with 
H2, Pd (C) in EtOAc at rt for 18 h to yield 81% of the crude carboxylic acid, which 
was reacted with tetradecylamine using TBTU/HOBt in DMF in the absence of base 
(to avoid racemisation). However, none of the desired β-N-glycolipid building block 
2.49 was obtained. Instead a novel cyclic by-product 2.54 (Figure 2.9) was obtained 
as a major product in the reaction (48%). The 1H NMR spectrum (Figure 2.9) of the  
product 2.54 with characteristic signals are highlighted including the H-2 proton 
with an unusually high chemical shift (6.1 ppm), the anomeric proton (5.5 ppm),  
the α-proton (4.2 ppm) and the β-protons (2.7 ppm – 3.2 ppm). The H-2 proton was 
found to resonate in a chemical environment typical for a succinimide product 
containing a carbamate group.[86] 13C NMR analysis, IR analysis and HR-MS 
confirmed its formation also. 
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Scheme 2.15 Reagents and conditions. a) TBTU, HOBt, DIPEA, DMF, 4Å MS, N2, rt, 18 h, 
71%; b) i) H2, Pd (C), EtOAc, rt, 18 h, 81%; ii) Tetradecylamine, HOBt, TBTU, DMF, rt, 4 h, 
48%.Desired glycoside 2.49 in step b was not isolated. 
Figure 2.9 
1H NMR spectrum of undesired succinimide product 2.54 with characteristic 
signals highlighted. 
 
It is well documented that L-aspartic acid derivatives are susceptible to cyclic imide 
formation through dehydration reactions so this cyclisation comes as no major 
surprise.[87] We hypothesise the formation of a thermodynamically favourable 5-
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membered ring could occur from the attack onto the activated carboxylic ester by 
the nucleophilic anomeric amide nitrogen atom, driven by the formation of the 
TBTU based leaving group. In order to combat this undesired cyclisation reaction, 
we changed the synthetic approach whereby we planned to functionalise the amino 
moiety with alkyl chains prior to functionalization of the carboxylic ester of building 
block 2.52 in the hope that it would discourage/minimise the cyclisation. 
2.8.3. Synthesis of N-glycolipid 2.21 
The revised synthesis of the novel L-aspartic acid derivative 2.21 proceeded 
smoothly, as shown in Scheme 2.16 .The synthesis began with the removal of the N-
Boc amine protecting group of the L-aspartic acid building block 2.53 under acidic 
conditions (TFA in CH2Cl2) to afford 74% of the free amine building block 2.55. A 
peptide coupling reaction of the free amine 2.55 (synthesised as described in 
section 2.8.1) with pre-activated decanoic acid with TBTU/HOBt, coupling 
conditions and DIPEA, gave the novel benzyl ester protected building block 2.56 in a  
yield of 54%. Reduction of the benzyl ester to give the free carboxylic acid by 
hydrogenolysis catalysed by Pd (C) afforded a yield of 61% of 2.57, which was used 
without further purification. A coupling reaction of acid 2.57 was performed using 
the TBTU/HOBt methodology in the absence of external base with tetradecylamine 
to give a 55% yield of the protected N-glycolipid 2.58. Finally, mildly basic cleavage 
of the acetyl protecting groups was performed with catalytic NEt3 in a homogenous 
solvent system (CH2Cl2/MeOH/H2O, 1:2:1) at 40 °C to yield the glycolipid 2.21 in a 
22% yield after 18 h. In order to push the reaction to completion, the remaining 
unreacted starting material was treated under the same conditions (NEt3 in 
CH2Cl2/MeOH/H2O). However, the reaction resulted in complete degradation of the 
starting material, with evident cleavage at the amide bonds as observed by 1H NMR 
spectroscopy. No further optimisations were performed to achieve higher yields of 
the N-glycolipid 2.21. 
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Scheme 2.16 Reagents and conditions. a) TFA, CH2Cl2, 0°C to rt,6 h, 74%; b)i) Decanoic acid, 
TBTU, HOBt, DIPEA, DMF, 4Å MS, N2, rt, 20 min ii) 2.55, 18 h, 54%; c) H2, Pd (C), EtOAc, rt, 3 
h, 61%; d) i)TBTU, HOBt, DMF, 4 Å MS, N2, rt, 30 min ii) Tetradecylamine, 3 h, 55%; e) NEt3, 
CH2Cl2/MeOH/H2O 1:2:1, 40 °C, 18 h, 22%. 
 
Structural elucidation of the acetyl protected glycolipid 2.58 was carried out with 1H 
NMR and 13C NMR spectrometry. Assignment of the signals was confirmed by 2D 
NMR (COSY, HSQC) experiments. The 1H NMR spectrum of glycolipid 2.58 (Figure 
2.10) clearly indicates only a single diastereoisomer 2.58 is present, corresponding 
to an L-configuration of the chiral center in the L-aspartic acid backbone. The 
characteristic signals belonging to the amide protons (NH(H-α), NH(C-1) and NHCH2 
at 7.6, 6.9 and 6.8 ppm respectively) are highlighted. Also highlighted are the 
signals corresponding to the H-α (4.8 ppm) and the methyl protons of the acetyl 
protecting groups (2-2.4 ppm). A signal present at 7.1 ppm (1: 0.1 desired N-
glycolipid 2.58: cyclised product 2.59) was indicative of the amide proton of a 
succinimide side-product 2.59 (Figure 2.11) which must have formed from 
intramolecular attack during the activation of the carboxylic acid 2.57, as discussed 
earlier. HR-MS confirmed its presence in the reaction mixture. 
Chapter 2: Alkyl Glycolipids as Anti-Microbial Agents and Organogelators 
37 
 
Figure 2.10 
1H NMR spectrum of acetyl protected N-glycolipid 2.58.  Characteristic signals 
are highlighted. 
 
O
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Figure 2.11 Structure of the undesired succinimide side-product 2.59. 
 
Structural elucidation was difficult to perform on the N-glycolipid 2.21 as the 
solubiliy of the final deprotected compound was poor in many organic solvents. 
After solubility tests in various different solvents, the N-glycolipid 2.21 was found to 
be partially soluble in Pyr. 1H NMR and 13C NMR analysis was performed in d6-Pyr. 
Structural elucidation was confirmed by HR-MS and IR spectrometry. The 1H NMR 
spectrum of the N-glycolipid 2.21 is shown in Figure 2.12. The characteristic signals 
are highlighted in the figure, including the proton signals of the amide protons (at 
10.1, 9.0, 8.5 ppm respectively), the anomeric proton (at 5.9 ppm) and the α-proton 
Chapter 2: Alkyl Glycolipids as Anti-Microbial Agents and Organogelators 
38 
 
(at 5.7 ppm). Fortunately, no signals corresponding to the deprotected cyclic 
product were observed, and this was confirmed by HR-MS.  
Figure 2.12 
1H NMR of N-glycolipid 2.21 in d6-Pyr. Characteristic signals are highlighted. 
 
2.8.4. Synthesis of N-glycolipid 2.22 
The construction of the hexadecanoyl derivative of L-aspartic acid 2.22 generally 
proceeded in a smooth fashion, with increased yields compared to the shorter 
chain N-glycolipid 2.21. The synthesis began with the reaction of the free amine 
2.55 (described in Section 2.8.3) with hexadecanoyl chloride to obtain a 42% yield 
of the building block 2.60 (Scheme 2.17). Hydrogenolysis of the benzyl ester with H2 
and Pd (C) allowed access to the carboxylic acid 2.61 in 86% yield, which was 
reacted with tetradecylamine with TBTU/ HOBT to afford the protected N-glycolipid 
2.62 in 98% yield. As discussed earlier in Section 2.8.3, a small signal at 7 ppm (1: 
0.2 ratio desired N-glycolipid 2.62: cyclic product), corresponding to a cyclic 
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succinimide side-product, was present in negligible amounts in the 1H NMR 
spectrum of the reaction mixture. 
 
Scheme 2.17 Reagents and conditions. a) Hexadecanoyl chloride, NEt3, CH2Cl2, 4Å MS, N2, 
rt, 18 h, 42%; b) H2, Pd (C), EtOAc, rt, 18 h, 86%; c) i) TBTU, HOBt, DMF, 4Å MS, N2, rt, 30 
min ii) tetradecylamine, 18 h, 98%; d) NEt3, CH2Cl2/MeOH/H2O 1:2:1, 40 °C, 18 h, 50%. 
 
Deprotection of the acetylated N-glycolipid 2.62 using NEt3 in CH2Cl2/MeOH/H2O 
afforded the novel β-N-glycolipid 2.22 as a white precipitate in a yield of 50%. 
Structural elucidation of the novel N-glycolipid 2.22 was carried out using 1H NMR 
and 13C NMR spectrometry. The assignment of the signals was confirmed by 2D 
NMR (COSY, HSQC) experiments.  The solubility of the deprotected N-glycolipid 2.22 
was limited in many organic solvents. 1H NMR and 13C NMR analysis was carried out 
in d6-Pyr. The 
1H NMR spectrum of β-N-glycolipid 2.22 is displayed in Figure 2.13. 
Possibly due to the limited solubility of the hexadecanoyl derivative N-glycolipid 
2.22 in d6-Pyr, the signals in the 
1H NMR spectrum are very broad.  Characteristic 
signals are evident in the spectrum, albeit the multiplicities of the signals were 
impossible to ascertain. No signals for the corresponding cyclisation side product 
were evident in the 1H NMR spectrum, and again this was confirmed by HR-MS 
spectrometry. 
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Figure 2.13 
1H NMR spectrum of N-glycolipid 2.22 in d6-Pyr. Characteristic signals are 
highlighted. 
 
2.8.5. Synthesis of N-glycolipid 2.23 
The novel tetracosanoyl derivative of L-aspartic acid 2.23, featured a long 
hydrocarbon (C24) acyl chain and was synthesised using very similar conditions to 
those used for the short acyl chain (C10) N-glycolipid 2.21 and medium chain (C16) 
derivative 2.22 (Scheme 2.18). Coupling of the free amine building block 2.55 with 
tetracosanoic acid using the TBTU/HOBt methodology afforded a yield of 42% of 
the desired compound 2.63 upon heating to 50 °C. The moderate yield was due to 
the poor solubility of the tetracosanoic acid in DMF. Deprotection of the benzyl 
ester of intermediate 2.63 afforded the carboxylic acid 2.64 in 55% yield, which was 
subsequently reacted with TBTU/ HOBT followed by tetradecylamine, to yield 45% 
of the acetylated N-glycolipid 2.65. As discussed previously (Sections 2.8.3 and 
2.8.4), a signal at 7 ppm (1: 0.4 desired N-glycolipid 2.65: cyclised product) was 
observed in the 1H NMR of N-glycolipid 2.65, indicating the formation of an 
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undesired intramolecular cyclisation product during the reaction of glycolipid 2.64, 
albeit in a small amount. Deprotection by mild basic conditions using NEt3 in a 
homogenous solvent system (CH2Cl2/MeOH/H2O, 1:2:1) was employed as in the 
previous cases (Sections 2.8.3 and 2.8.4) to afford the desired N-glycolipid 2.23 in 
79% yield.   
 
Scheme 2.18 Reagents and conditions. a) Tetracosanoic acid , TBTU, HOBt, DIPEA,DMF, 4Å 
MS, N2,50°C , 18 h, 42%; b) H2, Pd (C), EtOAc, rt, 18 h, 55%; c) i)TBTU, HOBt, DMF, 4Å MS, 
N2, rt, 20 min ii) Tetradecylamine, 18 h, 45%; d) NEt3, CH2Cl2/MeOH/H2O 1:2:1, 40 °C, 18 h, 
79%. 
 
Poor yields are prevalent in the synthesis of N-glycolipid 2.23 due to the poor 
solubility of the long C24 chain, with the notable exception of the deprotection step 
with the highest yield compared to the deacetylation of the L-aspartic acid 
derivatives 2.21 or 2.22. Again, this is attributed to the limited solubility of the N-
glycolipid 2.23; however, for this last step, this is advantageous. Structural 
elucidation of the final deprotected N-glycolipid 2.23 was extremely difficult for the 
same reasons. The precipitate 2.23 was partially soluble in d6-Pyr, which allowed 
1H 
NMR analysis to be carried out to confirm its structure. Figure 2.14 shows the 1H 
NMR of N-glycolipid 2.23. Characteristic signals include the amide proton at the 
anomeric centre (at 10.1 ppm), the amide proton of the α-carbon (at 9.0 ppm) and 
the amide proton linked to the tetradecyl alkyl chain (8.6 ppm). The signals in the 
1H NMR were assigned with the aid of a 2D COSY experiment. The solubility of N-
glycolipid 2.23 in d6-Pyr was so limited that it was not possible to carry out 
13C NMR 
spectrometry analysis or optical rotations. However, similarities in the 1H NMR 
spectrum to the shorter chain analogues 2.21 and 2.22 gave us sufficient evidence 
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that the desired compound was present, and this was further confirmed by HR-MS 
data.  
Figure 2.14 
1H NMR spectrum of N-glycolipid 2.23 in d6-Pyr. Characteristic signals are 
highlighted. 
 
2.9. Gelation and self-assembly properties of glycolipid 2.18, N-glycolipid 2.37, 
lipid 2.66, and L-aspartic acid N-glycolipids 2.58, 2.21 and 2.62 
The ability of a molecule to induce gelation in a certain solvent has wide 
applications in chemistry. These include their use as organic soft materials, drug 
delivery systems and water purification systems, to name but a few examples.[66-67] 
During the course of our research, we observed by chance that the L-aspartic acid 
derivative 2.62 formed a gel in certain organic solvents, and we recognised the 
potential applications of the N-glycolipid 2.62 to act as a LMWG. With this 
observation in mind, we decided to test the gelation abilities of a range of lipidic 
species such as compounds 2.18, 2.37, 2.66, 2.58, 2.21, 2.62 (Figure 2.15). This 
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group of diverse compounds were selected in order to investigate the structural 
features that may influence the ability to induce solvent gelation. All are 
amphiphilic in nature and they all feature the presence of  one or two saturated 
hydrocarbon chains, in which the length ranges from C8 (in compound 2.18) to C15 
(in compound 2.62). Other structural characteristics that may influence their 
behaviour as LMWG are the presence of aromatic groups, amide bonds or 
glycosidic moieties. For these reasons, an example of a simple glycolipid 2.18 
(described in Section 2.6), an aromatic containing N-glycolipid 2.37 (described in 
Section 2.7), a lipid derivative from N-Fmoc protected L-serine amino acid 2.66, 
with no carbohydrate head group (described in Chapter 4) and L-aspartic acid 
derivatives 2.58, 2.21 and 2.62 (described in Sections 2.8.3, 2.8.4, and 2.8.5) with 
increased hydrophobic characters were investigated. 
 
 
Figure 2.15 Structures of compounds 2.18, 2.37, 2.66, 2.58, 2.21 and 2.62 tested for gelling 
abilities in organic solvents. 
 
Gelation tests were performed using an “inverted test-tube method” as described 
by Tanake et al.[88] The glycolipids were placed in glass vials and the chosen solvent 
was added to give a concentration of 20 mg mL-1. The mixtures were heated in the 
chosen solvent, allowed to cool to rt and their ability to form a gel was analysed 
after 2 h. The gelation results are presented in Table 2.2. 
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Table 2.2 Gelation studies of lipid species 2.18, 2.37, 2.66, 2.58, 2.21, 2.62 in various                           
solvents in order of increasing polarity. 
 
S = soluble, pS =  partially soluble, I = insoluble, G = gel, A = aggregates. 
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No gelation was observed for the octyl-O-galactoside 2.18 or for the aromatic 
containing N-glycolipid 2.37 in any of the solvents quoted in Table 2.2. Both of 
these glycolipids have only one hydrocarbon chain, and neither of them features 
amide groups in their structure. The short chain C10 L-aspartic acid derivatives 2.58 
and 2.21, which have two hydrocarbon chains and peptide bonds in their structure, 
did not form a gel in any solvent either. However, gelation in MeOH and EtOH was 
observed for the C15 acetyl protected L-aspartic acid derivative 2.62. The minor 
difference between L-aspartic acid derivatives 2.62 and 2.58, varying by the length 
of one of the hydrocarbon chains, suggests the importance of Van der Waal 
interactions in a compound’s ability to act as a LMWG. In this case, the increased 
hydrocarbon content in 2.62 compared to 2.58 favours intermolecular assembly to 
form an organogelator. The lipidic amino acid derivative 2.66 also favourably 
formed a gel in toluene. 
For the L-aspartic acid derivative 2.62, the self-association behaviour was observed 
in some polar solvents: aggregates were formed in MeCN, but gelation only 
occurred in MeOH and EtOH. We were particularly excited about its gelation in 
EtOH, as EtOH is a biocompatible solvent and this result may open up the possibility 
for the use of this LMWG in drug-delivery systems. Images of the gels and 
aggregates formed through the self-assembly of L-aspartic acid derivative N-
glycolipid 2.62 in different solvents are illustrated in Figure 2.16. From these 
images, one can see aggregation occurring in MeCN and gelation in both MeOH and 
EtOH to give transparent gels. The formation of the LMWGs in MeOH and EtOH was 
found to be thermo-reversible, i.e. the gels turned into solutions upon heating and 
slowly reverted back into gels after cooling. The gel to sol transition temperatures 
(Tgs) were found to be 35 °C and 34 °C at 20 mg/mL concentrations, in EtOH and 
MeOH respectively. 
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Figure 2.16 Images of the gels and aggregates formed through the self-assembly of L-
aspartic acid derivative N-glycolipid 2.62 in a) MeCN (aggregates) b) MeOH (gel) and c)EtOH 
(gel). 
 
The critical gelation concentration (CGC) is defined as the threshold at which 
infinite percolation is achieved within a network system, although microgel network 
structures can still be observed below the CGC.[89] In simple terms it defines the 
point at which gelation can still occur for an organogelator in an excess of solvent. 
For the L-aspartic acid glycolipid derivative 2.62, the CGC in MeOH was quantified 
as the concentration at which the failure of the whole solvent to flow utilising the 
“inverted test tube method”, described above, was observed. The CGC value was 
found to be 20 mg mL-1. For the L-aspartic acid glycolipid derivative 2.62, the CGC in 
EtOH was found to give the same value of 20 mg mL-1. 
The self-assembly behaviour of the L-aspartic acid glycolipid derivative 2.62 in 
MeOH was investigated using FT-IR spectrometry. With this technique, we intended 
to probe the possibility that the formation of an intermolecular hydrogen-bonding 
network was implicated in the gelation process. In FT-IR spectrometry, differences 
in frequencies between solution and gel states can be attributed to differences in 
hydrogen-bonding patterns.[31b] The process involved the dissolution of the solid 
sample of glycolipid 2.62 in MeOH, followed by heating of the solution to 40 °C. FT-
IR analysis was then performed in real time as the MeOH gel was being formed 
MeCN (a) MeOH (b) EtOH (c) 
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(with deduction of the MeOH background). The FT-IR spectra are shown in Figure 
2.17. 
Figure 2.17 FT-IR spectra of LMWG 2.62 formation from solution to gel in MeOH. IR 
spectrum for LMWG 2.62 in solution phase is highlighted as spectrum a, while IR spectrum 
for LMWG 2.62 in gel phase is highlighted as spectrum f. The FT-IR measurements were 
performed over a period of 10 min, from 40 °C to rt. 
 
The wavenumber values of the functional groups of the glycolipid 2.62 in the gel 
phase (spectrum f) were compared to those of the glycolipid 2.62 in solution 
(spectrum a). Minor differences in the wavenumbers and in the intensity of the 
bands were observed. In the initial spectrum recorded (spectrum a), very weak 
bands are observed.  A difference was observed for the final spectrum (spectrum f) 
with three significant peaks.  The emergence of two broad N-H amide bands at 
3427 and 3182 cm-1 are indicative that the amide bonds may play a role in 
intermolecular hydrogen-bonding of the organogelator 2.62. Similarly, the carbonyl 
amide band at 1660 cm-1 in the solution phase (spectrum a) has increased in 
intensity and has slightly shifted to a lower frequency at 1654 cm-1 in the gel phase 
(spectrum f). This frequency shift indicates that hydrogen-bonding may play a role 
in the formation of the gel of 2.62 in MeOH.[90] It is more likely, due to the relatively 
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small shifts in frequency, that van der Waal interactions play a more dominant role 
in the formation of the network to support assembly of gel 2.62 in MeOH. A 
combination of these interactions is proposed. 
 
For the L-serine derivative 2.66, aggregates were formed in MeOH and hexane and 
gelation occurred only in toluene. Images of the self-assembled structures are 
shown in Figure 2.18. From these images, one can see aggregation occurring in 
MeOH, a polar protic solvent. More obvious to the naked eye is the aggregation in 
hexane and the gelling in toluene to give a clear gel; both solvents are non-polar. 
The formation of the gels in toluene induced by the self-assembly of the LMWG was 
found to be thermo-reversible with a gel to sol transition temperature (Tgs) of 38 °C. 
A CGC value of 10 mg mL-1 in toluene (measured as described earlier), was obtained 
for lipid 2.66. 
 
 
Figure 2.18 Images of the aggregates and gels formed through self-assembly of N-Fmoc-L-
serine tetradecyl 2.66 in a) hexane (aggregates), b) MeOH  (aggregates) and c) toluene 
(gel).  
 
The self-assembly behaviour of the LMWG 2.66 in toluene was investigated using 
FT-IR spectrometry, as performed for the L-aspartic acid derivative 2.62. The solid 
sample 2.66 was dissolved in toluene, heated and FT-IR analysis was performed in 
real time as the organogel was being formed (with deduction of the toluene 
background). The FT-IR spectra are shown in Figure 2.19. The wavenumbers of the 
bands corresponding to the different functional groups of lipid 2.66 in the gel state 
MeOH       
(b) 
Hexane     
(a) 
Toluene     
(c) 
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(spectrum f) were compared to those in solution state (spectrum a). Key differences 
in both the wavenumbers and the intensity of the bands were observed.  In the 
initial spectrum recorded (spectrum a), a broad band at 3474 cm-1 is representative 
of either the O-H stretching band or the N-H stretching band of lipid 2.66.  In the 
final spectrum recorded once the gel had formed (spectrum f), the band has shifted 
dramatically to a lower frequency to give a more intense band at 3392 cm-1. 
Similarly, the two bands in the initial spectrum (spectrum a) corresponding to the 
carbonyl amide (1681 cm-1) and the carbonyl carbamate (1727 cm-1), both shifted to 
lower frequencies to give more intense bands at 1662 and 1714 cm-1 respectively in 
the final spectrum (spectrum f). The amide II band at 1541 cm-1 in the initial 
spectrum has also been affected from the gelation and shifted to a lower frequency 
to 1534 cm-1. These changes indicate that hydrogen-bonding plays a role in the self-
assembly of L-serinyl compound 2.66 in toluene and that it occurs via the amide 
and carbamate functional groups and possibly through the free hydroxyl groups 
also.[31b] To investigate the potential role of the hydroxyl group of lipid 2.66 to act 
as a hydrogen-bond donor, we evaluated the gelation ability of its glycosylated 
product 2.67 (Figure 2.20). Details for the synthesis of glycolipid 2.67 will be 
discussed in Chapter 4. The “inverted test tube method” was performed as 
described above in toluene. No gel was formed in this case, indicating that the 
primary hydroxyl group may play an important role as hydrogen-bond donor in the 
self-assembly of L-serine derivative 2.66. It is likely also that π-π stacking 
interactions between the aromatic N-Fmoc carbamate groups in derivative 2.66 and 
toluene contribute to stabilise the supramolecular network that leads to the 
formation of the gel. 
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Figure 2.19 FT-IR spectra of LMWG 2.66 formation from solution to gel in toluene. IR 
spectrum for LMWG 2.66 in solution phase is highlighted as spectrum a, while IR spectrum 
for LMWG 2.66 in gel phase is highlighted as spectrum f. The FT-IR measurements were 
performed over a period of 5 min, from 40 °C to rt. 
 
O
NHFmoc
CONHC14H29
O
OBnBnO
BnO
BnO
2.67  
Figure 2.20. Structure of glycolipid 2.67 tested for organogelator properties in toluene. 
 
2.9.1. SEM imaging of N-glycolipid 2.62 and lipid 2.66 
Scanning Electron Microscopy (SEM) is a technique commonly employed to give 
information about a sample’s morphology. To gain a microscopic insight into the 
self-assembled structures 2.62 and 2.66 as LMWGs, the morphologies of galactosyl 
L-aspartic acid derivative 2.62 and L-serine derivative 2.66 were observed by SEM in 
the solid state (prior to gelation), as cryogels (obtained by the freeze-drying of the 
gels) and as xerogels (obtained by a drop casting method). The cryogels were 
obtained by prior formation of the toluene gel, as explained above, and the solvent 
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was removed by freeze-drying the sample.[91] The drop-cast technique involved 
heating of the LMWG in question in the gelling solvent, pipetting the solution onto 
a silicon wafer, and allowing the sample to evaporate at rt and atmospheric 
pressure.[92] The SEM micrographs were recorded at 8 kV. This low voltage ensured 
that the sample morphology remained intact during SEM imaging; however a trade-
off with the resolution of the SEM micrographs was incurred as a result. 
 
The SEM micrographs of a solid sample of L-aspartic acid derivative 2.62, obtained 
from rotary evaporation and the EtOH xerogel of 2.62 (prepared by the drop-cast 
method) appear in Figure 2.21. The surface of the solid sample of compound 2.62 
(Figure 2.21a) shows a rounded amorphous structure. The SEM micrograph for the 
drop-cast EtOH xerogel illustrated a different type of packing altogether (Figure 
2.21b,c).  The removal of the solvent in the gel revealed the network of thick 
bundles of the glycolipid 2.62 forming part of a “porous” structure. The cavities in 
which the solvent was entrapped in the gel can be clearly observed. The type of 
morphology shown in these images is consistent with those of xerogels obtained by 
similar methodologies described in the literature.[93] 
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Figure 2.21 SEM micrographs of a) solid sample of L-aspartic acid derivative 2.62; b) 
the EtOH xerogel of 2.62 from drop-cast method; c) magnification of the EtOH 
xerogel of 2.62 from drop-cast method. 
 
The SEM micrographs of a solid sample of L-serinyl derivative 2.66, the toluene 
cryogel and the toluene xerogel obtained by the drop-cast method (both prepared 
by forming a solution of 2.66 in toluene) appear in Figure 2.22. Quite a different 
surface morphology was observed for the solid sample of the lipid species 2.66, as 
compared to that of the solid sample of glycolipid 2.62, in that in this case none of 
the rounded structures described above were observed (Figure 2.21a). The SEM 
image for the toluene cryogel from 2.66 showed a dense and fragmented structure, 
which was most likely obtained from the collapse of the gel microstructure during 
the freeze-drying process (Figure 2.21b). A clear difference is illustrated in the SEM 
image of the drop-cast xerogel (Figure 2.21c,d) from toluene, compared to those of 
the EtOH xerogels from glycolipid 2.62 described earlier. The self-assembly of 
LMWG 2.66 in toluene results in a very compact three-dimensional network 
(a) (b) 
(c) 
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containing long thin fibrils that are woven tightly together in an ordered fashion 
(Figure 2.21c). These fibrils can further aggregate, forming highly entangled and 
thicker fibrous bundles and/or ribbons (Figure 2.21d). SEM micrographs of 
organogelators are commonly encountered as three dimensional fibrous networks, 
and our observations are in line with those reported.[93] 
 
 
Figure 2.22 SEM micrographs of a) solid L-serinyl derivative 2.66; b) toluene cryogel of 2.66 
c) toluene xerogel of 2.66 from drop-cast method; d) magnification of the toluene xerogel 
of 2.66 from drop-cast method . 
 
2.10. O-Glycolipid 2.19 and N-glycolipid 2.22 as anti-adhesion agents 
This section presents preliminary studies conducted by Dr. Ciara Wright (for the 
evaluation of glycolipid 2.19) and Ms. Lorna Abbey (for the evaluation of glycolipid 
2.22), in the laboratory of Dr. Siobhan McClean at the Institute of Technology 
Tallaght, Dublin. These studies aimed to investigate the potential for two 
representative glycolipids, such as O-glycolipid 2.19 and N-glycolipid 2.22, to inhibit 
the adhesion of strains of the pathogen Bcc to lung epithelial cells. 
Chapter 2: Alkyl Glycolipids as Anti-Microbial Agents and Organogelators 
54 
 
The anti-adhesion approach for O-glycolipid 2.19 was performed using a real-time 
PCR method, which was developed by Wright and colleagues to determine the 
attachment of B. multivorans (LMG13010) to lung epithelial cells and its subsequent 
inhibition with the synthetic glycolipid 2.19.[42, 94] One major problem encountered 
during the biological evaluation was the solubility of the long chain glycolipid 2.19, 
whereby it could not be fully solubilised in aqueous mixtures of DMF or DMSO. As a 
result, suspensions of glycolipid 2.19 were tested. The assays were performed on 
two separate batches of glycolipid 2.19 and repeated four times. Good 
reproducibility was reported, and two concentrations of the glycolipid (47 µM and 
90 µM) were tested. The results are presented in Figure 2.23. Attachment of the 
pathogen to epithelial cells in the absence of synthetic glycolipid 2.19 or 
monosaccharide was used as a control. Docosonol (the C22 alcohol) was not soluble 
in the above solvent mixtures and thus was not tested for its anti-microbial 
properties. From the data, we can conclude that glycolipid 2.19 does inhibit B. 
multivorans binding to lung epithelial cells. For example, at a concentration of 47 
µM, bacterial adhesion has reduced to 70% (compared to 100% for control). At a 
higher concentration of 90 µM, bacterial binding has reduced to 50%, a significant 
improvement (compared to 100% for control). This pronounced inhibition of the 
attachment was not observed in the presence of the monosaccharide alone (D-
galactose). 
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Figure 2.23 Study of inhibition of the attachement of B. multivorans to lung epithelial cells 
by O-glycolipid 2.19 and D-galactose. The results are presented from four independent 
experiments on two separate batches of O-glycolipid 2.19. 
 
A different technique was used for the biological evaluation of N-glycolipid 2.22. 
The anti-adhesion approach for the L-aspartic acid derivative 2.22 was investigated 
on a specific strain of Bcc, Burkholderia multivoran (LMG13010) on cells extracted 
from immuno-compromised CF patients using a colony counting technique. 
Epithelial cells incubated with a bacterial strain were used as a control. The bacteria 
were pre-treated with the N-glycolipid 2.22 and the inhibition of the bacterial 
adhesion to the epithelial cells was evaluated. The results are presented in Figure 
2.24. It was shown that the Bcc strain (LMG13010) adhesion to the epithelial cell 
was significantly reduced by treatment of the cells with the N-glycolipid 2.22 at 
higher concentrations (250 µM). Initially, at a concentration of 5 µM, the N-
glycolipid 2.22 seemed to aid in the bacterial adhesion, presumably by acting as a 
“bridge” between bacteria and host cell, an observation previously reported in the 
literature.[42, 95] At a higher concentration (250 µM), the N-glycolipid 2.22 inhibited 
the bacterial adhesion to the epithelial cell, with a 40% adhesion (compared to 
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100% of for control). This dramatic decrease in binding supports the hypothesis that 
the bacteria binds to the epithelial cell by a carbohydrate-protein interaction 
(described in Section 2.2); we can postulate that the free carbohydrates (N-
glycolipid 2.22) binds to the bacteria and renders the bacteria inactive to adhesion 
to the epithelial cell. 
 
Figure 2.24 Bacterial adhesion of Burkholderia cenocepacia (LMG13010) to lung epithelial 
cell upon treatment with N-glycolipid 2.22. 
2.11. Summary 
We described the successful syntheses of the O-glycolipids 2.18 and 2.19 using the 
Koenigs Knorr methodology. The solubility of the precursors and products proved to 
be the most challenging tasks. We completed the synthesis of an aromatic 
containing N-glycolipid 2.20 using a CuAAC cycloaddition reaction with little 
problems. Three enantiomerically pure L-aspartic acid derivatives 2.21-2.23 were 
successfully constructed, despite the initial problem of racemisation that occurred 
in the synthesis of the building block 2.45 (Section 2.8.1). Careful considerations 
and modifications in the synthetic sequence had to be taken into account, to 
preserve the optical purity of these N-aspartic acid derivatives. Undesired 
succinimide side products were also problematic in the synthetic strategies. 
However precipitation of the final N-glycolipids 2.21, 2.22 and 2.23 alleviated this 
problem.  
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The amphiphilic properties of various different lipid species were probed and 
gelling studies were performed. We found that the L-serinyl derivative 2.66 and the 
L-aspartic acid derivative 2.62 acted as LMWGs, with potential biological 
applications as drug delivery vehicles or in material science.  The self-assembly of 
these novel LMWGs leading to the formation of gels was investigated with the aid 
of FT-IR and SEM. We believe that the formation of EtOH and MeOH gels, induced 
by the self-assembly of 2.62 occurs primarily due to Van der Waal intermolecular 
interactions between the hydrophobic chains.  Hydrogen-bonding does not seem to 
be prevalent in these competitive solvents, as suggested by the FT-IR data obtained. 
On the other hand, intermolecular hydrogen-bonding may be a more determinant 
factor in driving the self-assembly of L-serinyllipid 2.66 in toluene, together with 
aromatic stacking interactions. Morphological studies performed on xerogels of 
these organogelators by SEM indicated their self-assembly patterns were very 
different to one another, whereby the L-aspartic acid derivative 2.62 displayed a 
more porous structure and the L-serinyl derivative 2.66 displayed dense three 
dimensional fibrous networks. 
Two representative glycolipids were selected for preliminary evaluation of the 
potential of this type of compounds as anti-microbial agents. An anti-adhesionl 
assay was performed on the O-glycolipid 2.19 using a PCR method and from the 
resulting data we can conclude that glycolipid 2.19 does inhibit B. multivorans 
binding to lung epithelial cells, although the poor solubility of the compound limited 
its further applications. A colony counting technique was employed to study the 
anti-adhesion properties of L-aspartic acid N-glycolipid 2.22 and preliminary results 
suggest it too inhibits bacterial binding to lung epithelial cells, albeit at 
concentrations higher than 100 µM. Our ultimate intention is to perform the anti-
adhesion assays on the other glycolipids 2.18 and 2.20 and the N-glycolipid 2.21 
mentioned in this chapter. 
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3.1. Introduction 
This chapter presents work conducted by the author over a 6 month period in the 
laboratory of Assoc. Prof. Spencer Williams at the University of Melbourne, 
Australia, supported by an Endeavour Fellowship in 2010.  
Tuberculosis (TB) is a disease that has infected one-third of the world’s 
population.[96] 2-3 million people develop active disease each year. Co-infection 
with human immunodeficiency virus (HIV) and the emergence of multi-drug 
resistant TB have brought this infectious disease to the attention of the medical and 
scientific research communities.  
3.2. Current tuberculosis treatment 
Current first-line treatments for TB involve the administration of multiple drugs, 
which consist of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), ethambutol 
(EMB) and streptomycin (SM).[97] Each anti-TB drug operates by different modes of 
action. For example, INH is a prodrug that disrupts the synthesis of the cell wall of 
the bacterium,[97] and RIF inhibits prokaryotic RNA synthesis (Figure 3.1).[97] 
Unfortunately, improper use or mismanaged treatments of this regimen can result 
in multidrug resistant tuberculosis (MDR-TB). Staggeringly, it has been reported 
that 500,000 cases of MDR-TB occur globally per annum.[97] Many of these reported 
cases involve patients with TB and HIV coinfection; the combination of which 
results in high fatality rates. Extensively drug-resistant tuberculosis (XDR-TB) is a 
form of TB that is resistant to both first and second line drugs currently used in the 
treatment of TB. The emergence of XDR-TB is attributed to the mismanagement of 
individuals with MDR-TB,[96] and only limited treatments are currently available for 
XDR-TB.[98] Totally drug resistant tuberculosis (TDR-TB) is a form of TB that is 
incurable. It was first identified in Italy, subsequently in Iran[99] and more recently in 
India.[99] It is again accredited to the misuse of first and second line drugs, and thus 
remains one of the most pressing problems in TB control today.  
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Figure 3.1 Structures of isoniazid (INH),  rifampicin (RIF), pyrazinamide (PZA), ethambutol 
(EMB) and streptomycin (SM): current first line treatment for TB.[97] 
 
As a consequence of drug resistance, the urgency and need for alternative drugs is 
evident. Promising drug candidates include a 1,2-ethyldiamine derivative SQ109,[100] 
which exhibited activity against drug-resistant strains of M. tuberculosis,  OPC-
67683,[101] a nitro-dihydro-imidazooxazole derivative  exhibiting a bioactivity similar 
to first-line drug RIF, PA-824, another nitroimidazooxazole which is believed to act 
as an intracellular NO donor[102] and a diarylquinoline TMC207,[103] whose clinical 
activity validates ATP synthase as a viable target for the treatment of tuberculosis. 
The structures of these promising drug candidates are presented in Figure 3.2. 
 
Figure 3.2 Promising drug candidates SQ109, OPC-67683, PA-824 and TMC207.[100-103] 
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3.3. Mycobacterial cell wall associated glycolipids  
Mycobacterium tuberculosis is the causative agent of TB in humans. M. tuberculosis 
possesses a unique and complex, multi-layered cell wall structure containing 
macromolecules of peptidoglycan, arabinogalactan and mycolic acids along with the 
membrane-associated lipids phosphatidyl-myo-inositol mannosides (PIMs), 
lipomannan (LM) and lipoaribinomannan (LAM). The structure of the cell wall 
complex is a major determinant of virulence for the bacterium; the structurally- 
related PIMs, LM and LAM play crucial roles in this virulence and are hence 
potential drug targets. As well, numerous studies have been devoted to the 
immunoregulatory effects of these glycolipids.[104] Glycolipids based on D-glucuronic 
acid termed Gl-A and Gl-X (Figure 3.3) have been isolated from C. glutamicum, a 
non-pathogenic bacterium phylogenetically related to M. tuberculosis.[12],[105] These 
glycolipids form the core of glycolipids termed Gl-LM that are closely related to the 
phosphoglycolipids LM which possess a PI core (sometimes termed PI-LM). 
Compared to the PIMs, LM and LAM, little is understood of the biosynthesis and 
immunological properties of these glycolipids. The lack of availability of these 
natural products makes it difficult to study their biological activity.  
 
Figure 3.3 Structure of Gl-A (C16:0/C18:1), and Gl-X (C16:0/C18:1) isolated from C. glutamicum 
iv 
                                                            
iv C16:0 /C18:1 refers to the glycerol having palmityl (C16:0) and olely (C18:1) residues at the sn-1 
and sn-2 positions respectively. For the palimtoyl residue, the 16 represents the number of 
carbon atoms in the lipid chain and the 0 represents the degrees of unsaturation in the 
lipid. 
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3.4. PIMs, LM and LAM  
PIMs, LM and LAM are found in the majority of bacteria from the 
Corynebacterineae family, including M. tuberculosis. Structural similarities of PIMs, 
LM and LAM are evident; PIM is the common anchor motif of LM and LAM, both of 
which are derived from the same biosynthetic pathway. The basic structure of 
phosphatidyl-myo-inositol mannosides (PIMs) consists of an acylated phosphatidyl-
myo-inositol (PI) anchor extended by α(1→6)- or α(1→2)-linked D-Manp units,v with 
further elongation at the C-6 position with D-Manp residues (Figure 3.4). They range 
from monomannosylated (PIM1) to hexamannosylated (PIM6) sugars with varying 
acylation patterns. The main fatty acids are palmitic (C16) and tuberculostearic acids 
(C19); however myristic (C14) and octadecanoic acids (C18) are also present in 
significant amounts.[106]  
 
Figure 3.4 General schematic of PIM1-6 (R, R’ = acyl chains, R” = 0-5 D-Manp residues), LM 
(R, R’ = acyl chains, R” = approx. 40 D-Manp residues), LAM (R, R’ = acyl chains, R” = approx. 
40 residues of D-Manp and approx. 70 residues of D-Araf).vi 
 
LM contain a PIM backbone elongated with α(1→6)-linear and single α(1→2)-
branched D-Manp residues. LAM contains the LM backbone and is further 
elaborated  with up to 70 highly branched D-Araf residues.[104a] Additional variability 
in the LAM structures arises from “capping” of the non-reducing termini of the 
arabinan core with D-Manp residues.[107] Although the chemical structures of PIMs, 
LM and LAM are well established, the enzymes and sequence of events leading to 
their biosynthesis and regulation remains incomplete. Scheme 3.1 provides an 
overview of the biosynthesis of these lipoglycans in M. smegmatis, a fast-growing 
                                                                                                                                                                            
 
v D-Manp  indicates D-mannopyranose and D-Araf indicates D-arabinofuranose. 
vi Details of arabinan attachments are unknown to date. 
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non-pathogenic mycobacterium that is often used as a model for M. 
tuberculosis.[108]  
 
Scheme 3.1 Metabolic pathway of PIMs, LM and LAM in M. smegmatis.[108]  vii,viii,ix,x 
3.5. Introduction to Gl-X, Gl-A, Gl-LM  
Drugs such as isoniazid and ethambutol operate by altering/modifying the bacterial 
cell wall composition of M. tuberculosis, the causative agent of TB, which results in 
the death of the bacteria. Whether Gl-X and Gl-A glycolipids are present in M. 
tuberculosis is of interest to scientists, whereby the understanding of their bacterial 
                                                            
vii Illustration procured from Morita and co-workers is edited by authors. 
viii The blue and pink areas indicate reactions taking place in different membrane 
compartments, respectively. 
ix Numbers next to some of the molecules indicate the cellular abundance in molecules per 
cell. 
x Sites of mannose and arabinan branches on LM/LAM are unknown.  
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cell wall roles, if any, may aid in the understanding of TB and the developments of 
novel drugs.  
 
Biochemical analyses performed by Tatituri and co-workers suggest that a novel 
glycolipid termed Gl-X (diacylglyceryl α-D-mannopyranosyl-1,4-α-D-glucuronoside) 
serves as an alternative glycolipid core to LM-like molecules in C. glutamicum.[12] 
Gene knockout studies in C. glutamicum revealed that  disruption of a specific gene 
NCg10452 (MgtA; formally known as PimB) had no effect on LAM levels or the 
biosynthesis of AcPIM2 (Scheme 3.1).
[12] Instead, loss of glycolipid Gl-X was 
observed. In addition, there was an accumulation of a glycolipid precursor to Gl-X, 
termed Gl-A which lacks the mannosyl residue (Figure 3.3). The absence of Gl-X led 
to a reduction in LM, a result that suggests that Gl-X is a biosynthetic precursor to 
LM-like molecules. As a result of these findings, the authors reassigned NCg10452 
as MgtA, an α-mannosyl-glucopyranosyluronic acid-transferase that catalyses the 
formation of Gl-X from Gl-A.  
 
Similar findings were reported for C. glutamicum by Lea-Smith and co-workers.[109] 
Deletion of the gene NCg12106 from C. glutamicum revealed a reduction in AcPIM2 
with a concomitant accumulation of AcPIM1, but had no effect on Gl-X. As 
expected, the pool of LAM was reduced as a direct result, but, surprisingly, the LM 
pool remained unaffected. Additional studies on this knock-out strain were 
performed by Mishra.[110] Collectively, these studies indicated that, in C. 
glutamicum, LM is assembled from two cores: a minor one assembled on a PI core 
that extends to LAM (called PI-LM) and a major one assembled on a Gl-A core 
(called Gl-LM).[110]  
 
Gl-A and Gl-X have not been identified in M. tuberculosis; however there is 
evidence that the biosynthetic machinery required for their biosynthesis is present. 
The orthologous genes mgtA, mptA and mptB in M. tuberculosis complemented the 
production of LM in C. glutamicum, which demonstrates their existence in 
functional form in M. tuberculosis.[105] Two Gl-A isoforms have been isolated from 
M. smegmatis,[111] a related bacterial species of the Corynebacternia family. The 
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structures were proposed to contain tuberculostearic acid (C19:0) and oleic acid 
(C18:1) at the sn-1 position and palmitic acid (C16:0) at the sn-2 position (Figure 3.5). 
Based on these findings, and those reported by Mishra,[110] a proposed biosynthetic 
pathway for Gl-LM from diacyl glycerol in M.tuberculosis is presented in Scheme 
3.2. 
 
Figure 3.5 Structures of Gl-A isoform (C19:0/C16:0) and isoform (C18:1/C16:0) isolated from M. 
smegmatis.
[111]
 
 
 
Scheme 3.2 Proposed biosynthetic pathway of Gl-LM in M. tuberculosis. 
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3.5.1. Biological function of Gl-X, Gl-A, Gl-LM  
The antigenicity of purified Gl-A was studied by Wolucka and co-workers.[111] They 
observed purified Gl-A bound to anti-M. avium and anti-M. tuberculosis rabbit sera 
by western blot-type TLC. Recently, synthetic Gl-A (C19:0/C16:0) was shown to 
stimulate a novel subtype of NKT cell in a CD1d dependent manner.[14] Gl-A loaded 
CD1d tetramer were selective for Vα10 NKT over the canonical Vα14 NKT cell and 
induced a dose dependent cytokine response biased towards TH2 cytokines 
(cytokines are discussed in detail in Chapter 4). Importantly the authors also 
demonstrated that the lipid composition and position of the glycerol was essential 
for bio-activity, as the regioisomeric variant iso-Gl-A (C16:0/C19:0) and a desmethyl 
analogue nor-Gl-A (C18:0/C16:0) were less active.  
 
The potency of GI-LM and PI-LM were investigated by Mishra and colleagues to 
stimulate the release of TNF-α using a human macrophage line.[112] Interestingly Gl-
LM was found to be as stimulatory as the PI-anchored LM. This evidence suggested 
that the PI moiety does not play a key role in lipoglycan pro-inflammatory activity. 
To the best of our knowledge, no known immunological studies have been carried 
out on Gl-X. 
3.6. Research objective 
Study of the immunological properties and biosynthesis of the structurally-complex 
Gl-X is hindered due to limited sources of the natural product. We aimed to 
undertake the synthesis of Gl-X analogue 3.1 as a synthetic model for the natural 
product Gl-X isolated from C. glutamicum (Figure 3.6). The targeted Gl-X analogue 
3.1 contains two important features present in the Gl-X molecule: i) a 1→4-α-D-
Manp linkage to a glucuronic acid residue, and ii) an α-D-GlcAp xi linkage to a 
dipalmitoyl glycerol moiety. The difference to the natural glycolipid is the 
replacement of the unsaturated alkyl chain by a saturated alkyl chain (Figure 3.6). 
The ultimate aim was to develop a synthesis of these compounds and to examine 
                                                            
xi D-GlcAp indicates D-glucopyranosuronic acid. 
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their biochemical properties in cell free assays in C. glutamicum. We hoped that 
these biochemical studies would allow understanding of the role of Gl-X in C. 
glutamicum, which in turn may give an insight into its potential role in TB, if present 
in M. tuberculosis.  
 
Figure 3.6 Structure of Gl-X analogue 3.1 (C16:0/C19:0). 
3.7. Design of Gl-X analogue 3.1 
The synthetic strategy to the target Gl-X analogue 3.1 (Figure 3.6) involved careful 
considerations: a suitable method for constructing a difficult α-glucosidic linkage 
and the use of protecting groups that could be removed in the presence of benzyl 
esters in the desired product. Of special concern was the timing for the introduction 
of the acid functionality, and as glucuronsyl donors are known to exhibit poor 
reactivity, the acid functionality was to be introduced post-glycosylation. The 
building blocks for the synthesis of the Gl-X analogue 3.1 are illustrated in Figure 
3.7. In building block 3.2, the ester protecting group at the C-2 position allows 
neighbouring group participation to afford a 1,2-trans mannoside linkage. Building 
block 3.3 is designed to serve as a glycosyl donor for intramolecular aglycon 
delivery (IAD; described in detail in Section 3.7.2) to provide a 1,2-cis-glucosidic 
linkage for the synthesis of glycolipid 3.1. As well, the careful choice of the 4-
bromobenzylidene group provides a means for accessing the C-6 position (by a 
regioselective reduction) for subsequent oxidation to the carboxylate group, and 
concomitantly installing a 4-O-(4-bromobenzyl) (PBB) ether, which can be removed 
in a two-step approach in the presence of unsubstituted benzyl ethers. Building 
block 3.4 acts as a glycosyl acceptor for the IAD glycosylation reaction with building 
block 3.3. 
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Figure 3.7 Proposed synthons for the synthesis of Gl-X analogue 3.1. 
 
A retrosynthetic pathway is proposed in Scheme 3.3. A selective deacylation of C-2’ 
and C-6 acetyl groups of glycolipid 3.5 in the presence of the diacylglycerol liberates 
the free hydroxyl groups, whilst maintaining the ester linkage of the diacylglycerol. 
Selective oxidation of the primary alcohol in the presence of the secondary alcohol 
using TEMPO, followed by global debenzylation allows the formation of the 
glycolipid 3.1. Reaction of the mannosyl trichloroacetimidate 3.2 (bearing an acetyl 
group at the C-2 position to allow neighbouring group participation) with the 
glycosyl acceptor 3.6 stereoselectively forms a 1,2-trans linkage as in glycolipid 3.5. 
Acetylation of the C-6 hydroxyl group on glyolipid 3.7, followed by PBB 
deprotection (whereby PBB can be removed by conversion to an p-aminobenzyl 
group via a Pd-mediated amination reaction followed by oxidation)[113] affords the 
desired glycosyl acceptor 3.6.  
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Scheme 3.3 Proposed synthetic pathway of Gl-X analogue 3.1. 
 
 
Regioselective ring-opening of the 4,6-p-bromobenzylidene group of glycolipid 3.8 
liberates a free hydroxyl group at the C-6 position, whilst the C-4 position is 
protected as a PBB ether as in glycoside 3.7. The glycolipid 3.8 is formed by 
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protection of the hydroxyl group by a Williamson ether synthesis of glycoside 3.9, 
followed by acidic cleavage of the isopropylidene protecting group and subsequent 
coupling to fatty esters. Since we considered the α-selective coupling of the D-
glucose residue 3.3 to the suitably protected sn-glycerolxii moiety 3.4 to be the most 
challenging glycosylation in the synthesis, the approach was designed where this 
linkage was constructed early in the synthesis (or late in the retrosynthesis). 
Thioglycoside 3.3 was designed to enable a 1,2-cis-glucosidic linkage using IAD 
methodologies. The p-methoxybenzyl (PMB) group at the C-2 position of this 
glycosyl donor 3.3 can be oxidatively coupled (DDQ) to the glycosyl acceptor 3.4 in 
the presence of the 4,6-p-bromobenzylidene group to produce the desired 1,2-cis 
linkage in glycoside 3.9 with a free hydroxyl group at the C-2 position.  
 
3.7.1. Synthesis of α-mannosyl donor 3.2  
Schmidt and coworker’s introduced glycosyl trichloroacetimidates, which are robust 
glycosyl donors suitable for glycosylation reactions of a wide variety of glycosyl 
acceptors (discussed in more detail in Chapter 4).[114] The glycosyl donor 3.2 was 
readily prepared following a literature procedure (Scheme 3.4).[115] 
 
 
Scheme 3.4 Reagents and conditions. a) i) catalytic H2SO4, Ac2O, 0 °C to rt, 3 h, 84% ii) 
HBr/AcOH, 0 °C to rt, 18 h, 92%, α-anomer b) py/ MeOH 2:1, rt,18 h, 57% c) i) NaOMe, 
MeOH, 1 h ii) NaH, BnBr, DMF, 0 °C to rt, N2,18 h, quant. d) HOAc, rt,18 h, 85% e) NCCCl3, 
DBU, CH2Cl2, 0 °C to rt, N2, 2.5 h, 58%, α-anomer. 
 
                                                            
xii
 the prefix 'sn' (for stereospecifically numbered) is used for glycerol to indicate it’s 
prochiral stereochemistry. 
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Acetylation of D-mannose by treatment with Ac2O and catalytic H2SO4 yielded the α-
anomer as the major product.[116] Anomeric bromination using 33% HBr/AcOH 
afforded the mannosyl bromide 3.11 exclusively as the α-anomer (88% over two 
steps). The α-stereoselectivity is attributed to the anomeric effect.[69] The mannosyl 
bromide 3.11 was treated with Pyr/MeOH mixture to afford the glycosyl 
orthoacetate 3.12 as a mixture of diastereoisomers (1:4 endo/exo) in a 57% yield. 
The proposed reaction mechanism for the formation of the orthoester 3.12 is 
shown in Scheme 3.5. Nucleophilic participation by the neighbouring acetyl group 
(discussed in Chapter 2) forms a dioxolenium ion, which is attacked at the  
electrophilic carbon by MeOH to form the orthoester 3.12.[69]  
 
Scheme 3.5 Mechanism for the formation of orthoacetate 3.12.[69]  
 
Deacetylation of 3.12 under standard Zemplén conditions followed by a Williamson 
ether synthesis afforded the benzyl orthoacetate 3.13 in quantitative yield (Scheme 
3.4). The orthoacetate group was cleaved using AcOH to afford the mannosyl 
hemiacetal 3.14 in 85% yield. Treatment of the mannosyl hemiacetal 3.14 with 
trichloroacetonitrile in the presence of catalytic DBU yielded the α-mannosyl donor 
3.2 in 58% yield. Characterisation of the trichloroacetimidate 3.2 was performed 
with the aid of 1H NMR data, which was in agreement with data reported in the 
literature.[115]  
3.7.2. Intramolecular Aglycon Delivery 
Controlling the stereochemical outcome of a glycosylation reaction is one of the 
most challenging tasks for carbohydrate chemists (discussed in detail in Chapter 2). 
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Intramolecular aglycon delivery (IAD) is an elegant approach designed to 
stereoselectively produce 1,2-cis glycosyl linkages (especially for β-mannosides) via 
a three-step process .[117] First, the glycosyl donor 3.16 and acceptor are tethered 
together in such a manner to allow for 1,2-cis delivery of the tethered acceptor 
(Scheme 3.6).[117a] Second, the glycosylation is performed by activation of the 
glycosyl donor. Finally, hydrolysis of the protecting group at the C-2 position of the 
1,2-cis glycoside intermediate affords the C-2 hydroxy 1,2-cis glycoside 3.17. In 
most cases steps 2 and 3 are combined, with the residual group at the C-2 position 
being cleaved during the glycosylation itself or workup.  
 
Scheme 3.6 The intramolecular aglycon delivery concept for the formation of 1,2-cis 
linkages in a glucopyranoside 3.17 involves tethering, activation, 1,2-cis aglycon delivery 
and hydrolysis.[117a]  
 
Barresi and Hindsgaul pioneered the concept of IAD.[118] They utilised an acid-
catalysed tethering approach from thioglycoside 3.18 to produce the mixed acetal 
3.19 that was activated and hydrolysed to form the 1,2-cis-β-mannoside 3.20 
(Scheme 3.7). Later, Stork introduced silicon-tethered IAD approaches.[119] Stork 
utilised the thiomannoside 3.21 to tether alcohol acceptors derived from 
dimethychlorolsilyl ethers (Scheme 3.8).[119] Oxidation of the anomeric substituent 
to give the glycosyl sulfoxide followed by glycosylation using Kahne’s conditions 
(Tf2O and DTBMP) afforded the intramolecular β-mannosides 3.22 and 3.23 in 
excellent yields.[120] 
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Scheme 3.7 Barresi and Hindsgaul IAD approach utilising acid-catalysed acetal tethering, 
glycosylation and hydrolysis to give 1,2-cis mannopyranoside 3.20.[119] 
 
Scheme 3.8 Examples of Stork’s silicon tethered IAD approach to produce 1,2-cis 
mannopyranosides 3.22 and 3.23.[119] 
 
Perhaps the most useful IAD approach involves an oxidative tethering introduced by 
Ogawa and Ito,[121] which is best explained using a mechanism proposed by their 
team (Scheme 3.9) .[122] This approach involves the tethering of the 2-O-PMB or 2-
O-naphthylmethyl ether of a glycosyl donor (fluoride or thioglycoside) such as 
glycoside 3.24 to an acceptor using DDQ in CH2Cl2 to produce a mixed acetal 
intermediate 3.25. Subsequent activation of the donor initiates the transfer of the 
tethered acceptor at the C-2 position of the glycosyl donor to the anomeric position 
to stereoselectively produce 1,2-cis-products after hydrolysis, such as the 
diasaccharide 3.26. Two distinct advantages lie in their method. First, the highly-
efficient oxidative tethering ensures there is no need for chromatographic 
separation of the mixed acetal intermediate. Second, good overall yields (40% to 
74%) and stereoselectivities were reported for both primary and secondary 
alcohols, indicating that a diverse range of acceptors could be used. Subsequent 
work carried out by Ito and Ogawa involved the use of thioglycosides as donors in 
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place of glycosyl fluorides, presumably due to the difficulties in controlling/curbing 
the highly reactive nature of glycosyl fluorides.[123]  
 
Scheme 3.9 Reaction mechanism proposed by Ogawa and Ito for IAD through 4-
methoxybenzylidene-tethered intermediate to give desired product 3.26.[122] 
 
3.7.3. Synthesis of Glycosyl Donor 3.3 for Intramolecular Aglycon Delivery 
As discussed earlier (Section 3.7), the glycosyl donor 3.3 was designed with 
orthogonality in mind, enabling the selective cleavage of certain groups in the 
presence of others (Scheme 3.3). Commercially-available diacetone glucose 3.27 
was chosen as the starting material for the synthesis of glycosyl donor 3.3 due to 
the accessibility of a free hydroxy group in the C-3 position (Scheme 3.10). This 
would subsequently allow for selective PMB protection of the C-2 position in the 
sequence. Benzylation of the diacetone glucose 3.27 afforded 3-O-benzyl diacetone 
glucose 3.28 in quantitative yield. Treatment of furanoside 3.28 with strongly acidic 
Dowex ion exchange resin (H+ form) at 70 °C resulted in hydrolysis of the acetonide 
protecting groups and simultaneous reversion to the more thermodynamically-
stable pyranose form, giving 3-O-benzyl-D-glucopyranose. The crude glycoside was 
acetylated using Ac2O and catalytic DMAP in Pyr to give the tetra-O-acetylated 
glucoside 3.29 as the β-anomer with a yield of 89% over two steps. The tetraacetate 
3.29 was reacted with butanethiol and BF3.OEt2 to afford the thioglucoside 3.30 in a 
yield of 75%. Next, thioglycoside 3.30 was treated with catalytic Na metal in MeOH 
to give a triol intermediate, which was subsequently treated with p-
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bromobenzylaldehyde dimethyl acetal and catalytic p-TsOH to afford the p-
bromobenzylidene thioglucoside 3.31 in 88% (over two steps). The synthesis of 
glycosyl donor 3.3 was completed by treating glycoside 3.31 with NaH and p-
methoxybenzyl bromide in a Williamson ether synthesis to yield the glycosyl donor 
3.3 in 88%.  
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Scheme 3.10 Reagents and conditions a) NaH, BnBr, 0 °C to rt, quant. b) i) Dowex 50WX2-
400 (H+ form), H2O, 70 °C ii) cat. DMAP, Ac2O, Pyr, rt, 89% (2 steps) c) BuSH, BF3.OEt2, rt, 
75% d) i) cat. Na, MeOH ii) bromobenzyaldehyde dimethyl acetal, p-TsOH, MeCN, 88% (2 
steps) e) NaH, PMBBr, DMF, 88%. 
 
Thioglycosides are versatile glycosyl donors (discussed in Chapter 4). They are 
stable to a range of chemical transformations.[69] In the current scheme, the early 
introduction of the thioglycoside allows for further protecting group manipulations 
on the sugar that may not be possible with other anomeric substituents. The 
thioglycoside substituent also allows for a subsequent IAD glycosylation. To suit the 
criteria needed to design the glycolipid 3.1 (Scheme 3.3), the anomeric substituents 
of the glycosyl donor must be applicable to IAD and be orthogonal to the overall 
synthesis. These criteria are not met by other potential anomeric substituents, such 
as trichloroacetimidates or fluorides. Also worth noting is the choice of the 
anomeric substituent. We chose to use SBu in our synthetic methodology in place 
of the more commonly utilised SMe substituent more commonly used in oxidative 
IAD.[123a, 123c] This action was taken to avoid the use of methanethiol as a starting 
material as it has an unpleasant odour relative to butanethiol. As well, it should be 
noted that arylthioglycosides have not been reported in IAD glycosylations, and it 
would appear that their reactivity it too low to be of use with the mild promoters 
used for IAD reactions. 
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As outlined in the synthetic strategy our route requires a means of accessing the C-
4 position of the glucoside 3.3 for glycosylation with the mannosyl donor 3.2. 
Benzylidene acetals can be ring opened to generate either 4-OH or 6-OH derivatives 
through careful choice of reagents. Garegg and co-workers were the first to report 
a regioselective ring opening of a benzylidene group to give the free C-4 hydoxyl 
product using a NaCNBH3-HCl system.
[124] The same group later reported the use of 
a borane-Lewis acid combination (BH3.NMe3-AlCl3) to yield the desired C-4 hydroxyl 
product. What they found was that the reaction was solvent dependent; the 
desired regioselectivity was observed in THF, however the free C-6 hydroxyl 
product was formed in toluene or CH2Cl2/ether solvent systems.
[125] Mechanistic 
studies exploring the regiochemical outcome of benzylidene protected sugars was 
carried out by Johnsson and colleagues.[126] They propose that the regioselectivity 
that results in C-4 hydroxyl products is determined by the formation of an initial 
complex with the borane, activated by the Lewis acid in THF. This is converted into 
an oxocarbenium ion, which is reduced to give the free C-4 hydroxyl product. In the 
same publication, stereoelectronic effects were observed by competition studies 
using 1:1 mixtures of a benzylidene sugar and a p-bromobenzylidene sugar. They 
noted a weak influence in acetal cleavage outcome from the electron-withdrawing 
group on the p-bromobenzylidene, but no change in regioselectivity. Incidentally, 
the use of cyclic protected groups (such as benzylidene or p-bromobenzylidene) on 
glycosyl donors have also been reported to increase the glycosylation yields in 
oxidative IAD reactions.[123a, 123c] It is believed that the increased rigidity of the 
system encourages an SN2-like reaction to occur. As such, the choice of the p-
bromobenzylidene protecting group serves many purposes in the synthesis of 
donor 3.3.  
 
Characterisation and assignment of the protons of the novel glycosyl donor 3.3 was 
achieved with a combination of 1H NMR data, 13C NMR, 2D NMR data and EI-MS. A 
section of the 1H NMR is shown below as a representative example (Figure 3.8). The 
conversion of the glycoside 3.31 into the desired glycosyl donor 3.3 involves the 
introduction of an PMB group into the structure. One defining feature of this new 
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substituent that indicates its presence in the glycosyl donor structure 3.3 is the 
appearance of a characteristic singlet at  3.8 ppm (3 H) representing the methyl 
protons of the PMB group. Signals corresponding to the methylene protons and the 
aromatic moiety of the PMB protecting group appear in regions of the 1H NMR 
spectrum where significant overlap occurs with other signals. Important signals 
confirming the structure of glycosyl donor 3.3 include the anomeric proton at 4.53 
ppm (d, J = 9.8 Hz, 1 H, H-1) and the benzylidene proton at 5.52 ppm (s, 1 H, 
CHArBr). Similarly, in the 13C NMR, diagnostic signals which correspond to the 
coupling of the PMB substituent are present at 55.27 ppm (ArOCH3) and 76.75 ppm 
(OCH2ArOMe) including additional aromatic signals. HR-MS confirmed the m/z ratio 
of the glycosyl donor 3.3. 
Figure 3.8 Section of 1H NMR spectrum of glycosyl donor 3.3 for IAD. Characteristic signals 
are highlighted. 
 
3.7.4. Initial Attempts at Intramolecular Aglycon Delivery Glycosylation 
For the oxidative tethering and subsequent glycosylation, the procedure set out by 
Bertozzi and co-workers was followed.[127] Under an inert atmosphere, the glycosyl 
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donor 3.3 and acceptor 3.4 were reacted with DDQ (freshly recrystallized from 
toluene) for 18 h in anhydrous CH2Cl2 containing 4Å MS to oxidatively tether the 
glycosyl acceptor 3.4 and the glycosyl donor 3.3 (Scheme 3.11). TLC analysis 
indicated the slow consumption of glycosyl donor 3.3 (over the 18 h period) and a 
corresponding appearance of a more polar product. No difference was observed at 
18 h compared to 16 h with regard to consumption of the starting material and was 
therefore quenched. 
 
Scheme 3.11 Attempted oxidative IAD conditions for formation of 1,2-cis product 3.9. 
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Scheme 3.12 Reagents and conditions a) DTBMP, MeOTf, DCE, 0 °C to rt, <10%. 
 
The reaction was quenched with ascorbate buffer and extracted. The mixed acetal 
3.34 was treated with MeOTf in the presence of DTBMP (which is added to diminish 
hydrolysis side-reactions) and allowed to stand for 18 h. A complicated mixture of 
products was evident from TLC analysis. The crude 1H NMR analysis of the reaction 
mixture indicated the consumption of the glycosyl donor 3.3. Flash column 
chromatography afforded the acetonide 3.35 (< 10% yield) along with a 
complicated mixture of unidentifiable compounds (Scheme 3.12), with no clear 
signs of formation of 1,2-cis-β-glucoside 3.9 (Scheme 3.11). The 1H NMR spectrum 
of side product 3.35 appears in Figure 3.9. Diagnostic signals are highlighted; these 
signals and others verify the structure of the side product 3.35.  
 
A proposed mechanism for the formation of acetonide 3.35 is outlined in Scheme 
3.13. The mechanism is based on the following assumptions: i) DDQ has fully 
oxidised the PMB group to give the free hydroxyl group at the C-2 position, ii) 
nucleophilic attack by water under Lewis acid conditions (MeOTf) has resulted in a 
free hydroxyl group at the anomeric position, and iii) ring opening of the p-
bromobenzylidene group has occurred under acidic conditions to give the benzyl 
protected sugar 3.36, which has free hydroxyl groups at the C-1, C-2, C-4 and C-6 
positions. The mechanism is based on the fact that 1,2-O-isopropylidene glycerol 
3.4 can undergo migration under acidic conditions that, in turn, can cause 
epimerisation of the glycerol.[128]  Under acidic conditions, the acetonide of the 
protected sn-glycerol 3.4 can ring open to give an oxocarbenium intermediate. One 
of the free hydroxyl groups on the sugar 3.36 can attack the electrophilic carbonyl 
to form a mixed acetal. Under acidic treatment, the sn-1 hydroxy of the glycerol can 
be protonated; the second carbenium intermediate can be formed with the 
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displacement of glycerol. The hydroxyl at the C-4 position of the sugar can then 
capture the oxocarbenium ion, which results in acetonide protection at the 4,6-
positions of the glycoside. By a similar mechanism, 1,2-acetonide transfer can occur 
to result in the 1,2:4,6-diacetonide 3.35.  
 
 
Scheme 3.13 Proposed mechanism for formation of isolated side product 3.35. 
In order to achieve glycosylation products with high yields, isopropylidene 
migration from the aglycon must be prevented. The difficulties associated with 
isopropylidene migration can be avoided with the use of different protecting groups 
on the aglycon such as silyl ethers or benzyl ethers. A new strategy was therefore 
sought to synthesise a suitable aglycon, one that may not undergo isopropylidene 
migration and also, one that will be reactive enough to undergo IAD. 
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Figure 3.9 1H NMR spectrum of IAD side product 3.35. Characteristic signals are highlighted. 
 
3.7.5. Investigations into Alternative Aglycons for their use in Intramolecular 
Aglycon Delivery  
The buildings blocks 3.36, 3.37 and 3.38 were investigated for their use as 
alternative glycosyl acceptors in IAD (Scheme 3.14). These building blocks were to 
be synthesised from 1,3:4,6-di-O-benzylidene mannitol 3.39, which can be obtained 
from D-mannitol. With a view to maintaining orthogonality in the synthesis of Gl-X 
analogue 3.1 (Figure 3.7), the most suitable glycosyl acceptor is sn-glycerol 
derivative 3.36 because the hydroxyl groups are protected as tert-butyldiphenylsilyl 
(TBDPS) protecting groups. These protecting groups are orthogonal to both the 
PMB and p-bromobenzylidene groups functional groups present on the glycosyl 
donor 3.3. 
Chapter 3: Synthesis of Gl-X based glycolipid for biochemical evaluation 
82 
 
 
Scheme 3.14 Suitable sn-glyercol derivatives 3.36, 3.37 and 3.38 synthesised from D-
mannitol derivative 3.39 for IAD glycosylation reaction. 
 
An attempt to synthesise sn-glycerol derivative 3.36 was undertaken as in Scheme 
3.15. 1,3:4,6-Di-O-benzylidene mannitol 3.39 was synthesised by a colleague from 
D-mannitol and benzaldeyde catalysed by H2SO4 in DMF, and purified by 
recrystallisation. Silylation of the secondary alcohols on sn-glycerol derivative 3.39 
with TBDPSCl using imidazole in DMF proceeded smoothly to give 3.40 in a yield of 
82%. Attempts at benzylidene hydrolysis to give the tetraol 3.41 failed under acidic 
conditions (HCl or TFA). Similarly, the hydrolysis did not proceed using pyridinium 4-
toluenesulfonate, a weak acid catalyst that is  commonly used to deprotect 
tetrahydropyran protecting groups.[129] Alternatively an approach involving 
regioselective oxidative cleavage of the bis-benzylidene acetals was attempted.[130] 
The D-mannitol derivative 3.40 was treated with KBrO3 and Na2S2O4 in a biphasic 
system of EtOAc/H2O to yield the diol 3.42 in a yield of 34%. The isolated yield of 
the desired regioisomer 3.42 was lower than the 88% yield reported by 
Senthilkumar et al. under the same reaction conditions.[130] The formation of the 
regioisomer 3.45 (Figure 3.10) was not observed in our work, despite its reported 
isolation by Senthilkumar et al.[130] Another inconsistency was the isolation of the 
mixed diol 3.46 (19%), which was not observed by Senthilkumar et al. (Figure 3.10). 
Silylation of the primary alcohols of D-mannitol derivative 3.42 using TBDPSCl and 
imidazole afforded 51% of the protected D-mannitol derivative 3.43. Surprisingly, 
standard Zemplén conditions (NaOMe) failed to remove the benzoate ester groups 
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to give silyl protected D-mannitol derivative 3.44. The synthetic methodology was 
abandoned owing to a limited time frame. 
 
Scheme 3.15 Reagents and conditions. a) Imidazole, TBDPSCl, DMF, 0 °C to 50 °C, 82%; b) 
KBrO3, Na2S2O4, EtOAc, H2O, 34%; c) imidazole, TBDPSCl, DMF, 0 °C to rt, 51%; d) cat. Na 
metal, MeOH. 
 
 
Figure 3.10 Potential side products 3.45 and 3.46 using Sentkilkumar regioselective ring 
opening reaction.[130] 
 
The PBB protected sn-glycerol 3.37 (Scheme 3.14) is not a suitable substrate for an 
IAD reaction with glycosyl donor 3.3. Deprotection of the p-bromobenzyl ether 
group of the intermediate glycoside for subsequent reaction with Schmidt’s 
trichloroacetimidate 3.2 would result in simultaneous cleavage of the PBB ether on 
the sn-glycerol backbone. However, to obtain a potential indication of the IAD 
approach for an α-selective sn-glycerol glycosylation, it was decided to pursue the 
synthesis of the aglycon 3.37. The synthesis of the PBB protected glycerol 3.37 is 
shown in Scheme 3.16. An approach previously executed in the laboratory was 
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pursued, whereby 1,3:4,6-di-O-benzylidene D-mannitol 3.39 was etherified with p-
bromobenzyl bromide using NaH in DMF, to give derivative 3.47 in a yield of 88%. 
Hydrolysis of the benzylidene protecting groups, in contrast to the attempted 
hydrolysis in the synthesis of the silyl protected glycerol 3.41 (Scheme 3.15), was 
successful. Treatment of the PBB-protected D-mannitol derivative 3.47 with 4 N HCl 
in EtOH afforded the tetraol 3.48 in 79% yield. Silylation of the primary alcohols of 
tetraol 3.48 with TBDPSCl and imidazole in DMF smoothly proceeded in 91% yield 
to give the cis diol 3.49. The cis diol 3.49 then underwent oxidative cleavage with 
NaIO4 to give an aldehyde intermediate that was subsequently reduced with NaBH4 
to afford the PBB-protected glycerol 3.37 in 62% yield (over two steps). 
 
O O
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OH OO
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OH O O
Ph
PBBO OO
Ph
OPBB
TBDPSO OH
PBBO OTBDPSOH
OPBB TBDPSO OH
OPBB
a b
c
3.39 3.47 3.48
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d
OH OH
PBBO OHOH
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HO OTBDPS
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Scheme 3.16 Reagents and conditions. a) NaH, p-BrBnBr, DMF, 0 °C to rt, 88%; b)4 N HCl, 
EtOH, 79%; c) Imidazole, TPDPSCl, DMF, 0 °C to rt, 93%; d) i) NaIO4, THF/H2O 4 :1 ii) NaBH4, 
EtOH/H2O 9:1, 62%. 
 
An IAD reaction was attempted using the glycoside 3.3 and PBB glycerol acceptor 
3.37 (Scheme 3.17) using the reaction conditions described earlier in Scheme 3.11. 
After 18 h, neither the acceptor 3.37 nor the donor 3.3 were fully consumed in the 
reaction based on TLC analysis. However, it was quenched because the reaction did 
not seem to progress further after 6 h. Formation of a new product was observed 
by TLC analysis, which was presumably the mixed acetal. After workup, activation of 
the thioalkyl group of the mixed acetal product was attempted using MeOTf and 
afforded a complicated mixture of products. Disappointingly, none of the desired 
1,2-cis product 3.50 was isolated. Only the diol 3.51 was isolated in a 10% yield. 
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Scheme 3.17 Reagents and conditions. a) i) DDQ, CH2Cl2, 4Å MS, rt b) DTBMP, 4Å MS 
,CH2Cl2, MeOTf, 0 °C to 45 °C, 10%. Desired glycoside 3.50 is highlighted. 
As a final attempt to demonstrate a successful IAD reaction using the glycosyl donor 
3.3, the PBB protected glycerol derivative 3.38 (Scheme 3.14) was considered. This 
glycerol derivative contains only robust PBB groups at the sn-1 and sn-2 positions of 
sn-glycerol. The proposed synthesis is shown in Scheme 3.18. Dibutyltin oxide can 
be used to form O-stannylene acetals on polyfunctional molecules containing 
vicinal and 1,3-diol systems. Subsequent regioselective alkylations/acylations at the 
stannylenated oxygen atoms have successfully been employed in many 
syntheses.[131] A rationale for the regioselectivity seen in alkylations is as follows. 
The oxygen atoms of the corresponding stannylene acetals are more nucleophilic 
than the other hydroxyl groups in the molecule owing to donation of electron 
density to oxygen. Secondly, addition of excess soluble halide shorten reaction 
times of stannylene acetal reactions from sluggish (3-4 days) reactions to tolerable 
(18 h) reactions.[131] The halide ions are believed to break up polymeric aggregates 
of the stannylene acetals and results in the formation of halide coordinated 
monomers or dimers. In these monomers, the oxygen atoms of the cis-diol function 
typically adopt apical and equatorial positions with respect to the coordinating tin 
atom, which adopts a trigonal bipyramidal geometry. Typically, primary oxygen 
atoms in a 1,2- or 1,3-diol occupy the apical position, which is more electron rich 
owing to electron channelling in the complex to the apical positions; thus, a 
selective alkylation/acylation can occur at this position. A regioselective 
stannylation of the primary alcohols in the tetraol 3.48 (previously synthesised in 
Scheme 3.16) was attempted using dibutyltinoxide in refluxing toluene, using a 
Dean-Stark apparatus for the continuous removal of water, to produce a 
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coordinated  dibutyltin acetal as in O-stannylene acetal 3.52 (Scheme 3.18). The 
stannylene acetal presumably formed was reacted in situ with excess BrBnBr and 
TBAB, and the reaction mixture was heated to reflux at 18 h. The formation of the 
p-bromobenzylated species 3.55 (Figure 3.11) together with the fact that none of 
compound 3.38 was isolated, strongly indicated a failure in this approach from the 
polyol 3.48 (Scheme 3.18).  
 
Scheme 3.18 Reagents and conditions. a) i) Bu2SnO, toluene, reflux ii) BrBnBr, TBAB, 
toluene, reflux b) 2,2-dimethoxypropane,p-TsOH, rt. 
 
 
Figure 3.11 Undesired side products 3.55 and 3.56 in synthesis of desired sn-glycerol  
derivative 3.38. 
 
Reaction of a polyol containing several different hydroxyl groups with an aldehyde 
or ketone under acidic conditions result in the formation of cyclic acetals. Generally, 
ketones (or dimethyl acetals) preferentially form 5-membered rings due to 
thermodynamic factors (unfavourable diaxial interactions in the 6-membered cyclic 
acetal), whereas aldehydes preferentially form 6-membered rings (previously 
discussed in Section 2.7.3). In addition, if the two hydroxyl groups are cis to one 
another, they are more likely to form an acetonide as too much ring strain exists in 
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an alternative trans configuration. Thus, in theory, selective protection of certain 
hydroxyl groups can be achieved. A reaction of D-mannitol derivative 3.48 with 2,2-
dimethoxypropane in p-TsOH was attempted (Scheme 3.18). Compound 3.54 was 
not isolated; instead complicated mixtures of products were observed. However 
the compound 3.56 (Figure 3.11) was isolated and its structure was identified by 1H 
NMR and 13C NMR. Due to the unfavourable results achieved to date in our 
syntheses, along with unfavourable IAD results reported in the laboratory using 
glycerol acceptors, the IAD approach to Gl-X was abandoned. 
3.8. Summary 
The successful syntheses of Schmidt’s trichloroacetimidate 3.2, the novel IAD 
glycosyl donor 3.3 and the glycosyl acceptor 3.4 for the synthesis of Gl-X analogue 
3.1 was described (Figure 3.7). We report unsuccessful IAD glycosylation reactions 
with glycosyl donor 3.3 and acceptors 3.4 and 3.37 and discussed various attempts 
to synthesise glycosyl acceptors from D-mannitol derivatives suitable for the IAD 
approach. The difficulties associated with the IAD approach and problems arising 
from incompatible protecting group strategies were highlighted. Time constraints 
did not allow the completion of this project, however subsequent efforts in the 
laboratory led to the overall synthesis of Gl-A (a precursor to Gl-X) and its analogues 
from M. smegmatis by halide ion catalysis using glycosyl iodides.[132] It is hoped that 
Gl-X will be synthesised by similiar methods in the future within the laboratory. 
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4.1. Introduction 
4.1.1. Immunological functions of iNKT cells 
Natural killer T (NKT) cells are a sublineage of T cells that share properties of both T 
lymphocytes and Natural Killer (NK) cells.[133] Vα14i NKT cells are the most 
abundant NKT cells in mice; they express an invariant TCRα chain (iTCRα chain) with 
Vα14-Jα18 rearrangement. Humans have a similar population that mostly expresses 
an invariant Vα24-Jα18 rearrangement (Vα24i NKT cells). Collectively, these 
populations are referred to as iNKT cells.[134] In vivo activation of iNKT cells involves 
the binding of a binary complex formed by the loading of an antigen (such as 
KRN7000) onto the CD1d protein to the iNKT cell  (Scheme 4.1).[135] Cytokines are 
released as a result and depending on the different types and amounts of cytokines 
released, different immunological responces are induced. 
 
 
Scheme 4.1 The immunological function of iNKT cells: presentation of CD1d-antigen binary 
complex to iNKT cell produces a ternary complex, which results in secretion of different 
types of cytokines to elicit different immunological effects.[135] 
 
The CD1d is a member of the CD1 family, along with four other isoforms termed 
Cd1a, CD1b, CD1c and CD1e. These proteins present lipidic antigens to NKT cells.[136] 
Upon binding, a rapid secretion of cytokines will take place. Cytokines are small cell-
signalling proteins that are secreted by numerous cells; they are used extensively in 
intercellular communication.  A variety of cytokine types can be produced,[137] but 
only T helper 1(TH1) and T helper 2(TH2) will be discussed in the context of this 
thesis. Pro-inflammatory cytokines (such as IFN-γ, IL-2) characterise a TH1 type 
response and are implicated in the treatment of tumours, bacterial and viral 
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infections.[22, 133a, 135] The release of immunomodulatory cytokines (IL-4, IL-5) leads 
to a TH2 type response; a role for these TH2 cytokines has been reported in the 
management of autoimmune disesases.[22]  
 
4.1.2. KRN7000 
Agelasphin-9b was isolated from the extract of a marine sponge called Agelas 
Mauritanus in 1993, and this glycosphingolipid was found to exhibit anti-tumour 
and immunostimulatory properties.[138] KRN7000 (or commonly termed α-GalCer) 
was developed soon after by researchers at Kirin Brewery Co., following structure-
activity relationship studies on agelasphins.[21] The structures of KRN7000 and 
agelasphin-9b are depicted in Figure 4.1. 
 
 
Figure 4.1 Structure of KRN7000 and agelasphin-9b.[21] 
KRN7000 was identified as a ligand for iNKT cells, and in pre-clinical trials, it 
exhibited anti-tumour properties in mice inoculated with B16 melonoma or EL-4 
lymphoma.[4] Not alone did they successfully achieve a relatively high rate of cured 
mice, but these mice were resistant to subsequent tumour challenge, indicating 
immune memory.[139] Phase 1 clinical trials were undertaken on 24 patients 
suffering from refractory solid tumours.[139] It was observed that the effects of 
KRN7000 on patients seemed to be reliant on their expression levels of iNKT cells, 
which was later confirmed by Kawano and colleagues in mice studies.[140] Many of 
the patients tested in the clinical trials had low levels of iNKT cells prior to testing, 
indicating that the number of iNKT cells could be a marker for tumour activity. As a 
result, no partial or complete tumour responses were observed in this trial and 
clinical trials were terminated. Several clinical trials have been conducted since 
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using a combination of KRN7000 and dendritic cells (DC) and more promising results 
have ensued.[141] Of special consideration also is that KRN7000 produces both TH1 
and TH2 responses upon presentation to iNKT cells. The biological effects of the TH2 
response (immunosuppressant) can counteract the desired TH1 response 
(proinflammatory) in cancer treatments. This accounts for another plausible reason 
why KRN7000 has not reached the marketplace as a suitable drug candidate for 
tumour treatment. Analogues of KRN7000 which could bias either response 
prompted an interest in the scientific community. Some of these examples will be 
discussed in Section 4.2. 
A breakthrough in the understanding of the immunological functions of KRN7000 
occurred when X-ray crystal structures of the human CD1d antigen presenting 
protein and the  CD1d-KRN7000 binary complex were obtained (Figure 4.2).[142] 
From the X-ray crystal structure of the CD1d-KRN7000 complex, it was discerned 
that the protein contained two large hydrophobic pockets (A’ and C’) which 
accommodated the alkyl chains of KRN7000. The hydrogen-bond network was 
elucidated, whereby the hydroxyl groups on the sugar moiety (except the hydroxyl 
group at the C-6 position) and the hydroxyl groups on the ceramide moiety were 
participating in hydrogen-bonding with the amino acid residues in the CD1d protein. 
It has been proposed that the affinity of antigens for CD1d contributes to the robust 
immunological response they produce. It has been proposed that the more stable 
the binary complex, the more bias towards a TH1 response and, conversely, the less 
stable the complex, the more bias towards a TH2 response.
[22, 143] Therefore the 
synthesis of analogues of KRN7000 which can stabilise/destabilise the binary 
complex has been a challenge for many chemists. 
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Figure 4.2 Antigen binding and recognition of KRN7000 in CD1d. (a) Side view 
of bound KRN7000. The hydrophobic antigen-binding groove, with pockets 
labeled A’ and C’ is gray; KRN7000 is orange; residues of CD1d are blue. (b) Hydrogen-
bonds between residues of CD1d and KRN7000.[142] 
 
4.2. KRN7000 Analogues 
Since its discovery, numerous analogues of KRN7000 have been synthesised with a 
view that structural alterations will tune the stability of the CD1d-antigen binary 
complex. Biological evaluations have been performed, with varying success.[22, 144] 
The main sites for modifications in KRN7000 are highlighted in Figure 4.3, and 
representative examples will be discussed in the following sections. These include i) 
variations at the anomeric centre including β-anomeric linked, S- and C-glycolipid 
analogues; ii) changes at the polar head group such as the use of glucose or 
functionalization at different positions on the carbohydrate; iii)  functionalization’s 
to the ceramide moiety including changes at the stereocentres and variations in the 
length of the alkyl chains and/or different degrees of saturation, or by introducing 
different functional groups in the chains, like aromatic groups. Some striking 
modifications (with increased/ decreased TH1 or TH2 bias compared to KRN7000) 
will be discussed in more detail in the following section. 
Chapter 4: Synthesis of L-serinyl based glycolipid  analogues of the immunostimulant 
KRN7000 
93 
 
 
Figure 4.3 Different types of modifications on KRN7000. 
 
4.2.1. Sugar modifications on O-glycoside analogues of KRN7000 
Variations to the carbohydrate residue have been investigated, and some have 
shown biased cytokine production. While it is well known that α-D-
mannosylceramide and β-D-galactosylceramide exhibit no immunological effects to 
date in the context of iNKT cell activation, α-D-glucosylceramide was reported to 
have similar bioactivities  to α-D-galactosylceramide (KRN7000) by Kawano and 
colleagues.[145] These immunogenic results were in line with affinity studies of the 
glycolipid/CD1d binary complex for the TCR on an iNKT cell.[146] It has recently been 
shown that β-D-mannosylceramide induced strong protection against cancer 
metastasis and it was reported to act in an iNKT cell-dependent manner, opening a 
window of opportunity for synthesis of a range of mannopyranosyl analogues of 
KRN7000.[147] The immunogenic properties of KRN7000 analogues bearing 
alternative glycosyl moieties to galactopyranosides have been met with limited 
success. Despite showing promising bioactivities, no examples of sugar modified O-
glycoside analogues display superior anti-tumour/autoimmune properties to 
KRN7000 to the best of our knowledge, thus cementing the importance of the 
galactose head group in the quest to synthesise a more efficient KRN7000 
analogue. Several analogues have been described in which modifications on the 
different positions of the D-galactose moiety have been performed. Some of the 
Configuration and nature 
of anomeric linkages Ceramide moiety functionalization 
Length and 
saturation 
of lipid 
chains 
Amide functionalization 
Polar head group modification 
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compounds were obtained by replacement of the hydroxyl groups on the sugar 
with other functional groups, indicated as R1, R2, R3 and R4 are shown in Table 4.1.  
 
Table 4.1 KRN7000 analogues obtained by substitutions on the sugar moiety KRN7000. 
+ in vivo test on mice; m in vitro test on mice cells; h in vitro test on human cells. 
In vitro studies on mice iNKT cells  performed with KRN7000 analogues, with 
replacement of the hydroxyl group at R1 with fluorine or methoxy substituents 
resulted in a complete loss of bioactivity compared to KRN7000 (Entries 1, 2 in 
Table 4.1), with no iNKT cell activation reported for either glycolipid.[148] 
Substitution at the R2 position of the galactose moiety resulted in a decreased iNKT 
cell activation compared to KRN7000 (Entry 3 in Table 4.1).[145]  
Modifications at the R4 position of the sugar moiety lead to interesting 
immunogenic results. The replacement of the hydroxyl group with an aromatic 
moiety (Entry 4 in Table 4.1) gave a slight bias towards a TH1 response compared to 
KRN7000,[149] presumably because of favourable aromatic π-π stacking occurring 
between the glycolipid and the Trp153 amino acid residue of the CD1d protein, 
Entry R1 R2 R3 R4 Activity compared to KRN7000 Ref.
1 F OH OH CH2OH No i NKT cell activation
m [147a]
2 OMe OH OH CH2OH No i NKT cell activation
m [147b]
3 OH OH CH2OH
 decreased i NKT cell            
activation m
[144]
4 OH OH OH Increased TH1 bias 
m+ [148]
5 OH OH OH COOH Increased TH1 bias m+,h [149]
6 OH OH OH CH2OMe Increased TH1 bias 
m+ [150]
7 OH OH OH Increased TH2 bias 
m+ [151]
Chapter 4: Synthesis of L-serinyl based glycolipid  analogues of the immunostimulant 
KRN7000 
95 
 
stabilising the ternary complex. Similarly, a good TH1 bias was reported for the 
replacement of the C-6 hydroxyl group with either a carboxylic acid [150] or a 
methoxy substituent (Entries 5 and 6  in Table 4.1).[151] Perhaps these results are 
not surprising since the crystallographic studies discussed earlier (Section 4.1.2.) 
showed that the C-6 hydroxyl group did not participate in hydrogen-bonding. The 
introduction of an amide functionality at the R4 position (Entry 7 in Table 4.1) 
resulted in an unexpected TH2 bias compared to KRN7000.
[152] As the biological 
process of iNKT cell activation is very intricate and many of the molecular details 
are yet to be understood, it is unknown precisely how the TH2 bias occurs in this 
situation.  The increased water solubility of the PEG glycolipid may play a role in the 
bioavailability of the antigen, in agreement with what was reported for other TH2 
ligands.[22] These reports seem to indicate functionalization at the C-6 position (R4) 
is superior to analogues with functionalizations at the other positions of the 
glycosyl moiety to date.  
4.2.2. Modifications on the ceramide backbone of the O-glycoside analogues of 
KRN7000 
As the hydroxyl groups on the ceramide moiety were found to be involved  in the 
hydrogen-bond network of the CD1d-KRN7000 binary complex, according to X-ray 
crystallographic studies,[142] modifications of these functional groups would have a 
significant influence on the stabilisation/destabilisation of the binary complex, 
which in turn may lead to improved bias towards either TH1 or TH2 responses. 
Structure-activity relationship studies have been carried out in this regard and the 
structure of some of these analogues are shown in Table 4.2. 
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Table 4.2. KRN7000 analogues obtained by modifications to the ceramide backbone. 
m in vitro test on mice cells; m+ in vivo test on mice; h in vitro tests on human cells. 
 
Unsurprisingly perhaps, the removal of the hydroxyl groups at the X and Y positions 
(Entry 1 in Table 4.2) and replacement with methylene groups (with no hydrogen-
bond donation ability) resulted in a complete loss of iNKT cell activation ability.[153] 
Park and colleagues carried out biostudies on stereoisomers of KRN7000.[154] They 
found that changing the stereochemistry at the 4’ position (Entry 2 in Table 4.2) had 
little or no effect on the TH1 bias compared to KRN7000. However, a dramatic loss 
of iNKT cell activation activity was reported with an inversion of stereochemistry at 
the 2’ position (Entry 3 in Table 4.2). Trappenier and co-workers focused on the 
replacement of hydroxyl groups with amines, and compared these analogues with 
their stereoisomers (Entries 4-7 in Table 4.2).[155] The biological effects were 
evaluated and, in all the cases studied, dramatic decreases in TH1 bias were 
observed compared to KRN7000. The authors believe these results are due to 
protonation of the amine functional groups at physiological pH, which destabilises 
the CD1d-antigen binary complex by repulsion with the positively charged Arg95. In 
summary, the chiral integrity of KRN7000 seems to be important in the synthesis of 
KRN7000 analogues in order to exhibit good bioactivities. 
 
Entry Configuration 2' X (Configuration 3') Y (Configuration 3') Activity compared to KRN7000 Ref.
1 S CH2 CH2 No  i NKT cell activation
m [152]
2 S CH-OH (S ) CH-OH (S ) Increased TH1 bias 
m,h [153]
3 R CH-OH (S ) CH-OH (S )
Decreased i NKT cell          
activation m, h
[153]
4 S CH-NH2 (S ) CH-OH (S ) Decreased TH1 bias
m+ [154]
5 S CH-NH2 (R ) CH-OH (S ) Decreased TH1 bias 
m+ [154]
6 S CH-OH (S ) CH-NH2 (S ) Decreased TH1 bias 
m+ [154]
7 S CH-OH (S ) CH-NH2 (R) Decreased TH1 bias
m+ [154]
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4.2.3. Modifications and/or functionalization of the lipid chains 
Modifications of the lipid chain length and/or functionalization at the amino acid/ 
sphingosine base positions have been explored, and for the most part have resulted 
in promising immunological outcomes. Table 4.3 summarises some of these 
findings in the literature.  
Table 4.3 Modifications and/or functionalisation to the lipid chain. 
m+ in vivo tests on mice; m in vitro test on mice cells; h in vitro tests  on human cells. 
Goff and colleagues altered the lipid lengths of KRN7000 and found that truncation 
of the lipid chain at the amino acid functionality (Entry 1 in Table 4.3) resulted in a 
decrease in TH2 bias, compared to KRN7000, by performing in vitro tests in mice.
[156] 
Interestingly, they observed the opposite outcome when testing the glycolipid in 
vitro with human cells, with an increased TH2 bias compared to KRN7000, however 
the authors provide no explanations for this observation. Oki and colleague set out 
to provide a rationale for the TH2 bias observed for truncated analogues of 
KRN7000, and proposed that shorter alkyl chain analogues failed to engage the TCR 
for a long enough period of time to induce IFN-γ secretion (TH1 bias).
[157] Conflicting 
evidence is provided by Wu and co-workers,[158] whereby crystal structures of a 
Entry R1 R2 Activity compared to KRN7000 Ref.
1 n C14H29 CH3
Decreased TH2 bias 
m, 
Increased TH2 bias 
h [155]
2 n C5H11 Similar TH2 
m [158]
3 n C14H29 (CH2)7Ph Increased TH1 bias 
m+, h [149]
4 n C14H29 Increaed TH2 bias 
h [30]
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truncated analogue of KRN7000 bound to CD1d was very similar to that obtained by 
Koch and colleagues, discussed earlier in Section 4.1.2.[142] Introducing unsaturation 
in the alkyl chains and shortening of the sphingosine base alkyl chain (Entry 2 in 
Table 4.3) resulted in similar TH2 responses to those of KRN7000.
[159] 
The introduction of aromatic groups at the amino acid functionality (Entry 3 in 
Table 4.2), together with a long alkyl chain resulted in an increased bias for TH1 
responses compared to KRN7000.[150] This result further highlights the influence of 
aromaticity on a TH1 bias, as described in Section 4.2.1 whereby the presence of 
aromatic functional groups at the C-6 position of the sugar moiety increased the 
IFN-γ secretion (TH1 response) compared to KRN7000. However, it seems that the 
long alkyl chain plays a dominant role in this selectivity also, as the 2-thienylacetyl 
analogue (Entry 4 in Table 4.3) resulted in a TH2 bias.
[30] 
Replacement of the amide functionality of the phytoshingosine backbone with  long 
chain triazole rings was performed by Lee and colleagues.[160] Triazoles can act as 
bio-isosteres to amide bonds (discussed later in this chapter), with hydrogen-
bonding donation occuring from the proton on the triazole ring. Additionally, 
hydrolytic cleavage is less problematic with triazole linkages compared to their 
amide bond counterparts also. Lee et al. observed that glycolipids 4.1 and 4.2 
(Figure 4.4) exhibited improved TH2 biased cytokine production in vitro on mice 
cells compared to KRN7000. However, the long alkyl chains were necessary for this 
bias to occur, as shorter analogues tested by the same group did not exhibit this 
effect. 
 
Figure 4.4 Structure of KRN7000 and triazole-containing analogues 4.1 and 4.2. 
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4.2.4. Miscellaneous analogues of KRN7000 
Many structurally diverse analogues of KRN7000 have been synthesised and their 
immunogenic properties have been assessed. The structures of representative 
glycolipids are shown in Figure 4.5. By changing the nature of the glycosidic bond, 
different physiological responses are anticipated. For example, changing from the 
native O-linkage to a C-, N- and S-glycosidic linkage limits the in vivo metabolism of 
the glycolipid by endogenous glycosidases.[161] 
 
Figure 4.5 Structure of KRN7000 and selected miscellaneous analogues 4.3, 4.4, 4.5, 4.6 
and  4.7.[162]   
The synthesis and in vitro mice studies of the C-glycoside 4.3 (Figure 4.5) was 
carried out by Kotobuki Pharmaceutical Co., and the analogue showed a stronger 
TH1 response compared to KRN7000.
[162a] However, since this pioneering C-
glycoside, no C-analogues have exhibited improved immunogenic properties 
compared to KRN7000 in the literature. S-glycosidic analogues of KRN7000 
emerged in 2008 by Dere and co-workers, with the synthesis of glycolipid 4.4.[162b] 
Shortly after, Blauvelt and colleagues performed in vitro and in vivo tests on this 
analogue, whereby no activation whatsoever of iNKT cells was observed.[163] A 
plausible reason for this inactivation is the length of the carbon-sulfur bond (182 
pm), which is longer than the carbon-oxygen bond length, which could destabilising 
the ternary complex. The synthesis of the oxime derivative 4.5 was undertaken by 
Harrak and colleagues.[162c] Despite the expected improved bioactivities due to the 
physiologically stable oxime linkage, a total loss of iNKT activation was observed, 
which was attributed to the additional length due to the oxime nitrogen atom. 
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More promising results were observed for the bioactivities of the carbasugar 4.6 
and the threitolceramide analogue 4.7.[162d, 162e]  The carbasugar 4.6 exhibited 
improved TH1 biased in vivo cytokine production compared to KRN7000, whilst the 
threitolceramide 4.7 exhibited good bioactivities. These results are attributed to the 
greater metabolic stabalities compared to KRN7000. Many other different types of 
KRN7000 analogues are discussed in the literature such as cyclitol, inositol and non-
glycoside analogues but will not be discussed in the present thesis.[22]  
4.2.5. β-glycoside analogues 
The synthesis and biological evaluation of β-linked KRN7000 analogues are rarer 
compared to the corresponding α-glycoside counterparts, despite the fact that it is 
believed that the endogenous iNKT cell ligand contains a β-glycosidic linkage if, in 
fact, it possesses an endogenous ligand at all. Much debate is on-going in this 
regard. The rationale for this belief stems from the fact that there are no known α-
glycosylated glycolipid antigens found in mammalian species to date. It has been 
recently reported that an abundant endogenous lipid, β-D-glucopyranosylceramide 
(β-GlcCer), was found to be a potent iNKT cell self-antigen in mice and humans.[164] 
Koezuka and colleagues were the first to synthesise and study the bioactivity of the 
β-anomer of KRN7000.[165] They observed a distinct reduction in anti-tumour 
activity compared to KRN7000. They similarly reported a decrease in anti-tumour 
activity of the β-glucosyl analogue of KRN7000 compared to the parent compound. 
Several groups have reported similar reductions in bioactivities when comparing β-
analogues to their α-counterparts.[166] 
One promising literature example described the immunogenic evaluation of a β-C-
glycoside analogue of KRN7000 4.8 (Figure 4.6).[167] The in vitro studies showed 
glycolipid 4.8 as a promising anti-tumour agent.  However, no in vivo studies have 
been performed on the glycolipid to date. So, despite the limited scientific interest 
in the synthesis and evaluation of β-glycolipid analogues of KRN7000, evidence 
suggests that they too have potential as immune regulating compounds. 
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Figure 4.6 Structure of β-C-KRN7000 analogue 4.8. 
4.2.6. L-Serine glycosides as KRN7000 analogues 
One emerging type of KRN7000 analogue of interest to our research group contains 
an L-serine residue in place of the phytoshingosine backbone of KRN7000. Fan and 
co-workers were the first team to investigate L-serine derivatives as potential 
KRN7000 analogues. They carried out  in vitro mice studies on the proliferation of 
mouse spleenocytes using KRN7000 and several L-serine based analogues.[168] They 
observed that the L-serine based analogue 4.9 (Figure 4.7) stimulated both IFN-γ 
(TH1) and IL-4 (TH2), albeit to a lesser degree compared to KRN7000. Interestingly, 
the longer chain analogue 4.10 did not exhibit any immunogenic properties.  
 
Figure 4.7 Structure of KRN7000 and L-serine analogues 4.9, 4.10, 4.11 and 4.12. [168-169] 
 
Another L-serine based glycolipid 4.11 (Figure 4.7), reported by Huang et al. was 
found to induce macrophage activation by a TLR4-signalling pathway.[169a] The 
effects of KRN7000 on TLR4 activation were also investigated, but proved to be 
inactive in that study. In a subsequent study by the same group, a series of L-serine 
analogues of KRN7000 were synthesised and tested for their abililty to act as TLR4 
activators.[169b] The glucosyl glycolipid 4.12 was found to be the best TLR4 activator, 
only marginally better than the corresponding galactosyl glycolipid 4.11 (Figure 
4.7). Thus, these componuds serve as potential drug candidates with 
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immunostimulator properties. No iNKT cell activation experiments were carried out 
by Huang and colleagues to investigate their potential usage as iNKT cell ligands.   
4.2.7. Perspective 
It seems obvious that minor changes to the structure of KRN7000 can have a major 
influence on the bioactivities exhibited. However, a few tentative conclusions can 
be drawn from the literature. First, modifications at the C-6 position of the sugar 
seems to be permitted and, in some cases, give desirable outcomes. Similarly, 
changes to the stereochemistry of the phytosphingosine backbone give undesirable 
results in many cases. Truncation  and/or unsaturation of the alkyl chains seem to 
elicit a TH2 response, whilst introduction of aromaticity elicits strong TH1 or TH2 
biased cytokine production. β-analogues of KRN7000, although relatively 
unexplored, remain possible iNKT cell ligands. Lastly, L-serine provides an 
alternative simple core for phytoshingosine in a relatively unexplored classification 
of KRN7000 analogues, one in which is exploited in the current thesis. 
4.3. Research objective  
In this chapter, the discussion is focussed on the synthesis of an L-serine-based 
building block suitable for the construction of L-serinyl-based KRN7000 glycolipid 
analogues. Our interest in synthesising L-serine based analogues stemmed from a 
few important considerations. First, L-serine is more readily available and cheaper 
than phytosphingosine. Second, a simpler synthetic approach was envisaged, as the 
L-serine backbone contains only one stereogenic centre compared to three 
steregenic centres present in the sphingosine backbone of KRN7000. Limited 
biological evaluations are reported in the literature regarding L-serine based 
KRN7000 analogues, despite the isosteric relationship that exists between L-serine 
and part of the phytosphingosine backbone. 
Glycosylation reactions were executed using various different glycosyl donors and 
suitable L-serinyl acceptors to produce the corresponding α- or β-glycoside building 
blocks (Figure 4.8). The glycosyl donors include per-acetylated galactosides, 
galactosyl bromides, galactosyl trichloroacetimidates, thiogalactosides and 
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galactosyl iodides. These donors are suitably protected with ester, ether or silyl 
ether protecting groups. The glycosyl acceptors contain an L-serine backbone with 
amine protecting groups including N-Boc, N-Fmoc and azides. The carboxylic acid is 
functionalised as a benzyl ester, methyl ester or tetradecylamide. L-Serine 
acceptors with silyl ethers also serve as glycosyl acceptors. 
 
Figure 4.8 Galactosyl donors and L-serinyl acceptors for formation of L-serinyl building 
block. 
 
With a suitable building block in place, we aimed to undertake the synthesis of L-
serinyl galactosyl analogues of KRN7000 such as glycolipids 4.13-4.16 (Figure 4.9) 
with a view to study their immunological properties as CD1d antigens for iNKT cell 
stimulation. This work will be carried out under the supervision of Dr. Derek 
Doherty in St. James hospital on human iNKT cells. 
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Figure 4.9 L-Serinyl KRN7000 analogues 4.13-4.16. 
 
4.4. Stereoselective synthesis of β-galactoside building blocks for KRN7000 
analogues 
Initially, we envisaged that the synthesis of a desired β-galactosyl building block 
would involve a simpler methodology than the corresponding α-derivative building 
block. With an ester group at the C-2 position of the galactosyl donor, neighbouring 
group participation can stereoselectively allow the formation of a 1,2-trans 
anomeric linkage to produce a β-galactosyl building block (as discussed in detail in 
Chapter 2).  The design of a suitable building block for the synthesis of KRN7000 
analogue 4.13 (Figure 4.9) was first explored.  
4.4.1. Design considerations for stereoselective β-galactosyl building block 
formation 
A synthetic approach for the formation of a β-galactosyl building block (Scheme 4.2) 
was designed based on the following considerations: i) the use of orthogonal 
protecting groups, ii) the need for an ester protecting group at the C-2 position of 
the galactosyl donor to give the desired 1,2-trans product and iii) the cost and 
availability of the starting materials and reagents. The proposed synthesis allows 
scope for the use of different ester protecting groups (P) on the sugar moiety, on 
the amino group (R) and on the carboxylic acid group (R’) of the L-serine amino 
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acid. Also, a variety of glycosyl donors with different leaving groups (L) were 
investigated. 
 
Scheme 4.2 General scheme for the synthesis of KRN7000 analogue 4.13 from a β-
galactosyl donor  and L-serinyl acceptor. Step a) involves the formation of a building block 
galactoside and step b) involves the synthesis of glycolipid 4.13. 
 
4.4.2. Use of galactosyl acetate donors for β-galactosyl building block formation 
The use of glycosyl acetate donors was first discovered by Helferich and Schmitz-
Hillerbrecht,[170] and their use has maintained steady occurrence in the literature 
ever since.  The anomeric acetate can be activated under Lewis acid conditions, 
displaced in an SN1 fashion (as discussed in Chapter 2) and attacked by the incoming 
nucleophile stereoselectively to yield the desired 1,2-trans glycosidic product. The 
great advantage of their use is the relative ease of preparation and stability of the 
donor. Glycosyl acetate donors have been applied to many synthetic 
methodologies. For example, the 2,3-unsaturated-4-keto glycosyl donor 4.17 and N-
acetylglucosamine donors 4.18 have been utilised as glycosyl donors (Figure 
4.10).[171] Also, glycosyl acetates are commonly employed as precursors in the 
synthesis of other types of glycosyl donors, including glycosyl bromides (discussed 
in Chapter 2), thioglycosides (discussed in Section 4.6.1.) and glycosyl 
trichloroacetimidates (discussed in Section 4.4.4.). 
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Figure 4.10 Examples of glycosyl acetate donors.[171]  
 
Initial investigations led us to synthesise the building block 4.21 illustrated in 
Scheme 4.3. The reaction of N-Boc-L-serine 4.19 with NEt3 and BnBr afforded the L-
serinyl acceptor 4.20 in a 70% yield. A subsequent glycosylation reaction between 
galactosyl donor 2.32 and L-serinyl derivative 4.18 was performed using BF3.OEt2 as 
a Lewis acid following a literature procedure.[172] After 18 h, some galactosyl donor 
2.32 remained unreacted in the reaction mixture (by TLC analysis), however due to 
the consumption of the glycosyl acceptor 4.18 and the indication of degraded 
material present in the reaction mixture, the reaction was terminated. 1H NMR 
analysis confirmed the presence of the recovered glycosyl donor 2.32 in a 30% 
isolated yield and an acetylated side product 4.22 in a 10% isolated yield. The 
remainder of the reaction mixture consisted of unidentifiable compounds. No 
desired product 4.21 was identified in the 1H NMR spectrum. Similarly, HR-MS 
reaffirmed this finding.  
 
Scheme 4.3 Reagents and conditions a) NEt3, BnBr, DMF, 4 Å MS , rt, N2, 3h, 70 °C b) 
BF3.OEt2, CH2Cl2, 4Å MS , rt, N2, 18 h, 10%. Glycoside 4.21, the desired product in step b was 
not isolated. 
 
The isolation of the side product 4.22 is evidence that a trans-esterification reaction 
is occurring during the glycosylation step. Undesired trans-esterification reactions 
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commonly occur in carbohydrate chemistry under acid,[173] basic[174] and sometimes 
neutral conditions.[175] Acyl migration is an intramolecular trans-esterification 
reaction where an acyl group moves from one functional group to another on the 
molecule. Acetyl esters are particularly susceptible to acyl migration. Extensive 
studies have been carried out on acyl migration reactions occurring in D-
galactopyranosides, and migration of the 4-acyl protecting groups is particularly 
common.[174-176] It is probable that the acetyl protecting group at the C-4 position of 
the galactosyl donor 2.32 participitated in the trans-esterification reaction, despite 
the fact that galactopyranoside containing a free hydroxyl group was not isolated in 
the reaction. Examples of a general trans-esterification reaction and an acetyl 
migration reaction are shown in Scheme 4.4. 
 
 
Scheme 4.4 Example of an intramolecular acyl migration occuring in a galactopyranoside 
and an intermolecular trans-esterification reaction occurring between a galactopyranoside 
and an alcohol. R indicates protecting groups on the galactopyranosyl starting 
materials, Ac indicates an acetyl group, L indicates a leaving group and R’ indicates 
an organic group.  
 
The glycosylation reactions using commercially available L-serine carboxylic acids 
4.19 and 4.23 with galactosyl donor 2.32 were also carried out, and involved the 
use of BF3.OEt2 as a promoter (Scheme 4.5). TLC analysis of the glycosylation 
reaction of the N-Fmoc protected L-serine derivative 4.23 with the per-acetylated 
galactose 2.32 showed consumption of the starting materials after only 3 h. The 
glycosylation reaction involving the N-Boc protected L-serine derivative 4.19 did not 
show full conversion after 3h. However, for comparison studies, both reactions 
were terminated after 3 h. In order to analyse whether the glycosylations were 
successful and for ease of purification, the products containing the free carboxylic 
Chapter 4: Synthesis of L-serinyl based glycolipid  analogues of the immunostimulant 
KRN7000 
108 
 
acids were benzylated with BnBr and NEt3 as described earlier, in an attempt  to 
yield the corresponding benzyl ester galactosides 4.26 and 4.21 respectively. 
 
Scheme 4.5 Reagents and conditions a) BF3.OEt2, CH2Cl2, 4 Å MS , rt, N2, 18 h; b) NEt3, BnBr, 
DMF, rt, N2, 18 h. For compound 4.26, 31% over two steps. For compound 4.21 no desired 
glycoside was isolated. 
 
More promising results were observed for the formation of the N-Fmoc galactoside 
4.26 than for the corresponding N-Boc protected galactoside 4.21. The desired β-
galactosyl building block 4.26 was isolated along in 31% yield over two steps with 
traces of contaminants. The 1H NMR data was in agreement with literature data.[177] 
The contaminants were difficult to separate by chromatographic methods. The 
undesired hemiacetal product 4.27 was isolated in 9% yield (Figure 4.11) suggesting 
the presence of competing H2O molecules in the reaction. The remainder of the 
reaction consisted of an unidentified mixture of compounds. 
 
Figure 4.11 Structure of hemiacetal product 4.27 in glycosylation reaction. 
 
In contrast to the N-Fmoc protected galactoside 4.26, no desired glycosylated 
product 4.21 was isolated. The 1H NMR spectra of the isolated fractions after flash 
chromatography were difficult to interpret, as mixtures of compounds were 
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present. HR-MS analysis however confirmed the presence of the undesired 
acetylated L-serine 4.22 and the galactosyl hemiacetal 4.27. It seemed that the N-
Fmoc protected L-serine acceptor 4.23 was a better choice for the formation of a 
building block suitable for synthesis of KRN7000 analogues. However, subsequent 
basic deprotection of the N-Fmoc protecting group on the building block 4.26 could 
cleave the base-labile acetyl groups present on the sugar moiety. This lack of 
orthogonality, together with the low yield of the reaction encouraged us to explore 
other strategies. A summary of the findings described above are shown in Table 4.4. 
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Table 4.4 Glycosylations utilising penta-O-acetyl-β-D-galactopyranoside 2.32 and L-serine  
acceptors 4.20, 4.23 and 4.19. 
 
*no benzylated reaction performed for Entries 1; ‡ 1 equiv of donor 2.32, 1.2 equiv of        
          acceptor, 3 equiv of BF3.OEt2 activator in all glycosylation reactions; ** 
Presence confirmed by HR-MS. 
 
4.4.3. A Koenigs-Knorr glycosylation for formation of a β-galactosyl building block  
We reasoned that the use of a galactosyl halide donor could overcome some of the 
problems encountered with the use of per-acetylated donor 2.32. A classic Koenigs-
Knorr reaction was performed by Yoshiizumi et al. using a galactosyl halide 2.33 and 
N-Boc protected L-serinyl derivative 4.20 using a combination of halophilic 
R1 R2 R3 Time‡
Yield A 
(%)
Yield 4.27 
(%)
Yield  B 
(%)
1 Boc Bn* Bn 18 h - - 10
2 Fmoc H Bn 3 h 31 9 -
3 Boc H Bn 3 h - Traces** Traces**
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activators of Ag2CO3 and AgClO4 (Scheme 4.6).
[178] The low yield (20%) reported for 
their synthesis of the N-Boc glycoside 4.21  suggested that undesirable side 
reactions were occurring during the glycosylation step.[178] A trans-esterification 
reaction (discussed in Section 4.4.2) is one of the probable causes of this low yield. 
One of the plausible solutions to this problem involves the use of the more acid 
stable benzoyl ester in place of the acetyl ester on the galactosyl bromide donor.   
 
 
Scheme 4.6 Reagents and conditions a) Ag2CO3, AgClO4, CH2Cl2, 4Å MS, dark, rt, N2, 18 h, 
20%.[178] 
 
An alternative glycosyl donor 4.30 was prepared following a literature procedure as 
shown in Scheme 4.7.[179] The reaction of D-galactose with benzoyl chloride in Pyr 
afforded 64% of the benzoyl protected α-D-galactopyranoside 4.29. Treatment of 
the galactosyl precursor 4.29 with a solution of HBr/AcOH and Ac2O in CH2Cl2 
yielded the galactosyl bromide 4.30 in a 96% yield.  
 
 
Scheme 4.7 Reagents and conditions. a)  BzCl, Pyr, 0°C to rt, 18 h, 64%; b) HBr/AcOH, Ac2O, 
CH2Cl2, 0 °C, N2, 2 h, 96%. 
 
The glycosylation reaction of glycosyl halide 4.30 with the L-serine acceptor 4.20 
was studied using two different halophilic activators (Ag2CO3 or AgOTf) as seen in 
Scheme 4.8. To our disappointment, neither reaction conditions yielded desirable 
results. Again, as in the case for reaction of the galactosyl acetyl donor 2.32 (Section 
4.4.2), mixtures of unidentifiable side products were obtained, with little or no 
evidence of desired product formation of 4.31. The corresponding benzoylated 
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galactosyl hemiacetal 4.32 was identified from 1H NMR and HR-MS analysis. It 
seemed that the use of benzoyl esters in place of acetyl esters seemed to reduce 
the reactivity of the galactosyl halide towards glycosylation, an observation that has 
precedence in the literature.[180] 
 
Scheme 4.8 Reagents and conditions. Ag2CO3 or AgOTf, CH2Cl2, rt, 18 h or 48 h. Desired 
product 4.31 was not isolated. 
 
 
4.4.4. Schmidt’s trichloroacetimidate glycosylation for the formation of β-
galactosyl building block  
The trichloroacetimidate donors were first reported in 1980 by Schmidt and 
colleagues, [114, 181]  and they are well regarded and extensively utilised in 
carbohydrate chemistry. The versatility of glycosyl trichloroacetimidates is 
illustrated by their use in various different syntheses and excellent yields and 
stereoselectivities are reported in the literature.[182] One advantage pertaining to 
the use of glycosyl trichloroacetimidates over glycosyl halides, thioglycosides and 
glycosyl acetate  donors involves the use of a catalytic amount of the Lewis acid 
promoter in trichloroacetimidate activation, compared to stoichiometric amounts 
needed for the later donors. Glycosyl trichloroacetimidates are conveniently 
prepared by the reaction of a hemiacetal with trichloroacetonitrile in the presence 
of a base. The anomeric stereoselectivity is controlled by the type of base used in 
the reaction, with weak bases (such as K2CO3) affording the kinetically favoured β-
trichloroacetimidate and strong bases (such as DBU) affording the 
thermodynamically favoured α-trichloroacetimidates (Scheme 4.9).[69]
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Scheme 4.9 Base promoted stereoselective formation of α- and β-trichloroacetimidates. 
 
The galactosyl trichloracetimidate donor 4.33 was prepared as described in the 
literature from 1,2,3,4,6-penta-O-acetyl-β-D-galactose 2.32 by selective 
deacetylation at the anomeric centre upon treatment with Me2NH, to give the 
galactosyl hemiacetal 4.27.[183] The reaction of this intermediate with 
trichloroacetonitrile and DBU (strong base) gave the desired α-galactosyl 
trichloroacetimidate 4.33 in a good overall yield of 92% over two steps (Scheme 
4.10).[183] The reaction of galactosyl trichloroacetimidate 4.33 and N-Boc-L-serine 
benzyl ester 4.20 was then performed under Lewis acid (TMSOTf) activation, to give 
the desired galactoside 4.21 in a 33% yield. The effects of time and different 
stoichiometric quantities of galactosyl donor 4.33 were explored to optimise the 
reaction yields, which are summarised in Table 4.5. 
 
 
Scheme 4.10 Reagents and conditions. a) Me2NH, CH3CN, rt, 24 h, quant.; b) CCl3CN, DBU, 
CH2Cl2, 3Å MS, N2, 3.5 h, 83%; c) 0.04 N TMSOTF, 4Å MS, CH2Cl2, -10°C to rt, N2, 18 h, 33%. 
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Table 4.5 Attempts to optimise reaction conditions used in the synthesis of β-galactoside 
building block 4.21 using trichloroacetimidate donor 4.33. 
 
 
* 1 equiv of acceptor, 0.1 equiv of 0.04 N TMSOTf, -10°C –rt in CH2Cl2 in all glycosylations.  
 
An initial glycosylation was carried out as in Scheme 4.10, with an excess of 
galactosyl donor 4.33 (1.2 equiv) for 18 h (Entry 1 in Table 4.5). This resulted in a 
33% yield of the desired galactosyl building block 4.21. The trans-esterification side 
product 4.22 and the N-Boc deprotected L-serinyl derivative 4.34 were isolated in 
34% and 7% yield respectively. A shorter reaction time of 3 h (Entry 2 in Table 4.5) 
resulted in the formation of the product 4.21 with a reduced yield of 30%. The 
undesired hemiacetal 4.27 was isolated in 20% yield under these reaction 
conditions. Increasing the stoichiometric equivalents of the galactosyl donor 4.33 
Entry
Equiv of glycosyl 
donor 4.33 *
Time
Yield 4.21 
(%)
Yield 4.27 
(%)
Yield 4.34 
(%)
Yield 4.22 
(%)
1 1.2 18 h 33 - 7 34
2 1.2 3 h 30 20 - -
3 1.3 3 h 28 25 - -
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(Entry 3 in Table 4.6) resulted in a poorer 28% yield of the building block 4.21 and a 
concomitant increase in the undesired hemiacetal product 4.27 formation (25% 
yield). These results suggested the best Schmidt glycosylation conditions involved a 
slight excess of galactosyl donor 4.33 (1.2 equiv) and a reaction time of 18 h (Entry 
1 in Table 4.5). 
In the 1H NMR spectrum of the crude reaction mixture of 4.21 (Scheme 4.10), a 
signal present at 6.3 ppm was indicative of an orthoester product. In a 1H NMR 
spectrum, a signal corresponding to an anomeric proton of an orthoester would 
have a higher chemical shift than the corresponding signal of the anomeric proton 
of a β-glycoside due to its different chemical environment. The coupling constant 
would also have a value closer to that of an α-glycoside as it has a similar diaxial 
angle to an α-glycoside. The anomeric proton of the purified β-glycoside 4.21 was 
found to resonate at 5.7 ppm.  
Extensive studies have been carried out on the formation of orthoesters as side 
products in glycosylation reactions; one of the domineering factors attributed to 
their formation is the presence of base in the glycosylation step.[184] Low 
temperature 1H and 13C NMR was utilised by Crich and his collegues with 13C-
labelled compounds in order to probe the mechanism by which they form in 
glycosylations with and without base. They provided evidence for the existence of 
orthoesters in buffered solutions but no evidence in the corresponding base-free 
glycosylation was given.[184c] Upon analysis of the reaction conditions in Scheme 
4.10, the presence of base is not immediately evident; however one suggestion is 
the possibility that the nucleophilic hydroxyl group of the L-serine acceptor 4.20 is 
also acting as a Lewis base as in Figure 4.12.  Intramolecular hydrogen-bonding of 
the hydrogen atom of the hydroxyl group to the nitrogen atom of the NHBoc 
protecting group increases the Lewis basicity of the oxygen atom.  
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Figure 4.12 Hydrogen bonding in L-serine derivative 4.20 increases the Lewis basicity of the 
primary alcohol. 
 
Thus the orthoester formation may have occurred due to the Lewis basic hydroxyl 
group of L-serine derivative 4.20. A proposed mechanism for this orthoester 
formation is shown in Scheme 4.11 whereby the nucleophilic acceptor 4.20 can 
attack the intermediate cyclic oxonium ion 4.35, leading to the formation of an 
orthoester 4.36. The presence of the base retards the acid catalysed decomposition 
of the cyclic oxonium ion into the oxycarbenium ion for formation of O-glycosides. 
The orthoester 4.36 was not observed after purification by flash chromatography in 
the glycosylation reaction described above. A rearrangement of the orthoester may 
have occurred to give the desired O-glycoside 4.21. If this was the case, this type of 
rearrangement is often accompanied by side reactions such as hydrolysis and trans-
esterification from the hydroxyl group at the C-2 position of the donor to a free 
hydroxy group on the acceptor.[185] This would account for the presence of the 
acetylated side product 4.22.  
 
 
Scheme 4.11 Proposed reaction mechanism for orthoester 4.36 formation. 
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The use of benzoyl esters in place of acetyl esters in glycosyl donors retards the 
formation of orthoesters due to the greater stability (and thus lesser reactivity) of 
the intermediate oxonium ion of the benzoate, therefore potentially improving 
yields as a result. Thus, the synthesis of the benzoyl protected galactosyl 
trichloroacetimidate donor 4.37 was undertaken (Scheme 4.12). Initial attempts to 
hydrolyze the anomeric benzoyl ester of per-benzoylated-D-galactose 4.29 
(described in Section 4.4.3) using Me2NH to produce the corresponding benzoylated 
hemiacetal 4.32 failed. The starting material 4.29 remained unconsumed in the 
reaction. This was attributed to the fact that benzoyl protecting groups are more 
stable to basic conditions than acetyl groups. However, when harsher basic 
conditions were employed, the selective anomeric deprotection was not achieved, 
with all or some of the benzoyl groups being removed. Therefore, the galactosyl 
benzoylated hemiacetal 4.32 was formed by the reaction of the glycosyl bromide 
4.30 (described in Section 4.4.3.) with Ag2CO3 in an acetone/H2O mixture (4:1) in 
90% yield. This was followed by reaction of hemiacetal 4.32 with 
trichloroacetonitrile and DBU to obtain the desired galactosyl trichloroacetimidate 
4.37 in an 89% yield (Scheme 4.12).[186] 
 
Scheme 4.12 Reagents and conditions. a) Me2NH, CH3CN, rt, 24 h; b) Ag2CO3, acetone/H2O 
4:1, rt, 2.5 h, 90%; c) CCl3CN, DBU, CH2Cl2, 3Å MS, 0°C , N2, 2 h,  89%. 
 
The glycosylation reaction of the benzoylated galactosyl donor 4.37 with the 
protected L-serine acceptor 4.20 was then carried out, however none of the desired 
β-galactosyl building block 4.31 was isolated, although its presence was detected by 
HR-MS analysis (Scheme 4.13). As in previous glycosylation attempts, unreacted 
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glycosyl acceptor 4.20 and the hemiacetal 4.32 were isolated from the reaction 
mixture as major components. A range of reaction conditions were explored in 
order to synthesise the desired O-glycoside 4.31 in a reasonable yield. A summary 
of these appear in Table 4.6.  
 
Scheme 4.13 Reagents and conditions. a) TMSOTF, CH2Cl2, 3Å MS, N2, 4 h. Desired product 
4.31 was not isolated. 
 
Some of the reaction parameters investigated were the amounts of glycosyl donor 
4.37 and acceptor 4.20 used (Entries 1-3 in Table 4.6), the concentration of the 
Lewis acid promotor (Entries 1,3-5 in Table 4.6), the temperature used ranging from 
-40° C to 28 °C (all entries in Table 4.6), the reaction time ranging from 30 s to 5 h 
(all entries in Table 4.6), the reaction solvent (Entries 1,4 in Table 4.6). Microwave 
glycosylation conditions were also investigated (Entries 6, 7 in Table 4.6). 
Microwave assisted glycosylations are prevalent in the literature in recent times 
due to their potential to being clean, cheap and convenient reactions.[187] In the 
literature, reaction times and yields can be improved using microwave irradiation 
compared to conventional methods, sometimes drastically.[188] However in the case 
of the glycosylations mentioned, no changes were observed compared to the 
conventional glycosylation reactions. The desired compound 4.36 was not isolated 
in any of the reactions carried out. 
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Table 4.6 Different reaction conditions explored to synthesise β-glycoside 4.31. 
* glycosylation product 4.31 detected by HR-MS analysis. 
 
Entry
Equiv of 
glycosyl 
donor 
4.37
Equiv of 
glycosyl 
acceptor 
4.20
Activator Equiv Temperature Time Solvent*
1 1 1.1 0.04 N TMSOTf 0.25 rt 4 h CH2Cl2
2 1.1 1 0.04 N TMSOTf 0.25 -10 °C - rt 5 h CH2Cl2
3 3 1 neat TMSOTf 0.25 -10 °C - rt 5 h CH2Cl2
4 1 1 neat TMSOTf 0.25 -10 °C - rt 2 h
Diethyl 
ether
5 1 1 0.04 N TMSOTf 0.1 -40 °C 3 h
Diethyl 
ether
6 1 1 0.04 N TMSOTf 0.1 28 °C 5 min CH2Cl2
7 1 1 0.04 N TMSOTf 0.1 28 °C 30 sec CH2Cl2
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4.4.5. Use of silylated glycosyl acceptors for the formation of a β-galactosyl 
building block   
The outcome of glycosylation reactions can depend on many factors and the choice 
of the glycosyl donors and glycosyl acceptors are vitally important. In the previous 
sections, we discussed the use of different galactosyl donors and acceptors for the 
synthesis of a desired β-galactosyl building block. We observed in the reaction of 
the galactosyl trichloroacetimidate donor 4.33 that the unreacted L-serine acceptor 
4.20 was recovered, together with a series of side products, as discussed earlier in 
Section 4.4.4. This suggested that an alternative and more reactive acceptor was 
needed in order for the glycosylation to be more effective. We postulated that the 
reaction between the trichloroacetimidate galactosyl donor 4.33 with silylated L-
serine derivatives could yield more promising results. 
The use of silyl ether glycosyl acceptors was reported by Murphy and co-
workers.[189] They were involved in a stereoselective synthesis of glycosides and 2-
deoxyglycosides by SnCl4 catalysed coupling of a lactone derivative with various silyl 
ether glycosyl acceptors. Scheme 4.14 illustrates one such example whereby the 
coupling of lactone 4.38 with L-serinederivative 4.39 resulted in a 51% yield of the 
α-glucuronoside 4.40. Nakamura reasoned that the use of silyl ether protected 
alcohols as nucleophiles could minimize the build-up of H2O, which in turn could 
lead to higher glycosylation yields compared to alcohol acceptors.[190]  
 
Scheme 4.14 Reagents and conditions. a) SnCl4, CH2Cl2, 4Å MS, rt, N2, 15 h, 51%. 
 
Two different silylated L-serine acceptors 4.41 and 4.42 were synthesised, which 
contained the labile TMS group and the more stable TES protecting group 
respectively (Scheme 4.15). Treatment of N-Boc-L-serine benzyl ester 4.20 with 
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TMSCl and NEt3 afforded TMS L-serine derivative 4.41 in a yield of 69%, and 
treatment of N-Boc-L-serine benzyl ester 4.20 with TESCl and NEt3 afforded L-serine 
derivative 4.42 in a yield of 67%. Glycosylation reactions were then carried out with 
the trichloroacetimidate donor 4.33 in Lewis acid promoted reactions (TMSOTf). 
The results are summarised in Table 4.7. 
 
Scheme 4.15 Reagents and conditions. a) For compound 4.41: TMSCl, NEt3, CH2Cl2, N2, 2 h, 
69%; For compound 4.42: TESCl, NEt3, CH2Cl2, N2, 3 h, 67%; b) TMSOTf, CH2Cl2, 4Å MS, -10° 
C to rt, N2, 2 h or 3 h. Desired product 4.21 was not isolated. 
 
The glycosylation involving the use of the TMS functionalised L-serine 4.41 (Entries 
1, 2 in Table 4.7) resulted in no formation of the desired compound 4.21. Similiarly, 
the TES protected L-serine acceptor 4.42 (Entry 3 in Table 4.7) resulted in none of 
the desired glycoside 4.21. Only the hemiacetal 4.27 (1:100 α/β) and the desilylated 
L-serine derivative 4.20 were isolated along with starting materials in this case. In 
hindsight, these results are in line with those obtained in competition studies 
between an alcohol acceptor and the corresponding silyl ether acceptor carried out 
by Kahne and colleagues.[191]  The team observed that the silyl ether acceptor 
remained unreacted in the presence of the alcohol acceptor. This indicated that silyl 
ethers react more slowly than unprotected alcohols as glycosyl acceptors 
presumably because they must be unmasked first in the Lewis acid conditions of a 
glycosylation.[191] The use of silylated L-serine acceptors were abandoned as a result 
of our findings and observations. 
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Table 4.7 Reaction conditions of glycosyl donor 4.33 and two L-serine acceptors 4.41 and 
4.42. 
* 1 equiv of acceptor, 0.1 equiv of 0.04 N TMSOTf, -10°C -rt, CH2Cl2 as solvent in all 
glycosylations; ‡ product has Rf value identical to hemiacetal 4.27 on TLC plate and cannot 
identify individual signal in 1H NMR spectrum. 
 
 
4.4.6. Investigation of nucleophilicity of L-serine acceptor for β-galactosyl building 
block formation 
In our attempt to understand why the glycosylation reactions involving the L-serine 
derivative 4.20 with various different donors were failing, we decided to investigate 
the nucleophilicity of the L-serine acceptor 4.20. Polt et al. had reported that the 
nucleophilicity of L-serine and some of its derivatives was poor due to unfavourable 
hydrogen bonding between the amino residue of the L-serine backbone and the 
Entry
Equiv of 
glycosyl 
donor 4.33
R Time
Yield 4.21 
(%) *
Yield 4.27 
(%)
Yield 4.20 
(%)
1 1 TMS 2 h - -‡ -
2 1.5 TMS 2 h - 26 35
3 1 TES 3 h - 23 -
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hydroxyl group at the C-4 position as shown in Figure 4.13.[192] The oxygen atom on 
the hydroxyl group can be deactivated by the proton of the amide bond, thus 
decreasing its nucleophilicity. Conversely, they postulated that if a favourable 
hydrogen bonding pattern could be generated via the use of different protecting 
groups on the amino residue of the L-serine, then the nucleophilicity of the 
hydroxyl group of the N-protected L-serine could be increased. They chose L-serine 
ester Schiff bases to induce hydrogen bonding favourable in glycosylation reactions. 
However, we were interested in utilising an azide moiety as the amino protecting 
group on L-serine.  Azides can be considered to be masked amino groups since they 
can easily be reduced to give the free amine after the glycosylation step in the 
synthesis of a β-galactosyl building block which could improve the yield of the 
glycosylation reaction. Azide derivatives of ceramides are commonly used as 
building blocks in the synthesis of KRN7000 analogues, as exemplified by the work 
of Gervay-Hague et al.[193] We believed that an azido functionalized L-serinyl 
compound would undergo favourable hydrogen-bonding similar to that observed 
by Polt  for Schiff bases which would increase the nucleophilicity of the acceptor 
(Figure 4.13). Finally, the introduction of the azido functionality at this point in the 
synthesis of a galactosylated L-serinyl building block would be convenient towards 
the preparation of the target triazole containing glycolipids 4.15 and 4.16.  
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Figure 4.13 Unfavourable hydrogen bonding in L-serine derivative due to amide bond and 
favourable hydrogen bonding in L-serine derivative due to azide functionality.  
 
The synthesis of an azide glycosyl acceptor 4.44 was thus undertaken as in Scheme 
4.17. The conversion of a primary amine into an azide is usually aided by a diazo-
transfer reagent; TfN3 being one of the most popular choices in the literature.
[194] 
However the explosive properties of TfN3 when anhydrous and its relatively short 
shelf life challenged us to explore other methods reported in the literature. 
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Goddard-Borger and colleagues reported an alternative diazo-transfer reagent, 
imidazole-1-sulfonyl azide 4.43, which was claimed to be shelf stable and safe to 
use at temperatures well below its decomposition point, rt preferably.[195] We 
undertook the synthesis of the diazo-transfer reagent 4.43 as shown in Scheme 
4.16 following a literature procedure.[195] Treatment of sulfuryl chloride with NaN3 
in MeCN afforded chlorosulfonyl azide, which was then reacted in situ with 
imidazole, and  treated with acid to give the hydrochloride salt 4.43  in a 39% yield. 
 
 
Scheme 4.16 Reagent and conditions. a) i)NaN3, MeCN, rt, 18 h  ii) Imidazole, 0 °C to rt, 3 h 
iii) HCl  in EtOH, 0 °C , 1 h, 39%. 
 
The formation of the L-serinyl azide derivative 4.44 was attempted following a 
procedure pioneered by Goddard-Borger and co-workers as shown in Scheme 
4.17.[195] The previously synthesised L-serine derivative 4.20 was N-Boc deprotected 
with 1 M HCl in a CH2Cl2/H2O biphasic system to give the corresponding free amine 
hydrochloride salt. Subsequent reaction with the diazo-transfer reagent 4.43 using 
a Cu(II) catalyst in basic conditions in MeOH resulted in the desired azide transfer 
but also complete trans-esterification of the benzyl ester, to give a quantitative 
yield of the L-serine methyl ester 4.45. Trans-esterification reactions typically occur 
under basic conditions with a reactive alcohol, such as MeOH. However bulkier 
alcohols, such as t-BuOH, are less likely to undergo this type of transformation. The 
reaction was thus carried out in t-BuOH with a Cu(II) catalyst in basic conditions to 
afford the desired compound 4.44 in a  yield of 61%, as in Scheme 4.17.  
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Scheme 4.17 Reagents and conditions. a) i) 1 M HCl, CH2Cl2 ii) 4.43, K2CO3, CuSO4.5H2O, 
MeOH, rt, 6 h, 100% or b) i) 1 M HCl, CH2Cl2 ii) 4.43, K2CO3, CuSO4.5H2O, t-BuOH, rt, 6 h, 
61%. 
 
4.4.7. L-Serine azido acceptor 4.43 for β-galactosyl building block formation 
The glycosylation reaction between the trichloracetimidate donor 4.33 and the 
azide L-serine acceptor 4.44 was attempted using Schmidt glycosylation conditions 
as in Scheme 4.18. For comparison purposes, the side product methyl ester glycosyl 
acceptor 4.45 (from the diazo-transfer reaction in MeOH described above) was also 
reacted with the trichloracetimidate donor 4.33, and both reactions were analysed 
and compared. The galactosyl donor 4.33 was activated under Lewis acid conditions 
and reacted with the acceptors 4.44 and 4.45 respectively as in Scheme 4.18. After 
3 and 4 h, respectively, they were quenched based on the consumption of the 
galactosyl donor 4.33 as indicated by TLC analysis, and the reaction mixtures were 
analysed by 1H NMR spectrometry. Neither reaction yielded the desired compounds 
4.45 or 4.46 respectively. Mixtures of products which could not be separated were 
formed, and only the corresponding acetylated side products 4.48 and 4.49 (2% and 
14% respectively) were identified. These results again indicated that the 
replacement of the protected amine function for an azide did not result in the 
expected increase in reactivity for L-serinyl acceptors 4.44 and 4.45. 
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Scheme 4.18 Reagents and conditions. a) For 4.48, 0.04 N TMSOTF, 4Å MS, CH2Cl2, rt, N2, 3 
h , 2%; For 4.49, 0.04 N TMSOTF, 4Å MS, CH2Cl2, rt, N2, 4 h , 14%. Desired products 4.46 and 
4.47 were not isolated. 
4.5. Mitsunobu conditions in formation of α/β-galactosyl building blocks  
In light of the fact that the glycosylation reactions explored so far gave 
unsatisfactory results for the most part, possibly due to the reduced nucleophilicity 
of the L-serinyl acceptors, a different synthetic approach was investigated. The 
proposed glycosylation strategy involved the use of a Mitsunobu reaction. 
Mitsunobu reactions are commonly used in organic chemistry and have been used 
successful to form glycosidic linkages.[196] However, little control is held over the 
stereoselective formation of the products, because the hemiacetal starting material 
is found, in most cases, as a mixture of anomers. The hemiacetal participates as the 
nucleophile in the reaction, and thus the products retain the original 
stereochemistry. Hemiacetal 4.27 (as a 1:100 α/β mixture of anomers) and L-serine 
derivative 4.20 were reacted in the presence of PPh3 and DIAD in CH2Cl2, as shown 
in Scheme 4.19. After 5 h, the starting material 4.20 had been consumed, as 
monitored by TLC analysis, and the reaction was terminated. However, no desired 
product 4.21(α/β) was isolated. Instead we believe the L-serine derivative 4.20 
underwent a β-elimination reaction to produce the dehydroalanine derivative 4.50, 
isolated in a 50% yield, whose 1H NMR data was in agreement with literature 
values.[197] The unreacted hemiacetal 4.27 was recovered. 
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Scheme 4.19 Reagents and conditions a) PPh3, DIAD, CH2Cl2, 4 Å MS, rt, N2, 5 h, 50%. 
Desired product 4.21 was not isolated. 
 
We believe that the L-serine was dehydrated due to the acidity of the H-α in the 
proposed reaction mechanism (Scheme 4.20). The PPh3 performs a nucleophilic 
attack on DIAD producing a betaine intermediate 4.51. As in a Mitsunobu reaction, 
the betaine intermediate 4.51 attacks the hydroxyl proton on the hemiacetal 4.27 
to produce the carbocation 4.52. The L-serine derivative 4.20 then attacks the 
electrophilic phosphorous atom on the carbocation 4.52 to displace a DIAD 
derivative. At this point, the DIAD derivative is sufficiently basic to deprotonate the 
H-α of the L-serine derivative 4.20, with the driving force of the formation of 
triphenylphosphine oxide to give the β-elimination product dehydroalanine 4.50. 
This forms preferentially over nucleophilic attack from the deprotonated 
hemiacetal to give the desired building block 4.21(α/β). 
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Scheme 4.20 Proposed reaction mechanism for E1sb elimination reaction of L-serine 
derivative 4.20 to give dehydroalanine 4.49. 
 
It is also possible that the reaction did not proceed according to this mechanism. It 
is possible that the glycosylation occurred and a subsequent retro-Michael reaction 
occurred thereafter. However, it is unlikely that it may have occurred in this 
manner as no desired product was evident by TLC at any stage of the reaction and 
no trace of desired compound 4.21(α/β) was observed by HR-MS. However O-
serinyl galactosides are known to undergo this reaction, so it is not beyond the 
realm of possibility.[192, 198] These observations highlight the base sensitivity of L-
serine derivatives due to the acidic α-proton, an important note for the continuing 
work on O-serinyl compounds. The formation of dehydroalanine 4.50, although 
undesired in our present circumstances could be useful in other applications such 
as in drug design. For example, dehydroamino acids are currently used as the basis 
for antibiotics.[197] For the present study, no further investigations were carried out 
in this area.  
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4.6. Design considerations for the synthesis of α/β-galactoside building blocks for 
KRN7000 analogues 
These results cemented our understanding of the electronic sensitivities of these 
reactions and the importance of matching donor and acceptor reactivity to achieve 
successful glycosylation reactions. With this in mind, we decided that a radical 
change in the glycosyl donor structure was needed to increase its armed character. 
The “armed-disarmed” terminology was coined by Fraser-Reid and co-workers in 
1988.[199] They observed that the protecting groups on glycosyl donors had a large 
impact on the resulting glycosylation yield, in particular the protecting group at the 
C-2 position of the glycosyl donor. Both esters and ether protecting groups are 
electron withdrawing; esters due to resonance and inductive effects and ethers due 
to inductive effects alone. Esters are more electron-withdrawing than ethers. 
Therefore they are more deactivating than the corresponding ethers and are less 
likely to induce the formation of an oxacarbenium ion. Thus they are less reactive 
and are termed disarmed. Ether containing glycosyl donors are more likely to 
induce the formation of an oxacarbenium ion. They are thus more reactive and are 
termed armed donors. This concept is fundamental to reactivity tuning of glycosyl 
donors used in one-pot oligosaccharide syntheses, as exemplified by Zhang et al.[200] 
Their strategy involved the use of the most reactive donor at the non-reducing end, 
and an unreactive donor was used for the reducing end of the given oligosaccharide 
target. With this in mind, we decided to alter the structure of the glycosyl donor to 
increase its armed character and achieve higher glycosylation yields. As an ester 
protecting group would no longer be present at the C-2 position of the sugar, 
neighbouring group participation could no longer occur, and a mixture of anomers 
should be expected. A retrosynthetic analysis is presented in Scheme 4.21. 
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Scheme 4.21 Retrosynthetic analysis of KRN7000 analogues 4.13-4.16 from their 
corresponding α- or β-galactoside building blocks, which are in turn synthesised from an 
armed donor. 
 
4.6.1. Armed thioglycosides for α/β-galactosyl building block formation 
A benzylated thioglycoside such as 4.54 could be a suitable armed donor for a 
subsequent glycosylation with L-serinyl acceptors (Scheme 4.22). Both α- and β-
building blocks necessary for the synthesis of KRN7000 analogues would now be 
accessible due to the presence of a non-participating ether protecting group at the 
C-2 position of the galactosyl donor 4.54. However, as an important drawback in 
this approach, we envisaged that chromatographic separations of the mixture of 
anomers may be difficult. Thioglycosides are a type of glycosyl donor commonly 
used in carbohydrate chemistry. One of the reasons they are so frequently utilised 
is due to their high stability to a range of different reaction conditions.[201] This 
would allow for chemical modifications on the glycosyl donor without activation of 
the anomeric leaving group. Thioglycosides have been employed in the work 
concerning three different chapters of this thesis: initially, for the synthesis of an 
IAD glycosyl donor (discussed in Chapter 3) and for the synthesis of O-serinyl 
building blocks for KRN7000 analogues (discussed in this chapter and in Chapter 5).  
 
The synthesis of the thioglycoside 4.54 began with the glycosylation of the acetyl 
protected galactosyl donor 2.32 with thiophenol under Lewis acid activation to yield 
79% of the thioglycoside 4.53 (Scheme 4.22). Subsequent Zemplén deprotection, 
followed by a Williamson ether synthesis, using BnBr and NaH, afforded the 
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benzylated galactosyl donor 4.54 in an overall yield of 79% (over two steps). The 
spectroscopic data were in agreement with those reported in the literature.[202] 
 
 
Scheme 4.22 Reagents and conditions a) HSPh, BF3.OEt2, rt, 18 h, 79%; b) i) NaOMe, MeOH 
, 0 °C to rt, 1.5 h; ii) NaH, BnBr, DMF, 0 °C to rt, 18 h, 79% (2 steps). 
 
 
4.6.2. Revised syntheses of L-serine azido acceptors 
The synthesis of L-serine azido acceptors 4.44 and 4.45 (previously described in 
Section 4.4.6) was revised. A correction  to the original report regarding the use of 
the diazo-transfer reagent 4.43 was published by the authors.[195] They outlined the 
explosive nature of the mother liquor of the hydrochloride salt 4.43, amongst other 
notable problems. We decided the synthesis and use of the diazo-transfer reagent 
4.43 was no longer appropriate, in particular on larger scale, which is a criterion 
necessary for building block formation. A publication superseding the efforts by 
Goddard-Borger and colleagues was presented by the same group whereby 
different acidic salts of the triazole transfer reagent 4.43 were precipitated and 
evaluated as diazo-transfer reagents.[203] They did not exhibit the same hazardous 
effects as the previously described hydrochloride compound 4.43 and were not as 
explosive when friction tested. The sulfuric acid salt of the transfer reagent 
compound 4.55 was synthesised as shown in Scheme 4.23. The only difference from 
the previous experimental procedure lay in the addition of sulphuric acid to 
precipitate to give the corresponding sulphuric acid salt 4.55. In our case, the salt 
4.55 did not precipitate out instantly as described in the literature. However, with 
the addition of petroleum spirits and gentle scratching with a spatula, the 
imidazolium salt 4.55 precipitated in a yield of 32%. The remaining filtrate, 
containing potential azido containing materials were carefully quenched by 
oxidation with NaIO4 and acidified with H2SO4 prior to disposal. 
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Scheme 4.23 Reagent and conditions. a) i)NaN3, MeCN, rt, 18 h;  ii) imidazole, 0 °C to rt, 3 h; 
iii) H2SO4, 0 °C , 1 h, 32%. 
 
Since the glycosylation reactions involving non-participating protecting groups 
(such as the benzyl ethers present in thioglycoside donors like donor 4.54) normally 
result in a mixture of stereoisomeric products, a number of strategies were 
investigated to bias the sterochemical outcome of these reactions. For this reason, 
we decided to synthesise the L-serine glycosyl acceptor 4.58. This derivative features 
the presence of a long hydrocarbon chain (C14), and this may impart stereoselective 
preferences due to steric bulk. The use of lipidic L-serinyl acceptors such as 
compound 4.58 will be discussed in more detail in Section 4.7.4. The synthesis of 
donor 4.58 began with the amide bond formation between the commercially 
available N-Boc-L-serine 4.18 and tetradecylamine, carried out with TBTU, HOBT 
and NEt3 to give the desired lipidic compound 4.56 in a 59% yield (Scheme 4.24). N-
Boc deprotection of L-serinyl derivative 4.56 and recrystallisaton afforded the free 
amine TFA salt 4.57 quantitatively, which was subsequently treated with the diazo-
transfer reagent 4.55 in basic conditions to give the desired L-serinyl acceptor 4.58 
in less than a 54% conversion. The resulting oil contained both the desired 
compound 4.58 and an undesired side product which could not be separated by 
chromatographic separation. The 1H NMR spectrum of the reaction mixture showed 
two signals corresponding to amide protons, one of them with an unusually high 
downfield resonance for an amide proton (7.5 ppm). This led us to believe that the 
unknown compound was a sulfonylamide, with chemical shifts observed in 
agreement with those reported in the literature for this class of compounds.[204] The 
side product was proposed to be the sulfonylamide derivative 4.58a (Figure 4.14). 
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Scheme 4.24 Reagents and conditions. a) NH2C14H29, TBTU, HOBt, NEt3, 4Å MS, rt, 18 h, 
59%; b) TFA, CH2Cl2, 0 °C to rt, 18 h, quant;. c)4.55, K2CO3, CuSO4.5H2O, MeOH, rt,18 h, 
<54%. 
 
 
Figure 4.14 Undesired side product 4.58a formed in the synthesis of  L-serine azide 4.58. 
 
The unsuspected side reactions leading to the formation of compound 4.58a was 
indeed unsettling and led us to abandon the imidazolinium based diazo-transfer 
reagents for the TfN3 route instead, which has been extensively reported in the 
literature, in order to achieve  the formation of the desired L-serinyl azido 
derivative 4.58.[194a] We revisited the synthesis of the L-serine methyl ester 
derivative 4.45 (previously described in Section 4.4.6) and the long chain L-serine 
derivative 4.58 (described above) by this method. The synthesis of L-serine methyl 
ester derivative 4.45 proceeded smoothly from the reaction of commercially 
available L-serine methyl ester 4.60 with TfN3 (which was made in situ by reaction of 
Tf2O and NaN3) catalysed by CuSO4.5H2O and NEt3 in H2O/MeOH/CH2Cl2 (3:10:3; 
Scheme 4.28).[194a] This ratio of solvents ensured that the reaction was carried out 
as a homogeneous solution and stopped the precipitation of TfN3 salts. As a 
precautionary measure, instead of large scale production, three separate reactions 
were carried out in parallel, which were combined, worked up and purified 
together. This synthesis allowed good access to glycosyl acceptor 4.45, available for 
glycosylation. A similar procedure was followed for the preparation of the long 
chain L-serine acceptor 4.58, as shown in Scheme 4.26, which afforded quantitative 
conversion to give the novel glycosyl acceptor 4.58. 
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Scheme 4.25 Reagents and conditions. a) i) CH2Cl2, H2O, 0 °C, N2, 2 h, approx. 60% of TfN3; 
ii) NEt3, CuSO4.5H2O, CH2Cl2/MeOH/H2O (3:10:3), rt, N2, 18 h, 57%. 
 
 
Scheme 4.26 Reagents and conditions. a) TfN3, NEt3, CuSO4.5H2O, CH2Cl2/MeOH/H2O 
(10:3:3), rt, 18 h, 100%. 
 
4.6.3. Glycosylation of armed thioglycosides with various acceptors for α/β-
galactosyl building block formation 
Thioglycoside activation with NIS and TfOH was first reported by Van Boom and co-
workers.[205] A general reaction mechanism for thioglycoside 4.54 glycosylation 
using NIS/TfOH is proposed in Scheme 4.27. Activation of the anomeric leaving 
group occurs by attack of the sulphur atom onto the thiophilic reagent NIS under 
acidic conditions. This activated thioglycoside drives the formation of an 
oxycarbenium ion in an SN2 fashion. The glycosyl acceptor (ROH) can then attack 
the anomeric position at either the top or the bottom face and produce the 
glycosylation product forming a new glycosidic bond. 
 
Scheme 4.27 Reaction mechanism for thioglycoside activation of 4.54 with NIS and TfOH 
results in formation of new glycoside formation. 
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Using this system, the galactosyl thioglycoside donor 4.54 (acting as a limiting 
reagent) was reacted with the glycosyl acceptor 4.45, using stoichiometric amounts 
of NIS and catalytic TfOH (Scheme 4.28).  By analysis of the crude 1H  NMR 
spectrum a mixture of α-anomer building block  4.59 and β-anomer building block 
4.60 were identified (77%, α/β = 2:1). Careful flash chromatography afforded both 
the desired α-anomer 4.59 (32% yield) and the β-anomer 4.60 (25% yield). A 
glycosyl succinimide side product 4.61 was isolated in 21% yield).  This side product 
reported by Zhang et al. can arise due to the formation of succinimide upon 
reaction of the galactosyl donor 4.54 with NIS.[200] The succinimide can act as a 
nucleophile, albeit a poor one and compete with the glycosyl acceptor 4.45 to form 
the galactosyl succinimide side product 4.61. This problem is evident in 
glycosylations involving unreactive glycosyl acceptors. These results corroborate 
that the presence of the azide functionality in the L-serine derivative 4.45 does not 
result in a significant increase the nucleophilicity of the L-serine acceptor, as 
discussed earlier. 
 
 
Scheme 4.28 Reagents and conditions. a) NIS, TfOH, CH2Cl2, 4Å MS, rt, N2, 18 h, 4.59 (32%) 
and 4.60 (25%), and 4.61 (21%). 
 
To clarify whether the azide functionality on the protected L-serine acceptor 4.45 
had increased the nucleophilicity of the acceptor, and thus lead to an increase in 
the yield of the subsequent glycosylation, the thioglycoside 4.54 was reacted with 
the N-Boc glycosyl acceptor 4.20. The reaction of the N-Boc protected acceptor 
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4.20 (deemed to be a poorer nucleophile due to unfavourable hydrogen-bonding) 
with the galactosyl donor 4.54 was performed (Scheme 4.29). 
 
 
Scheme 4.29 Reagents and conditions. a)NIS, TfOH, CH2Cl2, 4Å MS, rt, N2, 18 h, 4.62 (44%). 
No β-anomer 4.63 isolated in the reaction. 
 
Poorer yields were achieved in this reaction, as anticipated. Careful flash 
chromatography afforded only the α-anomer 4.62 in a 44%. It is probable that the 
corresponding β-anomer 4.63 was also formed, as TLC analysis indicated a product 
with an Rf value almost identical to the α-anomer 4.62. It was not possible to isolate 
it by chromatographic separation or to unambiguously identify it in the analysis of 
the remainder of the reaction products. Unreacted acceptor 4.20 and glycosyl 
succinimide 4.61 were also identified in this material. This result may indicate that 
the introduction of the azide functionality on L-serine derivative 4.45 moderately 
increases the yield of the glycosylation reaction.  
 
The reaction between the azido glycosyl acceptor benzyl ester 4.44 with the 
thioglycoside donor 4.54 was executed as shown in Scheme 4.30. In this case, the 
corresponding α-anomer 4.64 was the only product isolated in the reaction in a 
26% yield. Again the chromatographic separation proved to be a challenging step, 
and despite our best efforts, the remainder of the mixture of products could not be 
separated or characterised. As in the previous case the desired β-product 4.65 was 
most likely present due to a spot identified in TLC analaysis in a very similar Rf 
region to the α-anomer 4.64. 
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Scheme 4.30 Reagents and conditions. a) NIS, TfOH, CH2Cl2, 4Å MS, rt, N2, 3 h, 4.64 (26%). 
No β-anomer 4.65 was isolated in the reaction.  
4.7. Stereoselective synthesis of α-galactoside building blocks for KRN7000 
analogues 
With these results in mind we decided that the most promising glycosylation 
reaction so far involved the thioglycoside donor 4.54 and the L-serine methyl ester 
acceptor 4.45 (see Scheme 4.28), whereby separation of the various components of 
the reaction was more achievable than in the other glycosylation reactions explored 
(Scheme 4.29 and 4.30).  In order to increase the yield of the reaction and improve 
the α/β stereoselectivity, optimisation of the reaction conditions was carried out, 
with a bias to synthesise the more immunogenically relevant α-building block 4.59. 
The fact that a higher percentage of the α-anomer was isolated (α/β ratio 2:1), as 
discussed in Section 4.6.3, may indicate that the main mechanism by which the 
reaction proceeds is via an SN1 mechanism. It is possible also that it proceeded 
through of a mixture of SN1 and SN2 mechanism and as a result a mixture of 
anomers were isolated. As discussed in Chapter 2, an SN1 reaction can be affected 
by various parameters. In our study, we explored the effect of temperature and 
solvent choice on the stereochemical selectivity of the reaction. We preferentially 
wanted to synthesise α-building blocks as we anticipated better biological results. 
Therefore parameters that may increase the α-selectivity were investigated.  
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4.7.1. Effects of temperature and solvent on α-stereoselectivity of glycosylation 
reactions 
Temperature can affect the stereochemical outcomes of a glycosylation reasction. 
Kinetically controlled glycosylation reactions carried out at lower temperatures 
generally favour 1,2-trans glycoside formation. Nishizawi et al. reported a 
preference for the formation of β-glycosides (1,2-trans glycoside) at lower 
temperatures and α-glycosides at higher temperatures.[206] Wegmann and Schmidt 
had similar findings.[207] However, conflicting results have also been reported.[208] 
Different solvents can induce the stereoselective formation of 1,2-trans products or 
1,2-cis products, depending on their physicochemical properties. Polar solvents 
generally favour 1,2-trans products while solvents such as CH2Cl2 or toluene 
generally favour 1,2-cis products due to solvation effects.[209] For certain solvents, 
special participating effects, as well as solvating effects, can increase the 
stereoselectivity of desired 1,2-trans products (such as MeCN) or 1,2-cis products 
(such as Et2O). We tailored our solvent choice towards α-glycoside formation, the 
1,2-cis product in our glycosylation. Ether-type reaction solvents (such as Et2O, THF 
and dioxane) are known to participate in glycosylation processes.[210] Improved α-
stereselectivities in glycosylations have been reported when these solvents were 
used in comparison to other solvents.[211] The ether-type solvent acts as a 
nucleophile and attacks the anomeric position of the oxycarbenium ion to form a 
1,2-trans product, which is then subsequently attacked by the glycosyl acceptor in 
an SN2 type fashion to form the inverted 1,2-cis product as shown in Scheme 4.31.  
 
 
Scheme 4.31 Reaction mechanism for 1,2-cis glycosidic product formation induced by an 
ether-type solvent (THF). 
 
The reaction conditions investigated in order to improve the stereoselectivity of the 
glycosylation between thioglycoside donor 4.54 and azido acceptor 4.44 are 
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summarized in Table 4.8. The effects of temperature and solvent on the 
glycosylation stereoselectivity were investigated.  
 
Table 4.8 Summary of reaction conditions explored to optimise α-stereoselectivity in the 
formation of galactosyl building block 4.59. 
 
* 1 equiv of glycosyl donor 4.54, 2 equiv of glycosyl acceptor 4.45, 2 equiv of NIS, 0.01 
equiv of TfOH; ‡ α/β ratio was determined by 1H NMR analysis. 
 
Entry Temperature Solvent
Yield 4.59 
(%)*
Yield 4.60 
(%)
α/β ratio
1 rt CH2Cl2 32 25 2:1
2 -20 °C CH2Cl2  -
‡
 -
‡
1.8:1
‡
3 rt THF  -
‡
 -
‡
4:1
‡
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The effects of the temperature on the stereoselectivity of the glycosylation reaction 
were investigated (Entries 1 and 2 in Table 4.8). A decrease in temperature from rt 
to -20 °C resulted in a corresponding decrease in the α-stereoselectivity from a 2:1 
α/β ratio to a 1.8:1 α/β ratio. Therefore, we can predict the reaction is under kinetic 
control, whereby 1,2-trans products are preferentially formed at decreased 
temperatures. Increased temperatures should encourage higher α-selectivities as a 
direct result of this observation. However, this may lead to degradation of the 
reactants, so rt was chosen as the optimum temperature for glycosylation in our 
system. The effect of solvent was explored (Entries 1 and 3 in Table 4.8) by 
comparison between CH2Cl2 and THF as the glycosylation solvent. An increase in α-
selectivity was observed in THF compared to CH2Cl2, whereby the α/β ratio 
increased from 2:1 to 4:1. This observation was in agreement with the 
literature.[210] Thus, optimised glycosylation conditions in terms of temperature and 
solvent involved the reaction of galactosyl donor 4.54 and glycosyl acceptor 4.45 in 
THF as a reaction solvent and  at rt. 
 
4.7.2. Effects of remote protecting group participation using Li’s method on α-
stereoselectivity of glycosylation reactions 
The formation of a highly stereoselective 1,2-cis product is still one of the most 
challenging and daunting tasks in carbohydrate chemistry. In most cases, the 
formation of these stereoselective products involves very challenging 
methodologies. Gervay-Hague’s glycosyl iodide chemistry, although yielding 
excellent α-stereoselectivities, can be difficult to reproduce due to the high 
reactivity of these glycosyl donors.[143] IAD (discussed in detail in Chapter 3) is a 
method exemplified by Ito and Ogawa’s work, which requires tedious protection 
and deprotection chemistry to deliver a tether suitable for activation and 
subsequent aglycon delivery.[123a] These elaborate syntheses, although exhibiting 
beautiful chemistry lack the simplicity we desire in the synthesis of our building 
block. An ideal synthesis of an α-galactosyl building block would satisfy the 
following criteria: have very few synthetic steps, be accessibility to large scale, be 
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cheap and easy to handle, and also be highly stereoselective to minimise 
purification processes.  
Despite an observed improvement in α-selectivity for the glycosylation reaction of 
α-galactosyl building block 4.59 described above, relatively difficult 
chromatographic separations were still encountered. In order to alleviate this 
problem, an investigation was begun whereby a more stereoselective glycosylation 
reaction was desired. Interestingly, Li and co-workers reported highly α-selective 
galactopyranosyl donors based on the influence of remote protecting groups.[212]  
The α-selectivity reported by Li et al. is accredited to the influence of the remote 
protecting groups at the C-3 and C-4 positions of the glycosyl donor.[212]  If an SN1 
mechanism is in operation, a glycosyl oxycarbenium ion (described in Chapter 2) is 
the key intermediate. In general, two different conformations of glycosyl 
oxycarbenium ions, 4H3 and 
3H4 favour different stereochemical outcomes. The 
4H3  
glycosyl oxycarbenium conformations favour the formation of α-products as the 
chair-like transition state leading to the α-product is more stable than the 
corresponding one leading to the β-product (twist-boat  transition state). 
Conversely, the 3H4 conformation favours the formation of the β-products. Hence, 
mixtures of products are observed for many SN1 glycosylations. In the case of the 
galactosyl oxycarbenium ion with remote acetyl protecting groups shown in 
Scheme 4.32,[212] the carbonyl oxygen atoms can approach the anomeric carbon to 
form the participation intermediates 4.66 and 4.67. In the case of 4H3 oxycarbenium 
ion, an acetyl protecting group at the C-4 position can participate to give 
intermediate 4.66 while an acetyl group at the C-3 position can participate to give 
the intermediate 4.67. The incoming nucleophile can only approach from the 
bottom face of these conformations and result in the stereoselective formation of 
the α-galactoside 4.68. An important structural feature of these glycosyl donors is 
the non-participating group in the C-2 position of the conformations so 
neighbouring group participation cannot interfere. 
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Scheme 4.32 Mechanism of the remote protecting group directing effect.[212] 
 
The synthesis of a novel galactosyl donor 4.71 was undertaken and it was initiated 
with the global deacetylation of thioglycoside 4.53 with NaOMe in MeOH as in 
Scheme 4.33. The crude thiol was selectively protected at the C-3 and C-4 positions 
by an isopropylidene group to give the acetonide 4.69 in 70% yield (over two steps). 
Benzylation of the free C-2 and C-6 hydroxyl groups by treatment with NaH and 
BnBr in a Williamson ether synthesis yielded 75% of the glycoside 4.70. 
Deprotection of the isopropylidene group under acidic conditions allowed 
acetylation at the C-3 and C-4 positions to yield the galactosyl donor 4.71 in a good 
overall yield of 77% over 5 steps.  
 
 
Scheme 4.33 Reagents and conditions. a) i) cat. Na metal, MeOH, 0 °C to rt, 1.5 h; ii) H2SO4, 
acetone, rt, 18 h, 70% (2 steps); b) NaH, BnBr, DMF, 0 °C to rt, 18 h, 75%;  c) i) AcOH, 80 °C, 
4 h;  ii) Ac2O, DMAP, Pyr, rt, 1.5 h, 86% (2 steps). 
 
Following the reaction conditions described by Li and colleagues,[212] whereby the 
galactosyl donor 4.71 was reacted with L-serine acceptor 4.43 using a mixture of 
promoters (NIS/ TMSOTf) to give 66% of a mixture of diastereoisomers 4.72 and 
4.73 (Scheme 4.34). Analysis by 1H NMR spectroscopy of the crude reaction mixture 
indicated a 2:1 α/β stereoselectivity. After purification, only small amounts of the 
pure α-product 4.72 could be isolated (7%) for characterisation, and separation of 
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the β-product 4.73 proved to be impossible. Disappointed with the poor 
stereoselectivity observed, the methodology was abandoned. 
 
 
Scheme 4.34 Reagents and conditions. a)NIS, TMSOTf, CH2Cl2, 4Å MS, 0 °C, N2, 1 h, 66%  
4.72 and 4.73 (2:1 α/β). 
 
4.7.3. Effects of halide-ion catalysis on α-stereoselectivity of glycosylation using 
glycosyl iodides 
The use of glycosyl iodides as glycosyl donors has been reported to achieve 
excellent stereoselectivities.[143, 213] However, due to their highly reactive nature, 
the preparation and handling of glycosyl iodides can be problematic. Since the 
desired α-stereoselectivity was not observed using Li’s methodology, described 
above in Section 4.7.2, the preparation of 1,2-cis linkages using glycosyl iodides as 
glycosyl donors, as reported by Gervay-Hague and co-workers, was attempted.[193] 
Gervay-Hague capitalised on the effectiveness of halide-ion catalysis pioneered by 
Lemieux and colleagues, whereby α-glycosyl bromides were used to construct 
difficult 1,2-cis linkages. [214] Gervay-Hague developed Lemieux’s methodologies 
with the use of glycosyl iodide donors, TBAI and a hindered base to 
stereoselectively produce 1,2-cis glycosides in excellent yields.[215] The addition of 
the halide ion (TBAI) facilitates in situ anomerisation of the α-halide 4.71 to the 
more reactive β-halide 4.72. It is believed that the stereoselectivity arises from a 
Curtin-Hammett kinetic scheme whereby the glycosyl acceptor reacts in an SN2 
fashion to yield the 1,2-cis product 4.77. A schematic representation is shown in 
Scheme 4.35. 
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Scheme 4.35 Mechanism of glycosidic bond formation from glycosyl iodides in the 
presence of TBAI.[213] 
In the synthesis, the benzylated galactosyl acetate 4.79 was prepared by treatment 
of the thioglycoside 4.54 with NBS in wet acetone to give hemiacetal 4.78, followed 
by acetylation using Ac2O in Pyr, to give 41% of the acetylated donor 4.79 (Scheme 
4.36).  
 
Scheme 4.36 Reagents and conditions. a) NBS, wet acetone, 75 °C, 18 h, 61% (based on 
recovered starting material);  b) Ac2O, Pyr, 0 °C, rt, 18 h, 41%. 
 
The acetylated donor 4.79 was reacted under anhydrous conditions with TMSI in 
CH2Cl2 to form the α-glycosyl iodide 4.80, which was then reacted with the L-serinyl 
acceptor 4.46 in the presence of TBAI and DIPEA, in order to produce the desired α-
glycoside 4.81 following a literature procedure described by Wu and Gervay-Hague 
(Scheme 4.37).[193] However, none of the desired product 4.59 was isolated. 
Instead, the unreacted L-serine acceptor 4.45 was recovered, along with hemiacetal 
product 4.78. This observation indicates that, if the glycosyl iodide 4.81 had 
formed, it must have subsequently undergone hydrolysis to give the hemiacetal 
4.78.  
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Scheme 4.37 Reagents and conditions. i) TMSI, CH2Cl2, 0 °C, 20 min; ii) Benzene, TBAI, 
DIPEA, 65°C, 1.5 h. Desired product 4.59 was not isolated. 
 
In parallel with the conditions described above, the use of the fully TMS protected 
glycosyl donor 4.83 was investigated. The procedure for the formation and isolation 
of the silyl protected O-glycoside 4.83 were described by Besra and colleagues 
(Scheme 4.38).[216] The synthesis began with the TMS protection of D-galactose 4.28 
by reaction with TMSCl and NEt3 to produce compound 4.82 in 89% yield. The 
precursor 4.82 was reacted with TMSI in CH2Cl2 at 0 °C, for a subsequent 
glycosylation reaction with glycosyl acceptor 4.45 with TBAI and DIPEA as described 
before. Attempts of purification with flash chromatography resulted in poor yields 
of α-anomer 4.85 (15%), possibly because the TMS protected compounds were acid 
labile. This prompted us to repeat the synthesis and remove the silyl protecting 
groups of glycoside 4.85 and acetylate the hydroxyl groups prior to flash 
chromatography of product 4.85. This approach would give acetylated glycosyl 
donor 4.86.[193] Purification afforded an overall yield of 3% of the desired acetylated 
glycoside 4.86. A complicated array of acetylated products were present also. This 
glycosyl iodide method was abandoned due to the poor yields obtained in our 
synthesis of glycoside 4.86. 
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Scheme 4.38 Reagents and conditions. a) TMSCl, NEt3, DMF, 4Å MS,  0 °C to rt, 4 h, 89%; b) 
i) TMSI, CH2Cl2, 0 °C, 20 min;  ii) TBAI,DIPEA, benzene, rt, 48 h;  c) i) Dowex (H
+ form), 
MeOH, rt, 5 h;  ii) Ac2O, Pyr, rt, 18 h, 3% (overall yield). 
 
4.7.4. Synthesis of glycolipids 4.14 and 4.16 using lipidic L-serine acceptors  
Glycosylation conditions explored so far have resulted in moderate 
stereoselectivities and yields. Separation of the diastereoisomers proved to be even 
more problematic. We proposed that if a lipidic chain were introduced earlier in the 
synthesis, perhaps steric factors would influence the stereoselectively of the 
glycosylation, with a preference towards the α-glycosyl product. Additionally, the 
separation of the diastereoisomers may be easier than for previous attempts. This 
method is also a more convergent approach to the previously explored building 
blocks synthesis. The disadvantage of this approach lies with the fact that, for 
different lipidic chain lengths on the acid residue, the stereochemical outcome may 
be different and the reaction conditions may need to be optimised every time. With 
the target KRN7000 analogues 4.14 and 4.16 in mind (shown in Figure 4.15), we 
focussed our attention on the synthesis of an L-serine donor functionalised with a 
C14 hydrocarbon chain, such as protected glycolipid 2.67 (Scheme 4.39). 
 
Figure 4.15 KRN7000 and L-serine analogue targets 4.14 and 4.16. 
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The synthesis of the N-Fmoc protected L-serine derivative 2.66 (mentioned in 
Chapter 2) was therefore undertaken by the reaction of N-Fmoc-L-serine 4.23 with 
tetradecylamine, using the TBTU/HOBT standard coupling methodology to give a 
yield of the amide 2.66 in 73% yield (Scheme 4.39). A glycosylation reaction was 
then performed with the glycosyl acceptor 2.66 and the previously synthesised 
thioglycoside 4.54, using NIS and catalytic TfOH in THF under the optimised 
conditions described in Section 4.6.3. Analysis by TLC indicated that three 
compounds were present in the reaction mixture, namely the hemiacetal 4.78 
(Scheme 4.36), the unreacted glycosyl acceptor 2.66 and a single glycosylation 
product, suggesting the stereoselective formation of a single diastereoisomer. 
Purification by flash chromatography afforded 49% of the novel α-glycoside 2.67. 
No evidence of the formation of the corresponding β-glycoside was observed. 
 
Scheme 4.39 Reagents and conditions. a) NH2C14H29, TBTU, HOBt, DIPEA, 4Å MS, 0 °C to rt, 
18 h, 73%; b)NIS, TfOH, 4Å MS, THF, rt, 18 h, 49%. 
Deprotection of the N-Fmoc protecting group of glycoside 2.67 under basic 
conditions (10% piperadine in CH2Cl2) afforded the free amine product, which was 
reacted without further purification with decanoic acid using TBTU/HOBt coupling 
methodology to yield the protected glycolipid 4.87 in a 74% yield (over two steps) 
as shown in Scheme 4.40.  The 1H NMR of the novel benzyl protected glycolipid 4.87 
is shown as a representative example in Figure 4.16. Diagnostic signals are 
highlighted in the spectrum including the protons corresponding to the amide 
functionalities (at 7 and 6.8 ppm), and the anomeric proton (at 5.2 ppm, J = 3.7 Hz), 
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present at a chemical shift and containing a coupling constant characteristic for an 
α-galactoside.  
O
NHFmoc
CONHC14H29
O
OBnBnO
BnO
BnO
2.67
O
NHCOC9H19
CONHC14H29
O
OBnBnO
BnO
BnO
4.87
O
NHCOC9H19
CONHC14H29
O
OHHO
HO
HO
4.14
a b
 
Scheme 4.40 Reagents and conditions. a)i) 10% piperadine in CH2Cl2, rt, 1 h, ii) C9H19CO2H, 
TBTU, HOBt, DIPEA, DMF, rt, 18 h, 74% (2 steps); b) H2, Pd (C), EtOH, EtOAc, AcOH,  rt, 20 h, 
89%. 
Figure 4.16 
1H NMR spectrum of glycolipid 4.87. Characteristic signals are highlighted. 
 
Global debenzylation of glycolipid 4.87 was first attempted using H2(g) and a 10% 
w/w loading of Pd(C) in EtOH/EtOAc (3:1) at 4 Barr pressure for 18 h in a 
hydrogenator shaker apparatus. However no hydrogenation of the benzyl ethers 
was observed. Upon addition of catalytic AcOH and a higher loading with 50% w/w 
of Pd(C), the deprotection of the benzyl ether protecting groups with H2 at 4 Barr 
pressure yielded the literature known KRN7000 analogue 4.14 in 89% yield.[169a] 
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Structural characterisation was carried out on the analogue 4.14 with the aid of 
NMR, IR and HR-mass spectrometry and a specific optical rotation value was 
obtained, as characteristic data was not reported for the literature example.[169a] A 
representative example of the 1H NMR spectrum is shown in Figure 4.17. Diagnostic 
signals include the H-α proton (4.6 ppm), the sugar protons (3.6-4.0 ppm) and the 
methylene protons of the long chains (1.3 ppm). No signals were identified for the 
amide protons due to deuterium exchange with residual D2O in the d4-MeOD. 
 
Figure 4.17 1H NMR spectrum of glycolipid 4.14 in d4-MeOD. Characteristic signals are 
highlighted. 
 
The synthesis of the triazole containing analogue, glycolipid 4.16 (Figure 4.15), 
required the use of the azido lipidic L-serinylacceptor 4.58 (previously described in 
Section 4.6.2). Reaction of the thioglycoside 4.54 and the L-serinyl acceptor 4.58 in 
THF, with NIS and TfOH as the promoter system, gave a mixture of 
diastereoisomers 4.88 and 4.89 (α/β ratio of 2.7:1 in a 63% combined yield), with 
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isolation of 35% of the 1,2-cis product 4.88 (Scheme 4.41). In this case, the easier 
separation of the desired α-anomer 4.88 during flash chromatography 
compensated for the decrease in the stereoselectivity in the glycosylation reaction. 
Fortunately also, recovery of the unreacted glycosyl acceptor 4.58 allowed for its 
use in subsequent glycosylation reactions to be carried out. On the other hand, 
attempts to isolate the β-glycoside 4.89 in a pure form failed. 
 
Scheme 4.41 Reagents and conditions. a) NIS, TfOH, 4Å MS, THF, rt, 18 h, 63% (α/β ratio of 
2.7:1), 4.88 (35%). No pure β-anomer 4.89 was isolated. 
The galactosyl azide 4.88 was reacted with the commercially available pentadecyne 
in the presence of CuSO4.5H2O and sodium ascorbate in a CuAAC reaction 
(described in detail in Chapter 5), to afford 76% of the 1,4-disubstituted 1,2,3-
triazole containing glycolipid 4.90 in a regioselective manner (Scheme 4.42). The 1H 
NMR spectrum of the benzyl protected glycolipid 4.90 is shown in Figure 4.18, and 
diagnostic signals are highlighted. Interestingly, the coupling constant of the 
anomeric proton of the triazole glycolipid 4.90 (J = 6.3 Hz) is an unusually large 
coupling constant for an α-glycosidic linkage. However, the chemical shift of the 
anomeric proton (4.9 ppm) is characteristic of an α-product. Thus the formation of 
the triazole ring seems to have affected the conformation of the molecule.  Also of 
significance is the signal corresponding to the H-α proton (5.4 ppm), appearing at a 
much higher chemical shift than expected for an H-α proton. However, this 
observation is in agreement with data reported for amino acid based derivatives 
containing a triazole moiety at the C-α, although it is not explicitly discussed.[217]  
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Scheme 4.42 Reagents and conditions. a)Pentadecyne, CuSO4.5H2O, Na ascorbate, 
THF/MeOH/H2O (2:2:1), rt, 18 h, 71%; b) H2, Pd (C), EtOAc/EtOH. 
 
Figure 4.18 1H NMR spectrum of benzyl protected glycolipid 4.90. 
 
Difficulties arose with the global deprotection of the benzyl ether protecting groups 
of glycolipid 4.90. Hydrogenolysis involving 10% w/w loading of Pd(C) at 4 Barr 
pressure in a hydrogenator shaker apparatus for 18 h did not result in complete 
hydrogenation of the benzyl ethers. The use of Pearlmans catalyst (Pd(OH))  in a 
10% loading did not sufficiently catalyse the reaction as an alternative. Increased 
Chapter 4: Synthesis of L-serinyl based glycolipid  analogues of the immunostimulant 
KRN7000 
152 
 
quantities of Pd(C) ranging from 10% w/w up to 500% w/w loading were utilised in 
a systematic manner but complete deprotection was not achieved. The addition of 
AcOH, as performed for the glycolipid 4.14 did not yield favourable results either. 
Instead, degradation occurred with small amounts of partially protected 
compounds of glycolipid 4.90 detected in HR-MS analysis. In an attempt to further 
identify the possible degradation products in the reaction mixture or whether any 
of the desired glycolipid 4.90 had been formed, it was subjected to an acetylation 
reaction using Ac2O in Pyr for 18 h as in Scheme 4.42. 
1H NMR analysis indicated 
hydrocarbon by-products with no signals indicative of a triazole containing product. 
HR-MS analysis confirmed traces of the desired compound 4.91 and some per-
acetylated galactose 2.32 also. No other degradation products could be discerned. 
Due to a limited reservoir of the protected glycolipid 4.90 the debenzylation 
conditions could not be optimised.  
It was obvious that the forceful conditions necessary for the cleavage of the benzyl 
ethers resulted in a degradation of the product 4.90 to yield an unidentifiable 
mixture. Possible reasons for the need for such forceful conditions are outlined. The 
presence of residual CuSO4.5H2O from the previous CuAAC reaction may have 
hindered the rate of reaction, as Cu is known for poor hydrogenolytic activity, [218] 
thus harsh conditions would be necessary for the hydrogenolysis. Alternatively, 
competing coordination of the triazole moiety to the Pd(C) in glycolipid 4.90 may 
also have been responsible for the sluggish reaction. The degradation observed may 
have been accelerated due to the increased acidity of the H-α in the protected 
glycolipid 4.90. As a result of these observations, the synthesis of glycolipid 4.16 
was not repeated using the synthetic strategy proposed above.   
4.8. Concluding remarks 
It seems that, after analysing a range of different reaction conditions for the 
synthesis of an L-serine building block for KRN7000 analogues 4.13-4.16, the 
optimum glycosylation conditions involve the use of the thiogalactoside 4.54 with 
either the N-Fmoc protected L-serine acceptors 2.66 (Section 4.7.4) or the azido L-
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serine glycosyl acceptor 4.58 (Section 4.4.7) to give KRN7000 α-analogues 4.14 and 
the benzyl protected analogue 4.90, respectively. 
The β-analogues of KRN7000 4.13 and 4.15 were not synthesised. This was partially 
due to the problems arising from the disarmed ability of galactosyl donors bearing 
ester protecting groups (discussed in Section 4.4) leading to poor glycosylation 
yields of β-galactosyl building blocks, coupled with the inherently low 
nucleophilicity of their L-serinyl acceptors. Secondly, the inability to separate 
sufficient quantities of β-galactosyl building blocks during glycosylations involving 
armed donors (discussed in Section 4.6 and 4.7) hindered the subsequent synthesis 
of the β-analogues of KRN7000 4.13 and 4.15. 
In general, moderate yields were reported for the key synthetic step involving 
glycosylation to synthesise a suitable building block for KRN7000 analogues in this 
chapter. Most likely, the low nucleophilic nature of the L-serinyl glycosyl acceptors 
contributed to these moderate yields. However, excellent stereoselectivity was 
observed for the long chain N-Fmoc methodology (described in Section 4.7.4) and 
good separation of the azido glycolipid building block 4.88 (described in Section 
4.7.4) was reported. These optimisation reaction conditions would serve as a 
suitable methods for the synthesis of a C-6 functionalised L-serinyl KRN7000 
analogue (described in Chapter 5). Isolation of the α-glycolipids 2.67 and 4.88 
allowed for the synthesis of the KRN7000 analogue 4.14 and the benzyl protected 
precursor 4.90 respectively. The glycolipid 4.14 will be evaluated for its ability to 
serve as an iNKT cell stimulatory ligand. This in vitro study will be carried out by Dr. 
Derek Doherty in St. James hospital on human iNKT cells.  
The difficulties encountered during the deprotection of glycolipid 4.90 indicated 
that an alternative approach is necessary for the synthesis of triazole containing 
glycolipid 4.16. The use of PMB ethers in place of benzyl ethers in the synthetic 
stategy is one possible solution, whereby removal of the PMB ethers could occur 
with DDQ in the final deprotection step. 
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5.1. Introduction 
5.1.1. Carbohydrate macrocycles  
A macrocyclic compound is defined as a molecule containing a ring of 12 or more 
atoms. Over the past decade, the development of carbohydrate containing 
macrocyclic compounds has received considerable attention due to their diverse 
structural characteristics and interesting biological profiles.[219] The key design 
element in the formation of a carbohydrate containing macrocycle often involves a 
ring closing alkene metathesis (RCM) reaction, and some examples are shown in 
Figure 5.1.[219-220]  
 
Figure 5.1 Carbohydrate macrocycles synthesised by a RCM reaction.[219-220]  
 
The synthesis of macrocycle 5.1 (Figure 5.1) was explored by Dorner and 
Westermann and it involved RCM as a key synthetic step. Macrocycle 5.1 was 
obtained in 95 % yield.[219b] More recently, Doyle and Murphy synthesised a range 
of glycophanes using RCM (macrocycle 5.2 in Figure 5.1 is one such example) and 
ring closing alkyne metathesis (RCAM), to study host-guest interactions. However, 
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low aqueous solubility of these compounds restricted biological evaluation.[221]  
Tricolorin A and G (Figure 5.1) were isolated from Ipomoea tricolor Cav., a plant 
used in traditional medicine in Mexico to protect crops against invasive weeds 
(described in Chapter 1).[220] Subsequent SAR studies on Tricolorin A highlighted the 
importance of the intact macrocyclic lactone ring of Tricolorin A on plant growth 
inhibition.[222] The first total synthesis of Tricolorin G and the subsequent total 
synthesis of Tricolorin A were successfully achieved by  Fuerstner and colleagues 
utilising RCM as the key synthetic step in the formation of both these 
macrocycles.[10]  
5.1.2. Carbohydrate macrocycles formed by CuAAC reactions 
Since the discovery of the CuAAC click reaction (described in Section 5.1.3.), many 
applications in medicinal and biomedical chemistry have been explored utilising 
azides and alkynes. This is predominantly owning to the isosteric relationship of the 
1,4-disubstituted 1,2,3-triazoles to the amide bond (Figure 5.2), making them 
attractive substrates for many biological applications.[223] Examples of the formation 
of carbohydrate macrocycles involving the CuAAC reaction as a key synthetic step 
are scarce, most probably due to the difficulties involved in carbohydrate synthesis 
in general and the relative novelty of the CuAAC reactions to the scientific 
community (2002), not to mention the fact that macrocycles are difficult to 
prepare. Some examples in the literature are described below. 
 
Figure 5.2 Structure of amide bond in a peptide (left) and a 1,4-disubstituted 1,2,3 triazole 
mimic (right). C-α distances, hydrogen-bonding abilities, dipole moment and structural 
planarity are comparable.[223] 
 
Much interest has been focussed on cyclodextrins (CD), which have applications in 
drug delivery systems[224] and topical drug formulation[225] amongst many others, 
due to their enhanced biocompatibility and water solubility compared to other 
multivalent constructs. The synthesis of CD mimics were performed by  Bodine and 
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colleagues  through the use of CuAAC chemistry as in Scheme 5.1.[226] They 
reported a convergent click cyclodimerization of a bifunctionalised trimannoside 
using a CuI/DBU catalytic system to afford a 80% yield of the desired dimer 5.4, 
with a concomitant formation of an undesired cyclic trimer (15%). After global 
deprotection of the benzyl ether protecting groups to give dimer 5.5 in quantitative 
yield, the CD mimic was found to serve as a host to inclusion of ANS, a small organic 
molecule in a similar manner to β-CD. 
 
Scheme 5.1 Sythesis of macrocyclic dimer 5.5 from trimannoside 5.3.[226]  
 
Macrocycles incorporating amino acids are important in the pharmaceutical 
industry. These conformationally constrained peptidomimetics possess unique 
properties that aid in their utility as important molecular probes of biological 
processes and as potential drug leads.[227] Amino acid macrocycles combining 
carbohydrate moieties offer unique candidates as artificial receptors for small 
biomolecules as they possess functionalities that allow for most types of 
intermolecular interactions.[228] Billing and Nilsson synthesised C2-symmetric 
macrocyclic carbohydrate/amino acid hybrids through CuAAC chemistry.[228] One 
such example explored the reaction of the bifunctional precursor 5.6 with a CuI/ 
DBU catalytic system to yield 64% of the desired C2-symmetric macrocycle 5.7  
(Scheme 5.2). These novel carbohydrate based macrocycles were investigated as 
H2O soluble artificial receptors using computational methods.  
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Scheme 5.2 Synthesis of macrocyclic carbohydrate/ amino acid hybrid 5.7.[228] 
 
5.1.3. Cu catalysed azide-alkyne cycloaddition (CuAAC) 
The Huisgen 1,3-dipolar cycloaddition reaction involves the reaction of an organic 
azide and a  terminal alkyne to form a mixture of 1,2,3-triazole regioisomers upon 
thermal heating (Scheme 5.3).[229] This classical cycloaddition has gained 
considerable attention since the introduction of the Cu(I) catalysed azide-alkyne 
cycloaddition (CuAAC), reported independently by the groups of Mendel [230] and 
Sharpless.[231] It involves the regioselective transformation of organic azides and 
terminal alkynes into 1,4-disubstitutued 1,2,3-triazoles (Scheme 5.3).  
 
Scheme 5.3  A CuAAC reaction involves the regiospecific formation of a 1,4-disubstituted 
1,2,3-triazole product in the presence of Cu(I) (top); a Huisgen 1,3-dipolar cycloaddition 
under thermal irradiation affords a mixture of 1,4 and 1,5-disubstituted 1,2,3-triazole 
regioisomers (bottom). 
 
CuAAC reactions often satisfy the criteria for click chemistry, a term coined by 
Sharpless to describe a “near perfect” reaction that mimics nature by joining small 
modular units together.[232] A click chemistry reaction must be modular, wide in 
scope, high yielding, produce inoffensive by-products (if any), be stereospecific, 
have high atom economy, produce compounds that are physiologically stable, and 
exhibit a large thermodynamic driving force. The resulting 1,4-disubstituted 1,2,3-
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triazoles possess high chemical stability (generally inert to hydrolytic cleavage, 
oxidation or reduction), aromatic character and hydrogen bond accepting 
ability.[233] For this reason, triazole containing molecules can serve as hydrolytically 
stable amide mimics, which can be exploited in the quest to synthesise biologically 
active KRN7000 analogues (as described in Chapter 4).  
5.1.4. Mechanistic considerations of Cu(I) catalysed azide-alkyne cycloaddition 
The mechanism proposed by Mendal and Tornoe [234] for the CuAAC reaction is 
based on previous mechanistic studies whereby DFT calculations provided evidence 
for a stepwise mechanism, unlike the classical thermal cycloaddition which 
proceeds via a concerted mechanism.[234] The catalytic cycle is initiated by π 
coordination of the terminal alkyne to a Cu(I) species to form Cu(I) acetylide 
complex 5.8 (Scheme 5.4). This causes the alkyne proton to be more acidic, 
facilitating its removal (generally under basic conditions) to form the δ-acetylide 
intermediate 5.9. Mendal and Tornoe, with evidence from crystallographic 
structures, suggest that the acetylide carbon atom coordinates to three Cu atoms 
to form the Cu(I) species 5.9 (with m=3); however DFT calculations are needed to 
confirm such a hypothesis.[234] The formation of Cu(I) species 5.9 was found to be 
endothermic in MeCN (0.6 kcal/mol), but exothermic in H2O (11.7 kcal/mol).
[234] 
These findings were in good agreement with the literature, where it is well known 
CuAAC reactions proceed faster in aqueous media.[235]  
In the next step a Cu atom coordinates to the azide group as in transition states 
5.10A or 5.10B. Kinetic studies by Rodionov and colleagues revealed that the 
CuAAC reaction proceeded following second order kinetics with respect to the Cu, 
indicating that activation of the alkyne and azide occurred by different metal 
centres.[236] Structural evidence retrieved from X-ray crystallographic data and the 
kinetic studies described above seem to suggest that the acetylide and the azide are 
not necessarily bound to the same Cu atom as in 5.10A but to two separate Cu 
atoms as in 5.10B. Two possibilities for coordination and delivery of the azide to the 
alkyne during the transition state have been suggested (5.10A or 5.10B), whereby 
the complexation of the azide to the Cu atom activates it towards nucleophilic 
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attack at the secondary carbon of the acetylide to generate the regioselective 
metallocene intermediates 5.11A and 5.11B. Experimental confirmation of this 
mechanistic step is given by the fact that electron-withdrawing substituted alkynes 
accelerate the CuAAC reaction.[230] Ring contraction afforded by transannular 
association (of the nitrogen lone pair of electrons and the C(5)-Cu π* orbital) yields 
the metallated triazole 5.12. Electrophilic attack at the triazole (or protonation) 
yields the desired 1,2,3-triazole 5.13 and dissociation regenerates the Cu catalyst 
and ends the cycle. 
 
Scheme 5.4 Outline of plausible mechanisms for the Cu(I) catalysed reaction between 
organic azides and terminal alkynes.[237] 
 
5.2. Research objective  
In this chapter, we focused our attention on the synthesis of novel macrocyclic L-
serinyl glycolipid analogues of KRN7000, to probe whether they could be 
successfully synthesised using CuAAC reactions. The structures of the proposed 
macrocyclic targets 5.14 and 5.15 are presented in Figure 5.3. The idea of 
synthesising carbohydrate/amino acid macrocycles as KRN7000 analogues has not 
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been explored in the literature, to the best of our knowledge. The conformationally 
constrained analogues may prove to be interesting compounds for immunogenic 
studies. We aimed to investigate the effects that the introduction of rigidity and 
aromaticity on KRN7000 analogues would have on the activation of iNKT cells 
(discussed in Chapter 4), compared to KRN7000 and other acyclic analogues. The 
monomeric glycolipid 5.14, containing a fused tricyclic scaffold, would serve as the 
most rigid antigen with only one alkyl chain for the hydrophobic groove pockets of 
the CD1d protein. The formation of higher order oligomers (cyclic and acyclic), is 
commonly observed in macrocyclization reactions.[238] In this regard, the dimeric 
glycolipid 5.14 would serve as a more flexible cyclic system with two alkyl chains 
suitable for binding with the CD1d protein. The loading of such analogues to the 
CD1d protein would most likely result in an alteration in the presentation of the 
polar head groups to the TCR of the iNKT cell, which would alter the binding affinity 
of the ternary complex. This, in turn, may affect the subsequent cytokine release 
profile (as discussed in Chapter 4). 
 
Figure 5.3 Structures of macrocyclic L-serinyl glycolipids 5.14 and 5.15 as KRN7000 
analogues. 
 
Accounting for the findings in Chapter 3, a building block for macrocycle formation 
leading to glycolipids 5.14 and 5.15 was selected, based on the use of a 
thioglycoside donor with alkyne functionalization at the C-6 position and an L-
serinylacceptor with an azide functionality. CuAAC chemistry would be utilised to 
form the corresponding 1,4-disubstituted 1,2,3-triazole in the macrocyclic 
compounds 5.14 and 5.15, using different dilution conditions. As discussed in 
Chapter 4, we encountered problems in the removal of the benzyl ether protecting 
groups of triazole containing glycolipid 4.90. For this reason, we were aware that 
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the use of a benzylated glycosyl donor such as thioglycoside 5.16 may lead to 
complications, upon final deprotection of the target macrocycles. However, due to 
their stability and compatibility with the conditions used in CuAAC, they were still 
employed. The ultimate aim would be to assess the ability of the macrocyclic 
glycolipids 5.14 and 5.15 to serve as iNKT cell stimulatory ligands. 
5.3. Design strategy for the formation of macrocycles 5.14 and 5.15 
The synthetic pathway for the formation of the macrocycles 5.14 and 5.15 was 
designed as in Scheme 5.5. We envisaged an α-stereoselective coupling of glycosyl 
donor 5.16 and L-serinyl acceptor 4.56 to yield the L-serinyl galactosyl building block 
5.17 containing both azide and alkyne functionalities. Subsequent CuAAC reactions 
under optimised conditions and global deprotection would yield the macrocycles 
5.14 and 5.15 for biological evaluation. 
 
Scheme 5.5 Proposed synthetic design of macrocyclic glycolipids 5.14 and 5.15. 
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5.3.1. Synthesis of thiogalactsoyl donor 5.16 
The synthesis of the reported galactosyl donor 5.16,  differentially functionalised at 
the C-6 position, was undertaken as shown in Scheme 5.6.[239] The synthesis began 
with the deacetylation of thioglycoside 4.52 (previously synthesised in Chapter 4) 
using Zemplén conditions to yield 81% of a crude thiogalactoside, which was 
reacted with TBDMSCl and NEt3 to yield the thiogalactoside 5.18 protected at the C-
6 position in a 79% yield. The use of bulky silyl protecting groups (such as TBDMSCl) 
is common practise in carbohydrate chemistry as they selectively react with the 
least hindered primary hydroxyl group at the C-6 position.[69] A Williamson ether 
synthesis using NaH and BnBr was then undertaken following a literature 
procedure.[240] The benzyl protected thiogalactoside 5.19 was isolated in a yield of 
31%. This may be due to the hydrolysis of the TBDMS under the harshly basic (NaH) 
conditions.  
 
Scheme 5.6 Reagents and conditions. a) i) cat. Na metal, MeOH , 0 °C to rt, 1.5 h, 81%;  ii) 
Pyr, TBDMSCl, NEt3, -10 °C to rt, 21 h, 79%; b) NaH, BnBr, DMF, 0 °C, 2 h, 31 %; c)TBAF, THF, 
0 °C to rt, 6 h, 94%;  d) NaH, TBAI, propargyl bromide, THF,  0 °C to rt, 18 h, 47%. 
 
Deprotection of the bulky silyl ether (TBDMS) of galactoside 5.19 by treatment with 
TBAF was undertaken, following a literature procedure, to yield thioglycoside 
5.19.[241] Nucleophilic attack of the small fluoride anion (in TBAF) leads to formation 
of a pentavalent silicon centre due to hybridisation with the vacant d-orbitals of 
silicon. In addition, the formation of the strong Si-F bond is the driving force for a 
fast cleavage. Treatment of the free hydroxyl group at the C-6 position of the 
thiogalactoside 5.20 with propargyl bromide using NaH and TBAI afforded 47% of 
the desired alkyne functionalised thiogalactoside 5.16 in a Finkelstein-Williamson 
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ether hybrid reaction. A Finkelstein reaction is an SN2 reaction that involves the 
exchange of one halogen atom for another.[242] Halide exchange is an equilibrium 
reaction (previously met in Chapter 4), and the reaction can be driven to 
completion by different solubilities of halide salts, or large excesses of halide salts. 
In our case, the exchange of BnBr with TBAI results in BnI and TBAB. The TBAB is not 
soluble in THF and in turn drives the Williamson ether reaction to completion to 
give the thiogalactoside 5.16. 
Structural elucidation was performed on the thiogalactoside 5.16. Although it is a 
known compound,[239] no experimental data or synthesis was provided by the 
authors. 1H NMR, 13C NMR, 2D NMR experiments (COSY and HSQC), IR and HR-MS 
were utilized to confirm the structure of the galactosyl donor 5.16.  A diagnostic 
stretch appears in the IR spectrum for galactosyl donor 5.16, with the terminal 
alkyne C-H stretch appearing at 3287.6 cm-1. This band is not present in the 
precursor thiogalactoside 5.20. The 1H NMR spectrum is presented in Figure 5.4 and 
characteristic signals are highlighted. Although the region of the 1H NMR where the 
signal corresponding to the anomeric proton is obscured with other signals 
corresponding to the methylene protons of the benzyl ether protecting groups, 
HSQC directly correlates the signal corresponding to the anomeric carbon (87.7 
ppm) to a signal in this proton overlap as shown in Figure 5.5. From analysis of the 
COSY spectrum (Figure 5.6), a signal in this region (4.5 to 5 ppm) directly correlates 
to a signal appearing at 4 ppm corresponding to H-2. These observations correlate 
well with the HSQC data acquired. Thus, by the chemical shift and direct coupling 
observed in both the HSQC and COSY spectra, we can highlight the anomeric proton 
and from the same method elucidate the other ring protons. The characteristic 
signals for the propargyl functional appear at 4.1 ppm. The benzylic protons appear 
at 4.1 ppm and the proton corresponding to the alkyne is present at 2.5 ppm. IR, 13C 
NMR and HR-MS were in agreement with the 1H NMR data obtained. 
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Figure 5.4 
1H NMR spectrum of thiogalactoside 5.16. Characteristic signals are highlighted. 
 
Figure 5.5 Zoom in of 2D HSQC experiment for thiogalactoside 5.16. Direct coupling of 
signal corresponding to anomeric carbon to anomeric proton shown inset as a 
representative example. 
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Figure 5.6 2D COSY experiment for thiogalactoside 5.16. Direct coupling of signal 
corresponding to anomeric carbon to H-2 shown inset as a representative example. 
5.3.2. Synthesis of bifunctional galactosyl building block 5.17 
The glycosylation of the galactosyl donor 5.16 with the L-serinyl acceptor 4.58 
(prepared as described in Chapter 4) was performed using NIS and TfOH as a 
promoter system, at rt and in THF as a solvent (Scheme 5.7). After 18 h, the crude 
reaction mixture consisted of a mixture of diastereoisomers in a 2.3:1 ratio (α:β), 
which led to the desired α-anomer 5.17 in 16% isolated yield and the β-anomer 
5.21 in 5% isolated yield. No further optimisation was performed in order to 
improve the stereoselectivity obtained in the reaction. It is noteworthy that a 
similar stereoselectivity was obtained in the glycosylation reaction of the fully 
benzylated thioglycoside 4.54 and the L-serinyl azide derivative 4.58 (α/β ratio of 
2.7:1, as discussed in Chapter 4). 
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Scheme 5.7 Reagents and conditions a) NIS, TfOH, 4Å MS, THF, rt, 18 h, α/β (2.3: 1), 5.17 
(16%) and 5.21 (5%). 
 
Structural characterisation was carried out on the novel α-anomer 5.17 and the 1H 
NMR spectrum is shown in Figure 5.7. The characteristic signals are highlighted: the 
amide proton (at 6.6 ppm), the anomeric proton (under the overlapping signals at 
4.6-4.9 ppm), the alkyne proton (at 2.4 ppm) and the methylene protons (at 1.2 
ppm). Assignment was performed with the aid of 2D NMR. As in the previous case, 
the anomeric proton resonance was obscured by the methylene protons of the 
benzyl ethers. 13C NMR, IR, HR-MS and specific optical rotations were also 
performed on the novel glycoside 5.17, which features both azide and alkyne 
functionality. The IR spectrum showed the disappearance of the S-C stretch (3030 
cm-1) found in the precursor C-6 fuctionalised thioglycoside 5.16, and it now 
displayed characteristic stretches for alkyne and azide functionalities at 3777 and 
2103 cm-1 respectively. The 13C NMR showed a shift in the anomeric carbon atom 
from 87.7 ppm (in the precursor thioglycoside 5.16) to 98.8ppm (in the building 
block 5.17). 
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Figure 5.7 1H NMR spectrum of glycolipid 5.17. Characteristic signals are highlighted. 
 
Structural characterisation was performed on the β-anomer 5.21 and the 1H NMR 
spectrum is shown in Figure 5.8. In the 1H NMR spectrum some distinctive 
differences are observed compared to the spectrum of the α-anomer 5.17.  The 
signal corresponding to the anomeric proton resonates at a lower chemical shift 
value of 4.43 ppm and with a larger coupling constant of 7.8 Hz compared to the 
anomeric proton of the α-anomer 5.17.  Also, the signal for the methylene protons 
adjacent to the amide bond appear as a multiplet (at 3.1 ppm) in the β-anomer 5.21 
compared to two sets of dd (at 3.0 and 3.2 ppm) in the case of the α-anomer 5.17.  
This suggests that these methylene protons are in a similar chemical environment, 
in contrast to those of the α-anomer 5.17. In the 13C NMR spectrum, the β-
anomeric carbon atom resonates at a higher chemical shift (104.0 ppm) relative to 
its α-anomer 5.17. The corresponding IR spectrum of glycoside 5.21 was similar to 
the one of the α-anomer 5.17.  
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Figure 5.8 1H NMR spectrum of glycolipid 5.21. Characteristic signals are highlighted. 
 
5.3.3. Design Considerations of macrocycles 5.14 and 5.15 
If we consider the CuAAC reaction of the glycolipid building block 5.17, various 
different possible products can be obtained indicating the difficulties and 
challenges associated with this particular reaction. One possible scenario involves 
the reaction of one azide functional group of the glycolipid 5.17 reacting with an 
alkyne group from another molecule of glycolipid 5.17 to form the dimeric molecule 
5.22 (Figure 5.9). By the same vein, the free alkyne on the dimer 5.22 can react with 
another molecule of glycolipid 5.17 and form a trimeric molecule 5.23. This reaction 
can proceed in a polymeric fashion and yield various different acyclic oligomers. 
Alternatively, the azide and alkyne moieties on the glycolipid building block 5.17 
can react intramolecularly to form the corresponding fused tricyclic monomeric 
macrocycle 5.24. Similiarly, an intramolecular reaction can proceed between the 
azide and alkyne of the dimeric glycolipid 5.22 to form the corresponding dimeric 
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macrocycle 5.25. In a similar manner the trimeric macrocycle 5.26 could be formed. 
In principle, various different sized macrocycles could be formed. 
 
Figure 5.9 Structure of possible products from CuAAC of glycolipid 5.17 to give acyclic 
products 5.22 and 5.23 and macrocycles 5.24, 5.25 and 5.26. 
 
Being aware of the possible formation of a mixture of products using the CuAAC 
reaction, we conducted the reaction under different conditions to investigate the 
effect that parameters such as concentration, temperature and the catalyst would 
have on the reaction outcome. One technique commonly employed in macrocyclic 
chemistry to obtain cyclisation products is a high dilution approach.[243] High 
dilution involves using small quantities of reactants in large volumes of solvent. By 
using high dilution conditions, we could increase the probability to form 
macrocyclic products and minimise the formation of acyclic higher order oligomers, 
as shown in Scheme 5.8.  
The rationale for the use of high dilution conditions in a CuAAC macrocyclisation is 
that, in dilute solutions the formation of the cyclic product by an intramolecular 
reaction is thermodynamically favoured. Thermodynamic factors are governed by 
the Gibbs-Helmholtz equation (Equation 5.1).  
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∆ = 	∆ − ∆	 
Equation 5.1 Gibbs-Helmholtz equation where ΔG = change in gibbs free energy, ΔH = 
change in enthalpy, T = absolute temperature, ΔS = change in entropy. 
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Scheme 5.8 Formation of monomeric, dimeric and trimeric macrocycles. 
 
If ΔG<0, then the reaction is favoured thermodynamically (as it is spontaneous). 
Thermodynamically favoured reactions depend on temperature, enthalpy and 
entropy changes. A reaction is entropically favoured if i) n precursor molecules are 
converted to 2n products, or ii) the number of degrees of freedom are increased in 
a system.[244] The former point is not applicable in the case of an intramolecular 
CuAAC reaction as n molecules lead to n molecules. The latter is of special 
relevance under high dilution conditions. The entropy of a system is dependent on 
concentration changes because translational mobility increases with decreased 
viscosity.[245] This is the case for high dilution conditions and thus renders the 
reaction entropically favoured. A minor entropic contributor is also the probability 
of encounter between reactive end groups in the same molecule, whereby the 
reaction is more likely and hence faster than the competing products resulting from 
intermolecular cycloadditions. The entropic effects can sometimes be offset by 
enthalpic effects, caused predominantly by ring strain in cyclisation reactions. Thus, 
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the importance of temperatures, entropic effects and enthalpic effects in creating a 
thermodynamic bias is central to the success of an intramolecular CuAAC reaction. 
Kinetic factors also influence the intramolecular cyclisation reaction, whereby the 
formation of the unimolecular cyclised product is favoured compared to the 
bimolecular oligomers. Another consideration is the choice of Cu source in the 
CuAAC reaction to encourage selective formation of either the monomer 5.24 or 
dimer 5.25. 
5.3.4. Synthesis of products possibly containing macrocycles 5.24 and 5.25 
Initial investigations led us to execute the previously described CuSO4 and sodium 
ascorbate methodology (discussed in Chapter 4). We hoped to minimize 
oligomerisation/polymerisation reactions by using high dilution conditions, so as to 
encourage the formation of smaller macrocycles.  A 10% loading of CuSO4.5H2O, 
followed by a 20% loading of sodium ascorbate was added to a dilute solution (8.5 
mM) of the precursor building block 5.17 in a homogeneous system (THF: H2O: 
MeOH, 2:1:2). The reaction was analysed by TLC. After 18 h at rt, the reaction was 
not finished and CuSO4.5H2O and sodium ascorbate (same concentration as 
previously) was again added to the reaction mixture and the reaction was heated at 
45 °C. TLC analysis showed consumption of the starting material 5.16 after 3 h.  
After work up, the crude reaction mixture was analysed by 1H NMR spectrometry 
(Figure 5.10). It displays a broad spectrum, indicative of macrocyclic formation. 
Most promisingly was the disappearance of the alkyne functionality of the 
precursor 5.17 (as highlighted in Figure 5.8), and the concomitant presence of a 
broad signal at 7.8-8.1 ppm, presumably corresponding to one or more triazole 
protons. Disappearance of the signal corresponding to the amide proton of building 
block 5.17, and the appearance of a signal/s at 5.3 ppm indicated the formation of a 
new product. It was difficult to unambiguously conclude from the 1H NMR spectrum 
whether a mixture of macrocyclic products were present, however the broad signal 
at 5.3 ppm and the multiple signals at 7.8-8.1 ppm certainly points towards the 
formation of a mixture of products. A signal resonating at 2.0 ppm, possibly 
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representative of an alkyne proton is indicative that a certain amount of undesired 
straight chain oligomers are present such as 5.22 and 5.23 (Figure 5.9). 
 
Figure 5.10 1H NMR spectrum of the crude reaction mixture of CuAAC intramolecular 
reaction under high dilution conditions. 
TLC analysis of the reaction mixture did confirm the presence of two distinct 
compounds of similar Rf values (0.5-0.6 in PetEt:EtOAc 3:1), along with a very 
strongly UV absorbing baseline spot, that were clearly different in polarity to the 
starting material 5.17 (Rf value of 0.27 in PetEt:EtOAc 3:1). IR analysis of the crude 
reaction mixture gave little information on the macrocyclic formation (Figure 5.11). 
The disappearance of an azide signal (approx. 2100 cm-1) in an IR spectrum has 
been used as an indicator of a success of various CuAAC reactions in the 
literature.[246] However in the case of the reaction mixture, a signal is still present at 
2033 cm-1. This is not necessarily an indication of unreacted starting material as 
alkyne, azides and 1,2,3-triazole functionalities can all appear in this region. It may 
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also appear due to the straight chain oligomer products that may be present in the 
reaction mixture containing azide functionalities. 
Figure 5.11 Comparison of the IR spectra of starting material 5.17 and the crude reaction 
mixture. The precursor 5.17 is shown in red and the crude reaction mixture is shown in 
blue. 
The HR-MS mass spectrum for the CuAAC reaction mixture was recorded. 
Theoretically, the formation of the monomeric macrocycle 5.24 from the precursor 
5.17 would have no loss/gain of atoms and thus would exhibit the same m/z signal 
in the ESI spectrum, making it difficult to discern whether the reaction had 
proceeded to completion by mass analysis. However, from the 1H NMR data, we 
can assume that the precursor 5.17 was consumed in the reaction. The formation of 
the dimer macrocycle 5.25 and higher order macrocycles (or the straight chain 
oligomers) could be distinguished based on isotope pattern distributions in the 
Total Ion Chromatogram (TIC) of the HR-MS mass analyser.  
 
The isotope distribution pattern of a compound (analysed by mass spectrometry) 
gives characteristic information about the molecule of interest. This is commonly 
utilised by chemists to aid in the structural elucidation of halogenated compounds, 
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macromolecules, peptides and proteins and unknown compounds.[247] Each peak in 
the TIC corresponding to a distinct structural species will have a unique and 
characteristic isotopic pattern distribution. These are not to be mistaken with the 
peaks due to oligomerization of the sample (2M+1 or 3M+1) that may occur within 
the ionisation chamber of the electron spray. In our case, we were interested in the 
natural abundance of 13C isotope in carbon containing molecules (the possible 
macrocycles), whereby the 13C isotope generates a distict m/z signal relative to the 
12C m/z signal. A naturally occurring 12C/13C ratio (98.89 % 12C, 1.11 % 13C) allowed 
us to monitor the amount of 13C isotope present in our potential macrocycles 
compared to the 12C isotope. This, in turn allowed us to differentiate between the 
monomer macrocycle 5.24, dimer 5.25 and trimer 5.26 (or the corresponding 
straight chain oligomers) since they contain different amounts of naturally 
occurring 13C isotopes and as a result different isotope patterns. Differentiation 
between the macrocycles and the acyclic compounds would not be discerned by 
this method. 
 
In the TIC, two major isotopic clusters were detected, with base peaks at m/z 797 
and m/z 1616. A minor isotopic cluster was also detected with a base peak at m/z 
2391. These peaks possibly corresponded to the protonated monomer 5.24, 
protonated dimer 5.25 and molecular trimer 5.26 respectively. It is also possible 
that they may correspond to the straight chain oligomers. However it is more likely 
to be the macrocycles due to the broad NMR spectrum (indicative of strained 
macrocycles). The isotopic distribution pattern of the possible protonated 
monomer 5.25 and the theoretical isotope pattern based on its elemental formula 
are depicted in Figure 5.12. The protonated monomeric macrocycle 5.24 (or 
corresponding straight chain oligomer) shows a unique isotope distribution pattern 
consistent with the theoretical pattern in the inset. In analysing the isotope pattern 
of the protonated macrocyclic compound 5.24 (or the corresponding straight chain 
oligomer) with an empirical formula of C47H65N4O7, the base peak at m/z 797 has 
the major abundance compared to the protonated 13C isotope at m/z 798 in the 
isotope distribution pattern, as expected (Figure 5.12).  
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Figure 5.12 Isotope distribution pattern of the protonated monomer 5.24 (or 
corresponding straight chain oligomer), and the theoretical isotope pattern based on the 
elemental formula (inset). 
 
The isotope pattern of the protonated dimer 5.25 (or corresponding straight chain 
dimer) and the theoretical isotope pattern based on the elemental formula are 
depicted in Figure 5.13. As in the previous example, the data are in good 
agreement. A different scenario (compared to the proposed monomer 5.24) arises 
when analysing the isotope pattern of the potential protonated dimer 5.25, with an 
empirical formula of C94H128N8O14 (Figure 5.13). Now the mass spectral peak 
representing the protonated monoisotopic mass of 5.25 (or corresponding straight 
chain dimer) is not the most abundant peak in the spectrum. Statistically there 
should be roughly one 13C atom in the compound and this is observed with a base 
peak of m/z 1595. It is now the most abundant ion, as expected in the theoretical 
isotope pattern distribution (Figure 5.13, inset). This isotope pattern is only 
characteristic of the dimer 5.25 (or the corresponding straight chain dimer) formed 
in the cycloaddition, and not as a result of ionisation of a different species occurring 
in the chamber.  
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Figure 5.13 Isotope distribution pattern of the protonated dimer 5.25 (or corresponding 
straight chain dimer), and the theoretical isotope pattern based on the elemental formula 
(inset). 
 
Similarly to the proposed dimeric macrocycle, the molecular ion for trimer 5.26 (or 
the corresponding straight chain trimer) displays an isotope distribution pattern 
characteristic of the empirical formula, C141H192N12O21 as predicted in the 
theoretical isotope pattern (Figure 5.14). Therefore, we suggest that the reaction 
mixture contains the monomer 5.24, dimer 5.25 and the trimer 5.26 macrocycles 
and not the ionised products generated by the ionisation technique. It is also 
possible that the corresponding straight chain oligomers are responsible for the 
isotope distribution patterns. 
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Figure 5.14 Isotope distribution pattern of the molecular trimer 5.26 (or the corresponding 
straight chain trimer), and the theoretical isotope pattern based on the elemental formula 
(inset). 
 
To test whether different reaction conditions could result in the selective formation 
of either the fused monomeric macrocycle 5.24 or the dimeric macrocycle 5.25 
(over oligomerisation reactions), we explored the use of different solvent 
concentrations, temperatures and different sources of Cu (I) in the CuAAC reaction 
at a 0.05 mmol scale. A summary of the findings are presented in Table 5.1. It 
seemed that macrocyclic formation occurred under high dilution conditions of 8.5 
mM (Entries 1 and 3 in Table 5.1) but did not proceed in higher dilution conditions 
of 0.85 mM (Entries 2 and 4 in Table 5.1). Furthermore, it seemed, independently of 
the source of Cu(I) used, (CuSO4 or CuI,  Entries 1 and 3 in Table 5.1)  the desired 
macrocycles 5.24 or 5.25 could not be obtained selectively, if in fact they were 
formed at all. Instead, both reactions resulted in mixtures of compounds, indicated 
by 1H NMR spectroscopy and TLC analysis. It seemed that the reaction utilising 
CuSO4 was a superior choice. In the reactions carried out using CuI, smaller 
amounts of product suggested to be the macrocycles (33% w/w) could be isolated 
compared to the CuS04 method (83% w/w).  
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Table 5.1 Optimisation conditions altering reaction concentrations and source of Cu(I) for 
CuAAC reaction. 
* 0.1 equiv of CuSO4.5H2O and 0.2 equiv of CuI; ‡ 0.2 equiv of sodium ascorbate and 2 
equiv of DIPEA; ** Possible macrocyclic formation indicated by 1H NMR spectroscopy. 
 
The CuAAC reaction utilising CuSO4.5H2O and sodium ascorbate at 8.5 mmol was 
repeated on a larger scale (0.1 mmol). A similar 1H NMR spectrum of the crude was 
recorded as in the smaller scale reaction (Figure 5.10). Flash chromatography was 
performed to separate polar products (an Rf value of 0.5 in 3:1 PetEt/EtOAc) 
possibly corresponding to the straight chain oligomers, and also to purify and 
separate the possible macrocycles (baseline spot in 3:1 PetEt/EtOAc mixture). The 
more polar products, the proposed straight chain oligomers were successfully 
separated from the baseline product, the proposed macrocycles. However, they 
were present in small quantities (20% w/w), and as a result, were difficult to 
characterise by 1H NMR spectrometry.  Also mixtures of the acyclic dimer 5.22, 
trimer 5.23 and other potential linear oligomers would complicate the spectrum. 
However, the clear sharp signals observed suggested that these were not 
macrocyclic compounds. The 1H NMR spectrum of the mixture of possible acyclic 
oligomers is presented in Figure 5.15. Various resonances for alkyne protons in the 
region of 2-3 ppm suggest that the dimer 5.22 and extended oligomers were 
Solvent Ratio
Solvent 
Concentration
Time Temperature Cu(I) Source* Additives‡
Possible 
macrocyclic 
Formation**
1
THF: MeOH: H2O 
(2:2:1)
8.5 mM 23 h rt to 45°C CuSO4.5H2O Na ascorbate Yes (88% w/w)
2
THF: MeOH: H2O 
(2:2:1)
0.85 mM 23 h rt to 45°C CuSO4.5H2O Na ascorbate No
3 THF 8.5 mM 20 h rt CuI DIPEA Yes (33% w/w)
4 THF 0.85 mM 20 h rt CuI DIPEA No
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possibly formed. A 15N HSQC experiment indicated N-H coupling of amide protons 
in the region of 6-7 ppm characteristic for these compounds, with at least 4 
different couplings observed. Also, the distinctive triazole protons at 8.1 ppm were 
evident in the spectrum. HR-MS confirmed a m/z ratio corresponding to the 
empirical formula of the dimer 5.22. 
 
Figure 5.15 1H NMR spectrum of potential acyclic oligomers containing 5.22. Characteristic 
signals are highlighted. 
The individual compound, proposed to be macrocycles 5.24-5.26 could not be 
separated from one another using flash chromatography. Precipitation and 
recrystallization was also attempted with no success. Preparative Reverse Phase 
High Performance Liquid Chromatography (RP-HPLC) was performed to identify and 
separate the relatively polar suggested products 5.24-5.26. A number of conditions 
were investigated, using isocratic or gradient based mobile phases, but no 
separation could be achieved. This was due to the precipitation of the proposed 
macrocycles with the introduction of H2O in the mobile phase. It was evident that a 
major product elutes at 7 min, using 100% MeOH as the mobile phase. Mass 
analysis identified a m/z ratio indicative of the monomeric macrocycle 5.24, but the 
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other possible macrocycles 5.25 and 5.26 were not identified. This was presumably 
due to the small quantities of sample recovered in the HPLC run for analysis. A 
minor product eluting at 5 min was an impurity present in the MeOH, as the HPLC 
chromatogram for MeOH alone displayed a similar peak at this retention time. 
Interestingly, using a gradient system of H2O/MeOH to purify the proposed 
macrocycles resulted in no improvement in the resolution of the peaks.  A solvent 
system of 100% H2O (5 min) to a gradient system of 100% H2O to 100 MeOH (over 
10 min) to 100% MeOH was utilised. The proposed macrocyclic compounds only 
eluted when 100% MeOH was used and after 7 min, precisely as in the previous 
HPLC isocratic run. This demonstrated that the proposed macrocycles were water 
insoluble, even in H2O/MeOH mixtures. Thus we concluded that Preparative 
Reverse Phase HPLC was not a suitable method for separation of proposed 
macrocycles 5.24-5.26. 
 
5.3.5. Elucidation of proposed macrocyclic mixture containing macrocycles 5.24, 
5.25 and 5.26 
Unable to separate and isolate the proposed macrocyclic mixture of 5.24 and 5.25, 
we performed an array of NMR spectroscopic experiments in an attempt to assign 
and confirm the presence of these macrocyclic compounds. We also wanted to 
determine precisely the ratio of the proposed macrocyclic compounds if possible, 
despite the difficulties anticipated due to the broad 1H NMR spectrum. A 15N HSQC 
experiment illustrated nitrogen-carbon couplings diagnostic of three different 
amide regions.   
 
A small coupling was observed at 6.8 ppm, a larger coupling at 7 ppm and 2 
adjacent couplings resonating at 7.5 ppm. We propose that two adjacent couplings 
at 7.5 ppm are indicative of the dimeric macrocycle 5.25, with two amide bonds 
presumably in a similar chemical environment to one another resonating at a 
similar chemical shift. A signal at 7 ppm is most likely representative of the fused 
monomeric macrocycle 5.24 with a strong nitrogen-carbon coupling while the weak 
coupling at 6.8 ppm could represents one of the amide bonds of the trimeric 
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macrocycle 5.26. Assignment of the proton signals of the reaction mixture was 
performed with the aid of COSY and selective TOCSY experiments and the 1H NMR 
spectrum is shown in Figure 5.16.  The H-α proton which resonates at a chemical 
shift of 5.5 ppm was coupled to a signal at 4 ppm, characteristic of the H-β protons, 
as indicated by a selective TOCSY experiment. In a separate selective TOCSY 
experiment, upon irradiation at 1.5 ppm, the amide protons at 7.0 ppm coupled to 
the NHCH2 methylene protons at 3 ppm, which coupled to the methylene protons 
of the long chain at 1.2 ppm. Another TOCSY irradiated at 1.2 ppm showed coupling 
of these methylene protons to the terminal methyl group at 0.9 ppm. A selective 
ROESY irradiated at 8 ppm, the signal corresponding to the triazole proton, was 
performed in order to obtain insight into the structural conformation of these 
proposed macrocycles. Unsurprisingly, the triazole proton was found to be in close 
proximity to the aromatic benzyl ethers, with no other through space couplings 
observed.  
 
 
 
Figure 5.16 1H NMR spectrum of proposed macrocyclic mixture containing 5.24-5.26. 
Characteristic signals are highlighted. 
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With regards to the 13C NMR data extracted, poor spectral resolution was achieved 
and it is shown in Figure 5.17. Only methylene carbon atoms of hydrocarbon chains, 
a peak corresponding to a sugar carbon atom and aromatic carbons are identifiable. 
In an attempt to increase the sensitivity and resolution in the NMR experiment per-
dueteration was performed on the proposed macrocyclic mixture as it is known 
that incorporation of 2H into non-exchangeable positions in a molecule decreases 
the rate of 13C T2 relaxation and thus can increase the sensitivity and resolution in 
multidimentional NMR experiments.[248]  
 
 
 
Figure 5.17 13C NMR spectrum of proposed macrocyclic mixture containing 5.24-5.26. 
Characteristic signals are highlighted. 
 
An ED-HSQC experiment shed more light on the structural assignment of the 
reaction mixture than the 13C NMR spectrum and it is shown in Figure 5.18. Cross-
peaks corresponding to the anomeric carbon, the methylene carbons of the benzyl 
ethers, and the sugar carbons are observed, further suggesting the mixture of 
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macrocycles. Unfortunately, the ratio of macrocycles present in the reaction 
mixture could not be determined, hindered by the small amount of material 
available for these studies and the inherent poor spectral resolution of the NMR 
spectra. 
 
Figure 5.18 ED HSQC NMR experiment of proposed macrocyclic mixture containing 5.24, 
5.25 and 5.26. Characteristic couplings are highlighted. 
 
5.3.6. Global debenzylation of proposed macrocycles 5.24, 5.25 and 5.26 
Due to the inseparatable mixture of benzyl protected products, postulated to 
macrocycles 5.24-5.26, we proceeded to investigate the deprotection of the benzyl 
ethers which may facilitate future purification. We postulated that RP-HPLC may be 
more suitable to separate the deprotected polar compounds successfully. 
Conscious of the difficulties encountered in the removal of benzyl ethers (discussed 
in Chapter 4), a number of hydrogenolysis reaction conditions were used, in an 
attempt to afford the desired macrocycles 5.14, 5.15 and 5.27. Initially a 10% w/w 
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loading of Pd(C) was added to the proposed macrocyclic mixture dissolved in 
EtOH/EtOAc and subjected to a pressure of 4 Barr for 18 h on a hydrogenator 
shaker apparatus.  However, no deprotected macrocycles were isolated. Next, the 
reaction mixture containing proposed macrocycles 5.24-5.26 was dissolved in a 
mixture of EtOH/EtOAc (3:1) containing catalytic AcOH, was deoxygenated, and 
then reacted with H2 at 4 Barr pressure using a 50% Pd (C) loading for 24 h on a 
hydrogenator shaker apparatus (Scheme 5.9). The crude material was purified by 
washing through Celite with copious amounts of heated EtOH. TLC and 1H NMR 
analysis indicated the presence of starting material in the reaction mixture. Thus, 
the reaction mixture was treated with a higher loading of the catalyst (500%) and 
the reaction was repeated for 18 h. As in the previous case, unreacted or partially 
debenzylated sugar formed the majority of the reaction mixture. After purification, 
this hydrogenolysis was performed at a lower loading of Pd (C) (50%) at 4 Barr 
pressure and was shaken for 18 h. TLC analysis showed consumption of the starting 
material. The 1H NMR spectrum of the reaction mixture confirmed the consumption 
of starting material and presence of a small amount of partially deprotected 
compound, as indicated by the disappearance and reduction of the intensity of the 
benzyl ether aromatic signals. Trituerations were performed in order to remove the 
partially protected compounds from the reaction mixture, but were not fully 
successful.  
Difficulties now arose relating to the solubility of the reaction mixture. 1H NMR 
analysis was performed in CD2Cl2, d-MeOD and d6-Pyr but did not indicate the 
presence of any of desired macrocycles. Instead the spectra constituted mainly of 
residual solvent and indicated degradation had occurred during the deprotection of 
the benzyl ethers. Little or no evidence of the desired products 5.14, 5.15 or 5.27 
could be observed. In an attempt to grasp an understanding of the degradation 
products that were present in the reaction mixture, and bearing in mind the 
difficulties of solubilising deprotected glycolipids, we performed the acetylation of 
the mixture of reaction products using Ac2O in Pyr. After flash chromatography, 
none of the desired compound 5.28-5.30 were isolated, and no conclusive 
identification of by-products could be obtained.  The methodology was abandoned 
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as a direct result. As discussed previously in Chapter 4, it is possible that the 
presence of the triazole groups in this class of L-serinyl derivatives hindered the 
removal of the benzyl ethers. An additional complication in this case arises due to 
the macrocyclic nature of compounds 5.24-5.26, if indeed they are in fact 
macrocycles. The conformational strain inherent to macrocycles (specially fused 
tricyclic structures such as 5.24), may significantly facilitate the occurance of 
degradation reactions. It is also possible that steric factors complicated the 
debenzylation, due to the presence of the long hydrophobic chains. Thus, the 
harsher conditions necessary for their removal ultimately led to the destruction of 
the reaction mixture.  
 
Scheme 5.9 Reagents and conditions a) H2, Pd (C), EtOH/ EtOAc, AcOH, rt, 4 Barr, 60 h b) 
Ac2O, py, 18 h. 
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5.4. Conclusion and perspective 
In conclusion, the glycoside 5.17 served as a suitable building block for formation of 
either the macrocycles 5.24-5.26 as an inseperable mixture or their corresponding 
straight chain oligomers. NMR studies, coupled with HR-MS analysis indicates the 
formation of the macrocycles 5.24, 5.25 and 5.26, however no conclusive evidence 
was found. The potential macrocyclic formation occurred via a CuAAC reaction, and 
the synthesis of products, most likely the macrocycles 5.24, 5.25 and 5.26 was 
achieved successfully, albeit as an inseperable mixture. The selective formation of 
the monomeric macrocycle 5.14 or dimeric macrocycle 5.15 was not achieved 
under the conditions explored in our research. 
The groundwork for the synthesis of a range of macrocyclic analogues of KRN7000 
was put in place, where the difficult CuAAC reaction proved fruitful under dilute 
conditions. Most problematic in the current synthesis was the global deprotection 
of the benzyl ether protecting groups, discussed in Section 5.3.6, which had it been 
successful, would have allowed for the purification and biological evaluation of the 
glycolipids obtained. This would have led to an insight as to whether they would 
serve as effective iNKT cell ligands.  
Various different approaches could be adapted in order to successfully synthesise 
the macrocycles 5.14 and 5.15. The first approach would involve different 
conditions to cleave the benzyl ethers on the macrocycles. One such example 
involves the oxidation of the benzyl ethers followed by mildly basic deprotection to 
yield the desired alcohols.[249] Another approach would involve the choice of 
different protecting groups on the glycosyl donor such as the use of PMB ethers 
(described in Chapter 3) which could be oxidatively cleaved. Another suitable 
protecting group would be the acid labile TMS protecting groups. However these 
changes could have dramatic influences on the glycosylation yield and 
stereoselectivity, and/or the selective formation of potential macrocyclic 
compounds 5.14 and 5.15. Much more work is needed to synthesis these 
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aesthetically pleasing macrocycles 5.14 and 5.15 and to confirm their structure. 
However, important preliminary work towards their synthesis has been highlighted 
in this chapter. 
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6.1. Conclusions  
 
In conclusion a range of glycolipids were synthesised using a plethora of glycosyl 
donors and glycosyl acceptors. Various different protecting groups, including acetyl 
and benzoyl esters, benzyl and PMB ethers and benzylidene acetals were utilised to 
carry out regioselective and stereoselective glycosylation reactions for building 
block formations. Different activating groups including TfOH, TMSOTF, AgOTf and 
NIS were utilised to form stable glycosidic linkages. The syntheses of several O- and 
N-glycolipids were explored (Figure 6.1).   
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Figure 6.1 O- and N-glycolipids 2.18-2.23 were synthesised for anti-microbial evaluation.  
The L-serine based glycolipid 4.14 was synthesised for iNKT cell activation studies. The 
benzyl protected glycolipid 4.90 and the suggested macrocycle structures 5.24-5.26 (or 
corresponding straight chain oligomers) were synthesised for ongoing synthetic work to be 
carried out with the eventual goal of iNKT cell activation studies on their deprotected 
glycolipids. 
 
The O-glycolipids 2.18 and 2.19 were prepared to test their anti-microbial 
properties using an anti-adhesion methodology with a view to compare the effects 
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of alkyl chain length on anti-microbial adhesion. N-glycolipid 2.20 served as a 
means to test the effects of introducing aromaticity on anti-microbial adhesion 
studies. The synthesis of aspartic acid based N-glycolipids 2.21-2.23 was more 
challenging than the previous glycolipids discussed. Problems with racemisation 
and cyclisation side reactions hampered the progress of these reactions. However 
after careful considerations their synthesis was undertaken. As for the previous 
glycolipids, their ability to act as anti-microbial agents was of interest. Their 
increased hydrophobic character, compared to the other glycolipids, was the 
driving force for their synthesis and biological assessment. 
The L-serine base glycolipids 4.14, 4.90, 5.24-5.26 (Figure 6.1) were prepared with a 
view to test their ability to act as iNKT cell stimulatory ligands. Many difficulties lay 
in the synthesis of these glycolipids, with particular problems arising due to poor 
stereoselective formation of the α-glycosidic linkages and the inherent low 
nucleophilicity of the L-serine glycosyl acceptors. However glycolipid 4.14 was 
successfully synthesised. The benzyl protected triazole derivative 4.90 was 
synthesised using CuAAC cycloaddition chemistry. However its subsequent 
deprotection resulted in degradation, indicating an alternative synthetic approach 
was necessary. It was suggested that the macrocycles 5.24-5.26 were synthesised 
as an inseperarable mixture, however no conclusive evidence was given. Again, 
upon deprotection of the reaction mixture degradation occurred. 
The synthesis of a Gl-X analogue 3.1, described in Chapter 3 was not completed. 
The key synthetic step involving the formation of a 1,2-cis glycosidic linkage of a 
glucosyl donor 3.3 and glycosyl acceptors 3.4 and 3.37 using an intramolecular 
aglycon delivery approach. Although the synthesis was not completed, this 
preliminary work aided in the completion of a Gl-A analogue for NKT cell studies. 
6.2. Future work 
Preliminary anti-microbial evaluations were carried out on O-glycolipid 2.19 and N-
glycolipid 2.22, as described in Section 2.10. We wish to carry out the anti-adhesion 
studies of the O-glycolipid 2.18 and the N-glycolipids 2.20-2.23 to test their ability 
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to act as anti-microbial agents. We also wish to gain an insight into the parameters 
that may alter the anti-microbial results such as alkyl chain length, aromaticity and 
additional hydrophobic character of the glycolipids. In this regard, the anti-adhesion 
assays of the glycolipids would be compared and optimisation of the glycolipids 
would be performed, depending on the findings. 
The L-serine based glycolipid 4.14 will be tested against iNKT cell human cells and 
the biological results will be compared to KRN7000. The synthesis of the desired 
glycolipid 4.16 will be repeated as in Scheme 6.1, with the use of PMB ethers in 
place of benzyl ethers as global protecting group. The synthesis will begin with the 
stereoselective coupling of the glycosyl donor 6.1 with the previously synthesised 
serine azido derivative 4.58. A CuAAC reaction of the resulting O-glycoside 6.2 will 
then afford the 1,2-disubstituted 1,2,3-triazole product 6.3. Finally, mild oxidative 
cleavage with DDQ will afford the desired glycolipid 4.16. Its potential as an iNKT 
cell ligand will then be explored and compared to glycolipid 4.14.  
 
 
Scheme 6.1 Proposed synthesis of glycolipid 4.16 using PMB ether protecting groups on 
glycosyl donor 6.1.Step a involves stereselective glycosylation. Step b involves a CuAAC 
reaction. Step c involves oxidative cleavage to yield desired glycolipid 4.16. 
 
A similar approach could be followed for the synthesis of the desired macrocycles 
5.14 and 5.15 (described in Section 5.2) also with the use of PMB ethers (Scheme 
6.2), provided the synthesis of the glycolipid 4.16 proceeded without any major 
problems. As in the case for the benzyl protected potential macrocycles, we 
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anticipated the selective formation of either the monomer 5.14 or the dimer 5.15 
to be the most challenging task in the synthetic design. We also hoped that 
degradation would not occur with the milder oxidative conditions and that 
structural elucidation, separation of the macrocycles would be easier as a result of 
the different protecting group in place, the PMB in place of the benzyl ether group. 
 
Scheme 6.2 Proposed synthesis of glycolipid 5.14 and 5.15 using PMB ether protecting 
groups on glycosyl donor 6.4.Step a involves stereselective glycosylation. Step b involves a 
CuAAC reaction, followed by oxidative cleavage to yield desired glycolipid 5.14 and 5.15.
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7.1. General Procedures and Instrumentation 
All chemicals purchased were reagent grade and used without further purification 
unless stated otherwise. CH2Cl2 was distilled over CaH2 or NaH, dichloroethane and 
toluene over CaH2, MeCN over P2O5, MeOH over Na metal, THF over Na wire and 
benzophenone, Pyr over NaOH or was purchased from Sigma Aldrich. Anhydrous 
DMF was purchased from Sigma Aldrich. Molecular Sieves (MS) used for 
glycosylation were 8-12 Mesh and were ground and flame dried prior to use. 
Reactions were monitored with thin layer chromatography (TLC) on Merck Silica Gel 
F254 plates, using mixtures of petroleum ether-EtOAc unless otherwise stated. 
Detection was effected by either visualisation in UV light and/or charring in a 
mixture of 5% H2SO4-MeOH or phosphomolybdic acid in EtOH. Evaporation under 
reduced pressure was always affected with the bath temperature kept below 40 °C.  
NMR spectra were obtained on a Bruker Avance 300 MHz spectrometer operated at 
300 MHz for 1H and 75 MHz for 13C at 298 K or a Bruker Avance AV-600 MHz 
spectrometer (Trinity College Dublin) operated at 600 MHz for 1H and 150 MHz for 
13C at 298 K. In University of Melbourne, NMR spectra were obtained on a Varian 
Inova 500 instrument (Melbourne, Australia) or a Varian Inova 400 instrument 
(Melbourne, Australia). Proton and carbon signals were assigned with the aid of 2D 
NMR experiments (COSY, HSQC, ED-HSQC, TOCSY, 14N HSQC, ROESY or HCCOSW) 
and DEPT experiments. HCCOSW is a HSQC type of experiment. Dueterated CDCl3 
was used in NMR experiments unless otherwise stated. Flash column 
chromatography was performed according to the method of Still et al. with Merck 
Silica Gel 60, using adjusted mixtures of PetEt-EtOAc unless otherwise stated.[250] 
Silica plug chromatography involved the use of small quantities of silica in a glass 
column, generally for separation of baseline impurities. Optical rotation data was 
obtained using a AA-100 polarimeter. In University of Melbourne, optical rotation 
data was obtained using a JASCO DIP-1000 Polarimeter. [α]25D values are given in 
10-1cm2g-1. Melting points were determined on a Stuart Scientific SMP1 melting 
point apparatus and are uncorrected. In University of Melbourne, the melting 
points were obtained using a Gallenkamp melting point apparatus and are 
uncorrected.  High resolution mass spectra (HR-MS) were performed on an Agilent -
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LC 1200 Series coupled to a 6210 Agilent Time-Of-Flight (TOF) mass spectrometer 
equipped with an electrospray source both positive and negative (ESI+/-). In 
University of Melbourne, High resolution mass spectra (HR-MS) were performed on 
a Finnigan LCQ quadrupole ion-trap mass spectrometer equipped with a Finnigan 
electrospray ionisation source. Infra-red spectra were obtained in the region 4000–
400 cm−1 on a Nicolet Impact 400D spectrophotometer or using a Perkin Elmer 2000 
FTIR spectrometer. Either KBr disks or NaCl plates were used as templates. SEM was 
performed using a Hitachi S-3200-N with a tungsten filament and sample was 
coated in gold. UV-Vis spectra were recorded with a Jasco V-630BIO 
spectrophotometer at 25 °C. Hydrogenolysis reactions were performed on a Parr 
3911 Hydrogenation Apparatus at 4 Barr pressure for removal of benzyl ether 
protecting groups.  
7.2. Experimental procedures 
7.2.1. Experimental procedures for Chapter 2 
Octadecyl-1-O-β-D-galactopyranoside 2.18 
 
Na metal (1 mg approx., 0.02 mmol approx., 0.1 equiv approx.) was added to a 
solution of octadecyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.34 (68 mg, 
0.15 mmol) in MeOH (2 mL) at rt. It was stirred for 2 h; quenched with Amberlite 
ion-exchange resin (H+ form), filtered and concentrated in vacuo to yield the title 
compound 2.18 (39 mg, 90%, crude yield) as a white solid; mp = 104-106 °C (lit 154 
°C )[251];  1H-NMR (300 MHz, drop D2O in CDCl3): δ 0.88 (t, J = 7.0 Hz, 3 H, CH3), 1.26-
1.28 (m, 10 H, OCH2CH2(CH2)5CH3), 1.60-1.62 (m, 2 H, OCH2CH2), 3.41-3.43 (m, 1 H, 
OCHHCH2), 3.42-3.96 (m, 7 H, OCHHCH2H, , H-2, H-3, H-4, H-5, H-6, H-6’), 4.23 (d, J = 
8.0 Hz, 1 H, H-1).  
The NMR data is in agreement with the reported values.[72] 
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Dodecyl-1-O-β-D-galactopyranoside 2.19 
 
NEt3 (2 drops) was added to a solution of dodecyl-2,3,4,6-tetra-O-acetyl-β-D-
galactopyranoside 2.35 (0.122 g, 0.18 mmol) in THF/H2O/MeOH (5 mL, 2:2:1) at rt. 
It was stirred for 18 h; quenched with Amberlite ion-exchange resin (H+ form) and 
filtered. THF was added and the precipitate was filtered and dried to yield the title 
compound 2.19 (45 mg, 50%, crude yield) as a white solid; IR νmax (KBr disk): 3459.6, 
2919.1, 2849.4, 1637.9, 1384.6, 1080.7, 753.8 cm-1; 1H-NMR (300 MHz, d6-Pyr): δ 
0.88 (t, J = 6.4 Hz, 3 H, CH3), 1.31-1.34 (m, 36 H, OCH2CH2(CH2)19), 1.66-1.71 (m, 2 H, 
OCH2CH2), 3.67-3.75 (m, 1 H, OCHHCH2), 4.09-4.23 (m, 3 H, H-5, H-6, OCHHCH2), 
4.48-4.53 (m, 3 H, H-2, H-3, H-6’), 4.61-4.63 (m, 1 H, H-4), 4.81 (d, J = 7.7 Hz, 1 H, H-
1); 13C-NMR (75MHz, d6-Pyr): δC 16.2 (CH3), 24.9, 28.5, 31.6, 31.80, 31.9, 31.9, 32.3, 
34.1 (O(CH2)20), 64.5 (OCH2), 71.7, 72.3, 74.6, 77.4, 78.9 (C-2, C-3, C-4, C-5, C-6), 
107.3 (C-1). 
The NMR data is in agreement with the reported values.[252] 
1-(β-D-galactopyranosyl)-4-tridecyl-1,2,3-triazole 2.20 
 
Na metal (1 mg approx., 0.012 mmol approx., 0.1 equiv approx.) was added to a 
solution of 1-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-4-tridecyl-1,2,3-triazole 
2.37 (72 mg, 0.12 mmol) in MeOH (2 mL) at 0 °C. It was stirred for 1 h; quenched 
with Amberlite ion-exchange resin (H+ form), filtered and concentrated in vacuo to 
yield the title compound 2.20 (45 mg, 88%, crude yield) as a white foam; [α]25D = 
+8.82 (c, 0.68 in MeOH); IR νmax (NaCl plate, CH2Cl2): 3431.0, 2922.8, 2852.5, 2126.9, 
1641.9, 1094.5 cm-1; 1H-NMR (300 MHz, d4-MeOD): δ 0.92 (t, J = 6.8 Hz, 3 H, 
CH2CH3), 1.30-1.31 (m, 20 H,(CH2)10), 1.67-1.72 (m, 2 H, C=CCH2CH2), 2.72 (t, J  = 7.6 
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Hz, 2 H, C=CCH2CH2), 3.69-3.87 (m, 4 H, H-3, H-5, H-6, H-6’), 3.99 (d, J =2.3 Hz, 1 H, 
H-4), 4.15 (pt, J =9.2 Hz, 1 H, H-2), 5.55 (d, J = 9.2 Hz, 1 H, H-1), 7.99 (s, 1 H, C=CH); 
13C-NMR (75 MHz, d4-MeOD): δC 13.1 (CH3), 22.3, 24.9, 28.9, 29.1, 29.1, 29.3, 29.4, 
31.7 ((CH2)12), 61.0 (C-6), 69.0 (C-4), 70.0 (C-2), 73.9 (C-3 or C-5), 78.5 (C-3 or C-5), 
88.8 (C-1), 120.5 (C=CH), 147.9 (C=CH); HRMS m/z (ESI+) 414.2961, (C21H39N3O5H: 
[M+H]+ requires  414.2962). 
 
N
γ
-(β-D-galactopyranosyl)-N
α
-(decanosyl)-L-aspargine 1-tetradecylamide 2.21 
 
NEt3 (0.05 mL) was added to a stirred solution of N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-Nα-(decanosyl)-L-aspargine 1-tetradecylamide 2.58 (43 mg, 0.05 
mmol) dissolved in CH2Cl2: MeOH: H2O (5 mL, 1:2:1) at 40 
oC. The reaction mixture 
was vigorously stirred for 18 h. The precipitate formed was filtered through a 
vacuum to afford the title compound 2.21 as white crystals (7 mg, 21%, crude 
yield). The filtrate was reacted for a further 18 h under the same conditions 
whereby degradation occurred; [α]22D = -6.67 (c 0.6, Pyr); 
1H-NMR (300 MHz, d5-
Pyr): δ 0.81-0.88 (m, 6 H, CH3 × 2), 1.15-1.24 (m, 34 H, CO(CH2)2(CH2)6CH3, 
NH(CH2)2(CH2)11CH3), 1.50-1.58 (m, 2 H, NHCH2CH2), 1.70-1.75 ( m, 2 H, COCH2CH2), 
2.33 (t, J = 7.5 Hz, 2 H, COCH2), 3.25-3.27 (m, 2 H, H-β, H-β’), 3.44-3.35 (m, 2 H, 
NHCH2), 4.11 (pt, J = 6.0 Hz, 1 H, H-5), 4.17 (dd, J = 3.0 Hz, 9.2 Hz, 1 H, H-3), 4.35-
4.38 (m, 2 H, H-6, H-6’), 4.53 (pt, J = 9.2 Hz, 1 H, H-2), 4.57 (d, J = 2.9 Hz, 1 H, H-4), 
5.43 (dd, J = 6.8, 14.3 Hz, 1 H, H-α), 5.85 (t, J = 9.2 Hz, 1 H, H-1), 8.51 (t, J  = 5.7 Hz, 1 
H, NHC14H29), 8.94 (d, J = 7.9 Hz, 1 H, NHCOC9H19), 10.15 (d, J = 9.1 Hz, 1 H, NHC1); 
13C NMR (d5-Pyr, 75 Hz): δc 14.2 (CH3
xiii), 22.9, 22.9, 26.0, 27.25, 29.5, 29.6, 29.6, 
29.6, 29.7, 29.9, 29.9, 32.0, 32.1 (CO(CH2)2(CH2)6CH3, NH(CH2)(CH2)12CH3), 36.5 
(COCH2),  39.0 (C-β), 39.9 (NHCH2), 51.1 (C-α), 62.4 (C-6), 70.4 (C-4), 71.9 (C-2), 76.2 
                                                            
xiii Overlapping signals at 14.2 ppm for two methyl carbon atoms. 
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(C-3), 78.4 (C-5), 81.7 (C-1), 171.8 (C=O) , 171.9 (C=O) , 173.4 (C=O); HRMS m/z 
(ESI+) 666.4689, (C34H65O8N3Na: [M+ Na]
+
 requires 666.4664). 
N
γ
-(β-D-galactopyranosyl)-N
α
-(tetradecanosyl)-L-aspargine 1-tetradecylamide 2.22 
 
NEt3 (0.05 mL) was added to a vigorously stirred solution of N
γ-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-Nα-(tetradecanosyl)-L-aspargine tetradecylamide 2.62 
(54 mg, 0.06 mmol) in CH2Cl2: MeOH: H2O (5 mL, 1:2:1) at 40 
oC.  The reaction 
mixture was stirred for 18 h. The precipitate formed was filtered through a vacuum 
to afford the title compound 2.22 as white crystals (22 mg, 50%, crude yield). The 
filtrate was reacted for a further 18 h under the same conditions and degradation 
occurred; [α]27D = -8.00 (c 0.5, Pyr); 
1H-NMR (300 MHz, d5-Pyr): δ 0.85-0.87 (m, 6 H, 
CH3 × 2), 1.24-1.26 (m, 46 H, CO(CH2)2(CH2)12CH3, NH(CH2)2(CH2)11CH3) , 1.54-1.56 
(m, 2 H, NHCH2CH2), 1.71-1.73 (m, 2 H, COCH2CH2), 2.32-2.34 (m, 2 H, COCH2), 3.26-
3.28 (m, 2 H, H-β,  H-β’), 3.40-3.41 (m, 2 H, NHCH2), 4.12-4.16 (m, 2 H, H-3, H-5), 
4.35-4.38 (m, 2 H, H-6, H-6’), 4.44-4.58 (m, 2 H, H-2, H-4), 5.58-5.62 (m, 1 H, H-α), 
5.88-5.88 (m, 1 H, H-1), 6.94-6.96 (m, 2 H, OH × 2), 7.01 (s, 1 H, OH), 7.02 (s, 1 H, 
OH), 8.46-8.49 (m, 1 H, NHC14H29), 8.91-8.93 (m, 1 H, NHCOC15H31), 10.10-10.12 (m,  
1 H, NHC1); 13C NMR (d5-Pyr, 75 Hz): δc 14.2 (CH3)
xiv, 22.9, 26.1, 27.3, 29.6, 29.6, 
29.6, 29.8, 29.9, 29.9, 32.0, 32.1 (CO(CH2)2(CH2)11CH3, NH(CH2)(CH2)12CH3), 36.5 
(COCH2), 39.1 (C-β), 39.9 (NHCH2), 51.1 (C-α), 62.4 (C-6), 70.4 (C-4), 71.9 (C-2), 76.21 
(C-3), 78.4 (C-5), 81.7 (C-1), 171.7 (C=O), 171.9 (C=O), 173.4 (C=O); HRMS m/z (ESI+) 
728.5747, (C40H77O8N3H: [M+H]
+
 requires 728.5783). 
N
γ
-(β-D-galactopyranosyl)-N
α
-(tetracosyl)-L-aspargine 1-tetradecylamide 2.23 
 
                                                            
xiv Overlapping signals at 14.2 for two methyl carbon atoms. 
Chapter 7: Experimental details 
200 
 
NEt3 (0.05 mL) was added to a stirring solution of N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-Nα-(tetracosyl)-L-aspargine 1-tetradecylamide 2.65 (35 mg, 0.04 
mmol) dissolved in CH2Cl2: MeOH: H2O (5 mL, 1:2:1) at 40 
oC.  It was stirred for 18 h. 
The precipitate formed was filtered through a vacuum to afford the title compound 
2.23 as white crystals (23 mg, 79%, crude yield); 1H-NMR (300 MHz, d5-Pyr): δ 0.85-
0.89 (m, 6 H, CH3 × 2); 1.22-1.32 (m, 62 H, CO(CH2)2(CH2)20CH3, NH(CH2)2(CH2)11CH3) , 
1.54-1.59 (m, 2 H, NHCH2CH2), 1.73-1.77 (m, 2 H, COCH2CH2), 2.35 (t, J = 7.5 Hz, 2 H, 
COCH2), 3.21-3.29 (m, 2 H, H-β,  H-β’), 3.38-3.49 (m, 2 H, NHCH2), 4.13-4.20 (m, 1H, 
H-5), 4.36-4.56 (m, 3 H, H-6, H-6’, H-3), 4.60 (d, J = 2.9 Hz, 1 H, H-2), 4.73 (d, J = 6.1 
Hz, 1 H, H-4), 5.61-5.65 (m, 1 H, H-α), 5.90 (dd, J = 8.9 Hz, 17.9 Hz, 1 H, H-1), 8.50 (t, 
J  = 5.5 Hz, 1 H, NHC14H29), 8.90-9.02 (m, 1 H, NHCOC23H47), 10.14-10.20 (m, 1 H, 
NHC1). 
1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose 2.32
 [253] 
 
A suspension of anhydrous NaOAc (4.55 g, 56 mmol, 1 equiv) in Ac2O (52 mL, 560 
mmol, 10 equiv) was heated to reflux temperature in a round bottom flask. To this 
solution, D-galactose 4.28 (10 g, 56 mmol) was added in portions, until the reaction 
mixture went colourless. The reaction mixture was poured onto crushed ice (400 
mL) and stirred for 2 h. The precipitated product was filtered off, washed with 
water and recrystallised from EtOH to yield the β-anomer 2.32 (11.50 g, 39%) as 
white crystals; Rf =0.30 (hexane/EtOAc 2:1);  [α]
20
D = +24.00 (c, 0.01 in CH2Cl2); mp = 
139-140 °C (lit 140 °C)[254]; 1H NMR (300 MHz): δ 2.00 (s,  3 H, OC(O)CH3), 2.05 (s, 3 
H, OC(O)CH3 ), 2.12 (s, 3 H, OC(O)CH3 ), 2.16-2.17 (m, 6 H, OC(O)CH3 × 2), 4.05-4.09 
(m, 1 H, H-5), 4.13-4.20 (m, 2 H, H-6, H-6’), 5.07 -5.11 (dd, J = 3.1 Hz , 9.5 Hz ,1 H,  H-
3), 5.31 - 5.37 (dd, J = 6.0 Hz, 9.4 Hz, 1 H, H-2), 5.42-5.44 (m, 1 H, H-4),  5.71 (d, J = 
6.0 Hz, 1 H, H-1); 13C NMR (75 Hz): δC 20.5 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 
(OC(O)CH3), 20.8 (OC(O)CH3), 30.9 (OC(O)CH3), 61.0 (C-6), 66.8 (C-4), 67.8 (C-2) , 
70.8 (C-3), 71.7 (C-5), 92.1 (C-1), 168.9 (OC(O)CH3), 169.3 (OC(O)CH3), 169.9 
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(OC(O)CH3),  170.1 (OC(O)CH3), 170.3 (OC(O)CH3); HRMS m/z (ESI+) 413.1000, 
(C16H23O11 [M+H]
+ requires 413.1060).  
The NMR data are in agreement with the reported values.[255] 
2,3,4,6-Tetra-O-acetyl-1-bromo-α-D-galactopyranose 2.33 
 
HBr in AcOH (33%) (5 mL, 138 mmol, 27 equiv) was added to 1,2,3,4,6-penta-O-
acetyl-β-D-galactopyranose 2.32 (2 g, 5.12 mmol) at 0 °C. The reaction mixture was 
stirred for 18 h at rt. The reaction mixture was concentrated in vacuo and re-
dissolved in EtOAc (50 mL) and a red/orange solid was removed by filtration. The 
reaction mixture was diluted with CH2Cl2 (50 mL) and washed with satd. aq. Na2CO3 
(30 mL × 3) followed by brine (30 mL). The organic layers were dried over MgSO4, 
filtered, concentrated in vacuo, high-vacuum dried and stored in the fridge to yield 
the α-anomer 2.33 as a white foam (1.58 g ,75%, crude yield); Rf =0.5 
(hexane/EtOAc 2:1); [α]20D = +142.96 (c, 0.03 in CH2Cl2); 
1H-NMR (300 MHz): δ 1.99 
(s, 3 H, OC(O)CH3),  2.02 (s, 3 H, OC(O)CH3), 2.11 (s, 3 H, OC(O)CH3), 2.16 (s, 3 H, 
OC(O)CH3), 4.09-4.24 (m, 2 H, H-6, H-6’),  4.52 (pt, J= 6.4 Hz, 1 H, H-5), 5.04 (dd, J= 
3.9 Hz, 10.6 Hz, 1 H, H-2), 5.38 (dd, J= 3.2, 10.6 Hz, 1 H, H-3), 5.52 (d, J= 3.2 Hz, 1 H, 
H-4), 6.73 (d, J= 3.9 Hz, 1 H, H-1); 13C-NMR (75 MHz): δC 20.4 (OC(O)CH3), 20.3 
(OC(O)CH3), 20.2 (OC(O)CH3), 60.7 (C-6), 66.9 (C-2), 67.5 (C-4), 67.8 (C-3), 71.1 (C-5), 
88.4 (C-1), 169.3 (OC(O)CH3), 169.5 (OC(O)CH3), 169.8 (OC(O)CH3),169.9 
(OC(O)CH3).  
 The NMR data are in agreement with the reported literature values.[71] 
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Octadecyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.34 
 
Ag2CO3 (0.72 g, 2.63 mmol, 2 equiv) and I2 (33 mg, 0.13 mmol, 0.1 equiv) was added 
to 2,3,4,6-tetra-O-acetyl-1-bromo-α-D-galactopyranose 2.33 (0.54 g, 1.31 mmol) in 
CH2Cl2 (5 mL) at rt. Octanol (0.21 g, 1.31 mmol, 1 equiv) was added to the reaction 
mixture and was stirred for 22 h. The suspension was filtered through Celite, 
washing with CH2Cl2. The filtrate was washed with brine and the organic layer was 
dried over MgSO4, filtered and rotary evaporated. Flash column chromatography 
(hexane/EtOAc 3:1) afforded the β-anomer 2.34 (0.11 g, 17%) as a white solid; Rf 
=0.70 (hexane/EtOAc 3:1); 1H-NMR (300 MHz): δ 0.86 (t, J= 6.0 Hz, 3 H, CH3), 1.25-
1.26 (m, 10 H, OCH2CH2(CH2)5CH3), 1.53-1.59 (m, 2 H, OCH2CH2), 1.97 (s, 3 H, 
OC(O)CH3), 2.02-2.03 (m, 6 H, OC(O)CH3 × 2), 2.13 (s, 3 H, OC(O)CH3), 3.41-3.50 (m, 
1 H, OCHCH2), 3.83-3.91 (m, 2 H, H-5, OCHCH2), 4.08-4.46 (m, 2 H, H-6, H-6’), 4.45 
(d, J= 7.8 Hz, 1 H, H-1), 5.00 (dd, J = 3.3 Hz, 10.4 Hz, 1 H, H-3), 5.19 (dd, J = 7.8 Hz, 
10.4 Hz, 1 H, H-2), 5.37 (d, J = 3.3 Hz, 1 H, H-4); 13C-NMR (75 MHz): δC 14.0 (CH3), 
20.5 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 (OC(O)CH3)
xv, 22.6, 25.8, 29.2, 29.2, 29.4, 
31.8 ((CH2)6CH3), 61.3 (C-6), 67.1 (C-4), 68.9 (C-2), 70.2 (OCH2), 70.5 (C-5), 70.9 (C-3), 
101.3 (C-1), 169.3 (OC(O)CH3), 170.1 (OC(O)CH3), 170.2 (OC(O)CH3), 170.3 
(OC(O)CH3).  
The NMR data are in agreement with the reported values.[72] 
 
 
 
 
                                                            
xv Two overlapping signals. 
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Dodecyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.35 
 
Ground docosonol (583 mg, 2.14 mmol, 1.2 equiv) was added to a suspension of 
Ag2CO3 (494 mg, 1.79 mmol, 1 equiv) and I2 (45 mg, 0.18 mmol, 0.1 equiv) in CH2Cl2 
(10 mL) at rt in the dark. A solution of 2,3,4,6-tetra-O-acetyl-1-bromo-α-D-
galactopyranose 2.33 (0.54 g, 1.31 mmol) in CH2Cl2 (5 mL) was slowly added to the 
suspension and the reaction mixture and was stirred for 24 h. The suspension was 
filtered through Celite and washed with CH2Cl2. The filtrate was washed with brine 
and the organic layer was dried over MgSO4, filtered and rotary evaporated. Flash 
column chromatography (hexane/EtOAc 4:1) afforded the β-anomer 2.35 (0.13 g, 
11%) as a white solid; Rf =0.3 (hexane/EtOAc 4:1);  [α]
20
D = -8.25 (c, 0.04 in CH2Cl2); 
IR νmax (NaCl plate, CH2Cl2): 3059.6, 2919.2, 2850.9, 2119.0, 1751.3 cm
-1;  1H-NMR 
(300 MHz): δ 0.88 (t, J= 6.9 Hz, 3 H, CH3), 1.24-1.25 (m, 38 H, OCH2CH2(CH2)19CH3), 
1.59 (bs, 2 H, OCH2CH2), 3.43-3.51 (m, 1 H, H-5), 3.87-3.92 (m, 2 H, H-6’, OCHHCH2), 
4.09-4.22 (m, 2 H, H-6, OCHHCH2), 4.45 (d, J  = 7.9 Hz, 1 H, H-1), 5.02 (dd, J = 3.4 Hz, 
10.5 Hz, 1 H, H-3), 5.21 (dd, J = 7.9 Hz, 10.5 Hz, 1 H, H-2), 5.39 (dd, J =0.9 Hz, 3.4 Hz, 
1 H, H-4); 13C-NMR (75 MHz): δC 14.1 (CH3), 20.6 (OC(O)CH3), 20.7 (OC(O)CH3), 20.7 
(OC(O)CH3)
xvi, 22.7 (CH2CH3), 25.8 (CH2CH2CH2CH3), 29.4 (OCH2CH2(CH2)16), 29.6 
(CH2CH2), 31.9 (CH2CH2CH3), 61.3 (OCH2), 67.1 (C-4), 68.9 (C-2), 70.3 (C-6), 70.6 (C-
5), 70.9 (C-3),  101.4 (C-1), 169.4 (OC(O)CH3), 170.2 (OC(O)CH3), 170.3 (OC(O)CH3), 
170.4 (OC(O)CH3); HRMS m/z (ESI+) 657.4574, (C36H64O10H [M+H]
+ requires 
657.4572).  
 
 
 
                                                            
xvi Two overlapping signals. 
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2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-1-azido 2.36 
[74] 
 
TMSN3 (2.56 mL, 19.48 mmol, 2.5 equiv) was added to a solution 1,2,3,4,6-penta-O-
acetyl-β-D-galactopyranose 2.32 (3.04 g, 7.79 mmol) in CH2Cl2 (30 mL). SnCl4 (3.90 
mL, 3.90 mmol, 0.5 equiv) (1 M solution in CH2Cl2) was added to this solution and 
the reaction mixture was stirred for 18 h. Satd. aq. NaHCO3 (50 mL) was added and 
the suspension was extracted with CH2Cl2 (2 × 50 mL). The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo to afford the β-
anomer 2.36 (2.28 g, 80%, crude yield) as a white solid; Rf =0.55 (hexane/EtOAc 
1:1); 1H NMR (300 MHz): δ 1.93 (s, 3 H, OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 2.04 (s, 3 
H, OC(O)CH3), 2.12 (s, 3 H, OC(O)CH3), 3.98 (td, J = 5.6 Hz, 9.2 Hz, 1 H, H-5), 4.11-
4.13 (m, 2 H, H-6, H-6’), 4.57 (d, J = 8.6 Hz, 1 H, H-1), 5.00 (dd, J = 3.3 Hz ,  10.4 Hz, 1 
H, H-3), 5.11 (dd, J = 8.6 Hz, 10.4 Hz, 1 H, H-2), 5.37 (dd, J = 1.0 Hz, 3.3 Hz , 1 H, H-4); 
HRMS m/z (ESI+) 396.1010, (C14H19O9N3Na: [M+Na]
+
 requires 396.1014).  
The NMR data is in agreement with the reported values.[74]  
1-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-4-tridecyl-1,2,3-triazole 2.37 
 
CuSO4.5H2O (33 mg, 0.13 mmol, 0.1 equiv) was added to a solution of 2,3,4,6-tetra-
O-acetyl-β-D-galactopyranosyl-1-azido 2.36 (500 mg, 1.34 mmol) and pentadecyne 
(279 mg, 1.34 mmol, 1 equiv) in THF/H2O/MeOH (5 mL, 1:1:3) at rt. Sodium 
ascorbate (53 mg, 0.27 mmol, 0.2 equiv) was added and the reaction mixture was 
stirred for 48 h. The reaction mixture was filtered through Celite and rinsed with 
EtOAc. The reaction mixture was washed with brine (100 mL) and the organic layer 
was dried over Na2SO4, filtered and concentrated in vacuo to afford the β-anomer 
2.37 (692 mg, 89%, crude yield) as a white solid; Rf =0.25 (PetEt/EtOAc 3:1); [α]
25
D = 
-1.67 (c, 1.2 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 2924.9, 2854.2, 1754.9, 1369.8, 
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cm-1; 1H-NMR (300 MHz): δ 0.88 (t, J = 6.9 Hz, 3 H, CH2CH3),  1.24-1.26 (m, 20 H, 
(CH2)10), 1.68 (t,  J =  8.2 Hz, 2 H, C=CCH2CH2), 1.88 (s, 3 H, OC(O)CH3), 2.01 (s, 3 H, 
OC(O)CH3), 2.05 (s, 3 H, OC(O)CH3), 2.22 (s, 3 H, OC(O)CH3), 2.72 (t, J = 8.1 Hz, 2 H, 
C=CCH2CH2), 4.13-4.23 (m, 3 H, H-5, H-6, H-6’), 5.24 (dd, J = 3.3 Hz, 10.3 Hz, 1 H, H-
4), 5.53-5.59 (m, 2 H, H-2, H-3), 5.82 (d, J = 9.3 Hz, 1 H, H-1); 13C-NMR (75 MHz): δC 
14.1 (CH3), 20.2 (OC(O)CH3), 20.5 (OC(O)CH3), 20.6 (OC(O)CH3)
xvii, 22.7, 25.7, 29.2, 
29.2, 29.4, 29.6, 29.7, 30.3, 31.9 ((CH2)12CH3), 61.2 (C-6), 66.9, 67.8 (C-2, C-3), 70.9 
(C-4), 74.0 (C-5), 86.2 (C-1), 118.8 (C=CH),  149.2 (C=CH), 169.1 (C=O), 169.8 (C=O), 
169.9 (C=O), 170.3 (C=O); HRMS m/z (ESI+) 582.3389, (C29H47N3O9H: [M+H]
+ 
requires  582.3385). 
N
α
-Tetradecanosyl-L/D-aspartic acid-tetradecylamide 2.40(L/D)  
 
H2 gas was bubbled through a suspension of N
α-tetradecanosyl-L/D-aspartic acid-
tetradecylamide 4-benzyl ester 2.47(L/D) (96 mg, 0.13 mmol) and Pd (C) (10 mg, 10 
% w/w) in EtOAc (5 mL) at 50 °C at 1 atm. The reaction mixture was stirred for 2 h. 
The suspension was filtered through Celite, washed with EtOAc and was 
concentrated in vacuo to yield the title compound 2.40(L/D) (61 mg, 72%, crude 
yield) as a white solid; [α]23D = +0.10 (c 0.4, CH2Cl2); Data recorded for racemic 
mixture: 1H NMR (300 MHz): δ 0.86-0.88 (m, 6 H, CH3 × 2), 1.23-1.25 (m, 62 H, 
COCH2CH2(CH2)20CH3, NHCH2CH2(CH2)11CH3), 1.48 (t, J = 6.9 Hz, 2 H, NHCH2CH2), 
1.63 (t, J  = 7.2 Hz, 2 H, COCH2CH2), 2.17-2.25 (m, 2 H, COCH2), 2.67 (dd, J = 7.1 Hz, 
17.1 Hz, 1 H, H-β), 2.93 (dd, J = 3.6 Hz, 17.1 Hz, 1 H, H-β’), 3.19-3.25 (m, 2 H, 
NHCH2), 4.72-4.78 (m, 1 H, H-α), 6.96 (t, J = 4.8 Hz, 1 H, NHCH2), 7.01 (d, J = 7.6 Hz, 1 
H, NH(H-α)); HRMS m/z (ESI+) 1376.2602, (C42H84O4N2NH4: [M+NH4]
+
 requires 
1376.2614).  
 
 
                                                            
xvii Two overlapping signals. 
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2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-1-amino 2.44 
 
H2 gas was bubbled through a suspension of 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl-1-azido 2.36 (560 mg, 1.50 mmol) and Pd (C) (56 mg, 10% w/w) in 
EtOAc (5 mL) at 1 atm at rt. It was left to stir for 18 h. The suspension was filtered 
through Celite, washed with EtOAc and concentrated in vacuo to yield the β-
anomer 2.44 (498 mg, 96%, crude yield) as a white foamy solid; 1H NMR (300 MHz): 
δ 1.98 (s, 3 H, OC(O)CH3), 2.04 (s, 3 H, OC(O)CH3), 2.07 (s, 3 H, OC(O)CH3), 2.14 (s, 3 
H, OC(O)CH3), 3.89-3.91 (m, 1 H, H-5), 4.08-4.10 (m, 2 H, H-6, H-6’), 4.16 (d, J = 8.0 
Hz, 1 H, H-1), 5.02-5.04 (m, 1 H, H-3), 5.11 (dd, J = 8.0 Hz,  10.3 Hz, 1 H, H-2), 5.39 
(d, J = 1.8 Hz, 1 H, H-4); HRMS m/z (ESI+) 348.1279, (C14H21O9NH: [M+H] 
+
 requires 
348.1289).  
The NMR data is in agreement with the reported values. [74] 
N
α
-tert-Butoxycarbonyl-L/D-aspartic acid-tetradecylamide 4-benzyl ester 2.45(L/D) 
[82]
 
 
TBTU (1.09 g, 3.40 mmol, 1.1 equiv) and HOBt (0.460 g, 3.40 mmol, 1.1 equiv) were 
added to Boc-Asp(OBn)-OH 2.41 ( 1.00 g, 3.09 mmol) in DMF (15 mL) containing 4 Å 
MS under N2 at rt. The reaction mixture was stirred for 30 min and tetradecylamine 
(0.660 g, 3.09 mmol, 1 equiv) was added. The reaction mixture was stirred for 2.5 h, 
then concentrated in vacuo; diluted with EtOAc (4 mL), washed with H2O (4 mL), 
brine (4 mL), H2O (4 mL), dried over MgSO4, filtered and concentrated. 
Recrystallisation in i-PrOH afforded the title compound 2.45(L/D) (1.40 g, 87%) as 
white crystals; Data recorded for racemic mixture: Rf =0.67 (hexane/EtOAc 
2:1);[α]22D = 0 (c 0.9, CHCl3); IR νmax (KBr): 3339.8, 2910.3, 1736.6, 1664.8, 1519.1 
cm-1; 1H NMR (300 MHz):  δ 0.88 (t, J = 6.9 Hz, 3 H, CH3), 1.22-1.25 (m, 22 H, 
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(CH2)11CH3), 1.43-1.45 (m, 11 H, C(CH3)3, NHCH2CH2), 2.72 (dd, J = 6.5 Hz, 17.2 Hz, 1 
H, H-β’), 3.04 (dd, J = 4.5 Hz, 17.2 Hz, 1 H, H-β), 3.15-3.25 (NHCH2), 4.45-4.47 (m, 1 
H, H-α), 5.13 (d, J = 3.3 Hz, 2 H, CH2Ph), 5.65-5.65 (m, 1 H, NHCOOC(CH3)3), 6.43-
6.44 (m, 1 H, NHCH2), 7.26-7.37 (m, 5 H, Ph); 
13C NMR (75 Hz): δc 14.1 (CH2CH3), 
22.7, 26.8, 28.3, 29.3, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9 ((CH2)12CH3), 36.2 (C-β), 39.6 
(NHCH2), 50.7 (C-α), 66.8 (CH2Ph), 80.5 (OC(CH3)3), 128.2, 128.4, 128.5, 128.6 
(aromatics), 135.4 (C=O), 170.4 (C=O), 171.8 (C=O). 
N
α
-Tetradecanosyl-L/D-aspartic acid-tetradecylamide 4-benzyl ester 2.47 
 
TFA (2.93 mL, 34.70 mmol, 10 equiv) in CH2Cl2 (3 mL) was added drop-wise to a 
solution of Nα-tert-butoxycarbonyl-L/D-aspartic acid-tetradecylamide 4-benzyl ester 
2.45(L/D) (1.80 g, 3.47 mmol) in CH2Cl2 (10 mL). The reaction mixture was stirred for 
3 h and concentrated. It was diluted in CH2Cl2 (50 mL) and washed with satd. aq. 
NaHCO3 solution (50 mL), brine (50 mL) and H2O (50 mL). It was concentrated in 
vacuo to yield the crude amine 2.46(L/D) (1.29 g, 77%, crude yield) as a white solid. 
The compound was used without further purification. In a separate pot, TBTU (479 
mg, 1.49 mmol, 1.1 equiv) and HOBt (201 mg, 1.49 mmol, 1.1 equiv) were added to 
lignoceric acid (500 mg, 1.36 mmol) in DMF (10 mL) containing 4 Å MS under N2 at 
rt. It was stirred for 30 min and the crude amine 2.46(L/D) (706 mg, 1.36 mmol, 1 
equiv) was added. The reaction mixture was stirred for 18 h. It was concentrated in 
vacuo; diluted with EtOAc (4 mL), washed with H2O (4 mL), brine (4 mL), H2O (4 mL), 
dried over MgSO4, filtered and concentrated to yield the title compound 2.47(L/D) 
(935 mg, 89%, crude yield) as a white solid. A small sample was recrystallized in 
toluene for characterisation; Data recorded for racemic mixture: Rf =0.50 
(hexane/EtOAc 2:1); [α]23D = 0 (c 0.8, CHCl3); mp = 82-84 °C; IR νmax (KBr): 3298.3, 
2918.8, 2850.1, 1732.9, 1643.3, 1546.3, 1469.1, 1412.6, cm-1; 1H NMR (300 MHz):  δ 
0.86-0.88 (m, 6 H, CH3 × 2), 1.24-1.25 (m, 64 H, COCH2CH2(CH2)20CH3, 
NHCH2(CH2)12CH3), 1.44 (t, J  = 6.9 Hz, 2 H, COCH2CH2), 2.17-2.22 (m, 2 H, COCH2), 
2.64 (dd, J = 7.0 Hz, 16.9 Hz, 1 H, H-β), 2.98 (dd, J = 4.2 Hz, 16.9 Hz, 1 H, H-β’), 3.16-
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3.23 (m, 2 H, NHCH2), 4.78 (td, J =4.2 Hz, J = 7.0 Hz, J = 11.8 Hz, 1 H, H-α), 5.15 (d, J = 
3.0 Hz, 2 H, CH2Ph), 6.51 (t, J = 5.6 Hz, 1 H, NHCH2), 6.77 (d, J = 7.9 Hz, 1 H, NH(H-
α)), 7.35 (s, 5 H, Ph); 13C NMR (75 Hz): δc 14.1 (CH3)
xviii, 22.7, 25.6, 26.8, 29.3, 29.4, 
29.5, 29.6, 29.7, 29.7, 31.9 (COCH2(CH2)21CH3, NHCH2(CH2)12CH3), 35.7 (C-β), 36.6 
(COCH2), 39.7 (NHCH2), 49.1 (C-α), 66.9 (CH2Ph), 128.3, 128.4, 128.6, 138.6 
(aromatic), 170.1 (C=O), 172.2 (C=O), 173.4 (C=O); HRMS m/z (ESI+) 769.6815, 
(C49H88O4N2H: [M+H]
+
 requires 769.6817).  
N
α
-tert-Butoxycarbonyl-N
γ
-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-L/D-
aspargine tetradecylamide 2.49(L/D) 
 
H2 gas was bubbled through a suspension of N
α-tert-butoxycarbonyl-L/D-aspartic 
acid-tetradecylamide 4-benzyl ester 2.45(L/D)(500 mg, 9.65 mmol) and Pd (C) (50 
mg, 10% w/w) in EtOAc (5 mL) at 1 atm at rt. The reaction mixture was left to stir 
for 18 h. The suspension was filtered through Celite, washed with EtOAc and 
concentrated in vacuo to yield the crude carboxylic acid 2.48(L/D) (400 mg, 97%, 
crude yield) as a white solid. It was used without further purification. TBTU (43 mg, 
0.13 mmol, 1.1 equiv) and HOBt (18 mg, 0.13 mmol, 1.1 equiv) were added to the 
carboxylic acid 2.48(L/D) (52 mg, 0.12 mmol) in DMF (3 mL) under N2 at rt. The 
reaction mixture was stirred for 30 min and 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl-1-amino 2.44 (42 mg, 0.121 mmol, 1 equiv) was added. The 
reaction mixture was stirred for 18 h. It was concentrated in vacuo; diluted with 
EtOAc (4 mL), washed with H2O (4 mL), brine (4 mL), H2O (4 mL), dried over MgSO4, 
filtered and concentrated. Flash column chromatography (hexane/EtOAc 1:1) 
afforded the β-glycoside 2.49(L/D) (55 mg, 59%) as a white solid as a mixture of 
diastereoisomers (1.57:1 ratio); Data recorded for racemic mixture: Rf =0.22 
(hexane/EtOAc 1:1); 1H NMR (300 MHz): δ 0.86-0.88 (m, 6 H, CH3 × 2), 1.21-1.23 (m, 
20 H, (CH2)10CH3 × 2), 1.40-1.43 (m, 22 H, C=OOC(CH3)3 × 2, NHCH2CH2 × 2), 1.97 (s, 3 
                                                            
xviii Two overlapping signals. 
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H, OC(O)CH3), 1.98 (s, 3 H, OC(O)CH3), 2.02 (s, 3 H, OC(O)CH3), 2.03 (s, 3 H, 
OC(O)CH3), 2.05 (s, 3 H, OC(O)CH3), 2.13 (s, 3 H, OC(O)CH3), 2.13 (s, 3 H, OC(O)CH3), 
2.46-2.59 (m, 2 H,  H-β × 2), 2.75-2.84 (m, 2 H, H-β’ × 2), 3.14-3.20 (m, 4 H, NHCH2 × 
2), 3.97-4.14 (m, 6 H, H-5 × 2, H-6 × 2, H-6’ × 2), 4.39-4.43 (m, 2 H, H-α × 2), 5.08-
5.23 (m, 6 H, H-1 × 2, H-2 × 2, H-3 × 2), 5.41-5.42 (m, 2 H, H-4 × 2), 5.72 (d, J = 7.9 
Hz, 1 H, NHC=OOC(CH3)3 ), 6.17 (d, J = 8.5 Hz, 1 H, NHC=OOC(CH3)3 ), 6.61-6.75 (m, 4 
H, NH (C-1) × 2, NHCH2 × 2); 
13C NMR (75 Hz): δc 14.1 (CH2CH3), 20.5 (OC(O)CH3), 
20.6 (OC(O)CH3), 20.6 (OC(O)CH3), 20.7 (OC(O)CH3), 22.6 (OC(CH3)3), 26.8, 28.2, 
29.2, 29.3, 29.4, 29.5, 29.6, 29.6, 29.6, 29.6, 31.9 (CH2)13CH3), 39.6 (C-β), 50.9 (C-α), 
60.9 (C-6), 61.1 (C-4), 70.7 (C-2), 72.3 (C-3), 78.3 (C-5), 80.3 (C-1), 168.1 (C=0), 168.3 
(C=0), 168.3 (C=0), 168.6 (C=0), 168.8 (C=0), 168.9 (C=0), 169.4 (C=0); HRMS m/z 
(ESI+) 780.4237, (C37H63O13N3Na: [M+Na]
+
 requires 780.4253).  
N
α
-tert-Butoxycarbonyl-N
γ
-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-L-
aspargine 1-benzyl ester 2.53 
 
HOBt (1.30 g, 9.60 mmol, 2 equiv) was added to a stirred solution of N-boc-L-Asp-
OBn 2.52 (1.55 g, 4.80 mmol) and TBTU (3.08 g, 0.72 mmol, 2 equiv) in DMF (25 mL) 
under N2 at rt. The reaction mixture was stirred for 30 min and 2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl-1-amino 2.44 (2 g, 5.76 mmol, 1.2 equiv) dissolved in 
DMF (10 mL) was added drop-wise to the solution and was stirred for 18 h. The 
reaction mixture was concentrated in vacuo, diluted with EtOAc (20 mL), washed 
with H2O (20 mL), 0.1 N aq. HCl solution (20 mL), satd. aq. NaHCO3 (20 mL), dried 
over MgSO4, filtered and concentrated. Flash column chromatography 
(hexane/EtOAc 1:1) afforded the β-anomer 2.53 (1.70 g, 71%) as a white solid. This 
was used without further purification.  A small sample of N-glycoside 2.53 was 
recrystallised in CHCl3/ hexane to give white crystals used for characterisation; Rf 
=0.25 (hexane/EtOAc 1:1); [α]22D = +30.00 (c 1.2, CHCl3); mp = 148-150 °C; IR νmax 
(NaCl plate, CH2Cl2): 3348.7, 2965.2, 1749.6, 1499.7 cm
-1; 1H NMR (300 MHz): δ 1.41 
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(s, 9 H, C(O)OC(CH3)3), 1.98 (s, 3 H, OC(O)CH3), 1.99, ( s, 3 H, OC(O)CH3), 2.03 (s, 3 H, 
OC(O)CH3), 2.13 (s, 3 H, OC(O)CH3), 2.71 (dd, J = 3.4 Hz, 15.0 Hz, 1 H, H-β), 2.84-2.95 
(m, 1 H, H- β’), 3.97-4.15 (m, 3 H, H-5, H-6, H-6’), 4.56-4.58 (m, 1 H, H-α), 5.04-5.21 
(m, 5 H, CH2Ph, H-1, H-2, H-3), 5.42 (d, J = 3.6 Hz, 1 H, H-4), 5.70 (d, J = 9.2 Hz, 1 H,  
NHC=OCH2), 6.39 (d, J = 9.4 Hz, 1 H, NHC=OC(CH3)3), 7.33-7.34 (m, 5 H, Ph).  
The NMR data is in agreement with the reported values.[256] 
N
α
-tert-Butoxycarbonyl-2,4-dioxo-N
γ
-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-L-pyrrolidone 2.54 
 
H2 gas was bubbled through a suspension of N
α-tert-butoxycarbonyl-Nγ-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-L-aspargine 1-benzyl ester 2.53 (179 mg, 0.27 
mmol) and Pd (C) (17 mg, 10% w/w) in EtOAc (10 mL) at 1 atm at rt. The reaction 
mixture was left to stir for 18 h. The suspension was filtered through Celite, washed 
with EtOAc and was concentrated in vacuo to yield the crude carboxylic acid (125 
mg, 81%, crude yield) as a colourless oil. No further purification was performed. 
TBTU (0.321 g, 1.00 mmol, 1.1 equiv) and HOBt (0.135 g, 1.00 mmol, 1.1 equiv) 
were added to a stirring solution of the carboxylic acid (512 mg, 0.91 mmol) in DMF 
(40 mL) under N2 at rt. It was stirred for 30 min and tetradecylamine (194 mg, 0.91 
mmol, 1 equiv) was added to the reaction mixture. It was stirred for 4 h and was 
concentrated in vacuo, diluted with EtOAc (40 mL), washed with H2O (40 mL), 0.1 N 
aq. HCl solution (40 mL), satd. aq. NaHCO3 (40 mL), dried over MgSO4, filtered and 
concentrated. Flash column chromatography (hexane/EtOAc 2:1) afforded the 
succinimide β-glycoside 2.54 (215 mg, 48%) as a white foamy solid; Rf =0.17 
(hexane/EtOAc 1:1); [α]23D = +11.43 (c 0.7, CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 
3386.6, 2977.1, 1751.2, 1509.2 cm-1; 1H NMR (300 MHz): δ 1.44 (s, 9 H, 
C=OOC(CH3)3), 1.99 (s, 3 H, OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 2.05 (s, 3 H, 
OC(O)CH3), 2.21 (s, 3 H, OC(O)CH3), 2.74 (dd, J = 5.8 Hz, 15.3 Hz, 1 H, H-β), 3.06-3.15 
(m, 1 H, H- β’), 4.00-4.20 (m, 3 H, H-5, H-6, H-6’), 4.24-4.27 (m, 1 H, H-α), 5.08 (dd, 
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J= 3.2 Hz, 10.0 Hz, 1 H, H-3), 5.33-5.35 (m, 2 H, H-1, NH), 5.45-5.46 (d, J = 3.2 Hz, 1 
H, H-4), 6.09-6.10 (m, 1 H, H-2); 13C NMR (75 Hz): δc 19.6 (OC(O)CH3), 19.7 
(OC(O)CH3), 19.7 (OC(O)CH3),
xix 27.2 (OC(CH3)3), 34.4 (C-β), 48.4 (C-α), 60.5 (C-6), 
64.1 (C-2), 65.9 (C-4), 70.9 (C-3), 72.5 (C-5), 77.3 (OC(CH3)3), 79.9 (C-1), 154.1, 168.7, 
160.1, 169.4 (C=O); HRMS m/z (ESI+) 567.1773, (C23H32O13N2Na: [M+ Na]
+
 requires 
567.1797). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-L-aspargine 1-benzyl ester 2.55 
 
TFA (1.34 mL, 17.93 mmol, 10 equiv) in CH2Cl2 (1.34 mL) was added drop-wise to a 
solution of Nα-tert-butoxycarbonyl-Nγ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-L-aspargine 1-benzyl ester 2.53 (1.17 g, 1.79 mmol) in CH2Cl2 (10 
mL) at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 6 h. It 
was rotary evaporated. The reaction mixture was diluted in CH2Cl2 (50 mL) and 
washed with satd. aq. NaHCO3 solution (50 mL), brine (50 mL) and H2O (50 mL). It 
was concentrated in vacuo to yield the β-glycoside 2.55 (0.73 g, 74%, crude yield) as 
a white foam. The compound was used without further purification; 1H NMR (300 
MHz): δ 1.95 (s, 3 H, OC(O)CH3), 1.99 (s, 3 H, OC(O)CH3), 2.00 (s, 3 H, OC(O)CH3), 
2.10 (s, 3 H, OC(O)CH3), 2.40 (dd, J = 9.6 Hz, 5.3 Hz, 1 H, H-β’), 2.63-2.67 (m , 1 H, H- 
β), 3.65-3.68 (m, 1 H, H-α), 3.97-4.11 (m, 3 H, H-5, H-6, H-6’), 5.07-5.12 (m, 4 H, 
CH2Ph, H-2, H-3), 5.22 (t, J = 9.3 Hz, 1 H, H-1), 5.39 (d, J = 1.4 Hz, 1 H, H-4), 7.31-7.31 
(m, 5 H, Ph), 8.09 (d, J = 9.3 Hz, 1 H, NH); HRMS m/z (ESI+) 553.2024, (C25H33O12N2: 
[M+ Na]+ requires 553.2033). 
 
 
 
                                                            
xix Two overlapping signals. 
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N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(decanosyl)-L-aspargine 1-
benzyl ester 2.56 
 
TBTU (56 mg, 0.18 mmol, 1.1 equiv) and HOBt (24 mg, 0.18 mmol, 1.1 equiv) were 
added to decanoic acid (27 mg, 0.16 mmol) in DMF (2 mL) containing 4 Å MS under 
N2 at rt. It was stirred for 20 min and N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-L-aspargine 1-benzyl ester 2.55 (88 mg, 0.16 mmol, 1 equiv) in 
DMF (1 mL) was added drop-wise to the solution. It was stirred for 18 h. The 
reaction mixture was concentrated in vacuo; diluted with EtOAc (4 mL), washed 
with H2O (4 mL), brine (4 mL), H2O (4 mL), dried over MgSO4, filtered and 
concentrated. Flash column chromatography (hexane/EtOAc 1:1) afforded the β-
anomer 2.56 (60 mg, 54%) as a colourless oil; Rf =0.36 (hexane/EtOAc 1:1); [α]
22
D = 
+27.27 (c 1.76, CHCl3); IR νmax (NaCl plate, CH2Cl2): 3330.9, 2926.4, 1751.0, 1674.3, 
1530.8 cm-1; 1H NMR (300 MHz):  δ 0.86 (t, J = 7.0 Hz, 3 H, CH3), 1.23-1.25 (m, 12 H, 
(CH2)6CH3), 1.56-1.61 (m, 2 H, COCH2CH2), 1.98 (s, 3 H, OC(O)CH3), 1.99 (s, 3 H, 
OC(O)CH3), 2.03 (s, 3 H, OC(O)CH3), 2.13 (s, 3 H, OC(O)CH3), 2.19 (t, J = 7.3 Hz, 2 H, 
COCH2), 2.70 (dd, J = 4.4 Hz, 16.4 Hz, 1 H, H-β’), 2.90 (dd, J = 4.1 Hz, 16.5 Hz, 1 H, H-
β), 3.97 -4.15 (m, 3 H, H-5, H-6, H-6’), 4.87-4.93 (m, 1 H, H-α), 5.04-5.20 (m, 5 H, H-
1, H-2, H-3, CH2Ph), 5.42 (d, J = 2.0 Hz, 1 H, H-4), 6.49 (d, J = 8.7 Hz, 1 H, NHC1),  
6.73 (d, J = 8.3 Hz, 1 H, NHCOC9H19), 7.31- 7.33  (m, 5 H, Ph); 
13C NMR (75 Hz): δc 
14.1 (CH2CH3), 20.5 (OC(O)CH3), 20.5 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 (OC(O)CH3), 
22.6, 25.5, 29.2, 29.2, 29.3, 29.4 ((CH2)6CH3), 31.8 (COCH2CH2), 36.5 (COCH2), 37.4 
(C-β),  48.4 (C-α), 61.0 (C-6), 67.0 (C-4), 67.4 (CH2Ph), 68.1 (C-2), 70.7 (C-3), 72.4 (C-
5), 78.4 (C-1), 127.9, 128.3, 128.5, 135.2 (aromatics), 169.7 (C=O), 169.9 (C=O), 
170.3 (C=O), 170.8 (C=O), 170.9 (C=O), 171.5 (C=O), 173.1 (C=O); HRMS m/z (ESI+) 
707.3376, (C35H51O13N2: [M+ H]
+
 requires 707.3386). 
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N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(decanosyl)-L-aspargine  2.57 
 
H2 gas was bubbled through a suspension of N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-Nα-(decanosyl)-L-aspargine 1-benzyl ester 2.56 (56 mg, 0.08 
mmol) and Pd (C) (6 mg, 10% w/w) in EtOAc (10 mL) at 1 atm. It was stirred for 3 h. 
The suspension was filtered through Celite, washed with EtOAc and concentrated in 
vacuo to yield the carboxylic acid 2.57 (30 mg, 61%, crude yield) as a colourless oil; 
1H NMR (300 MHz):  δ 0.87 (t, J = 6.9 Hz, 3 H, CH3); 1.23-1.26 (m, 12 H, (CH2)6CH3), 
1.60-1.65 (m, 2 H, COCH2CH2), 2.00 (s, 3 H, OC(O)CH3), 2.05 (m, 6 H, OC(O)CH3 × 2), 
2.15 (s, 3 H, OC(O)CH3), 2.30 (t, J =  8.0 Hz, 1 H, COCH2), 2.77 (dd, J = 4.8 Hz, 16.5 Hz, 
1 H, H- β’), 2.87 (dd, J = 3.6 Hz, 16.5 Hz, 1 H, H-β), 4.00-4.25 (m, 3 H, H-5, H-6, H-6’), 
4.71-4.74 (m, 1 H, H-α), 5.10-5.16 ( m, 2 H , H-2, H-3), 5.32-5.38 (m, 1 H, H-1), 5.52 
(d, J = 1.7 Hz, 1 H, H-4), 6.56 (d, J = 9.4 Hz, 1 H, NHC1), 7.24 (d, J = 6.8 Hz, 1 H, 
NHCOC9H19); HRMS m/z (ESI+) 617.2900, (C28H44O13N2H: [M+ H]
+
 requires 
617.2916). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(decanosyl)-L-aspargine 1-
tetradecylamide 2.58 
 
TBTU (14 mg, 0.05 mmol, 1.1 equiv) and HOBt (6 mg, 0.05 mmol, 1.1 equiv) were 
added to Nγ-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-Nα-(decanosyl)-L-
aspargine  2.57 (25 mg, 0.04 mmol) in DMF (3 mL) containing 4 Å MS under N2 at rt. 
The reaction mixture was stirred for 30 min and tetradecylamine (9 mg, 0.04 mmol, 
1 equiv) was added to the solution under N2. The reaction mixture was stirred for 3 
h. It was subsequently concentrated in vacuo; diluted with EtOAc (4 mL), washed 
with brine (4 mL), H2O (4 mL), dried over MgSO4, filtered and concentrated. Flash 
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column chromatography (hexane/EtOAc 1:1) afforded the β-anomer 2.58 (18 mg, 
55%) as a white solid; Rf =0.10 (hexane/EtOAc 1:1); [α]
25
D = +20.00 (c 0.75, CH2Cl2); 
IR νmax (NaCl plate, CH2Cl2): 3286.1, 2924.1, 2853.8, 1751.2, 1642.6, 1546.1, 1466.7, 
cm-1; 1H NMR (300 MHz): δ 0.87-0.87 (m, 6 H, CH3 × 2); 1.24-1.26 (m, 34 H, 
CO(CH2)2(CH2)6CH3, NH(CH2)2(CH2)11CH3), 1.42-1.46 (m, 2 H, NHCH2CH2), 1.63-1.66 
(m, 2 H, COCH2CH2), 2.00 (s, 3 H, OC(O)CH3), 2.04 (s, 3 H, OC(O)CH3), 2.14 (s, 3 H, 
OC(O)CH3), 2.17 (s, 3 H, OC(O)CH3), 2.21-2.25 (m, 1 H, COCH2), 2.45 (dd, J = 5.6 Hz,  
15.5 Hz, 1 H, H-β’), 2.68 (dd, J = 3.4 Hz, 15.5 Hz, 1 H, H-β), 3.11- 3.18 (m, 2 H, 
NHCH2), 3.99-4.16 (m, 3 H, H-5, H-6, H-6’), 4.67-4.71 (m, 1 H, H-α), 5.10-5.23 (m, 3 
H, H-1, H-2, H-3), 5.44 (d, J = 1.6 Hz, 1 H, H-4), 6.74-6.79 (m, 2 H, NHC1, NHC14H29), 
7.58 (d, J = 7.6 Hz, 1 H, NHCOC9H19); 
13C NMR (75 Hz): δc 14.1 (CH2CH3)
xx, 20.5 
(OC(O)CH3), 20.6 (OC(O)CH3), 20.7 (OC(O)CH3), 20.9 (OC(O)CH3), 22.7, 22.7, 25.6, 
26.9, 29.3, 29.3, 29.4,  29.4, 29.6, 29.6, 29.6, 29.7, 31.8 (CO(CH2)2(CH2)6CH3, 
NH(CH2)(CH2)12CH3), 31.9 (COCH2CH2), 36.2 (COCH2), 36.6 (C-β), 39.6 (C-β), 49.8 (C-
α), 61.1 (C-6), 67.1 (C-4), 67.8 (C-2), 70.7 (C-3), 72.3 (C-5), 78.5 (C-1), 169.8 (C=O), 
170.0 (C=O), 170.3 (C=O), 170.4 (C=O), 172.3 (C=O), 173.0 (C=O),  173.8 (C=O); 
HRMS m/z (ESI+) 834.5079, (C42H73O12N3Na: [M+Na]
+
 requires 834.5086). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(hexadecanosyl)-L-aspargine 
1-benzyl ester 2.60 
 
NEt3 (57 µL, 0.411 mmol, 1 equiv) was added to N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-L-aspargine 1-benzyl ester 2.55 (227 mg, 0.411 mmol) in CH2Cl2 (8 
mL) and the reaction mixture was stirred for 10 min at rt under N2. Hexadecanosyl 
chloride (125 µL, 0.411 mmol, 1 equiv) was added drop-wise to the solution and it 
was stirred for 18 h. The reaction mixture was concentrated in vacuo; diluted with 
EtOAc (4 mL), washed with 0.1 N aq. HCl (4 mL), satd. aq. NaHCO3 (4 mL), brine (4 
mL), dried over MgSO4, filtered and concentrated. Flash column chromatography 
                                                            
xx Two overlapping signals. 
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(hexane/EtOAc 1:1) afforded the β-anomer 2.60 (136 mg, 42%) as a white solid; Rf 
=0.21 (hexane/EtOAc 1:1); [α]22D = +21.33 (c 0.75, CH2Cl2); IR νmax (NaCl plate, 
CH2Cl2): 3440.0, 2095.1, 1750.3, 1644.9, 1226.3 cm
-1; 1H NMR (300 MHz):  δ 0.86 (t, 
J = 6.9 Hz, 3 H, CH3), 1.22-1.24 (m, 24 H, (CH2)12CH3), 1.56-1.60 (m, 2 H, COCH2CH2), 
1.97 (s, 3 H, OC(O)CH3), 2.00 (s, 3 H, OC(O)CH3), 2.03 (s, 3 H, OC(O)CH3), 2.12 (s, 3 H, 
OC(O)CH3), 2.19 (t, J =  7.3 Hz, 2 H, COCH2), 2.70 (dd, J = 4.4 Hz, 16.4 Hz, 1 H, H-β’), 
2.90 (dd, J = 4.0 Hz, 16.4 Hz, 1 H, H-β), 3.97-4.14 (m, 3 H, H-5, H-6, H-6’), 4.87-4.92 
(m, 1 H, H-α), 5.07-5.19 (m, 5 H, H-1, H-2, H-3, CH2Ph), 5.42 (d, J = 2.0 Hz, 1 H, H-4), 
6.55 (d, J = 8.7 Hz, 1 H, NHC1),  6.75 (d, J = 8.3 Hz, 1 H, NHCOC15H31), 7.31- 7.32  (m, 
5 H, Ph); 13C NMR (75 Hz): δc 14.1 (CH2CH3), 20.5 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 
(OC(O)CH3), 20.7 (OC(O)CH3 ), 22.7, 25.5, 29.2, 29.3, 29.3, 29.5, 29.6, 29.7 
((CH2)12CH3), 31.9 (COCH2CH2), 36.5 (COCH2), 37.5 (C-β),  48.5 (C-α), 61.0 (C-6), 67.0 
(C-4), 67.4 (CH2Ph), 68.2 (C-2), 70.7 (C-3), 72.4 (C-5), 78.5 (C-1), 127.9, 128.4, 128.6, 
135.3 (aromatics), 169.8 (C=O), 169.9 (C=O), 170.3 (C=O), 170.9 (C=O), 170.9 (C=O), 
171.5 (C=O), 173.1 (C=O); HRMS m/z (ESI+) 792.4389, (C41H62O13N2H: [M+ H]
+
 
requires 792.4358). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(hexadecanosyl)-L-aspargine 
2.61 
 
H2 gas was bubbled through a suspension of N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-Nα-(hexadecanosyl)-L-aspargine 1-benzyl ester 2.60 (136 mg, 0.17 
mmol) and Pd (C) (14 mg, 10% w/w) in EtOAc (5 mL) at 1 atm at rt and was stirred 
for 18 h. The suspension was filtered through Celite, washed with EtOAc and the 
filtrate was concentrated in vacuo to yield the carboxylic acid 2.61 (104 mg, 86%, 
crude yield) as a white solid; 1H NMR (300 MHz):  δ 0.85 (t, J = 6.9 Hz, 3 H, CH3), 
1.21-1.24 (m, 24 H, (CH2)12CH3), 1.58-1.63 (m, 2 H, COCH2CH2), 1.98 (s, 3 H, 
OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 2.04 (s, 3 H, OC(O)CH3), 2.14 (s, 3 H, OC(O)CH3), 
2.29 (t, J = 8.0 Hz,  2 H, COCH2), 2.77-2.91 (m, 2 H, H-β, H- β’), 3.95- 4.25 (m, 3 H, H-
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5, H-6, H-6’), 4.70-4.72 (m, 1 H, H-α), 5.09-5.11 ( m, 2 H , H-2, H-3), 5.35-5.41 (m, 1 
H, H-1), 5.50-5.52 (m, 1 H, H-4), 6.76 (d, J = 9.5 Hz, 1 H, NHC1), 7.18 (d, J = 7.0 Hz, 1 
H, NHCOC15H31); HRMS m/z (ESI+) 701.3861, (C34H56O13N2H: [M+H]
+
 requires 
701.3855). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(tetradecanosyl)-L-aspargine 
1-tetradecylamide 2.62 
 
TBTU (51 mg, 0.16 mmol, 1.1 equiv) and HOBt (21 mg, 0.16 mmol, 1.1 equiv) were 
added to Nγ-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-Nα-(hexadecanosyl)-L-
aspargine 2.61 (27 mg, 0.03 mmol) in DMF (3 mL) under N2 at rt.  Tetradecylamine 
(61 mg, 0.29 mmol, 2 equiv) was added slowly to the solution and the reaction 
mixture was stirred for 18 h. The reaction mixture was concentrated in vacuo. Flash 
column chromatography (hexane/EtOAc 1:1) afforded the title compound 2.62 (120 
mg, 98%) as a white solid; Rf =0.17 (hexane/EtOAc 1:1); [α]
28
D = +5.71 (c 1.05, 
CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3292.3, 2921.0, 2851.5, 1750.4, 1645.9, 1546.1, 
1371.0, 1227.8, 1054.6 cm-1; 1H NMR (300 MHz):  δ 1.20-1.22 (m, 46 H, 
CO(CH2)2(CH2)12CH3,  NH(CH2)2(CH2)11CH3), 1.40-1.44 ( m, 2 H, NHCH2CH2), 1.57-1.61 
(m, 2 H, COCH2CH2), 1.97 (s, 3 H, OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 2.11 (s, 3 H, 
OC(O)CH3), 2.14 (s, 3 H, OC(O)CH3), 2.16-2.22 (m, 1 H, COCH2), 2.43 (dd, J = 5.7 Hz, 
15.7 Hz, 1 H, H-β’), 2.68 (dd, J = 3.6 Hz, 15.7 Hz, 1 H, H-β), 3.01- 3.16 (m, 2 H, 
NHCH2), 3.98-4.14 (m, 3 H, H-5, H-6, H-6’), 4.65-4.71 (m, 1 H, H-α), 5.11-5.25 (m, 3 
H, H-1, H-2, H-3), 5.42 (d, J = 1.3 Hz, 1 H, H-4), 6.78 (t, J = 5.6 Hz, 1 H, NHC14H29), 
6.89 (d, J = 8.5 Hz, 1 H, NHC1),  7.56 (d, J = 7.7 Hz, 1 H, NHCOC15H31); 
13C NMR (75 
Hz): δc 13.1 (CH2CH3)
xxi, 19.5 (OC(O)CH3), 19.7 (OC(O)CH3), 19.9 (OC(O)CH3),  20.0 
(OC(O)CH3), 21.7, 24.6, 25.9, 28.3, 28.4, 28.5, 28.6, 28.6, 28.7, 28.7, 
(CO(CH2)2(CH2)12CH3, NH(CH2)(CH2)12CH3), 30.9 (COCH2CH2), 35.3 (COCH2), 35.6 (C-
β), 38.6 (NHCH2), 48.8 (C-α), 60.1 (C-6), 66.1 (C-4), 66.9 (C-2), 69.8 (C-3), 71.4 (C-5), 
                                                            
xxi Two overlapping signals. 
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77.4 (C-1), 168.9 (C=O), 169.0 (C=O), 169.3 (C=O), 169.5 (C=O), 171.0 (C=O), 171.9 
(C=O), 172.8 (C=O); HRMS m/z (ESI+) 896.6226, (C48H85O12N3H: [M+H]
+
 requires 
896.6206). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(tetracosyl)-L-aspargine 1-
benzyl ester 2.63 
 
TBTU (59 mg, 0.18 mmol, 1.1 equiv) and HOBt (25 mg, 0.18 mmol, 1.1 equiv) were 
added to lignoceric acid (62 mg, 0.17 mmol) in DMF (3 mL) containing 4 Å MS under 
N2 at rt. It was stirred for 30 min and then N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-L-aspargine 1-benzyl ester 2.55 (88 mg, 0.16 mmol, 1 equiv) in 
DMF (2 mL) was added drop-wise to the solution. It was stirred for 2 h at 50 °C. The 
reaction mixture was concentrated in vacuo; diluted with EtOAc (4 mL), washed 
with H2O (4 mL), brine (4 mL), H2O (4 mL), dried over MgSO4, filtered and 
concentrated. Flash column chromatography (hexane/EtOAc 1:1) afforded the title 
compound 2.63 (93 mg, 62%) as a white solid; Rf =0.23 (hexane/EtOAc 1:1); [α]
25
D = 
+18.95 (c 0.95, EtOAc); IR νmax (NaCl plate, CH2Cl2): 2918.7, 2850.5, 1750.5, 1371.1 
cm-1; 1H NMR (300 MHz):  δ  0.86 (t, J = 7.0 Hz, 3 H, CH3), 1.23-1.25 (m, 40 H, 
(CH2)20CH3), 1.56-1.61 (m, 2 H, COCH2CH2), 1.99 (s, 3 H, OC(O)CH3), 2.03 (s, 3 H, 
OC(O)CH3), 2.04 (s, 3 H, OC(O)CH3), 2.13 (s, 3 H, OC(O)CH3), 2.19 (t, J =  7.5 Hz, 2 H, 
COCH2), 2.70 (dd, J = 4.4 Hz, 16.4 Hz, 1 H, H- β’), 2.90 (dd, J = 3.9 Hz, 16.4 Hz, 1 H, H-
β), 3.97-4.15 (m, 3 H, H-5, H-6, H-6’), 4.88-4.93 (m, 1 H, H-α), 5.07-5.20 (m, 5 H, H-1, 
H-2, H-3, CH2Ph), 5.42 (d, J = 2.0 Hz, 1 H, H-4), 6.49 (d, J = 8.6 Hz, 1 H, NHC1), 6.73 
(d, J = 8.3 Hz, 1 H, NHCOC23H47), 7.31- 7.33 (m, 5 H, Ph); 
13C NMR (75 Hz): δc 14.1 
(CH2CH3), 20.5 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 (OC(O)CH3), 20.6 (OC(O)CH3), 
22.7, 25.5, 29.2, 29.3, 29.3, 29.5, 29.6, 29.7 ((CH2)20CH3), 31.9 (COCH2CH2), 36.5 
(COCH2), 37.5 (C-β),  48.4 (C-α), 61.0 (C-6), 67.0 (C-4), 67.4 (CH2Ph), 68.1 (C-2), 70.7 
(C-3), 72.4 (C-5), 78.5 (C-1), 127.9, 128.4, 128.5, 135.2 (aromatics), 169.8 (C=O), 
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169.9 (C=O), 170.3 (C=O), 170.8 (C=O), 170.9 (C=O), 171.5 (C=O), 173.1 (C=O); 
HRMS m/z (ESI+) 904.5632, (C49H78O13N2H: [M+H]
+
 requires 904.5610). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(tetracosyl)-L-aspargine 2.64 
 
H2 gas was bubbled through a suspension of N
γ-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-Nα-(tetracosyl)-L-aspargine 1-benzyl ester 2.63 (67 mg, 0.07 
mmol) and Pd (C) (7 mg, 10% w/w) in EtOAc (5 mL) at 1 atm pressure and  stirred 
for 18 h. The suspension was filtered through Celite, washing with EtOAc and 
concentrated in vacuo to yield the title compound 2.64 (60 mg, 55%, , crude yield) 
as a white solid; 1H NMR (300 MHz):  δ 0.87 (t, J = 6.9 Hz, 3 H, CH3), 1.23-1.25 (m, 40 
H, (CH2)20CH3), 1.58-1.67 (m, 2 H, COCH2CH2), 2.00 (s, 3 H, OC(O)CH3), 2.05 (s, 3 H, 
OC(O)CH3), 2.06 (s, 3 H, OC(O)CH3), 2.15 (s, 3 H, OC(O)CH3), 2.26-2.37 (m, 2 H, 
COCH2), 2.74 (dd, J = 5.0 Hz, 16.5 Hz, 1 H, H-β’), 2.84-2.96 (m, 1 H, H-β), 4.02-4.22 
(m, 3 H, H-5, H-6, H-6’), 4.71-4.76 (m, 1 H, H-α), 5.10-5.12 ( m, 2 H , H-2, H-3), 5.28-
5.34 (m, 1 H, H-1), 5.50 (d, J = 1.2 Hz, 1 H, H-4), 6.61 (d, J = 9.2 Hz, 1 H, NHC1), 7.20 
(d, J = 7.0 Hz, 1 H, NHCOC23H47); HRMS m/z (ESI+) 813.5106, (C42H72O13N2H: [M+H]
+
 
requires 813.5107). 
N
γ
-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-N
α
-(tetracosyl)-L-aspargine 1-
tetradecylamide 2.65 
 
TBTU (12 mg, 0.04 mmol, 1.1 equiv) and HOBt (5 mg, 0.04 mmol, 1.1 equiv) were 
added to Nγ-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-Nα-(tetracosyl)-L-
aspargine 2.64 (27 mg, 0.03 mmol) in DMF (3 mL) containing 4 Å MS under N2 at rt. 
The solution was stirred for 20 min and tetradecylamine (7 mg, 0.03 mmol, 1 equiv) 
was added to the solution and was stirred for 18 h. The reaction mixture was 
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concentrated in vacuo; diluted with EtOAc (4 mL), washed with brine (4 mL), H2O (4 
mL), dried over MgSO4, filtered and concentrated. Flash column chromatography 
(hexane/EtOAc 1:1) afforded the title compound 2.54 (15 mg, 45%) as a white solid; 
Rf =0.20 (hexane/EtOAc 1:1); [α]
25
D = +9.23 (c 0.65, CH2Cl2); IR νmax (NaCl plate, 
CH2Cl2): 3426.0, 2918.5, 2850.5, 1750.7, 1641.8, 1228.5 cm
-1; 1H NMR (300 MHz):  δ 
0.87 (t, J = 6.9 Hz, 3 H, CH3), 1.23-1.25 (m, 62 H, CO(CH2)2(CH2)20CH3,  
NH(CH2)2(CH2)11CH3), 1.42-1.46 (m, 2 H, NHCH2CH2), 1.64-1.67 (m, 2 H, COCH2CH2), 
2.00 (s, 3 H, OC(O)CH3), 2.04 (s, 3 H, OC(O)CH3), 2.14 (s, 3 H, OC(O)CH3), 2.17 (s, 3 H, 
OC(O)CH3), 2.21-2.24 (m, 1 H, COCH2), 2.43 (dd, J = 5.6 Hz, 15.7 Hz, 1 H, H-β’), 2.68 
(dd, J = 3.5 Hz, 15.7 Hz, 1 H, H-β), 3.11- 3.26 (m, 1 H, NHCH2), 3.98-4.17 (m, 3 H, H-5, 
H-6, H-6’), 4.66-4.71 (m, 1 H, H-α), 5.10-5.26 (m, 3 H, H-1, H-2, H-3), 5.44 (d, J = 1.8 
Hz, 1 H, H-4), 6.73-6.78 (m, 2 H, NHC1, NHC14H29), 7.57 (d, J = 7.8 Hz, 1 H, 
NHCOC23H47); 
13C NMR (75 Hz): δc 14.1 (CH2CH3)
xxii, 20.5 (OC(O)CH3), 20.6 
(OC(O)CH3), 20.6 (OC(O)CH3), 20.9 (OC(O)CH3), 22.7,  25.6, 26.9, 29.3, 29.7 ( 
CO(CH2)2(CH2)20CH3, NH(CH2) (CH2)12CH3), 31.9 (COCH2CH2), 36.2 (COCH2), 36.6 (C-β), 
49.7 (C-α), 39.6 (NHCH2), 61.0 (C-6), 67.0 (C-4), 67.8 (C-2), 70.7 (C-3), 72.3 (C-5), 
78.5 (C-1), 169.8 (C=O), 170.0 (C=O), 170.3 (C=O), 170.4 (C=O), 172.2 (C=O), 173.0 
(C=O), 173.8 (C=O); HRMS m/z (ESI+) 1008.7429, (C56H101O12N3H: [M+H]
+
 requires 
1008.7458). 
N-(9-Fluorenylmethyloxycarbonyl)-L-serine tetradecyl amide 2.66 
[257] 
 
DMF (5 mL) was added to a mixture of N-(9-fluorenylmethyloxycarbonyl)-L-serine 
4.23 (1 g, 3.06 mmol), TBTU (1.08 g, 3.37 mmol, 1.2 equiv) and HOBt (455 mg, 3.37 
mmol, 1.2 equiv), DIPEA (1.07 mL, 6.12 mmol, 2 equiv) under nitrogen and was left 
to stir for 10 min. Tetradecylamine (652 mg, 3.06 mmol, 1 equiv) was then added 
under N2 to the reaction mixture and was left to stir for 18 h. It was rotary 
evaporated, re-dissolved in CH2Cl2 (25 mL); washed with brine (30 mL) and 0.2 N aq. 
                                                            
xxii Two overlapping signals. 
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HCl (30 mL). The aqueous layer was extracted with CH2Cl2 (25 mL x 3), and the 
combined organic layers were washed with satd. aq. NaHCO3 (30 mL). The organic 
layer was dried over MgSO4, filtered and concentrated. A silica plug was performed 
(CH2Cl2) to give the title compound 2.66 as a white solid (1.16 g, 73%); Rf = 0.36 
(PetEt/EtOAc 5:1); 1H NMR (300 MHz): δ 0.86-0.90 (t, J = 6.9 Hz, 3 H, CH3), 1.22-1.25 
(m, 22 H,  NHCH2CH2(CH2)11CH3), 1.45 (s, 2 H, NHCH2CH2), 3.18-3.24 (m, 2 H, 
NHCH2), 3.64-3.71 (m, 1 H, H-β), 4.03-4.06 (m, 1 H, H-β’), 4.16-4.21 (m, 2 H, H-α, 
CH(Fmoc)), 4.37-4.40 (m, 2 H, CH2(Fmoc)), 6.08 (d, J = 7.5 Hz, 1 H, NHFmoc), 6.75 (s, 
1 H, NHCH2), 7.26-7.76 (m, 8 H, aromatics); HRMS m/z (ESI+) 522.3438 (C32H46N2O4: 
[M*]+ requires 522.3452). 
The 1H NMR data is in agreement with the literature.[257] 
N-(9-Fluorenylmethyloxycarbonyl)-O-(2,3,4,6-tetra-O-benzyl-α-D-
galactopyranosyl)–L-serine tetradecyl amide 2.67 
 
NIS (29 mg, 0.128 mmol, 2 equiv) was added to a solution of phenyl-2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactopyranoside 4.54 (41 mg, 0.06 mmol), and N-(9-
fluorenylmethyloxycarbonyl)-L-serine tetradecyl amide 2.66 (67 mg, 0.13 mmol, 2 
equiv) in THF (3 mL) containing 4Å MS in the dark under N2. TfOH (1 µL, 0.0006 
mmol, 0.01 equiv) was added and the reaction mixture was stirred for 20 h and 
MeOH was added. It was rotary evaporated and then was diluted with CH2Cl2 (20 
mL) and washed with satd. aq. Na2S2O4 (20 mL) followed by brine (20 mL). The 
organic layer was dried (Na2SO4), filtered and concentrated. Flash column 
chromatography (PetEt/EtOAc 5:1) afforded the α-diastereoisomer 2.67 (34 mg, 
49%) as a white solid; Rf = 0.15 (PetEt/EtOAc 5:1); [α]
25
D = +75.79 (c, 0.95 in CH2Cl2); 
IR νmax (NaCl plate, CH2Cl2): 3300.1, 3031.5, 2923.6, 2853.5, 1686.0, 1644.9, 1535.4 
cm-1; 1H NMR (300 MHz): δ 0.87 (t, J = 6.9 Hz, 3 H, CH3), 1.23-1.25 (m, 24 H,  NHCH2 
(CH2)12CH3), 2.61-2.70 (m, 1 H, NHCHH), 3.05-3.10 (m, 1 H, NHCHH), 3.50-3.54 (m, 3 
H-β, H-β’, H-6’), 3.84-3.89 (m, 1 H, H-3), 3.93-4.03 (m, 3 H, H-4, H-5, H-6), 4.08-4.16 
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(m, 2 H, H-2, H-α), 4.20 (t, J = 6.7 Hz, 1 H, CH(Fmoc)), 4.38 (m, 2 H, CH2(Fmoc)), 4.34-
4.96 (m, 8 H, CH2Ph × 4), 5.03 (d, J = 3.0 Hz, 1 H, H-1), 6.07 (d, J = 6.4 Hz, 1 H, 
NHFmoc), 6.95 (s, 1 H, NHCH2), 7.25-7.40 (m, 24 H, aromatics), 7.59 (d, J = 7.3 Hz, 2 
H, aromatics), 7.74 (d, J = 7.4 Hz, 2 H, aromatics); 13C NMR (75 Hz): δC 13.1 (CH3), 
21.7, 25.8, 28.3, 28.4, 28.6, 28.7, 28.7, 30.9, 38.5 (NH (CH2)13CH3), 46.1 (CHFmoc), 
51.9 (C-α), 65.9 (CH2Fmoc), 67.9 (C-β), 68.0 (C-6), 68.9 (C-5), 71.7 (CH2Ph), 72.5 
(CH2Ph),  73.5 (CH2Ph), 73.7 (C-4), 73.7 (CH2Ph), 76.2 (C-2), 78.4 (C-3), 97.5 (C-1), 
118.9, 124.0, 124.1, 126.1, 126.3, 126.5, 126.6, 126.6, 126.7, 126.7, 126.8, 126.9, 
126.97, 127.1, 127.2, 127.2, 127.3, 127.3, 127.4, 127.4, 127.4, 127.5, 136.5, 136.7, 
137.3, 137.5, 140.3 (aromatics), 154.7 (C=O), 167.98 (C=O); HRMS m/z (ESI+) 
1045.5971 (C66H80N2O49H: [M+H]
+ requires 1045.5937). 
7.2.2. Experimental procedures for Chapter 3 
1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose  
 
Ac2O (5.29 mL, 55.5 mmol, 10 equiv) was added to D-mannose 3.10 (1.00 g, 5.55 
mmol) in Pyr (10 mL) at 0 °C. The reaction mixture was stirred for 18 h at rt. The 
suspension was diluted with ice-water (20 mL) and extracted with EtOAc (20 mL). 
The organic layer was washed successively with H2O (20 mL x 3), satd. aq. NaHCO3 
solution (20 mL), satd. aq. CuSO4 solution (20 mL) and H2O (20 mL). The organic 
layer was dried over MgSO4, filtered and concentrated under reduced pressure, 
yielding 1,2,3,4,6-penta-O-acetyl-α,β-D-mannopyranose (1.71 g, 78%, crude yield) 
(α /β 5:1) as a pale yellow oil; Data recorded for α-anomer: Rf =0.69 (hexane/EtOAc 
1:1);  1H NMR (500 MHz, α-anomer): δ 1.86 (s, 3 H, OC(O)CH3), 1.92 (s, 3 H, 
OC(O)CH3), 1.93 (s, 3 H, OC(O)CH3), 2.02-2.03 (m, 6 H, OC(O)CH3 × 2), 3.94-3.98 (m, 
2H, H-5, H-6’), 4.15 (dd, 1 H, J = 5.0 Hz,  12.5 Hz, H-6), 5.13 (dd, 1 H, J = 2.3 Hz, 4.2 
Hz, H-2), 5.22-5.23 (m, 1 H, H-3), 5.95 (d, J = 2.2 Hz, H-1). Ac2O (52.5 mL, 0.56 mol, 
10 equiv) was added to D-mannose 3.10 (10.0 g, 55.5 mmol) at rt. Catalytic H2SO4 (5 
drops) was added slowly to this solution at 0 °C .The reaction mixture was stirred 
for 3 h and the suspension was diluted with ice-water (200 mL) and extracted with 
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EtOAc (200 mL). The organic layer was washed with H20 (200 mL x 3), followed by 
aq. NaHCO3 solution (200 mL). The organic layer was dried over MgSO4, filtered and 
concentrated under reduced pressure, yielding 1,2,3,4,6-Penta-O-acetyl-α-D-
mannopyranose (17.6 g, 82%) (α-anomer) as a pale yellow oil.  
The NMR data are in agreement with the reported values. [116],[258] 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl bromide 3.11 
 
33% HBr/AcOH (53 mL) was added to 1,2,3,4,6-penta-O-acetyl-α-D-mannopyranose  
(17.6 g, 45.0 mmol) at 0 °C. The solution was allowed to warm to rt and was stirred 
for 18 h at rt. The reaction mixture was concentrated, diluted with CH2Cl2 (300 mL), 
washed with brine (300 mL) followed by satd. aq. NaHCO3 (300 mL × 2). The organic 
layer was dried over MgSO4, filtered and concentrated in vacuo to yield the α-
anomer 3.11 (16.6 g, 92%, crude yield) as a pale yellow oil; Rf =0.55 (hexane/EtOAc 
1:1); [α]22D = +111.7 (c, 2.5 in CHCl3); 
1H NMR (500 MHz) : 1.95 (s, 3 H, OC(O)CH3), 
2.02 (s, 3 H, OC(O)CH3),  2.05 (s , 3 H, OC(O)CH3), 2.12 (s , 3 H, OC(O)CH3), 4.09 (dd, J 
= 10.2 Hz, 12.5 Hz, 1 H, H-5), 4.15-4.18 (m, 1 H, H-6), 4.27 (dd, J = 4.9 Hz, 12.5 Hz, 
1H, H-6’), 5.31 (dd, J = 9.3 Hz, 10.2 Hz, 1 H, H-4), 5.38-5.39 (m, 1 H, H-2), 5.64-5.67 
(m, 1 H, H-3), 6.25 (s, 1 H, H-1).  
The NMR data is in agreement with the reported values.[258-259] 
3,4,6-Tri-O-acetyl-1,2-O-(methoxyethylidene)-β-D-mannopyranoside 3.12  
 
MeOH (1 mL) was added to a solution of 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl bromide 3.11 (1.00 g, 2.43 mmol) in Pyr (2 mL) under an inert 
atmosphere and the reaction mixture was stirred for 18 h at rt. The reaction 
mixture was added to ice-water (20 mL) and extracted with CH2Cl2 (5 mL × 3). The 
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organic layers were combined and subsequently washed with H2O. The organic 
layer was dried over MgSO4, filtered and concentrated, azeotroping with toluene. 
Flash column chromatography (PetEt/EtOAc 3:1) yielded the title compound 3.12 
(0.50 g, 57%) as a mixture of diastereoisomers (1:4 endo/exo); For the exo product: 
1H NMR (500 MHz): δ 1.70 (s, 3 H, CH3), 2.01 (s, 3 H, OC(O)CH3), 2.03 (s, 3 H, 
OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 3.23 (s, 3 H, OCH3), 3.64 -3.67 (m, 1 H, H-5), 4.09 
(dd, J = 3.0 Hz, 12.5 Hz, 1 H, H-6’), 4.18-4.21 (m, 1 H, H-6), 4.57 (dd, J = 2.9 Hz,  4.0 
Hz, 1 H, H-2), 5.12 (dd, J = 4.0 Hz,  10.0 Hz, 1 H, H-4), 5.23-5.27 (m, 1 H, H-3), 5.46 
(d, J = 2.9 Hz, 1 H, H-1).  
The NMR data is in agreement with the reported values.[115] 
3,4,6-Tri-O-benzyl-1,2-O-(methoxyethylidene)-β-D-mannopyranoside 3.13 
 
Na metal (1 mg approx., 0.064 mmol approx., 0.1 equiv approx.) was added to a 
solution of 3,4,6-tri-O-acetyl-1,2-O-(methoxyethylidene)-β-D-mannopyranoside 
3.12 (0.23 g, 0.64 mmol) in MeOH (2 mL) at rt. The reaction mixture was stirred for 
1 h; quenched with Amberlite ion-exchange resin (H+ form), filtered and 
concentrated in vacuo. The resulting solid was then dissolved in DMF (20 mL) and 
NaH (60% suspension in mineral oil) (1.16 g, 29.0 mmol, 6 equiv) was added in 
portions at 0 °C in an inert atmosphere. The reaction mixture was stirred for 30 
min. BnBr (2.58 mL, 21.7 mmol, 4.5 equiv) was added to this suspension and the 
reaction mixture was stirred for 18 h at rt. MeOH (1 mL) was added to the reaction 
mixture. The suspension was added to ice-water (40 mL) and extracted with 
toluene (3 × 20 mL). The combined organic extracts were dried over MgSO4, filtered 
and concentrated under reduced pressure. Flash column chromatography (PetEt/ 
EtOAc 10:1 to 8:1) afforded the title compound 3.13 (2.44 g, 100%) as a mixture of 
diastereoisomers (1:4 endo/exo); Rf =0.83 (hexane/EtOAc 3:1); For the exo product: 
1H NMR (500 MHz): δ 1.79 (s, 3 H, CH3), 3.33 (s, 3 H, OCH3), 3.46-3.48 (m, 1 H, H-5), 
3.74-3.81 (m 2 H, H-6, H-6’), 3.96-3.97 (m, 1 H, H-4), 4.44 (dd, J = 2.5 Hz, 4.0 Hz, 1 H, 
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H-3), 4.58-4.60 (m, 2 H, CH2Ph), 4.64-4.67 (m, 2 H, CH2Ph), 4.82 (d, J = 4 .0 Hz, 2 H, 
CH2Ph), 4.94-4.95 (m, 1 H, H-2), 5.38 (d, J = 2.5 Hz, 1 H, H-1), 7.27-7.45 (m, 15 H, Ph 
× 3). 
The NMR data is in agreement with the reported values.[260] 
2-O-Acetyl-3,4,6-tri-O-benzyl-α,β-D-mannopyranoside 3.14 
 
80% AcOH in water (200 mL) was added to 3,4,6-tri-O-benzyl-1,2-O-
(methoxyethylidene)-β-D-mannopyranoside 3.13 (6.22 g, 12.3 mmol) at rt and 
stirred for 18 h. The reaction mixture was added to a mixture of toluene (300 mL) 
and H2O (200 mL) and the organic layer was separated, and successively washed 
with H2O (200 mL), satd. aq. NaHCO3 (200 mL) and H2O (200 mL). NEt3 was added 
drop-wise until a pH of approx. 7 was reached and the reaction mixture was 
concentrated in vacuo. Flash column chromatography (PetEt/EtOAc 3:1) yielded the 
title compound 3.14 (5.12 g, 85%) as a mixture of anomers (1:100 α/β); Data 
recorded for β-anomer: Rf =0.15 (PetEt/EtOAc 3:1); 
1H NMR (500 MHz): δ 2.24 (s, 3 
H, OC(O)CH3), 3.74-3.75 (m, 1 H, H-5), 4.11-4.16 (m, 2 H, H-6, H-6’), 4.52-4.66 (m, 6 
H, CH2Ph × 3), 4.75-4.77 (m, 1 H, H-4), 4.93 (d, J = 11.0 Hz, 1 H, H-1), 5.25 (dd, J = 2.0 
Hz, 4.0 Hz, 1 H, H-3), 5.43 (dd, J = 2.0 Hz, 11.0 Hz, 1 H, H-2), 7.22-7.41 (m, 15 H, Ph × 
3).  
The NMR data is in agreement with the reported values. [260] 
2-O-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate 3.2 
 
Trichloroacetonitrile (40 μL, 0.40 mmol, 5 equiv) was added to a solution of 2-O-
acetyl-3,4,6-tri-O-benzyl-α,β-D-mannopyranoside 3.14 (39 mg, 0.08 mmol) in CH2Cl2 
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(2 mL), followed by DBU (0.50 μL, 0.01 mmol, 0.05 equiv) under an inert 
atmosphere at 0 °C. The reaction mixture was stirred for 2.5 h at rt and then 
concentrated in vacuo. Flash column chromatography was performed (PetEt/EtOAc 
5:1) to α-anomer  3.2 (29 mg, 58%) as a colourless oil; Rf =0.80 (PetEt/EtOAc 5:1); 
1H 
NMR (500 MHz): δ 2.12 (s, 3 H, OCOCH3), 3.72 (dd, J = 1.8 Hz , 11.2 Hz , 1 H, H-6’), 
3.85 (dd, J = 3.7 Hz, 11.2 Hz, 1 H, H-6), 4.00-4.01, 4.04-4.05 (m, 3 H, H-3, H-4, H-5), 
4.50-4.89 (m, 6 H, CH2Ph × 3), 5.50-5.51 (m, 1 H, H-2), 6.31 (d, J = 1.9 Hz, 1 H, H-1), 
7.18-7.36 (m, 15 H, aromatics), 8.68 (s, 1 H, NH).  
The NMR data is in agreement with the reported values.[115] 
3-O-benzyl-1,2:5,6-di-O-isopropylidene-α-D-glucopyranoside 3.28 
 
NaH (60% suspension in mineral oil) (3.02 g, 37.8 mmol, 2 equiv) was slowly added 
to a solution of diacetone-D-glucofuranose 3.27 (9.84 g, 37.8 mmol) in DMF (100 
mL) in an inert atmosphere at 0 °C. The reaction mixture was stirred for 30 min and 
then BnBr (6.73 mL, 56.7 mmol, 1.5 equiv) was added to the suspension at 0 °C. The 
reaction mixture was stirred for 2.5 h at rt. MeOH (10 mL) was added to this 
suspension. The organic layer was diluted with brine (200 mL) and extracted with 
EtOAc (2 × 200 mL). The organic layers were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure. Flash column chromatography (PetEt/ 
EtOAc 20:1 to 5:1) afforded the title compound 3.28 (10.2 g, 100%) as a waxy oil; Rf 
=0.50 (PetEt/EtOAc 10:1); [α]25D = -32.87 (c, 5.5 in CHCl3); 
1H NMR (500 MHz) : δ 
1.25 (s, 3 H, CH3), 1.33 (s, 3 H, CH3), 1.39 (s, 3 H, CH3), 1.44 (s, 3 H, CH3), 3.95-3.99 
(m, 2 H , H-6, CHHPh), 4.03-4.08 (m, 2 H, H-6’, CHHPh), 4.13 (dd, J = 3.2 Hz, 8.0 Hz, 1 
H, H-4), 4.34 (td, J = 1.5 Hz,  8.0 Hz, 1 H, H-5), 4.49-4.63 (m, 2 H, H-3, H-2), 5.84 (d, J 
= 3.5 Hz, 1 H, H-1), 7.21-7.32 (m, 5 H, Ph). 
The 1H NMR data is in agreement with literature values.[261] 
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1,2,4,6-Penta-O-acetyl-3-O-benzyl-β-D-glucopyranoside 3.29 [262] 
 
Dowex 50WX2-400 (H+ form) was added to a suspension of 3-O-benzyl-1,2:5,6-di-O-
isopropylidene-α-D-glucopyranoside 3.28 (1.71 g, 4.88 mmol) in H2O (12 mL) and 
the reaction mixture was stirred for 18 h at 70 °C. The reaction mixture was 
concentrated in vacuo, azeotroped with toluene to afford a white solid. This crude 
product (1.29 g, 4.76 mmol) was dissolved in Pyr (40 mL) and DMAP (64 mg, 0.52 
mmol, 0.11 equiv) was added followed by Ac2O (5.40 mL, 57.10 mmol, 12 equiv). 
The reaction mixture was stirred for 24 h. The reaction mixture was diluted with 
EtOAc (40 mL) and washed with ice-cold water (35 mL), 1 N aq. HCl (35 mL), satd. 
aq. CuSO4 solution (35 mL), H2O (35 mL), satd. aq. NaHCO3 solution (35 mL) and 
dried over MgSO4 and filtered. It was concentrated in vacuo and recrystallised in 
EtOH to afford the β-anomer 3.29 (1.0 g, 89% over 2 steps) as a white solid; Rf =0.49 
(PetEt/EtOAc 1:1); [α]22D= -0.86 (c, 0.4 in CHCl3) (lit [α]
25
D
 = -1 (c, 1.2 in CHCl3))
[262] ; 
mp = 104-106 °C (lit 107-108 °C )[262] ; 1H NMR (500 MHz) : δ 1.98 (s , 3 H, OC(O)CH3), 
1.98 (s , 3 H, OC(O)CH3), 2.08 (s, 3 H, OC(O)CH3), 2.10 (s, 3 H, OC(O)CH3), 3.71-3.77 
(m, 2 H, H-3, H-5), 4.10 (dd, J = 2.4 Hz,  12.5 Hz, 1 H, H-6’), 4.22 (dd, J = 4.9 Hz, 12.5 
Hz, 1 H, H-6), 4.61 (s, 2 H, CH2Ph), 5.14-5.19 (m, 2 H, H-2, H-4), 5.65 (d, J = 8.2 Hz, 1 
H, H-1), 7.22-7.35 (m, 5 H, Ph); HRMS m/z (ESI+) 456.1864 (C21H26O10NH4 [M+NH4]
+ 
requires 456.1903)  
Butyl 2,4,6-tri-O-acetyl-3-O-benzyl-1-thio-β-D-glucopyranoside 3.30 
 
Butanethiol (90 μL, 1.44 mmol, 1.2 equiv) was added to a solution of 1,2,4,6-Penta-
O-acetyl-3-O-benzyl-β-D-glucopyranoside 3.29 (0.53 g, 1.20 mmol) in CH2Cl2 (5 mL) 
followed by BF3.OEt2 (181 μL, 1.44 mmol, 1.2 equiv) and the reaction mixture was 
stirred for 3 h. NEt3 (199 μL, 1.44 mmol, 1.2 equiv) was added and the reaction 
mixture was washed with ice-cold H2O (5 mL), satd. aq. NaHCO3 (5 mL), H2O (5 mL) 
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and brine (5 mL), dried over MgSO4, filtered
 and concentrated in vacuo. Flash 
column chromatography (PetEt/ EtOAc 4:1) afforded the β-anomer 3.30 (0.42 g, 
75%) as a colourless oil; Rf =0.75 (PetEt/EtOAc 7:3); [α]
22
D= -32.96 (c, 0.55 in CHCl3); 
1H NMR (400 MHz): δ 0.90 (t, J = 7.3 Hz, 3 H, CH3), 1.34-1.44 (m, 2 H, CH2CH3), 1.53-
1.61 (m, 2 H, CH2CH2CH3), 1.95 (s, 3 H, OC(O)CH3), 2.00 (s, 3 H, OC(O)CH3), 2.04 (s, 3 
H, OC(O)CH3), 2.60-2.73 (m, 2 H, CH2CH2CH2CH3), 3.61-3.65 (m, 1 H, H-5), 3.73 (t, J = 
9.3 Hz, 1 H, H-3), 4.09 (dd, J = 1.9 Hz ,  12.2 Hz, 1 H , H-6’), 4.19 (dd, J = 5.4 Hz,  12.2 
Hz, H-6), 4.43 (d, J = 10.0 Hz, 1 H, H-1), 4.59-4.66 (d x 2, J = 11.8 Hz, J = 16.0 Hz, 2 H, 
CH2Ph), 5.03-5.11 (m, 2 H, H-4, H-2), 7.22-7.33 (m, 5 H, Ph); 
13C NMR (100 MHz): δC 
13.2 (CH2CH2CH2CH3), 20.3 (OC(O)CH3), 20.5 (OC(O)CH3), 21.4 (CH2CH2CH2CH3), 29.2 
(CH2CH2CH2CH3), 31.3 (CH2CH2CH2CH3), 62.2 (C-6) , 69.4 (C-4), 71.0 (C-2), 73.9 
(CH2Ph), 75.7 (C-5), 81.2 (C-3), 83.4 (C-1), 127.3 (Ph), 127.4 (Ph), 128.0 (Ph), 137.5 
(Ph), 168.8, 168.9, 170.1 (C=O x 3); HRMS m/z (ESI+) 959.3528 (C46H64O16S2Na 
[M+Na]+ requires 959.3533).  
Butyl 4,6-O-(p-bromobenzylidene)-3-O-benzyl-1-thio-β-D-glucopyranoside 3.31 
 
Na metal (13 mg approx., 0.58 mmol approx., 0.1 equiv approx.) was added to a 
solution of butyl 2,4,6-tri-O-acetyl-3-O-benzyl-1-thio-β-D-glucopyranoside 3.30 
(2.56 g, 5.83 mmol) in MeOH (20 mL) at rt. It was stirred for 1 h; quenched with 
Amberlite ion-exchange resin (H+ form), filtered and concentrated in vacuo. The 
resulting white solid was then dissolved in MeCN (10 mL) and p-
bromobenzyaldehyde dimethyl acetal (0.90 mL, 5.41 mmol, 1.2 equiv) was added to 
the solution followed by p-TsOH (16 mg, 0.09 mmol, 0.02 equiv) in an inert 
atmosphere. It was stirred for 3 h, NEt3 was added and the reaction mixture was 
concentrated in vacuo. Recrystallisation in MeOH afforded the title compound 3.31 
(2.29 g, 88% over 2 steps) as a white solid; Rf =0.57 (PetEt/EtOAc 3:1); [α]
22
D= -
283.85 (c, 0.5 in CDCl3); mp = 101-102 °C; 
1H NMR (500 MHz): δ 0.93 (t, J = 7.4 Hz, 3 
H, CH3), 1.39-1.47 (m, 2 H, CH2CH3),1.60-1.65 (m, 2 H, CH2CH2CH3), 2.55 (d, J = 2 Hz, 
1 H, OH), 2.71-2.74 (m, 2 H, CH2CH2CH2CH3), 3.46-3.48 (m, 1 H, H-5), 3.56-3.60 (m, 1 
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H, H-2), 3.65-3.72 (m, 2 H, H-4, H-3), 3.77 (pt, J = 10.3 Hz, 1 H, H-6’), 4.36 (dd, J = 5.0 
Hz, 10.3 Hz, 1 H, H-6), 4.44 (d, J = 9.7 Hz, 1 H, H-1), 4.83, 4.94 (d x 2, J = 11.7 Hz, J = 
11.7 Hz, 2 H, CH2Ph), 5.53 (s, 1 H, CHArBr), 7.30-7.53 (m, 9 H, aromatics);
 13C NMR 
(125 MHz): δC 13.6 (CH2CH2CH2CH3), 21.9 (CH2CH2CH2CH3), 30.1 (CH2CH2CH2CH3), 
32.1 (CH2CH2CH2CH3), 68.6 (C-6) , 70.7 (C-5), 73.2 (C-2), 74.7 (CH2Ph), 81.1 (C-3), 
81.5 (C-4), 86.9 (C-1), 100.6 (CHArBr), 123.1, 127.8, 127.9, 128.0, 128.5, 131.4, 
136.2, 138.3 (aromatics). 
Butyl 4,6-O-(p-bromobenzylidene)-2-O-(p-methoxybenzyl)-3-O-benzyl-1-thio-β-D-
glucopyranoside 3.3 
 
To a solution of butyl 4,6-O-(p-bromobenzylidene)-3-O-benzyl-1-thio-β-D-
glucopyranoside 3.31 (1.84 g, 3.63 mmol) in DMF (20 mL) was slowly added NaH 
(60% suspension in mineral oil) (0.17 g, 7.26 mmol, 2 equiv) under an inert 
atmosphere at 0 °C. The reaction mixture was stirred for 30 min and BnBr (0.74 mL, 
5.45 mmol, 1.5 equiv) was added to the suspension at 0 °C. The reaction mixture 
was stirred for 20 h at rt. To this suspension H2O (2 mL) was added. The organic 
layer was washed with brine (100 mL) and extracted with EtOAc (100 mL × 2). The 
organic layers were combined, dried over MgSO4, filtered and concentrated under 
reduced pressure. Flash column chromatography (PetEt/ EtOAc 4:1) afforded the 
title compound 3.3 (2.01 g, 88%) as a white solid; Rf =0.71 (PetEt/EtOAc 4:1); [α]
22
D= 
-26.35 (c, 0.55 in CHCl3); mp = 111-112 °C; 
1H NMR (500 MHz): δ 0.94 (t, J = 7.4 Hz, 3 
H, CH3),1.43-1.48 (m, 2 H, CH2CH3),1.62-1.66 (m, 2 H, CH2CH2CH3), 2.69-2.80 (m, 2 
H, CH2CH2CH2CH3), 3.40-3.47 (m, 2 H, H-2, H-5), 3.69 (pt, J = 9.3 Hz, 1 H, H-3), 3.75-
3.79 (m, 2 H, H-6’, H-4), 3.81 (s, 3 H, OCH3), 4.35 (dd, J = 5.0 Hz , 10.5 Hz , 1 H, H-6), 
4.53 (d, J = 9.8 Hz, 1 H, H-1), 4.76 (d, J = 9.8 Hz,1 H, CHHPh), 4.81-4.84 (d × 2, J = 9.8 
Hz, J = 11.4 Hz, 2 H, CHHPh, CHHArOMe), 4.92 (d, J = 11.4 Hz, 1 H, CHHArOMe), 5.52 
(s, 1 H, CHArBr), 6.87-6.88, 7.30-7.38, 7.50-7.53 (m, 13 H, aromatics); 13C NMR (125 
MHz): δC 13.6 (CH3), 21.9 (CH2CH3), 30.7 (CH2CH2CH3), 31.9 (CH2CH2CH2CH3), 55.3 
(ArOCH3), 68.7 (C-6), 70.1 (C-5), 75.2 (OCH2Ph), 76.8 (OCH2ArOMe), 81.1 (C-2), 81.5 
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(C-3), 82.8 (C-4), 86.2 (C-1), 100.4 (CHArBr), 113.8, 123.0, 127.7, 127.8, 127.9, 128.4, 
130.0, 130.1, 136.3, 138.4, 159.4 (aromatics); HRMS m/z (ESI+) 651.1401, 
(C32H37BrO6SNa [M+Na]
+ requires 651.1386). 
1-O-(t-butyldiphenylsilyl)-2-O-(p-bromobenzyl)-sn-glycerol 3.37 
 
NaIO4 (1.99 g, 9.32 mmol, 5.5 equiv) was added to a stirred solution of 1,6-di-O-(t-
butyldiphenylsilyl)-2,5-Di-O-(p-bromobenzyl)-D-mannitol 3.49 (1.69 g, 1.70 mmol) in 
THF: H2O (25 mL, 4:1) at rt under N2. The reaction mixture was stirred for 3 h. It was 
diluted with EtOAc (50 mL); the organic layer was separated, washed with H2O (25 × 
2 mL), brine (25 × 2 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. NaBH4 (771 mg, 20.40 mmol, 12 equiv) was slowly added to a 
solution of the resulting aldehyde in EtOH: H2O (24.5 mL, 9:1) and the reaction 
mixture was stirred for 2 h. AcOH with added drop-wise until the solution had a pH 
of approx. 8. The organic layer was extracted with EtOAc (20 mL × 3) and the 
combined organic layers were washed with satd. aq. NaHCO3 (30 mL) solution, H2O 
(30 mL). The reaction mixture was dried over MgSO4, filtered and concentrated 
under reduced pressure. Flash column chromatography (PetEt/EtOAc 5:1 to 4:1) 
afforded the title compound 3.37 (1.05 g, 62% over two steps) as a pale yellow oil; 
Rf =0.38 (PetEt/EtOAc 9:1); [α]
25
D
 = -14.5 (c, 1.0 in CHCl3); 
1H NMR (500 MHz): δ 1.09 
(s, 3 H, C(CH3)(CH3)2), 1.09 (s, 3 H, C(CH3)(CH3)2), 1.10 (s, 3 H, C(CH3)(CH3)2), 2.23 (bs, 
1 H, OH), 3.57-3.64 (m, 1 H, H-2), 3.72-3.76 (m, 1 H, H-3a), 3.78-3.84 (m, 3 H, H-3b, 
H-1a, H-1b), 4.51 (d, J = 12.1 Hz, 1 H, CHHArBr), 4.59 (d, J = 12.1 Hz, 1 H, CHHArBr), 
7.17-7.19, 7.40-7.46, 7.69-7.71 (m, 14 H, aromatics); 13C NMR (125 MHz): δC 19.1 
(C(CH3)3), 26.8 (C(CH3)3), 62.7 (C-3), 63.5 (C-1), 71.2 (CH2ArBr), 79.8 (C-2), 121.5, 
127.7, 127.9, 129.2, 129.8, 131.4, 133.1, 135.5, 135.5, 137.3 (aromatics); HRMS m/z 
(ESI+) 521.1119 (C26H31BrO3SiNa [M+Na]
+ requires 521.1118). 
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1,3:4,6-Di-O-benzylidene-2,5-di-O-(t-butyldiphenylsilyl)-D-mannitol 3.40 
 
Imidazole (0.40 g, 5.86 mmol, 2.1 equiv) was added to a solution of dibenzylidene 
D-mannitol 3.39 (1.00 g, 2.79 mmol) in DMF (5 mL) followed by t-
butyldiphenylchlorosilane (1.52 mL, 5.86 mmol, 2.1 equiv) under an inert 
atmosphere at 0 °C. The reaction mixture was stirred for 30 min, then stirred at 50 
°C for 24 h. The suspension with diluted with EtOAc (100 mL) and washed with 
brine (50 mL × 2) followed by H2O (50 mL). It was dried over MgSO4, filtered and 
concentrated under reduced pressure. Recrystallisation in EtOAc/ PetEt afforded 
the title compound 3.40 (1.35 g, 82%) as a white solid; Rf =0.61 (PetEt/EtOAc 5:1); 
[α]22D= +36.52 (c, 0.55 in CHCl3); mp = 171-173 °C; 
1H NMR (500 MHz): δ 1.12 (s, 18 
H, 2 × C(CH3)3), 3.51-3.55 (m, 2 H, H-2, H-2’), 3.88-3.91 (m, 2H, H-3, H-3’), 4.20-4.24 
(m, 4 H, H-1a, H-1b, H-1a’, H-1b’), 5.14 (s, 2 H, 2 × CHPh), 7.19- 7.64 (m, 30 H, 6 × 
Ph); 13C NMR (125 MHz): δC 19.4 (C(CH3)3), 26.9 (C(CH3)3), 61.8 (C-1), 71.7 , 78.4 (C-
2, C-3), 100.9 (CHPh), 126.4, 127.7, 127.7, 128.0, 128.7, 129.9, 133.1, 133.5, 134.8, 
135.8, 135.8, 137.7 (aromatics). 
2,5-Di-O-(tert-butyldiphenylsilyl)-3,4-di-O-benzoyl-D-mannitol 3.42 
[130, 263] 
 
Aq. KBrO3 solution (240 mg, 3.5 mL, 1.43 mmol, 6 equiv) was added to a solution of 
1,3:4,6-di-O-benzylidene-2,5-di-O-(t-butyldiphenylsilyl)-D-mannitol 3.40 (200 mg, 
0.24 mmol) in EtOAc (6 mL) followed by aq. Na2S2O4 solution (250 mg, 3.5 mL 1.43 
mmol, 6 equiv) and the biphasic mixture was vigorously stirred for 45 min. The 
organic layer was separated and washed with satd. Na2SO3 solution (10 mL). The 
aqueous layer was extracted with EtOAc (10 mL). The organic layers were 
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combined, dried over MgSO4, filtered and concentrated in vacuo. Flash column 
chromatography (EtOAc/Tol/PetEt 1:6:3) afforded the title compound 3.42 (73 mg, 
40%) as a white foamy solid; Rf =0.38 (PetEt/EtOAc/toluene 3:1:6); [α]
22
D
 = +68.59 
(c, 0.4 in CHCl3) (lit [α]
26
D = +74.5 (c, 1.0 in CHCl3))
[130, 263]; mp 179-183 °C (lit 180-184 
°C)[130, 263]; 1H NMR (500 MHz): δ 1.04 (s, 18 H, 2 × C(CH3)3), 3.52-3.60 (m, 2 H, H-1, 
H-6), 3.75-3.78 (m, 2H, H-2, 5), 5.74 (d, J = 5.3 Hz, H-3, H-4), 7.13- 7.92 (m, 30 H, 
aromatics); 13C NMR (125 MHz): δC 19.2 (C(CH3)3), 26.9 (C(CH3)3), 62.6 (C-1, C-6), 
72.3 (C-3), 72.6 (C-2), 127.6, 127.6, 127.7, 127.7, 128.2, 128.2, 128.3, 129.5, 129.7, 
129.8, 129.8, 132.3, 133.1, 133.8, 135.8, 135.9, 166.1 (aromatics).  
The NMR spectra are in agreement with literature. [130] 
1,6:2,5-Di-O-(t-butyldiphenylsilyl)-3,4-di-O-benzoyl-D-mannitol 3.43  
 
Imidazole (16 mg, 0.24 mmol, 2.05 equiv) was added to a solution of 2,5-di-O-(t-
butyldiphenylsilyl)-3,4-di-O-benzoyl-D-mannitol 3.42 (101 mg, 0.12 mmol) in DMF 
(5 mL) followed by t-butyldiphenylchlorosilane (62 μL, 0.24 mmol, 2.05 equiv) under 
an inert atmosphere at 0 °C. The reaction mixture was stirred for 30 min, heated to 
rt and left stirring overnight. The suspension with diluted with EtOAc (10 mL) and 
washed with brine (10 mL × 2) followed by H2O (10 mL). It was dried over MgSO4, 
filtered and concentrated under reduced pressure. Flash column chromatography 
(EtOAc/Tol/Pet 1:6:3) afforded the title compound 3.43 (80 mg, 51%) as a pale 
yellow oil; Rf =0.70 (PetEt/EtOAc/toluene 3:1:6); 
1H NMR (500 MHz): δ 1.03 (s, 18 H, 
C(CH3)3 × 2), 1.10 (s, 18 H, C(CH3)3 × 2), 3.75-3.82 (m, 4 H, H-1a, H-1b, H-6a, H-6b), 
3.86-3.87 (m, 2 H, H-2, H-5), 5.85 (d, J = 8.9 Hz, 2 H, H-3, H-4), 7.12-8.01 (m, 50 H, 
aromatics); 13C NMR (125 MHz): δC 19.0 (C(CH3)3), 19.2 (C(CH3)3), 26.6 (C(CH3)3), 
26.7 (C(CH3)3), 64.3 (C-1, C-6), 69.7 (C-2, C-5), 71.5 (C-3, C-4), 127.5, 127.7, 127.7, 
128.5, 129.5, 129.6, 130.0, 132.9, 133.4, 134.8, 135.5, 135.6 (aromatics). 
1,3:4,6-Di-O-benzylidene-2,5-di-O-(p-bromobenzyl)-D-mannitol 3.47 
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O O
Ph
PBBO OO
Ph
OPBB
3.47  
NaH (60% suspension in mineral oil) (2.24 g, 0.09 mol, 4 equiv) was slowly added to 
a solution of dibenzylidene D-mannitol 3.39 (5.00 g, 0.01 mol) in DMF (45 mL) under 
an inert atmosphere at 0 °C. The reaction mixture was stirred for 30 min and p-
bromobenzyl bromide (8.40 g, 0.03 mol, 2.4 equiv) was added to the suspension at 
0 °C. The reaction mixture was stirred overnight at rt. To this suspension H2O (2 mL) 
was added; the solution was diluted with EtOAc (100 mL) and washed with brine 
(100 mL × 2). The organic layers were combined, dried over MgSO4, filtered and 
concentrated under reduced pressure. Flash column chromatography (PetEt/ EtOAc 
9:1) afforded the title compound 3.47 (8.57 g, 88%) as a colourless oil; Rf =0.66 
(Pet/EtOAc 9:1);[α]22D= - 44.7 (c, 1.0 in CHCl3); 
1H NMR (500 MHz): δ 3.69 (t, J = 10.1 
Hz, 2 H, H-1a, H-6a), 3.97- 4.02 (m, 2 H, H-2, H-5), 4.04 (d, J = 9.3 Hz, 2 H, H-3, H-4), 
4.37 (dd, J = 5.0 Hz, 10.7 Hz, 2 H, H-1b, H-6b), 4.51-4.58 (d × 2, J = 12.0 Hz, 4 H, 
CHHArBr × 2, CHHArBr × 2), 5.41 (s, 2 H, CHPh × 2), 7.14-7.47 ( m, 18 H, aromatic); 
13C NMR (125 MHz): δC 66.7 (C-2, C-5), 69.4 (C-1, C-6), 71.6 (CH2ArBr × 2), 77.2 (C-3, 
C-4), 101.0 (CHPh x 2), 121.9, 126.1, 128.1, 128.9, 129.5, 131.5, 136.8, 137.4 
(aromatics); HRMS m/z (ESI+) 712.0904 (C34H32Br2O6NH4 [M+NH4]
+ requires 
712.0904). 
2,5-Di-O-(p-bromobenzyl)-D-mannitol 3.48 
 
4 N aq. HCl (16 mL) solution was added to a solution of 1,3:4,6-di-O-benzylidene-
2,5-di-O-(p-bromobenzyl)-D-mannitol 3.47 (8.57 g ,0.01 mol) in EtOH (200 mL) and 
the reaction mixture was refluxed for 18 h under N2. After cooling, satd. aq. NaHCO3 
(200 mL) was added to the reaction mixture and was stirred for 30 min. The 
aqueous layer was extracted with EtOAc (100 mL × 3). The combined organic layers 
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were subsequently washed with satd. aq. NaHCO3 (100 mL), brine (100 mL), H2O 
(100 mL), dried over MgSO4, filtered and concentrated under reduced pressure. 
Recrystallisation in PetEt/EtOAc afforded the title compound 3.48 (5.05 g, 79%) as 
colourless crystals; Rf =0.36 (MeOH/CHCl3 1:9); [α]
25
D
 = + 9.9 (c, 1.0 in MeOH); mp = 
128-129 °C; 1H NMR (500 MHz, CD3OD): δ 3.59-3.63 (m, 2 H, H-2, H-3), 3.78 (dd, J = 
4.6, 11.9 Hz, 2 H, H-1a, H-6a), 3.94-3.97 (m, 4 H, H-3, H-4, H-1b, H-6b), 4.58, 4.73 (d 
× 2, J = 11.6 Hz, 4 H, CH2Ph × 2), 7.32-7.48 (m, 8 H, aromatics);
 13C NMR (125 MHz): 
δC 62.2 (C-1, C-6), 70.1 (C-3, C-4), 72.6 (CH2ArBr), 81.5 (C-2, C-5), 122.2, 130.8, 
132.4, 139.5 (aromatics); HRMS m/z (ESI+) 536.0213 (C20H24Br2O6NH4 [M+NH4]
+ 
requires 536.0283). 
1,6-Di-O-(t-butyldiphenylsilyl)-2,5-Di-O-(p-bromobenzyl)-D-mannitol 3.49 
 
TBDPSCl (1.02 mL, 3.94 mmol, 2.05 equiv) was added to a stirred solution of 2,5-di-
O-(p-bromobenzyl)-D-mannitol 3.48 (1.00 g, 1.9 mmol) and imidazole (323 mg, 4.75 
mmol, 2.5 equiv) in DMF (3 mL) was added under N2 at 0 °C. The reaction mixture 
was allowed to warm to rt and was stirred for 18 h. The reaction mixture was 
diluted with EtOAc (70 mL) and washed with brine (50 mL), H2O (50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. Flash column 
chromatography (PetEt/EtOAc 9:1) afforded the title compound 3.49 (1.75 g, 93%) 
as a pale yellow oil; Rf =0.56 (PetEt/EtOAc 9:1); [α]
22
D = -5.85 (c, 1.0 in CHCl3); 
1H 
NMR (500 MHz): δ 1.06 (s, 18 H, C(CH3)3 × 2), 3.10-3.12 (m, 2 H, OH × 2), 3.70 (dd, J 
= 5.3 Hz , 11.2 Hz, 2H, H-2, H-5), 3.85-3.88 (dd, J = 4.9 Hz, 11.2 Hz, 2 H, H-1a, H-6a), 
3.94 (dd, J= 4.9 Hz, 11.2 Hz, 2 H, H-1b, H-6b), 4.05 (d, J= 5.3 Hz, 2 H, H-3, H-4), 4.49 
(d, J= 11.8 Hz, 2 H, CHHArBr × 2), 4.62 (d, J= 11.8 Hz, 2 H, CHHArBr × 2), 7.13-7.70 
(m, 28 H, aromatics); 13C NMR (125 MHz): δC 19.2 (C(CH3)3 × 2), 26.8 (C(CH3)3 × 2), 
64.0 (C-1, C-6), 69.9 (C-3, C-4), 72.3 (CH2ArBr × 2), 80.5 (C-2, C-5), 121.5, 127.8, 
127.8, 129.3, 129.8, 131.4, 132.9, 133.0, 135.6, 135.6, 137.3 (aromatics). HRMS m/z 
(ESI+) 995.2360 (C52H60Br2O6Si2H [M+H]
+ requires 995.2368). 
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7.2.3. Experimental procedures for Chapter 4 
O-(α-D-Galactopyranosyl)–N-(decanosyl)-L-serine tetradecyl amide 4.14 
 
AcOH (2 drops) were added to a solution of O-(2,3,4,6-tetra-O-benzyl-α-D-
galactopyranosyl)–N-(decanosyl)-L-serine tetradecyl amide 4.87 (52 mg, 0.05 mmol) 
in EtOH/EtOAc (3:1, 4 mL). The resulting solution was added to Pd(C) (26 mg, 50% 
w/w) and was then de-oxygenated. Hydrogenolysis was performed on the 
suspension at 4 Barr pressure on a hydrogenator apparatus and was shaken for 18 
h. It was filtered through Celite, washing with EtOH and concentrated in vacuo. The 
crude oily solid was re-subjected to hydrogenolysis for 4 h under the same 
conditions as described above. The reaction mixture was filtered through Celite, 
washing with EtOH and was concentrated in vacuo to yield the title compound 4.14 
(29 mg, 88%, crude yield) as a white solid; [α]25D = +26.92 (c, 0.52 in CH2Cl2); IR νmax 
(NaCl plate, CH2Cl2): 3409.9, 2922.4, 2851.9, 1718.8, 1634.7, 1466.5 cm
-1;  1H NMR 
(300 MHz, d4-MeOD): δ 0.90-0.92 (m, 6 H, CH3 × 2), 1.30-1.31 (m, 34 H, 
CO(CH2)2(CH2)6CH3,  NH(CH2)2(CH2)11CH3), 1.51-1.55 (m, 2 H, NHCH2CH2), 1.61-1.66 
(m, 2 H, COCH2CH2), 2.29 (t, J = 7.2 Hz, 2 H, COCH2), 3.18-3.22 (m, 2 H, NHCH2), 3.69-
3.89 (m, 9 H, H-1, H-2, H-3, H-4, H-5, H-6, H-6’, H-β, H-β’), 4.54 (t, J = 6.8 Hz, 1 H, H-
α); 13C-NMR (75 MHz): δC 13.0 (CH3)
xxiii, 22.3, 25.4, 26.6, 28.9, 29.1, 29.1, 29.2, 29.4, 
29.4, 31.7 (NHCH2(CH2)12CH3, COCH2(CH2)7CH3), 35.5 (COCH2), 39.2 (NHCH2), 53.3 
(C-α), 67.7 (C-6), 68.1 (C-β), 68.7, 69.1, 69.6, 70.0, 71.4 (C-2, C-3, C-4, C-5), 99.8 (C-
1), 170.8 (C=O), 175.3 (C=O); HRMS m/z (ESI+) 641.4635 (C33H64N2O8Na: [M+Na]
+ 
requires 641.4616).  
This compound is mentioned in the literature but NMR data is not reported.[169a] 
 
 
                                                            
xxiii Two overlapping signals. 
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N-tert-Butoxycarbonyl-L-serine benzyl ester 4.20 
 
NEt3 (9.51 mL, 68.2 mmol, 2 equiv) was added to a solution of N-(tert-
butoxycarbonyl)-L-serine 4.19 (7 g, 34.1 mmol) in DMF (30 mL) and the reaction 
mixture was stirred for 40 mins at rt. BnBr (11.59 mL, 97.5 mmol, 2 equiv) was 
added to this solution and the reaction mixture was stirred for 18 h. It was 
concentratred in vacuo. Brine (100 mL) was added and the suspension was 
extracted with EtOAc (100 mL × 2). The combined organic layers were dried over 
MgSO4, filtered, concentrated in vacuo. Flash column chromatography 
(hexane/EtOAc 2:1) afforded the title compound 4.20 (7.53 g, 75%) as a white solid; 
Rf =0.45 (hexane/EtOAc 1:1); [α]
20
D = + 7.58 (c, 0.04 in CH2Cl2); mp =  55 – 60 °C (lit. 
58-60 °C)[264]; IR νmax (NaCl plate, CH2Cl2): 3964.0, 3414.2, 3114.9, 3091.7, 3066.2, 
3034.7, 2977.9, 2935.3, 2889.1, 2725.3, 2636.2, 2400.1, 2343.9, 2290.6, 2125.2, 
1957.4, 1875.0, 1743.8, 1715.8, 1609.1, 1587.0, 1500.4 cm-1; 1H NMR (300 MHz, 
major product): δ 1.43 (s, 9 H, C=OOC(CH3)3), 3.27-3.30 (m, 1 H, CH2OH), 3.92 (dd, J 
= 9.0 Hz, 33.3 Hz , CH2OH), 4.39 (s, 1 H, H-α), 5.17 (s, 2 H, CH2Ph), 5.68 (d, J = 9.0 Hz, 
1 H NH), 7.34 (s, 5 H, Ph); 13C NMR (75 Hz): δ 28.3 (C=OOC(CH3)3), 55.9 (C-α), 63.2 
(CH2OH), 67.3 (CH2Ph), 80.2 (C=OOC(CH3)3), 128.1, 128.4, 128.6, 135.3 (aromatics), 
155.9 (C=O), 170.9 (C=O); HRMS m/z (ESI+) 318.1316, (C15H21NO5Na [M+Na]
+ 
requires 318.1312).  
The NMR data are in agreement with the reported values.[265] 
N-tert-Butoxycarbonylamino-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-L-
serine benzyl ester 4.21 
 
A mixture of boc-L-serine benzyl ester 4.20 (82 mg, 0.28 mmol) and 2,3,4,6-tetra-O-
acetyl-α-D-galactopyranosyl-1-trichloroacetimidate 4.33 (164 mg, 0.33 mmol, 1.2 
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equiv) in anhydrous CH2Cl2 (5 mL) containing 3Å MS (50 mg) was stirred at rt in an 
inert atmosphere for 30 min. A solution of 0.04 N TMSOTf (0.83 mL, 0.03 mmol) in 
anhydrous CH2Cl2 (3 mL) was added to the solution. The reaction mixture was 
stirred for 2 h. The 3Å MS  were filtered off and the solvent was evaporated under 
reduced pressure and the residue purified by flash column chromatography 
(hexane /diethyl ether 1:2) to give the β-anomer 4.21 as white crystals (0.17 mg, 
82%); Rf = 0.43 (hexane/EtOAc 2:1); [α]
20
D = +65.22 (c 0.01, CH2Cl2); mp = 42- 50 °C; 
IR νmax (NaCl plate, CH2Cl2): 3628.1, 3358.0, 3302.7, 3198.8, 3091.9, 3066.0, 3034.0, 
2977.7, 2749.2, 2415.4, 2288.5, 2127.2, 1996.8, 1958.6, 1875.4, 1751.3, 1636.0, 
1605.0, 1501.0 cm-1; 1H NMR (300 MHz): δ 2.04 (s, 3 H, OC(O)CH3), 2.05 (s, 3 H, 
OC(O)CH3), 2.07 (s, 3 H, OC(O)CH3), 2.12 (s, 3 H, OC(O)CH3), 4.10-4.14 (m, 3 H, H-5, 
H-6, H-6’), 4.23-4.29 (m, 2 H, H-2, CHNHC=OOC(CH3)3), 5.01 (dd, J = 3.3 Hz,   6.6 Hz, 
1 H, H-3), 5.20 (s, 2 H, CH2Ph), 5.40-5.42 (m, 2 H, H-4, NHC=OOC(CH3)3), 5.68 (d, J = 
6.1 Hz, 1 H, H-1), 7.35 (s,  5 H, aromatic); 13C NMR (75 Hz): δC 20.6 (OC(O)CH3) 20.7 
(OC(O)CH3), 20.7 (OC(O)CH3), 23.5 (OC(O)CH3), 28.3 (C=OOC(CH3)3), 53.7 (C-α), 61.2 
(C-6), 63.2 (C-β), 65.9 (C-4), 67.5 (CH2Ph), 69.2 (C-2), 71.4 (C-3), 73.8 (C-5), 80.2 
(COC(CH3)3), 97.4 (C-1), 128.6-128.1, 135.3 (aromatics), 155.4 (C=O), 163.6 (C=O), 
169.8 (C=O),170.1 (C=O), 170.2 (C=O), 170.5 (C=O); HRMS m/z (ESI+) 647.2204, 
(C29H39NO14Na [M+Na]
+ requires 647.2210). 
 The NMR data are in agreement with the reported values.[266] 
N-(9-Fluoroenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)–L-serine benzyl ester 4.26 
[267] 
 
BF3.OEt2 (96 µL, 0.77 mmol, 3 equiv) was added to a solution of 1,2,3,4,6-penta-O-
acetyl-β-D-galactopyranose 2.32 (100 mg, 0.26 mmol), and N-9-
Fluorenylmethyloxycarbonyl-Ser-OH 4.23 (101 mg, 0.31 mmol, 1.2 equiv) in MeCN 
(3 mL) under N2 at rt. The reaction mixture was stirred for 1.5 h. It was diluted with 
CH2Cl2 (20 mL) and washed with 1 N aq. HCl solution (5 mL) followed by H2O (5 mL). 
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The organic layer was dried over MgSO4, filtered and concentrated. NEt3 (71 µL, 
0.51 mmol, 2 equiv) was added to a stirring solution of the crude acid dissolved in 
DMF (3 mL) under N2 at rt. It was stirred for 10 min and BnBr (61 µL, 0.51 mmol, 2 
equiv) was added drop-wise to the solution. It was stirred for 18 h, concentrated in 
vacuo, re-dissolved in EtOAc (20 mL), washed with brine (20 mL). The organic layer 
was dried over MgSO4, filtered and rotary evaporated. Flash column 
chromatography hexane/EtOAc 3:1 to 1:1, loaded in toluene) afforded the β-
anomer 4.26 (59 mg, 31%) as a white solid; Rf =0.38 (hexane/EtOAc 1:1);  
1H NMR 
(300 MHz): δ 1.99 (s, 3 H, OC(O)CH3), 2.01 (s, 3 H, OC(O)CH3), 2.10 (s, 3 H, 
OC(O)CH3), 2.19 (s,  3 H, OC(O)CH3), 3.78-3.91 (m, 2 H, H-5, H-β’), 4.09-4.12 (m, 2 H, 
H-6, H-6’), 4.18-4.24 (m, 1 H, H-β), 4.28-4.37 (m, 1 H, H-α), 4.41-4.43 (m, 1 H, CH-
Fmoc), 4.48 (d, J = 6.7 Hz, 1 H, H-1), 4.98 (dd, J =3.4 Hz, 10.5 Hz, 1 H, H-3), 5.13-5.17 
(m, 1 H, H-2), 5.19-5.22 (m, 2 H, CH2Ph), 5.36 (dd, J = 0.9 Hz, 3.4 Hz, 1 H, H-4), 5.62 
(d, J = 8.0 Hz, 1 H, NH), 7.29-7.78 (m, 13 H, Ar-Fmoc, CH2Ph); HRMS m/z (ESI+) 
748.2576, (C39H41NO14H [M+H]
+ requires 748.2600).  
The NMR data is in agreement with the reported values.[177] 
2,3,4,6- Tetra-O-acetyl-α/β-D-galactopyranose 4.27 
 
Dimethylamine (3.83 mL, 7.66 mmol, 2 equiv) was added to a stirring solution of 
1,2,3,4,6-penta-O-acetyl-β-D-galactopyranose 2.32 (2 g, 3.83 mmol) in MeCN (20 
mL) and the solution was refluxed for 24 h. The reaction mixture was concentrated 
in vacuo. Brine (50 mL) was added and the suspension was extracted with CH2Cl2 
(50 mL × 3). The combined organic layers were dried dried over MgSO4, filtered, 
concentrated in vacuo and the crude product was purified by flash column 
chromatography (hexane/EtOAc 1:1) to yield the title compound 4.27 as a brown oil 
(1.24 g, 93%, 1:100 α/β); Data recorded for mixture of anomers: Rf = 0.28 
(hexane/EtOAc 1:1); [α]20D = +42.93 (c, 0.03 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 
3619.6, 3463.1, 3063.3, 2971.8, 2942.7, 2916.7, 2849.2, 2726.0, 2442.3, 2124.9, 
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1961.9, 1747.7, 1648.1 cm-1; Data recorded for α-anomer: 1H NMR (300 MHz): δ 
1.99 (s, 3 H, OC(O)CH3), 2.06 (m, 6 H, OC(O)CH3 × 2), 2.10 (s, 3 H,  OC(O)CH3), 4.08-
4.16 (m, 2 H, H-6, H-6’), 4.48 (pt, J = 6.0 Hz,1 H, H-5), 5.15 (dd, J =  3.4 Hz, 12.0 Hz, 1 
H,  H-2), 5.43 (dd, J =6.2 Hz, 12.0 Hz, 1 H, H-3), 5.47-5.48 (m, 1 H, H-4) , 5.71-5.72 
(m,  1 H, H-1); 13C NMR (75 Hz): δC 20.7 (OC(O)CH3), 20.7 (OC(O)CH3), 20.8 
(OC(O)CH3), 20.9 (OC(O)CH3), 60.5  (C-6), 65.9 (C-5), 68.2 (C-4), 68.4 (C-3), 68.7 (C-
2), 90.7 (C-1), 170.3 (C=O), 170.5 (C=O), 170.6 (C=O), 170.6 (C=O). 
 
The NMR data are in agreement with the reported values.[268] 
 
1,2,3,4,6-Penta-O-benzoyl-α-D-galactopyranose 4.29
 [269] 
 
Over a period of 30 min, benzoyl chloride (48.33 mL, 0.42 mol, 5.5 equiv) was 
added drop-wise to a solution of D-galactose 4.28 (13.64 g, 75.7 mmol) in Pyr (120 
mL) at 0 °C under N2. The reaction mixture was allowed warm to rt and stirred for 
18 h. Ice water (200 mL) was added to the reaction mixture and stirred for 1 h. It 
was concentrated in vacuo. Flash column chromatography (hexane/EtOAc 2:1) 
yielded the α-anomer 4.29 (33.9 g, 64%) as a white solid; Rf =0.52 (hexane/EtOAc 
2:1); 1H NMR (300 MHz): δ 4.49 (dd, J = 6.3 Hz, 11.2 Hz, 1 H, H-6’), 4.69 (dd, J = 6.3 
Hz , 11.2 Hz, 1 H, H-6), 4.94 (pt, J = 6.3 Hz, 1 H, H-5), 6.13 (dd, J = 3.3 Hz, 11.8 Hz, 1 
H, H-2), 6.24 (dd, J = 3.0 Hz, 11.8 Hz, 1 H, H-3), 6.26-6.30 (m, 1 H, H-4), 7.07 (d, J = 
3.3 Hz, 1 H, H-1), 7.19-8.17 (m, 25 H, aromatics); 13C NMR (75 Hz): δ 47.2 (C-6), 60.8 
(C-3), 61.9 (C-2), 66.4 (C-3), 66.7 (C-4), 67.5 (C-5), 89.6 (C-1), 127.2, 127.28, 127.3, 
127.6, 127.6, 127.6, 127.7, 127.9, 128.1, 128.2, 128.3, 128.4, 128.6, 128.8, 128.8, 
129.1, 132.1, 132.3, 132.4, 132.6, 132.8, 163.4, 163.5, 164.4, 164.5, 164.6, 164.8, 
164.9, 165.2 (aromatics); HRMS m/z (ESI+) 723.1811, (C41H32O11Na [M+Na]
+ requires 
723.1837).  
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2,3,4,6-Tetra-O-benzoyl-1-bromo-α-D-galactopyranose 4.30 [184a] 
 
HBr/AcOH (33%) (20 mL, 335 mmol, 27 equiv) was added to 1,2,3,4,6-penta-O-
benzoyl-α-galactopyranose 4.29 (8.72 g, 12.4 mmol) in CH2Cl2 at 0 °C under N2. Ac2O 
(0.48 mL) was added and the reaction mixture was stirred for 2 h. The reaction 
mixture was diluted with CH2Cl2 (50 mL), washed with ice-water (40 mL), aqueous 
sodium bicarbonate (40 mL). The organic layer was dried over MgSO4, filtered and 
rotary evaporated to yield the α-anomer 4.30 as a white solid (7.82 g, 96%, crude 
yield); Rf = 0.19 (hexane/EtOAc 4:1); For the α anomer: 
1H NMR (300 MHz): δ 4.48 
(dd, J = 6.0 Hz,  11.5 Hz, 1 H, H-6’), 4.66 (dd, J = 6.8 Hz,  11.5 Hz, 1 H, H-6), 4.94 (pt, J 
=6.3 Hz, 1 H, H-5), 5.70 (dd, J =3.9 Hz, 10.4 Hz, 1 H, H-2), 6.09 (dd, J =3.3 Hz, 10.4 Hz, 
1 H, H-3), 6.16 (dd, J = 1.0 Hz, 3.3 Hz, 1 H, H-4), 7.01 (d, J = 3.9 Hz, 1 H, H-1), 7.22-
8.09 (m, 20 H, aromatics); 13C NMR (75 Hz): δC 61.7 (C-6), 68.2 (C-4), 68.7 (C-2), 68.9 
(C-3), 71.9 (C-5), 88.4 (C-1), 128.4 ,128.5 ,128.6, 128.6, 128.8, 128.9, 129.5, 129.8, 
129.9, 129.9, 130.0, 130.1, 133.2, 133.4, 133.4, 133.7, 133.8, 165.4, 165.4, 165.6, 
165.9 (aromatics). 
The 1H NMR data is in agreement with the literature.[184a] 
2,3,4,6- Tetra-O-benzoyl-α/β-D-galactopyranose 4.32 
 
Ag2CO3 (0.48 mL,1.73 mmol, 3 equiv) was added to a stirring solution of 2,3,4,6-
tetra-O-benzoyl-1-bromo-α-D-galactopyranose 4.30 (0.38 g, 0.58 mmol) in 
acetone:H2O (10 mL, 4:1) in the dark and the suspension was stirred for 2.5 h. It was 
washed through Celite with CH2Cl2. The solution was dried over MgSO4, filtered and 
concentrated in vacuo to yield the title compound 4.32 as a brown oil (0.31 g, 90%,, 
crude yield, α:β 3:1); Data recorded for mixture of anomer:  Rf = 0.33 
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(toluene/EtOAc 9:1): 1H NMR (300 MHz): δ 4.37-4.43 (m, 2 H, H-6’ (α,β), 4.58-4.64 
(m, 2 H, H-6 (α,β), 4.90 (pt, J = 6.5 Hz, 1 H, H-5 (α,β), 5.15 (d, J = 7.4 Hz, 1 H, H-1β), 
5.73-5.78 (m, 3 H, H-2 (α,β), H-3 β),  5.89 (d, J = 3.4 Hz, 1 H, H-1 α), 6.03-6.05 (m, 1 
H, H-4β), 6.10-6.15 (m, 2 H, H-3α, H-4α), 7.18-8.11 (m, 20 H, aromatics). 
 The NMR data is in agreement with the reported values.[270] 
 
2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl-1-trichloroacetimidate 4.33 
[271] 
 
To a solution of 2,3,4,6-tetra-O-acetyl-α/β-D-galactopyranose 4.27 (918 mg, 2.64 
mmol) in anhydrous CH2Cl2 (5 mL) was added trichloroacetonitrile (1.52 mL, 15.18 
mmol), 1,8-diaza bicyclo[5.4.0]undec-7-ene (0.12 mL, 0.79 mmol) and 3 Å molecular 
sieves ( 500 mg) in an inert atmosphere. The reaction mixture was stirred for 3.5 h. 
The solvent was evaporated under reduced pressure and the residue purified by 
column chromatography (hexane/EtOAc 4:3) to give the α-anomer 4.33 as white 
crystal (1.08 g, 83%); Rf = 0.57 (hexane/EtOAc 1:1);   
1H NMR (300 MHz): δ 2.01 (s, 3 
H,  OC(O)CH3), 2.02 (s, 3 H,  OC(O)CH3), 2.03 (s, 3 H,  OC(O)CH3), 2.04 (s, 3 H,  
OC(O)CH3), 4.06-4.21 (m, 2 H, H-6, H-6’), 4.41 (td, J = 1.1 Hz, 12.6 Hz, 1 H, H-5), 5.34- 
5.46 (m, 2 H, H-2, H-3 ), 5.57 (dd, J = 1.1 Hz,  3.2 Hz, 1 H, H-4), 6.61-6.62 (d, J  = 3.0 
Hz, 1 H, H-1), 8.69 (s, 1 H, NH); 13C NMR (75 Hz): δC 20.5 (OC(O)CH3), 20.5 
(OC(O)CH3), 20.6 (OC(O)CH3), 20.6 (OC(O)CH3), 61.2 (C-6), 66.9 (C-3), 67.4 (C-4), 67.5 
(C-2), 68.9 (C-5), 93.5 (C-1), 160.9 (C=NH), 169.9 (C=O), 170.0 (C=O), 170.0 (C=O), 
170.2 (C=O). 
 
The NMR data are in agreement with the reported values.[272] 
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2,3,4,6-Tetra-O-benzoyl-α-D-galactopyranosyl-1-trichloroacetimidate 4.37 
 
To a solution of 2,3,4,6-tetra-O-benzoyl-α/β-D-galactopyranose 4.32 (99 mg, 0.17 
mmol) in anhydrous CH2Cl2 (1 mL) was added trichloroacetonitrile (0.08 mL, 0.83 
mmol, 5 equiv), 1,8-diaza bicyclo[5.4.0]undec-7-ene (3 µL, 0.02 mmol, 0.1 equiv) 
and 3Å molecular sieves (50 mg) in an inert atmosphere at 0 °C. The reaction 
mixture was stirred for 2 h at 0 °C.  The solvent was evaporated under reduced 
pressure to yield the title compound 4.37 as white crystal (110 mg, 89%, crude 
yield); Rf = 0.82 (toluene/EtOAc 9:1); [α]
22
D = +100 (c, 4 in CH2Cl2); 
1H NMR (300 
MHz): δ 4.41-4.48 (m, 1 H, H-6’), 4.58-4.65 (m, 1 H, H-6), 4.85-4.89 (m, 1 H, H-5), 
5.98-5.99 (m, 1 H, H-2), 6.06-6.10 (m, 1 H, H-3), 6.16-6.16 (m, 1 H, H-4), 6.91(d, J = 
3.6 Hz,1 H, H-1), 7.16-8.13 (m, 20 H, aromatics), 8.64 (s, 1 H, NH).  
The NMR data is in agreement with reported values.[270] 
 
N-tert-Butoxycarbonyl-O-trimethylsilyl-L-serine benzyl ester 4.41 
 
TMSCl (0.24 mL, 1.87 mmol, 1.1 equiv) was added to a solution of N-(tert-
butoxycarbonyl)-L-serine benzyl ester 4.20 (0.5 g, 1.70 mmol) in CH2Cl2 (4 mL) under 
N2 at rt. It was stirred for 10 min and NEt3 (0.24 mL, 1.87 mmol, 1 equiv) was added 
to this solution drop-wise producing a smoke in the round bottom. The reaction 
mixture was stirred for 2 h. It was concentratred in vacuo. Brine (10 mL) was added 
and the suspension was extracted with CH2Cl2 (10 mL × 2). The combined organic 
layers were dried over MgSO4, filtered, concentrated in vacuo to afford the title 
compound 4.41 (0.43 g, 69%, crude yield) as a white solid; Rf = 0.86 (toluene/EtOAc 
9:2); [α]26D = - 2.18 (c, 2.75 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3447.10, 2091.3, 
1642.9, 1499.8 cm-1; 1H NMR (300 MHz): δ 0.00 (s, 9 H, Si(CH3)3), 1.40 (s, 9 H, 
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NHCO2C(CH3)3), 3.75 (dd, J = 3.1 Hz, 10.1 Hz, 1 H, H-β’), 3.98 (dd, J = 2.4 Hz, 10.1 Hz, 
1 H, H-β), 4.33-4.36 (m, 1 H, H-α), 5.11 (dd, J = 12.4 Hz,  22.0 Hz, 2 H, CH2Ph), 5.40 ( 
d, J = 3.7 Hz, 1 H, NH), 7.26-7.29 (m, 5 H, Ph); 13C NMR (75 Hz): δC 0.0 (Si(CH3)3), 29.1 
(C(CH3)3), 56.3 (C-α), 63.8 (C-β), 67.8 (CH2Ph), 80.6 (C(CH3)3), 126.0, 127.7, 128.9, 
129.0, 129.0, 129.3, 129.4, 129.7, 129.8, 136.3 (aromatics), 156.2 (C=O), 171.5 
(C=O); HRMS m/z (ESI-) 366.1736, (C18H28NO5Si [M-H]
- requires 366.1742).  
N-tert-Butoxycarbonyl-O-triethylsilyl-L-serine benzyl ester 4.42 
 
TESCl (0.24 mL, 1.41 mmol, 0.85 equiv) was added to a solution of N-(tert-
butoxycarbonyl)-L-serine benzyl ester 4.20 (0.5 g, 1.70 mmol) in CH2Cl2 (4 mL) under 
N2 at rt. It was stirred for 10 min and NEt3 (0.24 mL, 1.87 mmol, 1 equiv) was added 
to this solution drop-wise producing a smoke in the round bottom. The reaction 
mixture was stirred for 2 h. It was concentratred in vacuo. Brine (10 mL) was added 
and the suspension was extracted with CH2Cl2 (10 mL × 2). The combined organic 
layers were dried over MgSO4, filtered, concentrated in vacuo to afford the title 
compound 4.42 (0.47 g, 67%, crude yield) as a white solid; Rf = 0.78 (toluene/EtOAc 
9:2);  [α]26D = +1.9 (c, 1.05 in CH2Cl2); IR νmax (KBr): 3452.9, 2956.2, 2806.1, 1717.3 
cm-1; 
1
H NMR (300 MHz) δ 0.53-0.58  (m, 6 H, Si(CH2CH3)3), 0.90 (t, J = 7.8 Hz,  9 H, 
Si(CH2CH3)3), 1.42-1.44 (m, 9 H, OC(CH3)3), 3.83 (dd, J = 2.9 Hz,  9.9 Hz, 1 H, H-β’), 
4.07 (dd, J = 2.1 Hz, 9.9 Hz, 1 H, H-β), 4.37-4.40 (m, 1 H, H-α), 5.17 (dd, J = 12.4 Hz, 
23.5 Hz, 2 H, CH2Ph), 5.42 (d, J = 8.5 Hz, 1 H, NH), 7.30-7.33 (m, 5 H, Ph); 
13C NMR 
(75 Hz): δC 3.2 (Si(CH2CH3)3), 5.6 (Si(CH2CH3)3), 27.3 (OC(CH3)3), 54.7 (C-α), 62.4 (C-β), 
66.0 (CH2Ph), 78.8 (OC(CH3)3), 126.0, 127.2, 127.3, 127.5, 127.6, 127.9, 128.0, 128.7 
, 134.5 (aromatics), 154.5 (C=O), 169.7 (C=O); HRMS m/z (ESI-) 408.2202, 
(C21H34NO5Si [M-H]
- requires 408.2212). 
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Imidazole-1-sulfonyl azide hydrochloride 4.43 
[195] 
 
Absolute EtOH (10 mL) was added to magnesium turnings (1 g) and I2 (0.1 g) under 
N2. The reaction mixture was heated until the solution underwent a colour change 
from dark red to colourless. Absolute EtOH (150 mL) was added and the solution 
was refluxed for 1 h to yield anhydrous EtOH. Sulfuryl chloride (5 mL, 61.7 mmol) 
was added drop-wise to an ice-cooled suspension of NaN
3 
(4.01g, 61.7 mmol, 1 
equiv) in MeCN (63 mL) and the mixture stirred for 17 h at rt under N2. Imidazole 
(8.40 g, 123.4 mmol) was added portion-wise to the ice-cooled mixture and the 
resulting slurry stirred for 3 h at rt. The mixture was diluted with EtOAc (133 mL), 
washed with H
2
O (133 mL × 2) then saturated aqueous NaHCO
3 
(133 mL × 2), dried 
over MgSO
4 
and filtered. (A solution of HCl in EtOH [obtained by the drop-wise 
addition of AcCl (6.58 mL, 92.5 mmol) to ice-cooled dry EtOH (25 mL)] was added 
drop-wise to the filtrate with stirring, the mixture chilled in an ice-bath, filtered and 
the filter cake washed with EtOAc (33 mL × 3) to give the title compound 4.43 (5.01 
g, 39%, crude yield) as colourless needles; IR νmax (KBr): 2172.9, 1322.4, 1162.7 cm
-1; 
1H NMR (300 MHz, D
2
O) δ 7.67-7.68 (m, 1 H, H-4), 8.07-8.10 (m, 1 H, H-5), 9.53 (s, 1 
H, H-2).  
This data is in agreement with the reported values.[195] 
N-Azido-L-serine benzyl ester 4.44
 [195] 
 
1 M aq. HCl solution (1 M, 0.5 mL) was added to N-boc-L-serine-benzyl ester 4.20 
(0.10 g, 0.34 mmol) in CH2Cl2 (0.5 mL) at rt. The biphasic mixture was vigorously 
stirred for 18 h and concentrated in vacuo. Imidazole-1-sulfonyl azide hydrochloride 
4.43 (109 mg, 0.52 mmol, 1 equiv) was then added to the resulting L-serine benzyl 
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ester hydrochloride salt (100 mg, 0.43 mmol) with K2CO3 (161 mg, 1.16 mmol, 2.7 
equiv) and CuSO
4
.5H
2
O (1 mg, 4.31 mmol, 0.01 equiv) in t-BuOH (5 mL) and the 
mixture stirred at 28 °C for 6 h. The mixture was concentrated, diluted with H
2
O (15 
mL), acidified with conc. HCl and extracted with EtOAc (10 mL × 3). The combined 
organic layers were dried over MgSO4, filtered and concentrated. Flash column 
chromatography (hexane/EtOAc 2:1) afforded the title compound 4.44 (58 mg, 61% 
over two steps) as a white solid; Rf = 0.44 (hexane/EtOAc 2:1); IR νmax (NaCl plate, 
CH2Cl2): 3443.5, 2110.5, 1740.3, cm
-1; 1H NMR (300 MHz): δ 1.96 (s, 1 H, OH), 3.93 
(d, J = 4.8 Hz, 1 H, H-β), 4.12 (t, J = 4.8 Hz, 1 H, H-α), 5.27 (s, 2 H, CH2Ph), 7.37-7.39 
(m, 5 H, Ph); 13C NMR (75 Hz): δC 62.8 (CH2OH), 63.4 (C-α), 128.4, 128.7, 128.7, 
134.8 (aromatics), 168.6 (C=O). 
This data is in agreement with the reported values.[273] 
N-Azido-L-serine methyl ester 4.45 [194a] 
 
Tf2O (2 mL, 11.8 mmol, 3 equiv) was added drop-wise to a pre-cooled (0 °C) 
vigorously stirring mixture of NaN3 (1.53 g, 23.55 mmol, 6 equiv) in H2O (5 mL) and 
CH2Cl2 (5 mL) in an inert atmosphere. It was stirred for 2 h at 0 °C. Satd. aq. NaHCO3  
(10 mL) was added to the reaction mixture slowly and transferred to a separating 
funnel upon evolution of gases. The aqueous layer was washed twice with CH2Cl2 
(30 mL × 2). The combined organic layers were washed with satd. aq. NaHCO3 (10 
mL) and the approx. 0.6 N TfN3 (65 mL) solution was used without further 
purification (based on 50% conversion). (ratio of H2O: CH2Cl2 = 1: 2.6) NOTE: highly 
explosive compound when dried so avoid concentration. In another round bottom, 
NEt3 (1.64 mL, 11.8 mmol, 3 equiv) was added to a mixture of L-serine methyl ester 
hydrochloride 4.60 (611 mg, 3.93 mmol) and CuSO4.5H2O (10 mg, 0.039 mmol, 0.01 
equiv) in H2O (65 mL) (ratio of H2O: CH2Cl2: MeOH 3:3:10). The prepared TfN3 
solution in CH2Cl2 (65 mL) was added slowly in the presence of N2. MeOH (210 mL) 
was added to the reaction mixture very slowly and it was stirred for 18 h. It was 
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concentrated in vacuo. Flash column chromatography (hexane/ EtOAc 2:1) afforded 
the title compound 4.45 (326 mg, 57%) as a colourless oil; Rf = 0.42 (hexane/EtOAc 
1:1); 1H NMR (300 MHz): δ 3.80 (s, 3 H, OCH3), 3.89-3.91 (m, 2 H, H-β, H-β’), 4.07 (t, 
J = 4.7 Hz, 1 H, H-α); 13C NMR (75 Hz): δc 53.0 (OCH3), 62.7 (C- β), 63.5 (C- α), 169.7 
(CO); HRMS m/z (ESI+) 313.0881, (C8H14N6O6Na: [2M+Na]
+ requires 313.0867).  
The NMR data are in agreement with the reported values.[274]  
N-tert-Butoxycarbonyl-alanine benzyl ester 4.50 
 
To a solution of PPh3 (127 mg, 0.48 mmol, 1.6 equiv) and 4 Å MS (50 mg) in 
anhydrous CH2Cl2 (2 mL) in an inert atmosphere was added a solution of  2,3,4,6-
tetra-O-acetyl-α/β-D-galactopyranose 4.27 (105 mg, 0.30 mmol) and N-Boc-L-
serine-benzyl ester 4.20 (89 mg, 0.54 mmol, 1.8 equiv) at rt and stirred for 15 min. 
DIAD (95 mg, 0.482 mmol, 1.6 equiv) in anhydrous CH2Cl2 (2 mL) was added to the 
reaction mixture drop-wise and the reaction mixture was stirred for 5 h. The 4 Å MS  
were filtered off and the solvent was evaporated under reduced pressure and the 
residue purified by flash column chromatography (toluene /EtOAc 1:1) to give 
dehydroalanine  derivative 4.50 as a colourless oil (41 mg, 49%); Rf = 0.87 
(toluene/EtOAc 1:1); 1H NMR (300 MHz): δ 1.46-1.48 (m, 9 H, O(CH3)3), 5.25 (s, 2 H, 
CH2Ph), 5.79 (s, 1 H, C=CHH), 6.18 (s, 1 H, C=CHH), 7.01-7.03 (m, 1 H, NH), 7.36-7.37 
(m, 5 H, Ph). 
 
The NMR data is in agreement with the reported values.[197] 
Phenyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 4.53 
 
Thiophenol (2.26 mL, 22.1 mmol, 1 equiv) was added to a solution of 1,2,3,4,6-
penta-O-acetyl-β-D-galactopyranose 2.32 (8.64 g, 22.1 mmol) in CH2Cl2 (100 mL) 
followed by BF3.OEt2 (8.33 mL, 66.3 mmol, 3 equiv) and the solution was stirred for 
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18 h. The reaction mixture was diluted with CH2Cl2 (100 mL) and washed with 1 M 
aq. NaOH (100 mL), brine solution (100 mL) and H2O (100 mL). The organic layer 
was dried over MgSO4,
 filtered and concentrated in vacuo. Flash column 
chromatography (hexane/ EtOAc 3:1) afforded the β anomer 4.53 (7.67 g, 79%) as a 
white foamy solid; Rf = 0.56 (hexane/EtOAc 2:1);  
1H NMR (300 MHz): δ 1.96 (s, 3 H, 
OC(O)CH3), 2.03 (s, 3 H, OC(O)CH3), 2.09 (s, 3 H, OC(O)CH3), 2.11 (s, 3 H, OC(O)CH3), 
3.92 (pt, J = 6.2 Hz, 1 H, H-5), 4.07-4.21 (m, 2 H, H-6, H-6’), 4.71 (d, J = 12.0 Hz, 1 H, 
H-1), 5.04 (dd, J = 3.1 Hz, 9.0 Hz, 1 H, H-3), 5.24 (dd, J = 9.0 Hz, 12.0  Hz, 1 H, H-2), 
5.41 (dd, J = 3.1 Hz , 6.2 Hz, 1 H, H-4), 7.29-7.52 (m, 5 H, Ph); HRMS m/z (ESI+) 
458.1501, (C20H24O9SNH4 [M+NH4]
+ requires 458.1479).  
The NMR data is in agreement with the reported values.[275] 
Phenyl-2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside 4.54 
 
Na metal (13 mg approx., 0.58 mmol approx., 0.1 equiv approx.) was added to a 
solution of phenyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside  4.53 (7.67 g, 
5.83 mmol) in MeOH (70 mL) at 0 °C. It was stirred at rt for 1.5 h; quenched with 
Amberlite ion-exchange resin (H+ form), filtered and concentrated in vacuo. The 
resulting white solid was then dissolved in DMF (10 mL) and NaH (60% suspension 
in mineral oil) (4.87 g, 0.12 mol, 8 equiv) was slowly added to it under an inert 
atmosphere at 0 °C. The suspension was stirred for 30 min and BnBr (10.83 mL, 0.09 
mol, 6 equiv) was added at 0 °C. The reaction mixture was stirred overnight at rt. To 
this suspension MeOH (20 mL) was added followed by concentration in vacuo. It 
was dissolved in Et2O (100 mL) and washed with water (100 mL × 2). The aqueous 
layers were combined and washed with Et2O (100 mL × 2). The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. 
Recrystallisation in EtOH afforded the β-anomer 4.54 (6.75 g, 79% over two steps) 
as white crystals; Rf = 0.75 (hexane/EtOAc 2:1); 
1H NMR (300 MHz): δ 3.59-3.68 (m, 
4 H, H-3, H-5, H-6, H-6’), 3.93 (d, J = 9.0 Hz, H-2), 3.98 (t, J = 3.3 Hz, 1 H, H-4), 4.45-
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4.50 (d × 2, J = 9.0 Hz, 2 H, CHPh × 2), 4.59-4.66 (d × 2, J = 9.0 Hz, 2 H, CHPh × 2), 
4.73-4.81 (m, 4 H, CH2Ph, CHPh, H-1), 4.97 (d, J = 12.0 Hz, CHPh), 7.18-7.20 (m, 3 H, 
SPh), 7.29-7.40 (m, 20 H, aromatics), 7.55-7.59 (m, 2 H, SPh); HRMS m/z (ESI+) 
633.2658, (C20H27NO9SH: [M+H]
+ requires 633.2669).  
The NMR data is in agreement with the reported values.[202] 
Imidazole-1-sulfonyl azide hydrogen sulfate 4.55 
[203] 
 
Absolute EtOH (10 mL) was added to magnesium turnings (1 g) and I2 (0.1 g) under 
N2. The reaction mixture was heated until the solution underwent a colour change 
from dark red to colourless. Absolute EtOH (150 mL) was added and the solution 
was refluxed for 1 h to yield anhydrous EtOH. Sulfuryl chloride (5 mL, 61.7 mmol) 
was added drop-wise to an ice-cooled suspension of NaN
3 
(4.01g, 61.7 mmol, 1 
equiv) in MeCN (63 mL) and the mixture stirred for 17 h at rt under N2. Imidazole 
(8.40 g, 123.4 mmol) was added portion-wise to the ice-cooled mixture and the 
resulting slurry stirred for 3 h at rt. The mixture was diluted with EtOAc (133 mL), 
washed with H
2
O (133 mL × 2) then satd. aq. NaHCO
3 
(133 mL × 2), dried over 
MgSO
4 
and filtered. Sulfuric acid (6.05 g, 61.7 mmol, 1 equiv) was added drop-wise 
to the solution (100 mL solution). It was stirred for 1 h. PetEt (100 mL) was added 
and the precipitate was filtered to give the title compound 4.55 (7.42 g, 20%) as 
white crystals; IR νmax (NaCl plate, CH2Cl2): 3107.2, 2173.3, 1579.7, 1508.9, 1449.7 
cm-1; 1H NMR (300 MHz): δ 7.51 (s, 1 H, H-2), 8.10 (s, 1 H, H-5), 8.96 (s, 1 H, H-4).  
The NMR data is in agreement with the reported values.[203] 
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N-tert-Butoxycarbonyl-L-serine tetradecyl amide 4.56 
[276] 
 
DMF (5 mL) was added to a mixture of N-boc-L-Serine 4.18 (250 mg, 1.22 mmol), 
TBTU (430 mg, 1.34 mmol) and HOBt (181 mg, 1.34 mmol) under N2 and was left to 
stir for 10 min. Tetradecylamine (286 mg, 1.34 mmol) and NEt3 (0.2 mL, 1.46 mmol) 
were then added under N2 to the reaction mixture and were stirred for 18 h.The 
reaction mixture was rotary evaporated, diluted in CH2Cl2 (25 mL); washed with 
brine (30 mL) and 0.2 N aq. HCl (30 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 25 mL), and the combined organic layers were washed with satd. aq. 
NaHCO3 (30 mL). The organic layer was dried over MgSO4 and filtered. The solvent 
was then evaporated under reduced pressure, vacuum dried to give an oil that was 
purified by column chromatography (hexane/EtOAc 1:1) to give the title compound 
4.56 as a white solid (337 mg, 59%); Rf = 0.42 (hexane/EtOAc 1:1); [α]
20
D = -8.58 (c, 
0.013 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3319.60, 3107.63, 2924.92, 2853.95, 
1706.41, 1650.17, 1174.77 cm-1; 1H-NMR (300 MHz): δ = 0.88 (t, J = 6.4 Hz, 3 H, 
CH2CH3), 1.25 (s, 24 H,  NHCH2(CH2)12CH3), 1.45 (s, 12 H; OC(CH3)3), 3.23-3.25 (m, 2 
H; NHCH2), 3.59-3.65 (m, 2 H,  H-β’, NHC=O), 4.04-4.14 (m, 2 H; H-α, H-β), 5.68 (d, J= 
7.5 Hz, 1 H, OH), 6.79 (s, 1 H, NH); 13C-NMR (75 MHz): δC 14.1 (CH2CH3), 22.7 
(CH2CH3), 28.3 (OC(CH3)3), 31.9-26.9 (NHCH2CH2(CH2)10), 39.5 (C=ONHCH2CH2), 54.8 
(NHCHCH2OH), 62.9 (NHCH2), 77.5-76.6 (m, CDCl3, CH2OH), 80.5 (C(CH3)3), 156.3 
(C=O), 171.3 (C=O). 
The 1H NMR data is in agreement with the literature. [276] 
L-Serine tetradecyl amide trifluroracetic acid 4.57 
[276] 
 
At 0°C to a solution of N-boc-L-serine tetradecyl amide 4.56 (1.09 g, 2.71 mmol) in 
CH2Cl2 (20 mL) was added TFA (3.03 mL, 40.70 mmol, 15 equiv). The reaction 
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mixture was stirred for 4 h at rt and then concentrated in vacuo. PetEt and diethyl 
ether was added to the waxy solid and the precipitate was filtered to give the title 
compound 4.57 (860 mg, 77%, crude yield) as a flaky white solid; 1H-NMR (300 
MHz, d6-DMSO): δ 0.85 (t, J = 6.9 Hz, 3 H, CH3), 1.22-1.24 (m, 22 H, 
NHCH2CH2(CH2)11CH3), 1.41 (s, 2 H, NHCH2CH2), 3.07-3.11 (m, 2 H, NHCH2CH2), 3.63-
3.74 (m, 3 H, H-α, H-β, H-β’), 5.49 (bs, 1 H, OH), 8.08 (bs, 3 H, NH3), 8.33 (t, J = 5.7 
Hz, 1 H, NH); HRMS m/z (ESI+) 301.285, (C17H36N2O2H: [M+H]
+ requires 301.2838).   
The NMR data is in agreement with the reported values.[276] 
N-Azido-L-serine tetradecyl amide 4.58  
 
Imidazole-1-sulfonyl azide hydrogen sulfate 4.55 (113 mg, 0.31 mmol, 1.2 equiv) 
was added to a reaction mixture containing L-serine tetradecyl amide trifluroracetic 
acid 4.57 (77 mg, 0.26 mmol), K2CO3 (78 mg, 0.57 mmol, 2.2 equiv) and CuSO4.5H2O 
(1 mg, 0.03 mmol, 0.1 equiv) in MeOH (3 mL) and the mixture stirred at rt for 18 h. 
The mixture was concentrated, diluted with H
2
O (15 mL), acidified with conc. HCl 
and extracted with EtOAc (10 mL × 3). The combined organic layers were dried over 
MgSO4, filtered and concentrated. Flash column chromatography (hexane/EtOAc 
3:1) afforded a mixture of the desired product 4.58 (characteristic data described 
below) and an undesired product 4.58a. A small amount of the undesired 
sulfonylamide product 4.58a was isolated; Rf = 0.10 (PetEt/EtOAc 2:1); 
1H-NMR (300 
MHz): δ 0.88 (t, J = 6.9 Hz, 3 H, CH3), 1.24-1.25 (m, 22 H, NHCH2CH2(CH2)11CH3), 
1.49-1.54 (m, 2 H, NHCH2CH2), 2.97-3.02 (m, 1 H, OH), 3.25-3.31 (m, 2 H, NHCH2), 
3.62-3.71 (m, 1 H, H-β), 4.14-4.20 (m, 1 H, H-β’), 4.34-4.39 (m, 1 H, H-α), 6.42-6.44 
(m, 1 H, NHCH2), 7.52-7.54 (m, 1 H, NHSO2N3). 
Tf2O (1.02 mL, 6.09 mmol, 3 equiv) was added drop-wise to a pre-cooled (0 °C) 
vigorously stirring mixture of NaN3 (792 mg, 12.18 mmol, 6 equiv) in H2O (2.5 mL) 
and CH2Cl2 (2.5 mL) in an inert atmosphere. It was stirred for 2 h at 0 °C. Satd. aq. 
NaHCO3 solution (5 mL) was added to the reaction mixture slowly and transferred 
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to a separating funnel upon evolution of gases. The aqueous layer was washed 
twice with CH2Cl2 (15 mL × 2). The combined organic layers were washed with satd. 
aq. NaHCO3 solution (5 mL) and the approx. 0.6 N TfN3 (35 mL) solution was used 
without further purification (based on 50% conversion). (ratio of H2O: CH2Cl2 1:2.6) 
NOTE: highly explosive compound when dried so avoid concentration of solution. In 
a separate round bottom, NEt3 (848 µL, 6.09 mmol, 3 equiv) was added to a mixture 
of L-serine tetradecyl amide trifluroracetic acid 4.57 (840 mg, 2.03 mmol) and 
CuSO4.5H2O (5 mg, 0.02 mmol, 0.01 equiv) in H2O (35 mL) (ratio of H2O: CH2Cl2: 
MeOH 3:3:10). The prepared TfN3 solution in CH2Cl2 (35 mL) was added slowly in 
the presence of N2 by an addition funnel. MeOH (117 mL) was added to the reaction 
mixture very slowly and it was stirred for 2.5 h. Solid Na2CO3 (511 mg, 6.09 mmol, 3 
equiv) was added and the reaction mixture was concentrated in vacuo. Flash 
column chromatography (PetEt to 3:1 PetEt: EtOAc) afforded the title compound 
4.58 (663 mg, 100%) as a white solid; Rf = 0.50 (PetEt/EtOAc 1:1);  [α]
25
D = +16.67 (c, 
0.6 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3903.2, 3840.1, 3435.5, 2925.2, 2853.0, 
2100.2, 1642.6 cm-1; 1H-NMR (300 MHz): δ = 0.87 (t, J = 6.4 Hz, 3 H, CH2CH3), 1.25 
(s, 24 H,  NHCH2(CH2)12CH3), 3.23-3.25 (m, 2 H, NHCH2), 3.98-4.02 (m, 2 H, H-β, H-
β’), 4.08-4.11 (m, 1 H, H-α), 6.43-6.49 (m, 1 H, NHCH2); 
13C-NMR (75 MHz): δC 14.1 
(CH3), 22.7, 26.8, 29.2, 29.4, 29.5, 29.6, 29.7, 31.9 (NHCH2(CH2)11CH3) 39.6 
(NHCH2(CH2)11CH3), 63.3 (C-β), 64.3 (C-α), 168.0 (C=O); HRMS m/z (ESI+) 327.2771, 
(C17H33N4O2H: [M+H]
+ requires 327.2755). 
N-Azido-O-(2,3,4,6-tetra-O-benzyl-α,β-galactopyranosyl)–L-serine methyl ester  
4.59 and 4.60 
 
NIS (256 mg, 1.58 mmol, 2 equiv) was added to a solution of phenyl-2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactopyranoside 4.54 (500 mg, 0.79 mmol), and N-azido-L-
serine methyl ester 4.45 (229 mg, 1.58 mmol, 2 equiv) in CH2Cl2 (10 mL) in the dark 
under N2. TfOH (1 µL, 0.008 mmol, 0.01 equiv) was added and the reaction mixture 
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was stirred for 18 h. The reaction mixture was diluted with CH2Cl2 (10 mL) and 
washed with satd. aq. Na2S2O4 (10 mL) followed by brine (10 mL). The organic layer 
was dried over MgSO4, filtered and concentrated to give a colourless oil (α/β ratio 
of 2.2:1). Flash column chromatography (hexane/EtOAc 3:1) afforded the α-anomer 
4.59 (169 mg, 32%) as a white solid, the β-anomer 4.60 (127 mg, 25%) as a 
colourless oil and an undesired succinimide by-product 4.61 (103 mg, 21%). Data 
recorded for α-anomer 4.59: Rf = 0.40 (PetEt/EtOAc 3:1); [α]
22
D = +21.33 (c, 1.5 in 
CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3435.1, 2103.0, 1642.5 cm
-1; 1H NMR (300 
MHz): δ 3.48-3.59 (m, 2 H, H-6, H-6’), 3.70 (s, 3 H, CH3), 3.85 (dd, J = 6.1 Hz, 10.6 Hz, 
1 H, H- β’), 3.93-4.13 (m, 6 H, H-2, H-3, H-4, H-5, H-α, H-β), 4.41-4.87 (m, 7 H, CHPh, 
CH2Ph × 3), 4.90 (d, J = 3.5 Hz, 1 H, H-1), 4.96 (d, J = 11.5 Hz, 1 H, CHPh), 7.29-7.39 
(m, 20 H, aromatic); 13C NMR (75 Hz): δc 52.7 (OCH3), 61.7 (C-α), 68.7 (C-β), 69.1 (C-
6), 70.0 (C-5), 73.0 (CH2Ph), 73.2 (CH2Ph),  73.4 (CH2Ph), 74.7 (CH2Ph), 75.1 (C-4), 
76.3 (C-2), 78.6 (C-3), 98.9 (C-1), 127.5, 127.6, 127.7, 128.2, 128.2, 128.2, 128.3, 
128.3, 137.9, 138.5, 138.7, 138.7 (aromatics), 168.7 (C=O); HRMS m/z (ESI+) 
690.2792, (C38H41N3O8Na : [M+Na]
+ requires 690.2786). Data recorded for β-anomer 
4.60: Rf = 0.29 (PetEt/EtOAc 3:1);  [α]
28
D = +2.67 (c, 0.75 in CH2Cl2); IR νmax (NaCl 
plate, CH2Cl2): 3428.0, 2105.6, 1641.9, 1260.6 cm
-1; 1H NMR (300 MHz): δ 3.49-3.58 
(m, 4 H, H-3, H-4 or H-5, H-6, H-6’), 3.74 (s, 3 H, CH3),  3.77-3.83 (m, 1 H, H-2), 3.85-
3.90 (m, 2 H, H-β’, H-4 or H-5) 4.07 (t, J = 5.9 Hz, 1 H, H-α), 4.19 (dd, J = 5.9 Hz , 10.3 
Hz , 1 H, H-β), 4.39 (d, J = 7.6 Hz, 1 H, H-1), 4.42-4.95 (m, 8 H, CH2Ph × 4), 7.25-7.39 
(m, 20 H, Ph × 4); 13C NMR (75 Hz): δc 52.8 (CH3), 61.6 (C-α), 68.6 (C-β), 68.7 (C-6), 
73.1 (CH2Ph), 73.6, 73.5 (C-4, C-5), 73.7 (CH2Ph),  74.6 (CH2Ph), 75.1 (CH2Ph), 79.1, 
82.1 (C-2, C-3), 103.9 (C-1), 127.5, 127.6, 127.8, 127.9, 128.2, 128.2, 128.3, 128.3, 
128.4, 128.5, 137.9, 138.4, 138.5, 138.7 (aromatics), 168.7 (C=O); HRMS m/z (ESI+) 
690.2798, (C38H41N3O8Na : [M+Na]
+ requires 690.2786). 
The data recorded for the succinimide byproduct 4.61 is in agreement with the 
reported values.[200] 
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N- tert-Butoxycarbonyl-O-(2,3,4,6-tetra-O-benzyl-α-galactopyranosyl)–L-serine 1-
benzyl ester 4.62 
 
NIS (256 mg, 1.58 mmol, 2 equiv) was added to a solution of phenyl-2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactopyranoside 4.54 (500 mg, 0.79 mmol) and N-Boc-L-serine-
benzyl ester 4.20 (467 mg, 1.58 mmol, 2 equiv) in CH2Cl2 (5 mL) in the dark under 
N2. TfOH (1 µL, 0.008 mmol, 0.01 equiv) was added and the reaction mixture was 
stirred for 18 h. It was diluted with CH2Cl2 (10 mL) and washed with satd. aq. 
Na2S2O4 solution (10 mL) followed by brine (10 mL). The organic layer was dried 
over MgSO4, filtered and concentrated. Flash column chromatography 
(hexane/EtOAc 4:1) afforded the α-anomer 4.62  (199 mg, 44%) as a yellow oil; Rf = 
0.37 (PetEt/EtOAc 3:1);  [α]24D = + 41.05 (c, 0.95 in CH2Cl2); IR νmax (NaCl plate, 
CH2Cl2): 3427.6, 2097.9, 1642.1  cm
-1;  1H NMR (300 MHz): δ 1.41 (s, 9 H, 
C=OOC(CH3)3), 3.49- 3.54 (m, 2 H, H-6, H-6’), 3.78-3.82 (m, 2 H, H-3, H-β’), 3.85-3.91 
( m, 2 H, H-4, H-5), 4.00 (dd, J = 3.7 Hz, 10.1 Hz, 1 H, H-2), 4.16 (dd, J = 3.0 Hz,  10.6 
Hz, 1 H, H-β), 4.39 (d, J = 11.9 Hz, 1 H, CHHPh), 4.49-4.56 (m, 3 H, CHHPh × 2, H-α), 
4.60 (d, J = 11.4 Hz, 1 H, CHHPh), 4.67-4.80 (m, 4 H, CH2Ph, CHHPh, H-1), 4.91 (d, J = 
11.4 Hz, 1 H, CHHPh), 5.10 (s, 2 H, CO2CH2Ph), 5.79 (d, J = 8.9 Hz, 1 H, NH), 7.16-7.35 
(m, 25 H, aromatic); 13C NMR (75 Hz): δC 28.3 (C=OOC(CH3)3), 54.4 (C-α), 67.1 
(CO2CH2Ph), 68.7 (C-6), 69.8 (C-4), 70.4 (C-β), 73.0 (CH2Ph), 73.2 (CH2Ph), 73.5 
(CH2Ph), 74.8 (C-5), 76.4 (CH2Ph), 77.2 (C=OOC(CH3)3), 78.7 (C-2), 79.9 (C-3), 99.3 (C-
1), 127.4, 127.5, 127.6, 127.7, 127.7, 127.8, 127.9, 128.2, 128.2, 128.3, 128.4, 128.5, 
135.4, 137.9, 138.6, 138.7, (aromatics), 155.6 (C=O), 170.4 (C=O); HRMS m/z (ESI+) 
1657.7469, (C98H110N2O20Na: [2M+Na]
+ requires 1657.7544). 
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N-Azido-O-(2,3,4,6-tetra-O-benzyl-α-galactopyranosyl)–L-serine 1-benzyl ester  
4.64 
 
NIS (78 mg, 0.35 mmol, 1 equiv) was added to a solution of phenyl-2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactopyranoside 4.54 (220 mg, 0.35 mmol), and N-azido-L-
serine benzyl ester 4.44 (77 mg, 0.35 mmol, 1 equiv) in CH2Cl2 (5 mL) in the dark 
under N2. TfOH (1 µL, 0.003 mmol, 0.01 equiv) was added and the reaction mixture 
was stirred for 3 h. The solution was diluted with CH2Cl2 (5 mL) and washed with 
satd. aq. Na2S2O4 (5 mL) followed by brine (5 mL). The organic layer was dried over 
MgSO4, filtered and concentrated. Flash column chromatography (hexane/EtOAc 
3:1) afforded the α-anomer 4.64 (47 mg, 26%) as a white solid; Rf = 0.43 
(PetEt/EtOAc 3:1); IR νmax (NaCl plate, CH2Cl2): 3420.7, 2743.9, 2107.5, 1726.2 cm
-1;  
1H NMR (300 MHz): δ 3.44-3.56 (m, 2 H, H-6, H-6’), 3.81-4.13 (m, 6 H, H-α, H-β, H-β’, 
H-2, H-3, H-5), 4.37-4.94 (m, 9 H, CH2Ph × 4, H-4), 4.86 (d, J = 3.5 Hz, 1 H, H-1), 5.10 
(dd, J = 12.3 Hz, 25.0 Hz, 2 H, CO2CH2Ph), 7.24-7.34 (m, 25 H, aromatics); 
13C NMR 
(75 Hz): δC 60.7 (C-α), 66.7 (CO2CH2Ph), 67.7 (C-6), 68.1 (C-β), 69.0 (C-4), 72.1 
(CH2Ph),  72.4 (CH2Ph), 73.7 (CH2Ph), 73.8 (CH2Ph), 73.7 (C-2), 75.3 (C-5),77.6 (C-3), 
97.9 (C-1), 126.5, 126.5, 126.6, 126.7, 126.7, 126.7, 127.2, 127.2, 127.3, 127.3 
127.3, 127.4, 127.5, 127.6, 128.9, 133.9, 136.9, 137.5, 137.7, 137.7 (aromatics), 
167.3 (C=O); HRMS m/z (ESI+) 744.3279 (C44H45N3O8H: [M+H]
+ requires 744.3281). 
Phenyl 3,4-O-(isopropylidene)-1-thio-β-D-galactopyranoside 4.69 
 
Na metal (2 mg approx., 0.10 mmol approx., 0.1 equiv approx.) was added to 
phenyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 4.53 (420 mg, 0.99 
mmol)  in THF/H2O/MeOH (2:1:2, 5 mL) at 0 °C. It was stirred for 1 h and quenched 
with Amberlite ion exchange resin. The solution was filtered and concentrated in 
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vacuo. H2SO4 (100 µL) was added drop-wise to the crude glycoside (240 mg, 0.88 
mmol) in acetone (6 mL) at rt and the reaction mixture was stirred for 36 h at rt. 
NEt3 was added drop-wise to give a pH of 7. The reaction mixture was concentrated 
in vacuo. Flash column chromatography (PetEt/ EtOAc 1:1) yielded the β-anomer 
4.69 (122 mg, 44%) as a white foam; IR νmax (NaCl plate, CH2Cl2): 3406.2, 2101.7, 
1632.1, 1480.8  cm-1; 1H NMR (300 MHz): δ 1.33 (s, 3 H, CH3), 1.41 (s, 3 H, CH3), 3.57 
(dd, J = 7.0 Hz, 10.1 Hz, 1 H, H-2), 3.79-3.89 (m, 2 H, H-5, H-6’), 3.98 (dd, J =7.2 Hz, 
11.1 Hz, 1 H, H-6), 4.11 (pt, J = 5.8 Hz, 1 H, H-3), 4.17 (dd, J = 1.6 Hz, 5.3 Hz, 1 H, H-
4), 4.48 (d, J =10.1  Hz, 1 H, H-1), 7.29-7.52 (m, 5 H, aromatics). HRMS m/z (ESI-) 
348.0742, (C15H20O5SCl: [M+Cl]
- requires 348.0758).  
The NMR data is in agreement with the reported values.[277] 
Phenyl 2,5-di-O-benzyl-3,4-O-(isopropylidene)-1-thio-β-D-galactopyranoside 4.70 
 
To a solution of phenyl 3,4-O-(isopropylidene)-1-thio-β-D-galactopyranoside 4.69 
(303 mg, 0.97 mmol) in DMF (10 mL) was slowly added NaH (60% suspension in 
mineral oil) (155 mg, 3.88 mmol, 4 equiv) under an inert atmosphere at 0 °C. The 
reaction mixture was stirred for 30 min and BnBr (346 µL, 2.91 mmol, 3 equiv) was 
added to the suspension at 0 °C. The reaction mixture was stirred for 18 h at rt. To 
this suspension MeOH (2 mL) was added and was concentrated in vacuo. Flash 
column chromatography (PetEt/ EtOAc 9:1) afforded the title compound 4.70 (442 
mg, 92%) as a white solid; Rf = 0.30 (PetEt/EtOAc 9:1); IR νmax (NaCl plate, CH2Cl2): 
3421.8, 2921.9, 1638.1, 1081.8 cm-1; 1H NMR (300 MHz): δ 1.34 (s, 3 H, CH3),1.40 (s, 
3 H, CH3), 3.53 (dd, J = 6.0 Hz, 9.5 Hz, 1 H, H-2), 3.79 (dd, J = 1.9 Hz, 6.2 Hz, 2 H, H-6, 
H-6’), 3.94 (td, J = 1.9 Hz, 5.9 Hz, 1 H, H-5), 4.19-4.27 (m, 2 H, H-3, H-4), 4.49-4.84 
(m, 5 H, CH2Ph × 2, H-1), 7.20-7.56 (m, 15 H, aromatics). 
The NMR data is in agreement with the reported values.[277] 
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Phenyl 2,5-di-O-benzyl-3,4-di-O-acetyl-1-thio-β-D-galactopyranoside 4.71 
[212] 
 
To phenyl 2,5-di-O-benzyl-3,4-O-(isopropylidene)-1-thio-β-D-galactopyranoside 4.70 
(53 mg, 0.11 mmol) was added 80% AcOH (200 mL). The reaction was heated to 80 
°C and was heated for 4 h. It was cooled and concentrated in vacuo. The waxy solid 
was diluted with CH2Cl2 and washed with H2O, dried over MgSO4, filtered and 
concentrated to yield the crude tetraol. Ac2O (1 mL) was added to the compound 
dissolved in Pyr (2 mL) at rt at 0 °C. DMAP (2 mg, 0.007 mmol, 0.1 equiv) was added 
and the reaction mixture was stirred for 1.5 h at rt. The reaction mixture was 
concentrated in vacuo and the reaction mixture was re-dissolved in CH2Cl2 (10 mL). 
It was washed with satd. aq. NaCO3 (10 mL × 3) followed by brine (10 mL). The 
organic layers were combined, dried over MgSO4, filtered and rotary evaporated. 
Flash column chromatography (PetEt/ EtOAc 1:1) afforded the title compound 4.71 
(35 mg, 93%) as a white solid; Rf = 0.23 (PetEt/EtOAc 3:1); [α]
24
D = -4.3 (c, 0.93 in 
CH2Cl2);  IR νmax (NaCl plate, CH2Cl2): 3423.2, 2095.5, 1642.1 cm
-1; 1H NMR (300 
MHz): δ 1.90 (s, 3 H, OCH3), 2.03 (s, 3 H, CH3), 3.46-3.52 (m, 1 H, H-6’), 3.56-3.62 (m, 
1 H, H-6), 3.73 (t, J = 9.6 Hz, 1 H, H-2), 3.85 (t, J = 6.1 Hz, 1 H, H-5), 4.29-4.86 (m, 5 H, 
CH2Ph × 2, H-1), 5.03 (dd, J = 3.3 Hz, 9.6 Hz, 1 H, H-3), 5.47-5.48 (m, 1 H, H-4), 7.25-
7.60 (m, 15 H, aromatics); 13C NMR (75 Hz): δC 19.7 (CH3 × 2), 66.9 (C-6), 67.2 (C-4), 
72.5 (CH2Ph), 73.3 (C-3), 74.4 (C-2, CH2Ph), 74.7 (C-5), 86.9 (C-1), 126.6, 126.8, 
126.8, 126.9, 127.3, 127.4, 127.9, 130.9, 132.5, 136.6, 136.9 (aromatics), 168.8 
(C=O), 169.1 (C=O); HRMS m/z (ESI+) 577.1562 (C30H32O7SK: [M+K]
+ requires 
577.1506). 
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N-Azido-O-(2,5-di-O-benzyl-3,4-di-O-acetyl-α,β-galactopyranosyl)–L-serine 1-
methyl ester 4.72 and 4.73
[212] 
 
NIS (196 mg, 0.87 mmol, 1.1 equiv) was added to a cooled solution of N-azido-L-
serine benzyl ester 4.44 (115 mg, 0.79 mmol) and phenyl 2,5-di-O-benzyl-3,4-di-O-
acetyl-1-thio-β-D-galactopyranoside 4.71 (468 mg, 0.87 mmol, 1.1 equiv) on ice in 
anhydrous CH2Cl2 (5 mL) containing pre-dried 4Å MS in the dark under N2. TMSOTf 
(40 µL) was added and the reaction mixture was stirred for 1 h. NEt3 (160 µL) was 
added and the reaction mixture was concentrated in vacuo. Flash column 
chromatography (PetEt/EtOAc 5:1, loaded with toluene) afforded an inseperable 
mixture of anomers 4.72 and 4.73 (287 mg, 63% as a mixture of diastereoisomers 
(2:1 α:β)). A re-column (PetEt/EtOAc 5:1) afforded a small amount of α-anomer 
4.72 for characterisation; Data recorded for α-anomer 4.72: Rf = 0.52 (PetEt/EtOAc 
3:1); [α]25D = + 11.43 (c, 0.35 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2):  3435.7, 2100.3, 
1642.3 cm-1; 1H NMR (300 MHz): δ 1.98 (s, 3 H, COCH3), 2.02 (s, 3 H, COCH3), 3.44-
3.48 (m, 2 H, H-6, H-6’), 3.74 (s, 3 H, CO2CH3), 3.76-3.86 (m, 2 H, H-β, H-2), 4.03 (dd, 
J = 3.8 Hz,  10.6 Hz, 1 H, H- β’), 4.15-4.23 (m, 2 H, H-α, H-5), 4.41-4.70 (m, 4 H, 
CH2Ph × 2), 4.90 (d, J = 3.5 Hz, 1 H, H-1), 5.28 (dd, J = 3.1 Hz, 10.3 Hz, 1 H, H-3), 5.48-
5.49 (m,1 H, H-4), 7.29-7.33 (m, 10 H, aromatics); 13C NMR (75 Hz): δC 20.7 (OCH3),  
20.8 (OCH3),  52.9 (CO2CH3), 61.7 (C-α), 67.9, 68.2, 68.5, 69.0, 69.6, 72.8, 73.4, 73.6 
(C-2, C-3, C-4, C-5, C-6, C-β, CH2Ph × 2), 98.5 (C-1), 127.6, 127.8, 128.4, 137.6, 138.1 
(aromatics), 168.5 (C=O), 169.9 (C=O), 170.1 (C=O); HRMS m/z (ESI+) 1167.4288 
(C56H66N6O20Na: [2M+Na]
+ requires 1167.4284). 
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2,3,4,6- Tetra-O-benzyl-α/β-D-galactopyranose 4.78 
[278] 
 
NBS (1.69 g, 9.48 mmol, 3 equiv) was added to a stirring solution of phenyl-2,3,4,6-
tetra-O-benzyl-1-thio-β-D-galactopyranoside 4.54 (2 g, 3.16 mmol) in acetone/H2O 
(24 mL, 5:1) and the solution was heated to 75 °C for 24 h. The reaction mixture 
was concentrated in vacuo. Satd. aq. NaHCO3 (50 mL) was added and the 
suspension was extracted with EtOAc (50 mL). The organic layer was washed with 
brine (50 mL). The organic layer was dried over MgSO4, filtered, concentrated in 
vacuo and the crude product was purified by flash column chromatography (PetEt/ 
EtOAc, 9:1, loaded in toluene) to yield the title compound 4.78 as a colourless oil 
(931 mg, 61% based on recovered starting material) as a mixture of anomers (2:1 
α/β); Data recorded for mixture of anomers:  Rf = 0.55 (PetEt/EtOAc 3:1); Data 
recorded for α-anomer:  1H NMR (300 MHz): δ 3.56-3.69 (m, 3 H, H-6, H-6’, H-5), 
4.04-4.06 (m, 1 H, H-3), 4.11-4.13 (m, 1 H, H-2), 4.28 (pt, J = 6.4 Hz, 1 H, H-4), 4.45-
5.06 (m, 8 H, CH2Ph × 4), 5.39 (d, J = 2.3 Hz, 1 H, H-1α), 7.39-7.48 (m, 20 H, 
aromatics); HRMS m/z (ESI+) 540.2510 (C34H36O6: [M*+]
+ requires 540.2506).  
The NMR data is in agreement with the reported values.[278] 
1-O-Acetyl-2,3,4,6- tetra-O-benzyl-α/β-D-galactopyranose 4.79 
 
Ac2O (2 mL) was added to 2,3,4,6-tetra-O-benzyl-α/β-D-galactopyranose 4.78 (872 
mg, 1.61 mmol) in Pyr (3 mL) at 0 °C. The reaction mixture was stirred for 18 h at rt 
and was rotary evaporated. Ice-water (200 mL) was added and the organic layer 
was extracted with EtOAc (100 mL × 2). The organic layers were combined, dried 
over MgSO4, filtered and concentrated. Flash column chromatography (PetEt/ 
EtOAc 5:1) afforded the title compound 4.79 (367 mg, 41%) as a colourless oil (1:1 
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α/β); Data recorded for mixture of anomer: Rf = 0.86 (PetEt/EtOAc 3:1); 
1H NMR 
(300 MHz): δ 2.02 (s, 3 H, OC(O)CH3),  2.11 (s, 3 H, OC(O)CH3), 3.49-3.63 (m, 5 H, H-6 
(α), H-5 (α), H-6 (β), H-6’ (β), H-5 (β)), 3.67-3.72 (m, 1 H, H-6 (α)), 3.86-4.04 (m, 5 H, 
H-3 (α), H-4 (α), H-2 (β), H-3 (β), H-4 (β)), 4.17 (dd, J = 3.7 Hz, 10.1 Hz, 1 H, H-2 (α)), 
4.36-4.97 (m, 8 H, CH2Ph × 4), 5.57 (d, J = 8.1 Hz, 1 H, H-1(β)), 6.37 (d, J =3.7 Hz, 1 H, 
H-1(α)), 7.27-7.32 (m, 40 H, aromatics); HRMS m/z (ESI+) 605.2510 (C36H38O7Na: 
[M+Na]+ requires 605.2536).  
The NMR data is in agreement with the reported values.[279] 
1,2,3,4,6-Penta-O-trimethylsilyl-α-D-galactopyranose 4.82 
 
NEt3 (766 µL, 5.5 mmol, 5.5 equiv) was added to D-galactose 4.28 in anhydrous 
DMF (2 mL) under N2. TMSCl (698 µL, 5.5 mmol, 5.5 equiv) was added to the 
solution and additional DMF (2 mL) was added to solubilise the resulting 
precipitate. The reaction mixture was stirred at rt for 4 h. Pentane (50 mL) and 
crushed ice (50 mL) was added to the suspension. The aqueous layer was extracted 
with pentane (50 mL × 2). The combined organic layers were washed with H2O (50 
mL × 2), brine (50 mL × 2), dried over MgSO4, filtered and concentrated in vacuo to 
afford the α-anomer 4.82 (0.46 g, 89%, crude yield) as a colourless oil; Rf = 0.88 
(PetEt/EtOAc 20:1); 1H NMR (300 MHz): δ 0.11-0.27 (m, 15 H, Si(CH3)3 × 5), 3.60 (dd, 
J = 5.7 Hz, 9.6 Hz, 1 H, H-6’), 3.70 (pt, J = 9.6 Hz, 1 H, H-6), 3.86-3.88 (m, 2 H, H-4, H-
2), 3.95-3.97 (m, 2 H, H-3, H-5), 5.11 (d, J = 3.2 Hz, 1 H, H-1); 13C NMR (75 Hz ): δC -
0.5 (OCH3), 0.2 (OCH3), 0.3 (OCH3), 0.5 (OCH3), 0.6 (OCH3),  61.2, 70.0, 70.5, 71.1, 
72.3 (C-2, C-3, C-4, C-5, C-6), 94.6 (C-1).  
The NMR data is in agreement with the reported values.[280] 
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2-Azido-3-(2,3,4,6-tetra-O-trimethylsilyl-α-D-galactopyranosyl)–L-serine 1-methyl 
ester  4.85 
[216] 
O
N3
CO2Me
4.85
O
OTMSTMSO
TMSO
TMSO
 
TMSI (46 µL, 0.034 mmol, 1 equiv) was added to a solution of 1,2,3,4,6-penta-O-
trimethylsilyl-α-D-galactopyranose 4.82 (184 mg, 0.34 mmol) in CH2Cl2 (2 mL) at 0 °C 
under argon. The reaction mixture was stirred under argon for 15 min at rt. 
Benzene (2 mL) was added and the reaction mixture was concentrated in vacuo. 
2,3,4,6-Tetra-O-trimethylsilyl-α-D-galactopyranose iodide 4.83 was re-dissolved in 
CH2Cl2 (2 mL) and kept under argon. In another round bottom, N-azido-L-serine 
methyl ester 4.45 (16 mg, 0.112 mmol, 0.33 equiv), TBAI (251 mg, 0.68 mmol, 2 
equiv), DIPEA (89 µL, 0.51 mmol, 1.5 equiv) and 4Å MS in CH2Cl2 (2 mL) were stirred 
for 15 min. 2,3,4,6-Tetra-O-trimethylsilyl-α-D-galactopyranose iodide 4.83 was 
added over a period of 15 min and the reaction mixture was stirred for 18 h. The 
reaction mixture was concentrated in vacuo, re-dissolved in Et2O (20 ml), washed 
with H2O (20 mL), dried over MgSO4, filtered and concentrated in vacuo. Flash 
column chromatography (PetEt/ EtOAc 20:1 to 9:1) afforded the α-anomer 4.85 (67 
mg, 15%) as a colourless oil; Data recorded for α-anomer 4.85: Rf = 0.32 
(PetEt/EtOAc 9:1); [α]20D = + 120.00 (c, 0.20 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 
3601.2, 3343.2, 2920.9, 1250.8 cm-1; 1H NMR (300 MHz): δ  0.11-0.16 (m, 12 H, 
Si(CH3)3 × 5), 3.40-3.50 (m, 1 H, H-β’), 3.60-3.66 (m, 7 H, H-β, H-5, H-6, H-6’, CH3), 
3.76 ( dd, J = 2.7 Hz, 9.2 Hz, 1 H, H-3), 3.85-3.93 (m, 2 H, H-2, H-4), 3.97(t, J = 6.9 Hz, 
1 H, H-α), 5.14 (d, J = 3.5 Hz, 1 H, H-1); 13C NMR (75 Hz): δC -0.9 (Si(CH3)3), -0.2 
(Si(CH3)3), 0.0 (Si(CH3)3), 0.2 (Si(CH3)3), 60.5 (CO2CH3), 69.6, 70.4, 71.2, 71. 4 , 76.8 
(C-β, C-2, C-3, C-4, C-5, C-6), 93.4 (C-1). 
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2-Azido-3-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)–L-serine 1-methyl ester  
4.86
[193] 
 
TMSI (1.11 mL, 8.12 mmol, 1.1 equiv) was added to a pre-cooled solution of 
1,2,3,4,6-penta-O-trimethylsilyl-α-D-galactopyranose 4.82 (3.99 mg, 7.38 mmol) in 
CH2Cl2 (6 mL) at 0 °C under argon. The reaction mixture was stirred under argon for 
20 min at 0 °C. Benzene (20 mL) was added and the reaction mixture was rotary 
evaporated to give a viscous yellow oil. 2,3,4,6-Tetra-O-trimethylsilyl-α-D-
galactopyranose iodide 4.83 was re-dissolved in CH2Cl2 (6 mL) and kept under 
argon. In a separate round bottom, N-azido-L-serine methyl ester 4.45 (719 mg, 
2.43 mmol, 0.33 equiv), TBAI (4.09 g, 11.07 mmol, 1.5 equiv), DIPEA (1.93 mL, 11.07 
mmol, 1.5 equiv) and 4Å MS in CH2Cl2 (10 mL) were stirred for 15 min. 2,3,4,6-
Tetra-O-trimethylsilyl-α-D-galactopyranose iodide 4.83 was added over a period of 
15 min and the reaction mixture was stirred for 48 h. The reaction mixture was 
concentrated in vacuo. 2-Azido-3-(2,3,4,6-tetra-O-trimethylsilyl-α-D-
galactopyranosyl)–L-serine 1-methyl ester 4.85 was suspended in MeOH (30 mL) 
and Dowex (H+ form) (2g) was added. The reaction mixture was stirred for 5 h, 
filtered and rotary evaporated to yield a deacetylated brown oil. Ac2O (1.84 mL, 
19.44 mmol, 8 equiv) was added to the tetraol (747 mg, 2.43 mmol) in Pyr (2 mL) 
and the reaction mixture was stirred for 18 h. It was rotary evaporated. Flash 
column chromatography (3:1 PetEt/ EtOAc) afforded the title compound 4.86 (430 
mg) as a white foam containing impurities. Repeated chromatography 
(EtOAc/Tol/PetEt 10:60:30) afforded the α-anomer 4.86  (32 mg, 3% , crude yield) 
as a yellow oil; Data recorded for α-anomer 4.86:  Rf = 0.25 (PetEt/EtOAc 2:1); [α]
20
D 
= + 66.67 (c, 0.93 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3421.6, 2108.9, 1743.3, 
1639.1 cm-1;  1H NMR (300 MHz): δ 1.99 (s, 3 H, OC(O)CH3), 2.06 (s, 3 H, OC(O)CH3), 
2.09 (s, 3 H, OC(O)CH3), 2.14 (s, 3 H, OC(O)CH3), 3.82 (bs, 3 H, CH3), 3.81-3.87 (m, 1 
H, H-β’), 4.05-4.12 (m, 4 H, H-α, H-β, H-6, H-6’), 4.25 (pt, J = 6.8 Hz, 1 H, H-5), 5.10 
(dd, J  = 3.7 Hz, 10.8 Hz, 1 H, H-2), 5.16 (d, J = 3.7 Hz, 1 H, H-1), 5.33 (dd, J = 3.3 Hz, 
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10.8 Hz, 1 H, H-3), 5.47-5.48 (m, 1 H, H-4); 13C NMR (75 Hz): δC 20.6 (OCH3), 20.6 
(OCH3), 20.7 (OCH3),  52.9 (CH3), 61.4 (C-α), 61.7 (C-6), 66.9 (C-5), 67.3 (C-3), 67.9, 
67.9 (C-2, C-4), 68.5 (C-β), 96.9 (C-1), 168.3 (C=O), 169.9 (C=O), 170.1 (C=O), 170.4 
(C=O), 170.6 (C=O); HRMS m/z (ESI+) 476.1533 (C18H25N3O12H: [M+H]
+ requires 
476.1511). 
O-(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)–N-(decanosyl)-L-serine 
tetradecyl amide 4.87 
 
10% Piperadine in CH2Cl2 (50 µL in 500 µL) was added to N-(9-
fluorenylmethyloxycarbonyl)-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)–L-
serine tetradecyl amide 2.67 (50 mg, 0.05 mmol) and the reaction mixture was 
stirred for 1h at rt. The solution was diluted with CH2Cl2 (10 mL) and washed with 1 
M  aq. HCl solution (10 mL × 3), brine (10 mL), dried over MgSO4, filtered and 
concentrated to afford a crude amine (45 mg, 100%, crude yield) as a yellow oil; 1H 
NMR (300 MHz): δ 0.87 (t, J = 6.9 Hz, 3 H, CH3), 1.23-1.25 (m, 22 H,  
NHCH2CH2(CH2)11CH3), 1.25-1.63 (m, 2 H, NHCH2CH2), 3.37-3.43 (m, 2 H, NHCH2), 
3.51-4.16 (m, 9 H, H-2, H-3, H-4, H-5, H-6, H-6’, H-β, H-β’, H- α), 4.93-4.99 (m, 9 H, 
CH2Ph × 4, H-1), 7.26-7.35 (m, 20 H, aromatic), 7.75 (d, J = 7.3 Hz, 1 H, NHCH2); 
HRMS m/z (ESI+) 823.5255 (C51H70N2O7H: [M+H]
+ requires 823.5256). DMF (5 mL) 
was added to a round bottom containing decanoic acid (15 mg, 0.087 mmol), TBTU 
(31 mg, 0.0957 mmol, 1.2 equiv), HOBt (13 mg, 0.0957 mmol, 1.2 equiv) and DIPEA 
(45 µL, 0.261 mmol, 3 equiv) under N2 and was stirred for 10 min. The crude amine 
(72 mg, 0.087 mmol, 1 equiv) was then added to the reaction mixture and was 
stirred for 18 h. The reaction mixture was concentrated, re-dissolved in CH2Cl2 (10 
mL); washed with brine (10 mL). The organic layer was dried over MgSO4, filtered 
and evaporated under reduced pressure. Flash column chromatography 
(chloroform/ether 95:5) and repeated flash column chromatography (PetEt/EtOAc 
5:1) afforded α-anomer 4.87 (40 mg, 47%) as a white solid; Rf = 0.37 (PetEt/EtOAc 
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4:1); [α]27D = +34.67 (c, 0.75 in CH2Cl2); IR νmax (NaCl plate, CH2Cl2): 3821.8, 3301.9, 
2922.2, 2852.5, 1635.2, 1542.9  cm-1; 1H NMR (300 MHz): δ 0.87 (t, J = 6.9 Hz, 3 H, 
CH3), 1.24-1.26 (m, 36 H, CO(CH2)2(CH2)6CH3, NH(CH2)(CH2)12CH3), 1.57-1.62 (m, 2 H, 
COCH2CH2), 2.16 (t, J = 8.0 Hz, 2 H, COCH2), 2.56-2.65, 3.02-3.13 (m × 2, 2 H, 
NHCH2), 3.38-3.45 (m, 1 H, H-β), 3.51-3.59 (m, 2 H, H-6’, H-6), 3.85 (dd, J = 2.5 Hz, 
10.1 Hz, 1 H, H-3), 3.93-4.00 (m, 3 H, H-4, H-5, H-β’), 4.11 (dd, J = 3.7 Hz, 10.1 Hz, 1 
H, H-2), 4.33-4.95 (m, 8 H, CH2Ph × 4), 5.13 (d, J = 3.7 Hz, 1 H, H-1), 6.61 (d, J = 6.3 
Hz, 1 H, NHCOCH2), 7.03 (t, J = 5.2 Hz, 1 H, NHCH2), 7.26-7.38 (m, 20 H, aromatics); 
13C NMR (75 Hz): δC 13.1 (CH3)
xxiv, 21.7, 21.7, 24.5, 25.5, 25.8, 28.3, 28.3, 28.4, 28.4, 
28.6, 28.7, 28.7, 30.9, 30.9 (NHCH2 (CH2)12CH3, COCH2(CH2)7CH3), 35.5 (COCH2), 38.4 
(NHCH2), 50.2 (C-α), 66.9 (C-β), 67.8 (C-6), 68.9 (C-5), 71.6, 72.5, 73.8 (CH2Ph × 4), 
73.5 (C-4), 76.2 (C-2), 78.4 (C-3), 97.3 (C-1), 126.3, 126.6, 126.7, 126.8, 126.9, 127.1, 
127.2, 127.3, 127.4, 127.4, 127.5, 127.7, 136.4, 136.8, 137.3, 137.5 (aromatics), 
168.3 (C=O), 171.9 (C=O); HRMS m/z (ESI+) 977.6628 (C61H88N2O8H: [M+H]
+ requires 
977.6613). 
N-Azido-O-(2,3,4,6-tetra-O-benzyl-α/β-D-galactopyranosyl)–L-serine tetradecyl 
amide 4.88 and 4.89 
 
NIS (276 mg, 1.23 mmol, 2 equiv) was added to a solution of phenyl-2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactopyranoside 4.54 (388 mg, 0.61 mmol), and N-azido-L-
serine tetradecyl amide 4.58 (200 mg, 0.61 mmol, 1 equiv) in THF (6 mL) in the dark 
under N2. TfOH (1 µL, 0.006 mmol, 0.01 equiv) was added and the reaction mixture 
was stirred for 20 h. MeOH was added and the solution was concentrated in vacuo. 
The reaction mixture was diluted with CH2Cl2 (20 mL) and washed with satd. aq. 
Na2S2O4 (20 mL) followed by brine (20 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated. Flash column chromatography (PetEt/EtOAc 5:1) 
afforded the mixture of diastereoisomers 4.88 and 4.89 (328 mg, 63%) as a 
                                                            
xxiv Two overlapping signals. 
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colourless oil (α/β ratio 2.7:1). Additional flash column chromatography (PetEt to 
PetEt/EtOAc 9:1 to 5:1) afforded α-anomer 4.88 (81 mg, 35%); Rf = 0.13 
(PetEt/EtOAc/toluene 3:1:6);  Data recorded for α-anomer 4.88:  [α]25D = +34.29 (c, 
0.35 in CH2Cl2);  IR νmax (NaCl plate, CH2Cl2): 3350.5, 2924.3, 2858.2, 2108.2, 1726.4, 
1452.2 cm-1;  1H NMR (300 MHz): δ 0.87 (t, J = 7.3 Hz, 3 H, CH3), 1.24-1.25 (m, 20 H, 
(CH2)10CH3), 1.37-1.44 (m, 2 H, NHCH2CH2(CH2)10CH3), 2.95-3.07 (m, 1 H, NHCH), 
3.16-3.23 (m, 1 H, NHCH), 3.52-3.54 (m,2 H, H-6, H-6’ ), 3.68-3.76 (m, 1 H, H-β’), 
3.90-3.96 (m, 3 H, H-3, H-4, H-5), 4.04-4.13 (m, 3 H, H-α, H-β, H-2), 4.38-4.95 (m, 8 
H, CH2Ph × 4), 4.87 (d, J = 3.1 Hz, 1 H, H-1), 6.59 (t, J = 5.0 Hz, 1 H, NH), 7.26-7.36 
(m,20 H, aromatics); 13C-NMR (75 MHz): δC 14.2 (CH3), 26.9, 29.3, 29.4, 29.5, 29.6, 
29.6, 29.7, 29.7, 31.9 (NHCH2(CH2)12CH3), 39.6 (NHCH2(CH2)12CH3), 63.0 (C-α), 68.9 
(C-6), 69.1(C-β), 70.0 (C-5), 73.1, 73.6, 74.8 (CH2Ph × 4), 74.9, 78.8 (C-3, C-4), 98.9 
(C-1), 127.4, 127.5, 127.6, 127.6, 127.7, 127.8, 127.9, 127.9, 128.1, 128.2, 128.3, 
128.3, 128.4, 128.4, 137.9, 138.5, 138.6, 138.7 (aromatics), 166.9 (C=O); HRMS m/z 
(ESI+) 849.5190, (C51H68N4O7H: [M+H]
+ requires 849.5161). 
1-(O-(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)-L-serine tetradecyl amide)-4-
(tridecyl)-1,2,3-triazole 4.90 
 
CuSO4.5H2O (2 mg, 9.54 µmol, 0.1 equiv) was added to a solution of N-azido-O-
(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)–L-serine tetradecyl amide 4.88 (81 
mg, 0.09 mmol) and pentadecyne (20 mg, 0.09 mmol, 1 equiv) in THF/H2O/MeOH (5 
mL, 2:1:2) at rt. Sodium ascorbate (4 mg, 0.02 mmol, 0.2 equiv) was added and the 
reaction mixture was stirred for 18 h. The white precipitate was filtered, dissolved 
in CH2Cl2 (10 mL) and washed with brine (10 mL). The filtrate was reacted again 
under the exact conditions, concentrated, diluted with CH2Cl2 (10 mL) and washed 
with brine (10 mL). The organic layers were combined, dried over Na2SO4, filtered 
and concentrated in vacuo. Flash column chromatography (PetEt/EtOAc 5:1) 
afforded the title compound 4.90 (72 mg, 75%) as a white solid; Rf = 0.38 
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(PetEt/EtOAc 3:1); [α]25D = +40.00 (c, 0.65 in CH2Cl2);  IR νmax (NaCl plate, CH2Cl2): 
3746.3, 3738.6, 3434.3, 2924.7, 2853.7, 2795.1, 2091.3, 1642.4, 1453.5, 1261.6, 
1096.1, 696.7, 427.6, 411.1 cm-1; 1H NMR (300 MHz, α anomer): δ 0.87 (t, J = 6.9 Hz, 
3 H, CH3), 1.24-1.25 (m, 44 H, NHCH2(CH2)12CH3, C=CCH2CH2(CH2)10CH3), 1.59-1.64 
(m, 2 H, C=CCH2CH2), 2.65 (t, J = 8.3 Hz, 2 H, C=CCH2CH2), 2.80-2.93 (m, 1 H, 
NHCHH), 3.01-3.13 (m, 1 H, NHCHH), 3.44-3.58 (m, 2 H, H-6, H-6’), 3.81 (dd, J =2.6 
Hz, 10.1 Hz, 1 H, H-3), 3.90-3.94 (m, 2 H, H-4, H-5), 4.05 (dd, J = 2.6 Hz, 6.3 Hz, 1 H, 
H-2), 4.11-4.15 (m, 2 H, H-β H-β’), 4.39-4.93 (m, 8 H, CH2Ph × 4), 4.90 (d, J = 6.3 Hz, 
1 H, H-1), 5.36 (t, J = 6.1 Hz, 1 H, H-α), 6.45 (t, J = 5.8 Hz, 1 H, NHCH2), 7.26-7.37 (m, 
20 H, aromatic), 7.57 (s, 1 H, C=CH); 13C-NMR (75 MHz):δC 13.1 (CH3)
xxv, 16.5, 21.7, 
24.7, 25.8, 28.2, 28.2, 28.3, 28.4, 28.4, 28.5, 28.60, 28.6, 28.7, 30.9 
(NHCH2(CH2)12CH3, C=C(CH2)12CH3), 38.74 (NHCH2), 62.3 (C-α), 67.6 (C-β), 68.2 (C-6), 
69.1 (C-5), 71.9 (CH2Ph), 72.5 (CH2Ph),  72.8  (CH2Ph), 73.6 (C-4), 73.8 (CH2Ph), 75.2 
(C-2), 77.9 (C-3), 98.2 (C-1), 120.3 (C=CH), 126.4, 126.6, 126.7, 126.8, 126.8, 126.9, 
127.1, 127.2, 127.3, 127.4, 127.5, 136.8, 137.0, 137.3, 137.4 (aromatics), 165.1 
(C=O); HRMS m/z (ESI+) 1057.7359, (C66H96N4O7H: [M+H]
+ requires 1057.7352). 
7.2.4. Experimental procedures for Chapter 5 
Phenyl-2,3,4-tris-O-benzyl-6-O-propargyl-1-thio-β-D-galactopyranoside 5.16 
 
NaH (60% suspension in mineral oil) (10 mg, 0.240 mmol, 2 equiv) was slowly added 
to phenyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside 5.20 (65 mg, 0.12 mmol) 
dissolved in THF (5 mL) under an inert atmosphere at 0 °C. The reaction mixture 
was stirred for 30 min and then TBAI (2 mg, 0.006 mmol, 0.05 equiv) and propargyl 
bromide (80% in toluene) (32 µL, 0.3 mmol, 2.5 equiv) were added in succession. 
The reaction mixture was stirred for 18 h at rt. Ice-water (5 mL) was added and 
extracted with diethyl ether (10 mL). The aqueous layer was washed with diethyl 
ether (5 mL × 3). The organic layers were combined and concentrated in vacuo. 
                                                            
xxv Two overlapping signals. 
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Flash column chromatography (hexane/ EtOAc 3:1) followed by recrystallization in 
EtOH afforded the title compound 5.16 (33 mg, 47%) as a white solid; Rf = 0.75 
(PetEt/EtOAc 3:1); [α]25D = + 5.71 (c 0.35, CH2Cl2; IR νmax (NaCl plate, CH2Cl2): 3287.6, 
3030.3, 2922.6, 1724.0, 1583.8, 1496.7, 1454.7 cm-1; 1H NMR (300 MHz): δ 2.38  (t, 
J = 2.4 Hz, 1 H, CH2C≡CH), 3.57-3.63 (m, 2 H, H-3, H-5), 3.66-3.69 ( m, 2 H, H-6, H-6’), 
3.91-4.06 (m, 4 H, CH2C≡CH, H-2, H-4), 4.62-5.01 (m, 7 H, CH2Ph × 3, H-1), 7.20-7.59 
(m, 20 H, aromatics); 13C NMR (75 Hz): δC 58.6 (CH2C≡CH), 68.4 (C-6), 72.7 (CH2Ph), 
73.4 (C-4), 74.4 (CH2C≡CH), 74.8 (CH2Ph), 75.7 (CH2Ph), 77.1, 77.3 (C-2, C-3), 79.4 
(CH2C≡CH), 84.1 (C-5), 87.7 (C-1), 127.1, 127.5, 127.6, 127.7, 127.9, 128.2, 128.3, 
128.5, 128.8, 131.7, 134.0, 138.2, 138.3, 138.8 (aromatics); HRMS m/z (ESI+) 
620.1933, (C36H35KO5SH: [M+H]
+ requires 620.1948). 
This compound is mentioned in the literature but NMR data is not reported.[239] 
N-Azido-O-(2,3,4 -tris-O-benzyl-6-O-propargyl-α/β-D-galactopyranosyl)–L-serine 
tetradecyl amide 5.17 and 5.21 
 
NIS (68 mg, 0.61 mmol, 2 equiv) was added to a solution of phenyl-2,3,4-tris-O-
benzyl-6-O-propargyl-1-thio-β-D-galactopyranoside 5.16 (176 mg, 0.30 mmol) and 
N-azido-L-serine tetradecyl amide 4.58  (99 mg, 0.30 mmol, 1 equiv) in THF (4 mL) 
containing 4Å MS in the dark under N2. TfOH (1 µL, 0.0006 mmol, 0.01 equiv) was 
added and the reaction mixture was stirred for 18 h. MeOH was added and the 
reaction mixture was concentrated in vacuo. The resulting solid was diluted with 
CH2Cl2 (20 mL) and washed with satd. aq. Na2S2O4 (20 mL) followed by brine (20 
mL). The organic layer was dried over Na2SO4, filtered and concentrated to yield a 
mixture of diastereoisomers (α/β ratio 2.3:1). Flash column chromatography 
(PetEt/EtOAc 5:1) afforded the α-anomer 5.17 (39 mg, 16%) as a white solid; Data 
recorded for α-anomer 5.17:  Rf = 0.27 (PetEt/EtOAc 3:1); [α]
25
D = +37.04 (c, 0.27 in 
CH2Cl2);  IR νmax (NaCl plate, CH2Cl2): 3776.6, 3370.1, 2103.4, 1642.7 cm
-1; 1H NMR 
(300 MHz): δ 0.88 ( t, J = 6.9 Hz, 1 H, CH3), 1.23-1.25 (m, 22 H, (CH2)11CH3), 1.42 (pt, 
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J = 6.7 Hz, 2 H NHCH2CH2), 2.40 (t, J = 2.4 Hz, 1 H, CH2C≡CH), 2.96-3.08 (m, 1 H, 
NHCHH), 3.15-3.27 (m, 1 H, NHCHH), 3.54-3.57 (m,2 H, H-6, H-6’), 3.68-3.73 (m, 1 H, 
H-β’), 3.89-3.96 (m, 3 H, H-3, H-4, H-5), 4.05-4.14 (m, 5 H, H-α, H-β, H-2, CH2C≡CH), 
4.62-4.98 (m, 7 H, CH2Ph × 3, H-1), 6.63 (t, J = 6.0 Hz, 1 H, NH), 7.25-7.39 (m, 15 H, 
aromatics); 13C-NMR (75 MHz): δC 22.7 (CH3), 26.9, 29.3, 29.4, 29.5, 29.6, 29.6, 29.7, 
29.7, 31.9 (NHCH2(CH2)12CH3), 39.6 (NHCH2(CH2)12CH3), 58.5 (CH2C≡CH), 63.0 (C-α), 
68.5 (C-6), 69.1 (C-β), 69.8 (C-5), 73.1 (CH2Ph), 73.5 (CH2Ph), 74.7 (CH2Ph), 74.8, 
74.9, 78.7 (C-3, C-4, CH2C≡CH), 76.6 (CH2C≡CH), 79.4 (C-2), 98.8 (C-1), 127.5, 127.6, 
127.7, 127.8, 127.9, 128.3, 128.3, 128.4, 138.2, 138.4, 138.5, 138.6 (aromatics), 
166.9 (C=O); HRMS m/z (ESI+) 797.4848, (C47H64N4O7H: [M+H]
+ requires 797.4823). 
A small amount of the β diastereoisomer 5.21 was isolated for characterisation; 
Data recorded for β-anomer 5.21:  Rf = 0.26 (PetEt/EtOAc 3:1);  [α]
23
D = +48.88 (c, 
0.45 in CH2Cl2);  IR νmax (NaCl plate, CH2Cl2): 3430.2, 2105.8, 1642.5, 1261.4 cm
-1; 1H 
NMR (300 MHz): δ 0.88 (t, J = 6.9 Hz, 1 H, CH3), 1.23-1.24 (m, 22 H, (CH2)11CH3), 1.44 
(pt, J = 6.9 Hz, 2 H, NHCH2CH2), 2.40 (t, J = 2.4 Hz, 1 H, CH2C≡CH), 3.12-3.28 (m, 2 H, 
NHCH2), 3.51-3.56 (m, 2 H, H-6, H-6’), 3.55-3.63 (m, 2 H, H-3, H-5), 3.80-3.90 (m, 2 
H, H-4, H-2), 4.04-4.15 (m, 5 H, H-α, H-β, H-β’, CH2C≡CH), 4.43 (d, J =7.8 Hz, 1 H, H-
1), 4.65-4.98 (m, 6 H, CH2Ph × 3), 6.43 (t, J = 5.7 Hz, 1 H, NH), 7.29-7.34 (m, 15 H, 
aromatics); 13C-NMR (75 MHz): δC 14.1 (CH3), 22.7, 26.8, 29.2, 29.4, 29.5, 29.6, 29.7, 
29.7, 31.9 (NHCH2(CH2)12CH3), 39.6 (NHCH2), 58.5 (CH2C≡CH), 63.3 (C-α), 68.3 (C-6), 
70.2 (C-β), 73.1 (CH2Ph), 73.2 (C-4), 73.4 (C-5), 74.6 (CH2Ph), 74.8 (CH2C≡CH), 75.3 
(CH2Ph), 79.4 (C-2), 79.3 (CH2C≡CH), 82.0 (C-3), 104.1 (C-1), 127.5, 127.6, 127.7, 
127.9, 128.2, 128.3, 128.4, 138.3, 138.5, 138.6 (aromatics), 166.7 (C=O); HRMS m/z 
(ESI+) 797.4842, (C47H64N4O7H: [M+H]
+ requires 797.4823). 
Phenyl-6-O-tert-butyldimethylsilyl-1-thio-β-D-galactopyranoside 5.18 
[281]
  
 
Na metal (4 mg approx., 0.17 mmol approx., 0.1 equiv approx.) was added to a 
solution of phenyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 4.53 (737 
mg, 1.67 mmol) in MeOH (2 mL) at 0 °C. The reaction mixture was stirred at rt for 
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1.5 h; quenched with Amberlite ion-exchange resin (H+ form), filtered and 
concentrated in vacuo. The resulting white solid (368 mg, 81%) was then dissolved 
in Pyr (10 mL) and TBDMSCl (407 mg, 2.70 mmol, 2 equiv) was slowly added under 
an inert atmosphere at -10 °C. NEt3 (2 drops) was added and the reaction mixture 
was stirred for 1 h at -10 °C. The reaction mixture was allowed to warm to rt and 
stirred for 21 h at rt. The solution was diluted with CH2Cl2 (40 mL) and poured into 
ice-water (40 mL). The separated aqueous layer was extracted with CH2Cl2 (40 mL × 
3). The combined organic layers were washed with satd. aq. NaHCO3 (40 mL), brine 
(40 mL), dried over MgSO4, filtered and concentration in vacuo. Flash column 
chromatography (hexane/ EtOAc 1:1) afforded the title compound 5.18 (410 mg, 
79%) as a colourless oil; Rf = 0.40 (PetEt/EtOAc 1:1); 
1H NMR (300 MHz): δ 0.07 (s, 
3H, SiCH3), 0.09 (s, 3H, SiCH3), 0.89 (s, 9 H, SiC(CH3)3), 3.51 (pt, J = 5.3 Hz, 1 H, H-5), 
3.59 (dd, J = 3.1 Hz,  9.1 Hz, 1 H, H-3), 3.75 (pt, J = 9.1 Hz, 1 H, H-2), 3.87-3.90 (m, 2 
H, H-6, H-6’), 4.05-4.07 (m, 1 H, H-4), 4.54 (d, J = 9.6 Hz, 1 H, H-1), 7.25-7.28, 7.52-
7.56 (m, 5 H, aromatics); 13C NMR (75 Hz): δC -5.5 (Si(CH3)2),  -5.4 (Si(CH3)2), 18.2 
(SiC(CH3)3), 25.8 (SiC(CH3)3), 63.1 (C-6), 69.4 (C-4), 69.8 (C-2), 75.0 (C-3), 78.3 (C-5), 
88.7 (C-1), 127.6, 128.9, 132.0, 133.0 (aromatics); HRMS m/z (ESI+) 387.1656, 
(C18H30O5SSiH: [M+H]
+ requires 387.1660). 
Phenyl-2,3,4-tris-O-benzyl-6-O-tert-butyldimethylsilyl-1-thio-β-D-
galactopyranoside 5.19
[240]
    
 
NaH (60% suspension in mineral oil) (55 mg, 1.37 mmol, 6 equiv) was slowly added 
to phenyl-6-O-tert-butyldimethylsilyl-1-thio-β-D-galactopyranoside 5.18 (88 mg, 
0.23 mmol) dissolved in DMF (2 mL) under an inert atmosphere at 0 ° C. The 
reaction mixture was stirred for 30 min and BnBr (162 µL, 1.37 mmol, 6 equiv) was 
added to the suspension at 0 ° C. The reaction mixture was stirred for 2 h at 0 ° C. 
To this suspension MeOH (2 mL) was added and poured into ice-water (1 mL); 
extracted with CH2Cl2 (2 mL × 2). The combined organic layers were washed with 
water, dried over MgSO4, filtered and concentration in vacuo. Flash column 
Chapter 7: Experimental details 
268 
 
chromatography (hexane/ EtOAc 20:1) afforded the title compound 5.19 (46 mg, 
31%) as a colourless oil; Rf = 0.18 (PetEt/EtOAc 20:1); 
1H NMR (300 MHz): δ 0.03 (bs, 
6 H, Si(CH3)2), 3.45 (pt, J = 6.6 Hz, 1 H, H-5), 3.60 (dd, J = 2.7 Hz, 9.2 Hz, 1 H, H-3), 
3.66-3.79 (m, 2 H, H-6, H-6’), 3.91-3.97 (m, 2 H, H-2, H-4), 4.61-5.00 (m, 7 H, CH2Ph 
×3, H-1), 7.16-7.58 (m, 5 H, aromatics); 13C NMR (75 Hz): δC  -5.5 (Si(CH3)2), -5.3 
(Si(CH3)2), 18.2 (SiC(CH3)3), 26.1 (SiC(CH3)3), 61.6 (C-6), 72.8 (CH2Ph), 73.5 (C-2), 74.5 
(CH2Ph), 75.6 (CH2Ph), 76.6 (C-4), 78.9 (C-5), 84.3 (C-3), 87.7 (C-1), 127.0, 127.4, 
127.6, 127.7, 127.7, 128.0, 128.2, 128.3, 128.4, 128.4, 128.8, 131.4, 138.4, 138.4, 
138.9 (aromatics). 
1H NMR data is in agreement with the literature.[240]  
Phenyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside 5.20 
 
A solution of TBAF (1 M in THF) (50 µL) was added drop-wise to phenyl-2,3,4-tris-O-
benzyl-6-O-tert-butyldimethylsilyl-1-thio-β-D-galactopyranoside 5.19 (42 mg, 0.06 
mmol) and crushed 4Å MS suspended in THF (3 mL) under an inert atmosphere at 0 
° C and was allowed to warm to rt for 1 h. The reaction mixture was then stirred for 
6 h at rt and concentrated in vacuo. It was re-dissolved in EtOAc and filtered 
through Celite, rinsing with EtOAc. The filtrate was washed with satd. aq. NaHCO3, 
water, dried over MgSO4, filtered and concentrated in vacuo. Flash column 
chromatography (hexane/ EtOAc 1:1) afforded the title compound 5.20 (33 mg, 
94%) as a colourless oil; Rf = 0.63 (PetEt/EtOAc 1:1); 
1H NMR (300 MHz): δ 3.42-3.46 
(m, 1 H, H-6), 3.49-3.54 (m, 1 H, H-6’), 3.61 (dd, J = 2.8 Hz, 9.3 Hz, 1 H, H-3), 3.81-
3.86 (m, 2 H, H-4, H-5), 3.95 (pt, J= 9.3 Hz,  1 H, H-2), 4.62-5.00 (m, 7 H, CH2Ph × 3, 
H-1), 7.21-7.55 (m, 20 H, aromatics); HRMS m/z (ESI+) 543.2191, (C33H34O5SH: 
[M+H]+ requires 543.2200). 
 This NMR data is in agreement with the literature.[282]  
 
Chapter 7: Experimental details 
269 
 
Macrocyclic Compounds 5.24, 5.25 and 5.26
xxvi
 
 
CuSO4.5H2O (1 mg, 4.33 µmol, 0.1 equiv) was added to a solution of N-azido-O-
(2,3,4 -tris-O-benzyl-6-O-propargyl-α-D-galactopyranosyl)–L-serine tetradecyl amide 
5.17 (81 mg, 0.09 mmol)  in THF/H2O/MeOH (5 mL, 2:1:2, 8.5 mM concentration) at 
rt. Sodium ascorbate (2 mg, 0.02 mmol, 0.2 equiv) was added and the reaction 
mixture was stirred for 18 h. CuSO4.5H2O (1 mg, 4.33 µmol, 0.1 equiv) was added to 
the reaction mixture, followed by the addition of sodium ascorbate (2 mg, 0.02 
mmol, 0.2 equiv).  The reaction mixture was stirred at 45 °C for 3 h. The reaction 
mixture was then diluted with CH2Cl2 (50 mL) and washed with brine (20 mL). The 
organic layer was dried over Na2SO4, filtered and concentrated in vacuo. Flash 
column chromatography (PetEt/EtOAc 2:1 to EtOAc/PetEt  2:1 to MeOH) afforded 
the title compounds 5.24, 5.25 and 5.26 (53% w/w) as a white solid and as a 
mixture of compounds; IR νmax (NaCl plate, MeOH): 3429.8, 2925.2, 2853.9, 2099.0, 
1642.9, 1496.9, 1454.4 cm-1; 1H NMR (600 MHz): δ 0.85-0.88 (m, 10 H), 1.22-1.24 
(m, 41 H), 2.88-2.96 (m, 2 H), 2.99-3.14 (m, 2 H), 2.22-1.24 (m, 3 H), 3.32-3.38 (m, 1 
H), 3.49-3.63 (m, 4 H), 3.73-4.24 (m, 14 H), 5.36-5.45 (m, 1 H), 7.26-7.33 (m, 29 H), 
                                                            
xxvi
 Experimental data presented most likely represents the macrocyclic structures. However 
conclusive evidence is not given for the formation of these products. 
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7.90-7.91 (m, 2 H); 13C-NMR (150 MHz): δC 14.1 (CH3), 22.7, 26.7, 26.9, 29.3, 29.7, 
31.9, 69.1, 127.4, 127.7, 128.4, 129.8; HRMS m/z (ESI+) for monomer 5.24, 
797.4871, (C47H64N4O7H: [M+H]
+ requires 797.4848); for dimer 5.25, 1615.9497, 
(C94H128N8O14Na: [M+Na]
+ requires 1615.9442); for trimer 5.26, 2412.4150, 
(C141H192N12O21Na: [M+Na]
+ requires 2412.4217). 
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